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Abstract 
Introduction: Malignant Rhabdoid Tumours (MRT) are unique malignancies caused by 
biallelic inactivation of a single gene (SMARCB1). SMARCB1 encodes for a protein that 
is part of the SWI/SNF chromatin remodelling complex, responsible for the regulation 
of hundreds of downstream genes/pathways. Despite the simple biology of these 
tumours, no studies have identified the critical pathways involved in tumourigenesis. 
The understanding of downstream effects is essential to identifying therapeutic targets 
that can improve the outcome of MRT patients. 
Methods: RNA-seq and 450K-methylation analyses have been performed in MRT 
human primary malignancies (n > 39) and in 4 MRT cell lines in which lentivirus was 
used to re-express SMARCB1 (G401, A204, CHLA-266, and STA-WT1). The MRT cell 
lines were treated with 5-aza-2 -deoxycytidine followed by global gene transcription 
analysis (RNA-seq and 450K-methylation) to investigate how changes in methylation 
lead to tumourigenesis. 
Results: We show that primary Malignant Rhabdoid Tumours present a unique and 
distinct expression/methylation profile which confirms that MRT broadly constitute a 
single and different tumour type from other paediatric malignancies. However, despite 
their common cause MRT can be can sub-group by location (i.e. CNS or kidney). We 
observe that re-expression of SMARCB1 in MRT cell lines determines 
activation/inactivation of specific downstream pathways such as IL-6/TGF beta. We 
also observe a direct correlation between alterations in methylation and gene expression 
in CD44, GLI2, GLI3, CDKN1A, CDKN2A and JARID after SMARB1 re-expression. 
Loss of SMARCB1 also promotes expression of aberrant isoforms and novel transcripts 
and causes genome-wide changes in SWI/SNF binding. 
Conclusion: Next generation transcriptome and methylome analysis in primary MRT 
and in functional models give us detailed downstream effects of SMARCB1 loss in 
Malignant Rhabdoid Tumours. The integration of data from both primary and functional 
models has provided, for the first time, a genome-wide catalogue of SMARCB1 
tumourigenic changes (validated using systems biology). Here we show how a single 
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deletion of SMARCB1 is responsible for deregulation of expression, methylation status 
and binding at the promoter regions of potent tumour-suppressor genes. The genes, 
pathways and biological mechanisms indicated as key in tumour development may 
ultimately be targetable therapeutically and will lead to better treatments for what is 
currently one of the most lethal paediatric cancers. 
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 Atypical Teratoid Rhabdoid Tumours (ATRT) 1.1
Atypical Teratoid Rhabdoid Tumour (ATRT) is an aggressive malignancy of the central 
nervous system (CNS). Central nervous system tumours represent 20% of all childhood 
neoplasms and are the most common cause of death in this age group (Peris-Bonet, 
Martinez-Garcia et al. 2006). Just 1- 2% of all paediatric brain tumours are Atypical 
Teratoid Rhabdoid Tumour., however they account for ~10% of all CNS tumours in 
infants with an incidence rate of 1.38 per 1,000,000 person-years in children (Woehrer, 
Slavc et al. 2010). New studies underline that in infancy the Atypical Teratoid Rhabdoid 
Tumour.occur with a frequency similar to Medulloblastoma and CNS Primitive 
Neuroectodermal Tumour PNET (17.3%, 16.0%, and 13.3%, respectively) (Woehrer, 
Slavc et al. 2010). 
Despite the fact that Atypical Teratoid Rhabdoid Tumours were first described as a 
Malignant Rhabdoid tumours (MRT) of the central nervous system in 1987, Atypical 
Teratoid Rhabdoid Tumours have been recognized as a unique class of primarily brain 
and spinal tumours in 1996 (Rorke, Packer et al. 1996). Atypical Teratoid Rhabdoid 
Tumour  are characterised by a unique combination of Rhabdoid cells, primitive 
neuroectodermal cells and tumour cells with mesenchymal, neuronal or glial 
differentiation (Figure 1.1). 
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Figure 1.1 Immunohistochemistry of Atypical Teratoid Rhabdoid Tumour: A) 
negative SMARCB1 staIning. B) SMARCB1 positive staIning in endothelial 
and inflammatory cells (Sigauke, Rakheja et al. 2006). 
On average 50% of these tumours reside in the cerebellum (Ronald 2005) or 
cerebellopontine angle (Kufe, Pollock et al. 2003), often with contiguous brain stem 
involvement. About 40% of tumours develop as a mass in the cerebral or suprasellar 
supratentorial regions (Figure 1.2). Despite a well characterised biology, Atypical 
Teratoid Rhabdoid Tumours  can be misdiagnosed often as Medulloblastoma, primitive 
neuroectodermal tumour (PNET), choroid plexus carcinoma or germ cell tumour, since 
they develop in identical areas of the CNS (Biegel 1997, Bikowska, Grajkowska et al. 
2011). The discovery of the role of SMARCB1 gene as a tumour suppressor gene in 
Atypical Teratoid Rhabdoid Tumours (Versteege, Sevenet et al. 1998, Sevenet, Sheridan 
et al. 1999, Biegel, Kalpana et al. 2002) has led to a more accurate diagnosis of the 
pathology. Nowadays screening for biallelic inactivation of the SMARCB1 gene is often 
used as an adjunct to histology in the differential diagnosis of Rhabdoid Tumours 
(Haberler, Laggner et al. 2006). 
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Figure 1.2 Magnetic resonance image of a patient with Atypical Teratoid 
Rhabdoid Tumour. This sagittal-plane magnetic resonance image of the 
brain shows a mass in the posterior fossa (Parwani, Stelow et al. 2005) 
 
 Epidemiology 1.1.1
Atypical Teratoid Rhabdoid Tumour’s incidence in childhood is still an approximate 
evaluation: often the diagnosis is inaccurate due to a lack of characteristic location and 
morphology and absence of systematic diagnostic evaluative protocols. However the 
discovery of changes in chromosome 22 and mutation in SMARCB1 are leading to a 
better diagnosis, even retrospectively (Reinhard, Reinert et al. 2008) 
Recent population-based study by the Austrain Brain tumour registry (Woehrer, Slavc et 
al. 2010) shows Atypical Teratoid Rhabdoid Tumours are more common than previously 
reported. In fact this cohort reveals that almost 50% of Atypical Teratoid Rhabdoid 
Tumours were misdiagnosed and in particular before the introduction of a systematic 
analysis of SMARCB1 protein (Burger, Yu et al. 1998, Hilden, Meerbaum et al. 2004, 
Haberler, Laggner et al. 2006). Nowadays, Atypical Teratoid Rhabdoid Tumours are 
considered one of the six most malignant central nervous system entities in childhood 
(Woehrer, Slavc et al. 2010). Atypical Teratoid Rhabdoid Tumours present a peak 
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incidence from birth to three years of age, with a median age of 1.44. In this age class 
Atypical Teratoid Rhabdoid Tumours have an incidence comparable with other CNS 
tumours (Woehrer, Slavc et al. 2010), indicating these malignancies are common 
especially in infants (Figure 1.3).  
Atypical Teratoid Rhabdoid Tumours appear to be more aggressive than other CNS 
tumours, in fact the overall survival is 10 months from diagnosis and metastatic patients 
present a significantly shorter overall survival (Figure 1.4). A younger age at diagnosis 
provides a worse prognosis, although the overall survival is not affected by age 
(Buscariollo, Park et al. 2012). 
 
 
Figure 1.3 Relative frequencies of the 6 most common malignant central 
nervous system (CNS) tumours. PNET = Primitive Neuroectodermal 
Tumour ; patients are divided by age into five categories. In comparison to 
the other malignancies Atypical Teratoid Rhabdoid Tumours presents a peak 
incidence between 0 and 3 years age group (Woehrer, Slavc et al. 2010). 
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Figure 1.4 Kaplan-Meier curves illustrate overall survival (OS) for patients 
with Atypical Teratoid Rhabdoid Tumours. (A) The median OS for entire 
group was 10 months (n = 144). (B) The median OS for patients who 
presented with metastases was 3 months; The median OS for patients 
without metastases was 13 months (P <.001) (Buscariollo, Park et al. 2012). 
 Genetic epidemiology 1.1.2
In most Atypical Teratoid Rhabdoid Tumours deletions or abnormalities are detected in 
chromosome 22q11, implying the existence of a tumour suppressor gene at this locus. In 
fact Atypical Teratoid Rhabdoid Tumours (~50%) often present a loss of one copy of the 
entire chromosome 22 (monosomy 22) or a deletion or translocation in the band 
22q11.2 (Versteege, Sevenet et al. 1998). Moreover, Extra Cranial malignant Rhabdoid 
tumour (ECRT) show partial or complete deletions of chromosome 22 suggesting a 
common origin with Atypical Teratoid Rhabdoid Tumours, despite the differences in 
anatomic location.  
Mutations have also been identified throughout the coding sequence, frequently 
occurring in exons 2 and 9, followed by 5, 4 and 7. Mutations in exons 2, 6 and 7 were 
commonly reported in kidney tumours (Eaton, Tooke et al. 2011), while exons 5 and 9 
are frequently mutated in CNS tumours (Biegel, Tan et al. 2002). Single nucleotide 
polymorphism (SNP) oligonucleotide array analysis demonstrated that 98% of 
Rhabdoid Tumours (Atypical Teratoid Rhabdoid Tumours, renal and extra renal 
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tumours) show deletions or loss of heterozygosity (LOH) involving the SMARCB1 locus 
on chromosome 22 but the absence of other recurrent genomic alteration (Jackson, 
Sievert et al. 2009, Lee, Stewart et al. 2012, Hasselblatt, Isken et al. 2013, Hoell, 
Gombert et al. 2013) (Figure 1.5). 
 
Figure 1.5 SNP array analysis of chromosome 22 copy number alterations. 
There are 3 major groups: the top cluster, large deletions; the middle 
cluster, small deletions; and the bottom cluster, large regions of CN LOH. In 
general, tumours with large deletions or large regions of CN LOH were 
almost exclusively brain tumours. Soft tissue tumours were found primarily 
to have small deletions.(Jackson, Sievert et al. 2009) 
 
The presence of germ-line mutations in patients with Atypical Teratoid Rhabdoid 
Tumours and Rhabdoid Tumours supports the hypothesis of genetic predisposition 
(Biegel 1999, Bourdeaut, Lequin et al. 2011, Eaton, Tooke et al. 2011). It has been 
estimated that 30-35% of all CNS Rhabdoid Tumours present germline mutation or 
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deletion (Bourdeaut, Lequin et al. 2011, Eaton, Tooke et al. 2011). Presence of germline 
mutation was also described as a factor denoting poor prognosis (Tomlinson, Breslow et 
al. 2005, Kordes, Gesk et al. 2010, Bourdeaut, Lequin et al. 2011) (Figure 1.6). 
 
 
Figure 1.6 Kaplan-Meier curves illustrate overall survival (OS) for patients 
characterised by SMARCB1 germline mutation. A) Overall survival of 
Atypical Teratoid Rhabdoid Tumours patients with SMARCB1 germline 
mutation versus patients with normal constitutional SMARCB1 gene (p ≤ 
0.02); B) Overall survival at tumour onset (p ≤ 0.0004) (Bourdeaut, Lequin 
et al. 2011). 
 
 
 The majority of mutations are acquired, but de novo mutations have been identified in 
the germline that are accompanied by somatic loss of the remaining allele (Biegel et al., 
1999; 2002) and more frequent in patients younger than 2 years (Figure 1.7) 
(Bourdeaut, Lequin et al. 2011).  
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Figure 1.7 Observed frequency of SMARCB1 germline mutation. Patients 
are divided by age into five categories. 60% of the Rhabdoid Tumours 
occurring before 6 months of age are correlated with SMARCB1 germline 
mutation (Bourdeaut, Lequin et al. 2011). 
 
 Treatment  1.1.3
The most frequently used treatment for these neoplasms consists of intensive multi-
modal therapy with surgery, chemotherapy and/or radiation therapy (Garre and Tekautz 
2010). Initially surgical treatments are used to reduce the neoplastic mass, following by 
a supplementary therapy. The resection of the primary tumour mass is associated with 
improved survival, however gross total removal is possible in only 50% of cases and 
depends on the infiltration of the tumour (Bansal and Goel 2007). 
In children younger than 2 years irradiation is typically avoided and high dose 
chemotherapy in conjunction with autologous stem cell transplantation are often used 
(Dunkel, Boyett et al. 1998). Recently an innovative treatment of cycles of carboplatin, 
doses of thiotepa and cycles of conventional induction chemotherapy resulted in 5 of 10 
Atypical Teratoid Rhabdoid Tumour patients alive 42 months from diagnosis (Tekautz, 
Fuller et al. 2005). Radiotherapy is often given to children older than 3 years, due to 
 10 
 
radio-toxicity which causes severe effects in developing brain. Radiotherapy prolongs 
the survival of older children but seems to be especially effective in the first stages of 
the regimen (Bansal and Goel 2007). Recent cohort studies demonstrate that 
radiotherapy had a strong impact on survival even in younger patients (<1 year and 1-3 
years) (Buscariollo et al, 2012 (Benesch, Bartelheim et al. 2014)). Despite potentially 
severe side effects such as cognitive delay and endocrine dysfunction. Radiotherapy is 
still considered one of the most effective treatments for Atypical Teratoid Rhabdoid 
Tumours. Patients with localised mass can benefit from radiotherapy, since they can be 
treated with focal irradiation to minimise toxicities. In Europe treatment in patients 
younger than 18 months (Benesch, Bartelheim et al. 2014, Slavc, Chocholous et al. 
2014) is more conservative and consists of a multistep therapy. In particular, in the 
United Kingdom after first surgery nine cycles of ifosfamide, carboplatin and etoposide 
(ICE), vincristine, cyclophosphamide, adriamycin (VCA) and doxorubicin are 
administered to patients between 0 and 12 months. After 7 months a second surgery is 
typically suggested and usually after 13 months of life the more aggressive high-dose-
chemotherapy (HDCT) is adopted. HDCT is based on carboplatin and thiotepa given 
with a daily dose respectively of 500mg/m2 and 300mg/m2. Radiotherapy is adopted in 
patients younger than 18 months just following the 9 cycles of chemotherapy. In 
patients older than 18 months radiotherapy is suggested to start as soon as possible and 
different strategies are taken on the basis of age and type of malignancies. In particular, 
in children with localised tumour mass irradiation with 36 Gy (1.8Gy daily, 5 fractions 
per week) is recommended. Metastatic patients aged between 18 months to 3 years are 
treated using craniospinal radiotherapy with 24.0 Gy (1.6 Gy daily), in children older 
than 3 years the axis dose is increased to 35.2 Gy (CCLG registry). 
Retrospective analysis of the European Rhabdoid registry (EU-RHAB) suggests 
radiotherapy following gross total resection and HDCT could positively impact on the 
outcome of kids older than 18 months and with localised disease (Figure 1.8). However 
in non-irradiated patients (younger than 18 months) HDCT is only occasionally 
successful (Benesch, Bartelheim et al. 2014).  
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Despite the relatively positive outcome in older children, radiotherapy application 
remains controversial because of severe side effects. In particular, neurocognitive and 
vascular side effects have been observed especially in infants, even a long time after 
completion of the radiotherapy. The treatments used in the clinic for Atypical Teratoid 
Rhabdoid Tumours are often ineffective and with severe side effects that are the results 
of progressive attempts to increase survival in these patients. The importance of 
understanding the biological mechanisms that drive tumour formation in order to find 
an effective therapy is increasingly evident. 
 
 
Figure 1.8 Kaplan–Meier plots of the estimated PFS rate for 19 study 
patients. (b) Kaplan–Meier plots of the estimated OS rate for 19 study 
patients (Benesch, Bartelheim et al. 2014) 
 
 Extra Cranial Rhabdoid Tumours (ECRT)  1.1.4
The Brain is not the only location in which Rhabdoid Tumours can be found. In fact 
Malignant Rhabdoid Tumours have been reported in other locations of the body, 
including the brain, liver, soft tissues, lung, skin, and heart. However Extra Cranial 
Rhabdoid Tumours (ECRT) have the same deletions of the SMARCB1 gene indicating 
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that Atypical Teratoid Rhabdoid Tumours and ECRT are related entities, despite the 
different location. Moreover Rhabdoid Tumours at all locations display similar 
histological, clinical, and demographic features. Moreover, as well as Atypical Teratoid 
Rhabdoid Tumours, 15-30% of Extra Cranial Rhabdoid Tumours have been associated 
with germline mutation at chromosome 22q11.2 (Trobaugh-Lotrario, Finegold et al. 
2011). Usually patients with SMARCB1 germline mutation develop multiple Rhabdoid 
malignancies in first year of life and all have very poor prognoses regardless of the 
location of the tumour (Biegel 1999, Savla, Chen et al. 2000, Jackson, Shaikh et al. 
2007).  
Extra Cranial Rhabdoid Tumours can be further divided into renal and extra-renal 
malignancies. This sub-classification is due to the observation that Rhabdoid Tumours 
located in the kidneys tend to develop earlier and tend to progress in the brain 
(Tomlinson, Breslow et al. 2005). Patients with extra-renal Rhabdoid tend to be older 
and not show multiple metastasis or have a limited progression to the musculoskeletal 
system (Sultan, Qaddoumi et al. 2010). 
Like Atypical Teratoid Rhabdoid Tumours, Extra Cranial ECRT are lethal and new 
treatments have indicated limited improvement on the survival. In particular in the UK 
just 31% of 106 the patients have 1-year survival from 1993-2010 (Brennan, Stiller et 
al. 2013). 
 Rhabdoid predisposition syndrome in CNS tumours and tumours with 1.1.5
SMARCB1 germ line mutation  
The new screening techniques have been helpful to highlight the hereditary nature of 
Rhabdoid tumour predisposition. Systematic investigation revealed that a significant 
number (30%) of patients harboured a germline SMARCB1 mutation, regardless of the 
location of the primary tumour (Eaton, Tooke et al. 2011). Moreover screening of 
parents reveals that 32% of the tested parents carried mutation at the same loci. 
Germline mosaism has been recently hypothesised, since affected siblings may have 
negative testing parents (Mobley, McKenney et al. 2010). 
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Other malignancies have been linked to germline SMARCB1 mutation, such as 
Schwannomatosis (Rousseau, Noguchi et al. 2011), chordomas (Mobley, McKenney et 
al. 2010), Choroid Plexus Carcinoma, Medulloblastoma (Sevenet, Sheridan et al. 1999) 
and Epithelioid Sarcoma (Modena, Lualdi et al. 2005). The finding of germ-line 
SMARCB1 mutation in other embryonal tumours of the central nervous system suggests 
these malignancies share common pathways of oncogenesis with Malignant Rhabdoid 
tumours. SMARCB1 alteration is nowadays used in clinics as a molecular marker to 
define this spectrum of tumours. 
1.1.5.1 Biological and molecular differences between Atypical Teratoid Malignant 
Rhabdoid Tumours and other embryonal tumours of the CNS 
Embryonal tumours are the most common central nervous system malignancies in 
infants and young children (typically aged between 0 and 36 months). The World Health 
Organization (WHO) includes in this classification Medulloblastoma (MB), 
Supratentorial Primitive Neuroectodermal Tumour (PNET) and Atypical Teratoid 
Rhabdoid Tumours.  
Embryonal tumours present very similar microscopic features, characterised by an 
undifferentiated small and round stem-like cells. However, pathologically these 
malignancies have been classified in different subclasses (Figure 1.9): classic 
Medulloblastoma, desmoplastic Medulloblastoma, Medulloblastoma with extensive 
nodularity, large-cell variant Medulloblastoma, anaplastic Medulloblastoma, Atypical 
Teratoid Rhabdoid Tumours and PNET. Despite having similar histological 
characteristic and location, these malignancies are genetically divergent. Molecular 
profiling of these malignancies has disclosed their heterogeneity, introducing a more 
complex and complete understanding of these malignancies. 
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Figure 1.9 Embryonal tumour microscopy features. A) Classic Medulloblastoma are 
characterised by a poor differentiated cells. B) Desmoplastic/nodular 
Medulloblastoma presents reticulum free pale nodules of cells with neuronal or 
astrocytes differentiation (asterisk). C) Medulloblastoma with extensive 
nodularity contains cell clustered in nodules with a characteristic elongated shape. (As 
seen in this panel, both patterns can co-exist in a single tumour. D) Atypical 
Teratoid/Rhabdoid Tumours shows an undefined appearance; moreover Rhabdoid cells 
are very sparse. E) CNS primitive neuroectodermal tumours presents anaplastic foci 
(asterisks) and also undifferentiated cells (Eberhart 2011). 
In particular Medulloblastoma has been divided into four different subgroups: Sonic 
Hedgehog subgroup (Shh) in which the Sonic Hedgehog signalling pathway drives the 
tumourigenesis having high levels of expression of MYCN; Wnt subgroup characterised 
by somatic mutations of CTNNB1 encoding β-catenin; Group 3 and Group 4 have been 
separated by transcriptional profile, which is for these two groups the gold standard. 
Moreover, while in Group 3 tumours present frequent amplification of MYC Group 4 
tumours have low expression of both MYC and MYCN (Taylor, Northcott et al. 2012). 
New studies show that SMARCB1-deficiency is not the only biomarker we should use to 
classify Rhabdoid Tumours and Atypical Teratoid Rhabdoid Tumours. In particular, 
despite the majority of malignancies presenting homozygous deletion or point mutations 
associated with loss of heterozygosity (LOH) or double point mutations of the 
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SMARCB1 gene, rare cases of missense mutation which do affect just the protein 
function have been found. Moreover, immunohistochemistry alone is not accurate to 
detect those tumours which have low numbers of Rhabdoid cells. In addition other 
SMARCB1-deficient tumours with a similar location (Chorious Plexus Carcinoma and 
PNET) of Atypical Teratoid Rhabdoid Tumours have been observed (Figure 1.10) 
 
 
Figure 1.10 HES (A-C) and anti-SMARCB1 (B-D) Immunohistochemical 
staIning of SMARCB1 negative tumours non compatible with Rhabdoid 
morphology. A-B) PNET tumours show typical rosette like structures 
(arrows) and negativity for anti-SMARCB1; C-D) Choroid plexus 
carcinomas reveal positivity in epithelial structures (arrows) and negativity 
for anti-hSNF5/SMARCB1. (Bourdeaut, Freneaux et al. 2007).  
 
Although SMARCB1-negative tumours present morphology incompatible with Atypical 
Teratoid Rhabdoid Tumours these malignancies have similar poor outcome and are 
common in children and infants (Figure 1.11) (Bourdeaut, Freneaux et al. 2007).  
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Figure 1.11 Age at diagnosis of patient with SMARCB1 negative 
malignancies. The black columns represent tumours with histological 
features not compatible with Rhabdoid Tumours (Bourdeaut, Freneaux et al. 
2007) 
 
With the application of genetic screening it has become clear that histology alone is 
inadequate for the diagnosis and classification for CNS tumours. WHO histological 
classification must been supplemented with genetic analysis that clarifies the molecular 
difference between these tumours.  
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 Epigenetic changes in cancer 1.2
Epigenetic dysregulation plays an essential role in cancer development as well as 
genetic alterations. Disruption of the epigenetic mechanisms primarily leads to changes 
in gene expression without alteration in DNA sequence. Alteration in the epigenetic 
machinery have been attributed to changes in chromatin organisation including DNA 
methylation, histone modification, nucleosome remodelling and non-coding regulatory 
RNAs (Figure 1.12) (Jones and Baylin 2002, Herman and Baylin 2003, Portela and 
Esteller 2010, Sharma, Kelly et al. 2010). 
 
Figure 1.12 The coding and structural mechanism of chromatin. DNA 
methylation and covalent histones modifications and chromatin remodeller 
contribute to nucleosomal remodelling, allowing gene transcription (2008). 
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Genetic and epigenetic factors are closely associated, as epigenetic marks and DNA 
modifications are the direct consequence of interactions between epigenetic modifiers 
and DNA. Mutation, deletion or the altered expression of one of these epigenetic 
modifiers can significantly disarrange the epigenetic apparatus and lead to tumour 
evolution (Esteller 2008). Contrarily, a subset of aggressive malignancies presents a 
strong genomic stability (like Rhabdoid Tumours) suggesting the involvement of 
epigenetic alterations in oncogenesis (McKenna, Sansam et al. 2008, McKenna, Tamayo 
et al. 2012). 
 
 DNA methylation  1.2.1
DNA methylation is a chemical modification of the DNA structure that occurs at the 
cytosine residues in CpG dinucleotide. The cytosine is altered by a family of DNA 
methyltransferase enzymes (DNMTs) converted to 5-methylcytosine by addition of a 
methyl group. CpG dinucleotides are usually located in short CpG rich DNA portion 
called CpG Islands or in regions with highly repetitive sequence (Bogdanovic and 
Veenstra 2009).  
In normal mammalian cells CpG islands are sited in the gene promoters (60%) or in the 
gene body (Figure 1.13A) (Wang and Leung 2004). Those that occupy promoter regions 
are usually unmethylated, while those located in the repetitive genomic region are 
heavily methylated. CpG island promoters show an unmethylated profile especially 
during development and in undifferentiated tissue (Tsai and Baylin 2011). In contrast 
hyper-methylation in the repetitive genomic fractions prevents chromosomal instability 
silencing non coding DNA and Transposable elements (TEs) (Figure 1.13B) (Suzuki 
and Bird 2008)  
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Figure 1.13 Schematic representation of the mammalian DNA methylation 
mechanism. A) DNA regions characterised by CpG rich portion. CpG island 
(CGI) promoters, CGI shores (up to 2 kb away from promoters), orphan 
CGIs and intron–exon. (B) DNA methylation and gene transcription 
(me=methylation; ON=activation of gene expression; OFF= gene 
repression. Gene activation is generally promoted by unmethylated CpG 
islands in the promoter region, associated with methylation in the gene body 
(left). Methylation of the CpG island on the promoters and consequent 
demethylation in the body gene is primarily correlated with gene repression 
(right) (Ndlovu, Denis et al. 2011). 
 
Abnormality of the methylation machinery is frequent in cancer cells. In particular, gain 
of methylation at promoter genes has been found to affect very well documented tumour 
suppressors (Baylin and Herman 2000), causing transcriptional repression and loss of 
gene function. Genes such as BRCA1/2, PTEN and RB have been found to be 
hypermethylated and therefore down regulated, leading to a dysregulation of the cell 
cycle control and DNA repair; this tumourigenic mechanism induces tumourigenesis in 
a similar way when the same genes have been deleted or mutated (Yoo and Jones 2006). 
Moreover, changes in promoter methylation of DNA-repair genes such as MGMT make 
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cells more susceptible to mutation of oncogenes such as TP53 and KRAS, as result of 
genetic instability (Baylin and Jones 2011). 
Loss of methylation seems a less frequent event than hypermethylation, however it is 
strongly associated with early carcinogenesis and tumour progression in chronic 
myeloid leukaemia, cervical tumours and hepatocellular carcinoma (Ehrlich 2009). 
Demethylation causes genomic instability and therefore tumourigenesis mainly by 
promoting chromosomal rearrangement. For example, hypomethylation at the 
retrotransposon level is responsible for their activation and eventually promotes their 
displacement to other regions of the genome (Eden, Gaudet et al. 2003, Howard, Eiges 
et al. 2008). In addition, loss as well as gain of methylation causes activation of genes 
promoting cell growth (example R-ras in gastric samples) and loss of imprinting (IGF2 
in Wilms’ tumours) (Sharma, Kelly et al. 2010). 
Methylation plays a critical role in carcinogenesis throughout the activation or 
inhibition of delicate mechanisms that regulate gene expression. Genomic instability 
and epigenomic modification are strictly connected and the deregulations of these 
mechanisms lead to tumourigenesis. 
 
 Changes in histone modification  1.2.2
The nucleosome plays an important role in chromatin organization. It is assembled in an 
octameric structure around which 147 pairs of DNA are tightly wrapped. The protein 
cores are composed of two copies each of histones H2A, H2B, H3 and H4, which are 
structurally high conserved (Figure 1.14). Modulation of chromatin dynamics is made 
possible by specific modification of the histones and in particular by alternating its 
charge or recruiting other proteins throughout selective recognition. 
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Figure 1.14 Structure of a nucleosome: DNA wound around a histone 
core. (Tsankova, Renthal et al. 2007) 
 
Histone proteins are characterised by highly basic histone amino (N)-terminal tails, 
which can be methylated, acetylated, ubiquitylated and phosphorylated following post-
transcriptional covalent modification (Figure 1.15). Histone modifications are 
controlled by enzymes dedicated to introducing or removing acetyl groups (such as 
histone acetyltransferases -HATs and deacetylase - HDACs) or methyl groups (such as 
methyltransferases- HMTs and demethylases - HDMs). Histone modification is also 
driven by Polycomb group proteins (PcGs) and trithorax group proteins (TrxGs). These 
modifying complexes and the resulting histone conversions play a key role in cellular 
processes such as transcription, DNA replication and repair by either repressing or 
activating gene expression.  
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Figure 1.15 Most common histone modifications, including acetylation, 
methylation and phosphorylation at several amino acid residues. K= lysine 
residue; S= serine residue. Acetylation is promoted by histone 
acetyltransferases (HATs) and reversed by histone deacetylases (HDACs); 
methylation is maintained by histone methyltransferases (HMTs) and 
reversed by histone demethylases (HDMs); and phosphorylation is catalysed 
by protein kinases (PK) and reversed by protein phosphatases (PP) 
(Tsankova, Renthal et al. 2007).  
 
The two most common post-translational modifications are acetylation and methylation 
of histone lysine residues, which are involved in the transcriptional mechanisms of 
activation of euchromatic state (Jones and Baylin, 2002; Jones and Baylin, 2007; 
Blackledge and Klose, 2011; Poetsch and Plass, 2011). In particular these histone 
modifications make DNA accessible to the transcription machinery and other DNA 
binding proteins, changing the tightly compacted nucleosomes DNA conformation 
(heterochromatin) into a more relaxed state (euchromatin) (Jones and Baylin, 2002). 
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In somatic cells the majority of genes present unmethylated CpG islands at their 
promoters and possibly enhancers; almost 60% of the human genes have nucleosome-
depleted regions (NDRs) at the transcriptional start site (TSS). The nucleosomes located 
nearby NDRs present trimethylation of lysine 4 and 36 of histone 3 (H3K4me3 and 
H3K36me3) mediated by trithorax group proteins (TrxGs) and acetylation of key 
lysines of H3 and H4; also they are associated with the histone variant, H2.AZ, which 
destabilises the nucleosome structures and promotes initiation of transcription (Figure 
1.16). Downstream of the TSS, in the repetitive elements and in gene bodies the DNA 
structure is predominantly methylated and therefore inactive. Promoters are silenced not 
just through methylation, but also by polycomb group proteins (PcGs). In eukaryotic 
cells, the complex PRC2 mediates trimethylation of lysine 27 of histone 3 (H3K27me3), 
which inhibits transcriptional elongation by ubiquitylation and chromatin compaction 
by recruitment of the complex PRC1 (Muller and Verrijzer 2009); (Stock et al.2007) 
(Eskeland et al., 2010). 
PcGs and TrxGs interactions are essential in cellular memory system, stem cell renewal, 
as well as cell homeostasis. Genetic lesions that cause gain of PcGs and loss of TrxG 
expression has been linked to cancer predisposition by alterations in gene expression 
level, as well as chromosomal deletion, amplification or translocation (Mills 2010). It is 
evident that mutations of these enzyme families cause aberrant post-translational histone 
modifications, thus affecting chromatin dynamics and access to coding, promoter and 
non-promoter sequences. These enzymes have been often mutated in cancer cells, 
affecting the delicate transcription machinery and therefore leading to aberrant gene 
expression. For example, the HATs family are often mutated in colon, uterine, lung 
tumours and leukaemia (Esteller 2007). Mutation of HDACs has been observed in 
breast, lung, prostate, gastric and colorectal cancer. Also HMT and HDMC somatic and 
germline mutation have been reported in a variety of malignancies (Miremadi, 
Oestergaard et al. 2007). 
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Figure 1.16 Model of histone modifications in normal human cells. At the 
top of the figure: silent genes (red X over the transcriptional start site) 
present promoter region occupied by a Polycomb group complex 
(represented by a red oval) responsible for repressive histone modification 
such as trimethylation of lysine 27 on histone 3 (H3K27me3). At the bottom 
of the figure: genes with fully active transcription state have unmethylated 
CpG dinucleotides islands within the promoter region (blue pale circles), 
nucleosomes positioned over the transcriptional start sites and heavily 
methylated regions upstream of the promoter (red circle); the permissive 
state is also characterised by active histone H3 lysine 4 and lysine 36 
trimethylation (H3K4me3 and H3K36me) and by histones H3 and H4 
acetylated at key lysines.  
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 Chromatin remodelling complexes 1.2.3
Nucleosome organisation is a critical process in the epigenetic regulation of gene 
expression. The nucleosome occupancy is regulated by chromatin remodelling 
complexes in an ATP-dependent manner. Chromatin remodelling complexes modulate 
DNA accessibility via two major mechanisms. The first is responsible for transcriptional 
activation, by the translocation of the nucleosome along the DNA; the second promotes 
DNA repair, by dimer replacement (Figure 1.17).  
Mammalian ATPase chromatin-remodellers have been divided into four main families: 
the NuRD (nucleosome remodelling and deacetylation)/Mi-2/CHD (chromo-domain, 
helicase, DNA binding) family, INO80 (inositol requiring 80) family 8 and 11, the 
SWI/SNF (switching defective/sucrose non-fermenting) family and the ISWI (imitation 
SWI) family. These complexes present similar ATPase domains but different chromatin 
interacting domains (chromo, bromo and SANT domain respectively), suggesting a 
specialised and distinct role in chromatin remodelling (Boyer, Latek et al. 2004, Ho and 
Crabtree 2010). In particular, NuRD/Mi-2/CHD family are correlated with 
transcriptional repression and activation of rRNA in the nucleus (Hsu, Lee et al. 2012, 
Xie, Ling et al. 2012); instead INO80 remodelling complexes activate and repress genes 
implicated in DNA damage (Van Attikum, Fritsch et al. 2004). The primary function of 
SWI/SNF and ISW remodelling complexes is to re-organise the nucleosome. However 
while SWI/SNF complexes promote accessibility for transcription-factor binding and 
gene activation (Reisman, Glaros et al. 2009, Ronan, Wu et al. 2013), ISW types induce 
transcriptional repression, activation and elongation (Corona and Tamkun 2004). 
 26 
 
 
Figure 1.17 Mechanism of transcription activation driven by chromatin 
remodelling complexes. Remodelling proteins bind to the chromatin using 
the energy of ATP hydrolysis. The disaggregation of the nucleosome allows 
the transcription factors to bind and begin transcription.  
 
Dysregulation of ATPase chromatin remodelling complexes results in tumour 
development and progression. CHD5 subunit of the NuRD/Mi-2/CHD complexes have 
been found deleted in Medulloblastoma (White, Thompson et al. 2005), acute 
myelogenous leukaemia (AML), chronic myelogenous leukaemia (CML), non-
Hodgkin’s lymphoma, colon cancer , cervix cancer and breast cancer (Bagchi, 
Papazoglu et al. 2007), indicating a role as tumour suppressor gene. NuRD/Mi-2/CHD 
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subunit-MTA1 (metastasis –associated gene 1) has been also reported as highly 
expressed in breast, oesophageal, colorectal and gastric carcinomas (Bowen, Fujita et al. 
2004). Several SWI/SNF subunits also are found mutated or deleted in a variety of 
malignancies. SNF5 subunits undergo a biallelic deletion in Rhabdoid Tumours 
(Sevenet, Sheridan et al. 1999), renal carcinomas and melanomas (Sevenet, Lellouch-
Tubiana et al. 1999, Lin, Wong et al. 2009) and mutations in ARID1A/ BAF250a have 
been significantly associated with ER-/PR-/HER2- breast cancers (Zhang, Zhang et al. 
2012). In addition, SMARCA4 ATPase subunit mutations have been identified in lung, 
Medulloblastoma, Rhabdoid and prostate cancer (Wilson and Roberts 2011). 
Reorganisation of the chromatin structure, as well as histone modification regulates a 
wide range of cellular processes. In particular, ATPase chromatin remodelling 
complexes regulate transcriptional events, DNA-damage response, DNA replication and 
cell cycle progression. The mutation of even one subunit of these complexes results in 
an altered chromatin structure that can initiate tumourigenesis. Despite the evidence 
implicating ATPase remodelling complexes in tumour development, its role in 
regulating genome-wide epigenetic regulation still remains to be explained.  
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 SWI/SNF  complexes 1.3
The SMARCB1 gene encodes SMARCB1 protein which is part of the core of the 
SWI/SNF chromatin remodelling complex; a modulator of the chromatin structure. The 
ATP-dependent SWI/SNF complex plays an important role in the remodelling of DNA 
in order to allow the activation or repression of genes (Utley, Cote et al. 1997) 
In mammals the SWI/SNF complexes are evolutionarily conserved and present in 
diverse isoforms, with different biochemical functions, each of them are formed of 8-10 
subunits, including either Brahma (BRM) or Brahma-related gene 1 (SMARCA4), 
which constitute the ATPase core (Wang, Cote et al. 1996). 
The action of the SWI/SNF complex on chromatin remodelling is made possible by the 
translocation of the nucleosome along the DNA in cis. This causes the DNA target sites 
which were previously occluded by the histone octamer to become exposed, and allows 
the progression of other nuclear processes (Kingston and Narlikar 1999).  
Although the mechanism by which the SWI/SNF complex acts in the remodelling of the 
chromatin structure is not yet fully explained, two different theories have been 
proposed. One theory hypothesises that the SWI/SNF complex alters the structure of the 
DNA using torsional force, by the interaction on the surface of the nucleosome histone 
core. This torsion results in an alteration of the DNA twist on the surface of the 
nucleosome allowing the propagation of this twist over the surface of a nucleosome. 
This mechanism is often referred to as “twist defect diffusion” (Flaus and Owen-
Hughes, 2001). A second theory was prompted by the discovery that SWI/SNF 
complexes are able to modify the chromatin structure by interacting directly with the 
surface of the histone octamer (Saha, Wittmeyer et al. 2005). The dissociation of the 
DNA allows the SWI/SNF complex to form a loop of DNA extending out from the 
nucleosome. It was found that the loops are able to diffuse into the zones next to the 
core of the histone octamer, shifting the loop in the DNA strand from 5’ to 3’, like the 
RNA polymerases (Figure 1.18) (Halliday, Bock et al. 2009). Nowadays this Bulge 
theory is the most favoured model because large impediments to DNA twisting (hairpin 
crosslinks), do not prevent nucleosome sliding. The possibility of the SWI/SNF 
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complex to act on the DNA in the presence of hairpins indicates that that nucleosome 
sliding does not principally occur following a twisting-diffusion mechanism. In fact the 
DNA orientation, during the process, does not change: it maintains the same rotational 
orientation to the histone surface and it appears partially dissociated from the 
nucleosome (Aoyagi and Hayes 2002). 
 
 
Figure 1.18: Scheme of the bulge mechanism. The DNA is wrapped around the 
core histone protein octamer. The SWI/SNF complex binds to DNA in the weak 
association between DNA and histone. The SWI/SNF complex forms a loop of DNA of 
about 52 base pairs. The loop of DNA propagates around the core histone octamer and 
then released.(Zofall, Persinger et al. 2006) 
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 Role of SWI/SNF complexes in transcriptional regulation  1.3.1
Yeast studies indicate that SWI/SNF complexes regulate approximately 5% of yeast 
genes (Sudarsanam, Cao et al. 1999). In human cells the SWI/SNF is present at different 
SWI/SNF-like complexes and this suggests that in humans its gene regulatory function 
is even more elaborate. Generally SWI/SNF complexes have a role in cell 
differentiation (Gresh, Bourachot et al. 2005), proliferation (Hah, Kolkman et al. 2010), 
neural development (Yoo and Crabtree 2009, Weinberg, Flames et al. 2013) and 
malignant processes. 
In eukaryote cells this process is driven by a very complex mechanism, mainly resulting 
from condensation and relaxation of the chromatin. SWI/SNF complexes play an 
important role in the dynamic regulation of chromatin structure and consequentially in 
gene regulation mainly by manipulation of the nucleosome structure (Kadam and 
Emerson 2003). SWI/SNF complexes drive both repression and activation of lineage 
and tissue specific genes (Lessard 2007, Kaeser, Aslanian et al. 2008). CD4 and CD8 
are both silenced and activated by SMARCA4 and BAF57 during T lymphocyte 
development (Chi 2002). In embryonic stem cells SMARCA4 not only represses 
transcription of genes associated with differentiation, but also trigger genes of 
pluripotency (Ho 2009, Ho and Crabtree 2010).  
SWI/SNF complexes are also recruited to individual genes regulating their expression 
and therefore transcription specificity. Selective recruitment of SWI/SNF to particular 
promoters requires interactions with specific activator or repressive factors (Ahringer 
2000, Sudarsanam and Winston 2000, Kadam and Emerson 2003). Euskirchen et al 
have tried, using ChIP-seq, to provide a more exhaustive mapping of SWI/SNF binding 
in Hela cells. In particular, they discovered that the majority of SWI/SNF binding sites 
are located near protein coding genes (±2.5 kb), which confirms its important role in 
gene expression. ChIP-seq demonstrated that SMARCB1, SMARCA4, BAF155 and 
BAF170 frequently bind transcription start sites (TSSs), enhancers, CTCF regions and 
many regions occupied by RNA Polymerase II and III (Pol II and Pol III) (Euskirchen, 
Auerbach et al. 2011). This intermediate interaction could facilitate subsequent step 
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activation, such as recruitment of TATA-binding protein (TBP) at core promoter and 
transcriptional elongation (Ryan, Jones et al. 1998) (Figure 1.19). 
 
 
Figure 1.19 SWI/SNF complexes facilitate activation of gene expression by 
interaction with TATA-binding proteins. Upstream activators (green and 
purple) recruit RNA polymerase II (Pol II); subsequently SWI/SNF complex 
is recruited, disrupting nucleosome structure. This facilitates the binding of 
TATA-binding proteins (TBP) to the TATA box in promoter region.  
 
Studies of the contribution of SWI/SNF to gene expression reveal that SMARCA4 and 
SMARCB1 subunits are necessary and their lack causes a concomitant decrease of RNA 
levels (Euskirchen, Auerbach et al. 2011, Euskirchen, Auerbach et al. 2012). 
SMARCA4 regulates the access of STAT proteins to DNA. In particular, in HepG2 
cells SMARCA4 binds STAT3 to the cdkn1A promoter, causing acetylation of histone 
H3 (Giraud, Hurlstone et al. 2004). Moreover SMARCA4 is recruited by STAT3 at the 
IRF1 promoter, indicating a direct involvement of SMARCA4 in the IL-6 pathway (Ni 
and Bremner 2007). SMARCA4 also plays an important role in pluripotency and self-
renewal in stem cells and in particular is involved in blastocyst development occupying 
pluripotency genes, lineage-specific genes, and epigenetic modifier genes (Kidder, 
Palmer et al. 2009). Interestingly SMARCA4 is required at the promoter of genes that 
are essential for pluripotency in the stem cell, such as Oct4, Sox2 and Sall4, suggesting 
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that SMARCA4 is directly involved during preimplantation development but only after 
the establishment of pluripotency (Kidder, Palmer et al. 2009). SMARCB1 acts as 
transcriptional cofactor and is essential for recruitment of SMARCA4 at the promoter 
region of genes such as CDKN2A, CDKN1A and Cdk (Betz, Strobeck et al. 2002, Chai, 
Charboneau et al. 2005). Although SMARCB1 is mainly involved in gene activation, it 
also contributes to the mechanism of repression; in particular SMARCB1 represses 
Cyclin D1 and Aurora A, in a histone deacetylase dependent manner by recruitment of 
HDAC1 (Zhang, Davies et al. 2002, Lee, Cimica et al. 2011). 
These results evidence the recruitment of SWI/SNF complex promoted by SMARCB1 to 
induce gene expression. However SMARCB1’s role in gene expression remains still 
unclear; in particular how SMARCB1 loss affects the SWI/SNF complex and therefore 
gene expression. 
1.3.1.1  The critical role of the SWI/SNF complex in cancer development 
The SWI/SNF complex regulates a variety of biological activities, such as DNA 
methylation, repair, recombination and replication (Narlikar, Fan et al. 2002). Loss of 
function can easily contribute to malignant formation (Bultman, Gebuhr et al. 2000, 
Glaros, Cirrincione et al. 2007). Moreover, it has been recently discovered that the 
SWI/SNF complex interacts with proteins produced by oncogenes (Figure 1.20), such as 
c-Jun (Ito, Yamauchi et al. 2001), MYC (Cheng, Davies et al. 1999) and MLL (Zuqin et 
al, 2003) and also with tumour suppressor proteins such as pRb (Dunaief, Strober et al. 
1994, Trouche, Le Chalony et al. 1997, Strobeck, Knudsen et al. 2000) TP53 (Lee, Kim 
et al. 2002) (Jia, Osada et al. 1997) BRCA1 (Jia, Osada et al. 1997, Biegel 1999) and 
AKT (Forest, David et al. 2012). 
The SWI/SNF complex also influences cellular differentiation and proliferation, 
controlling the cell-cycle using two different pathways. Its ATPase subunits BRM and in 
particular SMARCA4 are recruited by the Rb protein, inducing growth arrest at G1-S 
(Trouche, Le Chalony et al. 1997, Strobeck, Knudsen et al. 2000). Dominant negative 
mutant SMARCA4 cell lines show resistance to growth arrest, caused by a disruption of 
the RB pathway: SMARCA4 is necessary to mediate RB signalling to Cyclin A/Cdk2, 
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resulting in G1 arrest (Strobeck, Knudsen et al. 2000) Moreover, Rb interacts with 
histone deacetylase (HDAC) and the hSWI/SNF, resulting in an inhibition of 
transcription of genes coding for cyclins E and A and in the arrest at the G1 phase of the 
cell cycle (Zhang, Davies et al. 2002). 
 
Figure 1.20: Structure of the SWI/SNF complex figure shows direct interaction between 
SMARCB1 and SMARCA4/BRM with tumour suppressor proteins (red), oncogenes 
(blue) and AKT.  
 
Experiments by Lee et al suggest that the SWI/SNF complex is necessary for proper 
induction of the p53 pathway (Lee, Kim et al. 2002). For instance, studies of dominant 
negative mutations of SMARCA4 and SMARCB1 null cell lines show a decrease in the 
expression of p53, preceded by a down regulation of p21. This complex plays an 
important function in DNA repair, too. Also it was discovered that, following damage to 
DNA, the SWI/SNF complex is recruited in order to facilitate the nucleotide excision 
repair and the double-stranded break repair (Halliday, Bock et al. 2009).  
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  SWI/SNF subunits and tumourigenesis  1.3.2
1.3.2.1 SWI/SNF subunits are frequently mutated in a variety of tumours 
The increased study of these complexes has disclosed an extreme polymorphic structure 
with specialised function in specific tissues (Wang, Cote et al. 1996). The discovery of 
SMARCB1 biallelic mutation in Rhabdoid Tumours (Versteege, Sevenet et al. 1998, 
Biegel 1999) has identified that SWI/SNF complexes acting as tumour suppressors. 
Kadoch and colleges showed that in human tumours SWI/SNF subunits are more 
frequently mutated than all other chromatin remodelling complexes, suggesting an 
important role in tumourigenesis (Kadoch, Hargreaves et al. 2013). 
Recent genome wide sequencing showed that other SWI/SNF subunits are implicated in 
tumourigenesis and now it is recognised that 20% of all human tumours contain 
mutation in at least one of the subunits (Figure 1.21) (Kadoch, Hargreaves et al. 2013). 
Interestingly, SMARCB1 is not one of the most mutated subunit. Nevertheless a wide 
variety of solid tumours show mutation of SWI/SNF subunit genes ARID1A and 
SMARCA4, with a high incidence in aggressive malignancies such as clear cell ovarian 
cancer, gastric cancer, Medulloblastoma and melanoma (Biegel, Busse et al. 2014). 
 Few malignancies show a complete loss of heterozygosity (LOH) of one of the 
SWI/SNF gene subunits. In fact 50% of the cases present multiple mutations at the 
SWI/SNF subunits, such as missense mutation or gene fusion in a variety of different 
tumours (carcinoma renal, clear-cell ovarian, colorectal carcinoma, gastric cancer 
melanoma lung cancer, Glioma, breast cancer) (Biegel, Busse et al. 2014). The presence 
of other mutations in more than one SWI/SNF subunit might disrupt the complex 
functionality, as results resulting of compound heterozygosity (Kadoch, Hargreaves et 
al. 2013). 
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Figure 1.21 Multiple mutations of the mammalian SWI/SNF subunits can 
occur in human cancers. Frequency of patients harbouring a mutation is 
presented according to a graded colour scale: in dark blue is indicated 
frequency of patients harbouring a mutation equal or greater than 10%, in 
pale yellow no mutation detected. A variety of aggressive malignancies have 
mutation of ARID1A and SMARCA4 subunits genes. 
 
SWI/SNF complexes have a highly specialised activity to unwrap the chromatin, 
allowing gene regulation. The selectivity of the SWI/SNF complex is due to their 
extremely complicated structures, whereby every subunit has a synchronous but 
specialised role. Co-occurring mutations in multiple subunits or a complete deletion of 
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just one component of these complexes disrupts a delicate balance and finally leads to 
tumourigenesis.  
 
1.3.2.2 The ATPase subunits of SWI/SNF complex: role in tumourigenesis 
SWI/SNF is characterised by the presence of two alternative ATPse subunits, which are 
able to hydrolyse ATP to ADP namely SMARCA4 and BRM. These subunits do not co-
exist in the same complexes and play differential roles in cellular proliferation and 
differentiation (Phelan et al, 2009). Although mammalian SMARCA4 and BRM differ 
only in the first 60 amino-acids sharing an approximate identity of 75% at the protein 
level, they have different biological functions in animal models (Muchardt and Yaniv 
1999). In particular, in mice SMARCA4 knock-out leads to embryonic death at the peri-
implantation stage (Bultman, Gebuhr et al. 2000). Other experiments show that tumour 
cells with a deletion of BRM are able to activate alternative mechanisms for controlling 
the cell cycle (Medina and Sanchez-Cespedes 2008). However there is the possibility 
that SMARCA4 and BRM may compensate for each other in some cases (Coisy-Quivy, 
Disson et al. 2006). BRM null mice are characterised by a level of expression of 
SMARCA4 threefold higher than the wild type BRM animal (Reyes, Barra et al. 1998).  
It was demonstrated that a loss of BRM causes a modification to the cell cycle that not 
even over-expression of SMARCA4 can compensate for. In particular, in 3T3 fibroblasts 
lacking BRM a delay of S phase, an increase in the duration of the M phase and frequent 
faulty chromosome segregation events in anaphase were observed (Coisy-Quivy, Disson 
et al. 2006). Moreover studies in BRM null mice reveal that they are predisposed to 
develop tumours; knock-out BRM mice present about 10 times more lung tumours 
larger than that of the wild type models. However, the absence of BRM does not modify 
the penetrance of tumours following SMARCA4 alteration, but may change the types of 
tumour that occur. These data suggest that BRM and SMARCA4 could be involved in 
different stages of tumourigenesis, specifically tumour Initiation and tumour 
progression respectively (Glaros, Cirrincione et al. 2007). 
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Analysis in a number of lung cancer and other cell lines reveal that expression of BRM 
and SMARCA4 is lost in about 30-40% of cases however the loss of both subunits has a 
low frequency (Reisman, Glaros et al. 2009). Decristofaro et al, also report the loss of 
both SMARCA4 and BRM protein expression in 10% of established tumour cell lines 
(Adenocarcinoma of Kidney Adrenal Cortex, Pancreas, Ovary, Prostate and colon; 
Breast Tumour; Rhabdoid and Medulloblastoma) (Decristofaro, Betz et al. 2001). In 
addition, a loss of expression is found in about 15-20% of primary non-small-cell lung 
cancers. In 10-20% of all bladder, colon, breast, melanoma, oesophageal, head/neck, 
pancreas and ovarian cancer immunohistochemical staIning has demonstrated a loss of 
expression of both SMARCA4 and BRM (Reisman, Glaros et al. 2009). 
 
1.3.2.3 The role of SMARCB1 in Malignant Rhabdoid Tumours  
The role of SMARCB1 (also known as BAF47 and hSNF5) in Malignant Rhabdoid 
tumours tumourigenesis was recently discovered (Versteege et al, 1998). Most Atypical 
Teratoid Rhabdoid Tumours tumours have biallelicaly inactivated their SMARCB1 
genes either by deletion of part of or the entire gene or by point mutation. Moreover the 
identification of SMARCB1 germline mutation indicates this gene as a classical tumour 
suppressor gene (Sevenet, Sheridan et al. 1999, Biegel 2006). 
The tumour-suppressing role of SMARCB1 was studied in mice. Homozygous deletion 
of SMARCB1 in mice causes death in the peri-implantation stage of gestation (Guidi, 
Sands et al. 2001). Instead SMARCB1+/- mice develop normally, however 25% of them 
develop Rhabdoid Tumours and undifferentiated sarcomas, with aggressive and 
metastatic characteristics primarily on the head and neck (Klochendler-Yeivin, Fiette et 
al. 2000). In addition, 100% of the conditional SMARCB1 knock-out mouse models 
developed malignancies (mature CD8+T cell lymphoma or Rhabdoid Tumours ) with a 
median onset of only 11 weeks (Figure 1.22) (Roberts, Leroux et al. 2002).  
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Figure 1.22 Survival of SMARCB1 target mice. SMARCB1+/− mice show 
predisposition to develop Rhabdoid Tumours. Mx+ SMARCB1Cond/− mice 
rapidly develop bone marrow and organ failure following injection with 
Polyinosinic–polycytidylic acid (Poly(I)/Poly(C)) and eventually die. 
Overall 90% of the mice die within 3 weeks. Mx+ SMARCB1nv/− mice show 
high tumour penetrance (100%) with average life time of 11 weeks after 
injection with Poly(I)/Poly(C) (Roberts, Leroux et al. 2002). 
 
The accumulation of phosphorylated p53 and increased aberrant mitotic features 
following SMARCB1 inactivation in murine embryonic fibroblasts indicate that 
SMARCB1 has an important role to play in the DNA damage response. 100% of 
SMARCB1+/- p53-/- mice develop tumours within 19 weeks; instead just 28% of the 
SMARCB1 +/- mice develop tumours with a mean latency of 42 weeks (Klochendler-
Yeivin, Picarsky et al. 2006). This indicates a strong genetic interaction between these 
two tumour suppressor genes. 
Vesteege (2002) demonstrated that rexpression of wild type SMARCB1 in Malignant 
Rhabdoid tumours cells leads to the arrest of the cell cycle in G1, blocking entry into 
the S phase. The result of cell cycle arrest is the appearance of flattened cells and the 
activation of senescence-associated protein, down-regulation of E2F (activator of the 
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transcription of cyclins) and of Cyclin D1, activation of Rb and up regulation of 
CDKN1A and CDKN2A (Versteege, Medjkane et al. 2002, Chai, Charboneau et al. 
2005). Interestingly, studies in cell lines lacking pRB function have showed that it is not 
possible for SMARCB1 to arrest the cell cycle in G1 phase. This underlines the 
complementary role of SMARCB1 and pRb in the cell cycle to induce a G1 arrest in 
Malignant Rhabdoid tumours cells (Versteege, Medjkane et al. 2002). Moreover studies 
in SMARCB1 deficient Malignant Rhabdoid tumours cell lines show that the rexpression 
of Rb or CDKN2A induces a cell cycle arrest, indicating that SMARCB1 regulates pRb 
and E2F target genes (Versteege, Sevenet et al. 1998, Versteege, Medjkane et al. 2002) 
SMARCB1 loss directly disrupts SWI/SNF activation of promoter regions of various 
genes involved in different pathways. ChIP assays performed by Zhang et al showed 
that in Rhabdoid MON cells SMARCB1 is directly recruited to the Cyclin D1 promoter, 
and the absence of SMARCB1 causes an increase in binding to the Cyclin D1 promoter 
DNA as observed by CHIP. Interestingly chip assays have indicated that SMARCB1 
does not interact directly with pRb but its activity is linked to the recruiting of CDKN2A 
(Oruetxebarria, Venturini et al. 2004): a SMARCB1 binding site was localised to the 
p16INK4a promoter, suggesting that its presence is correlated with transcriptional 
activation. Expression analysis has also demonstrated that in Rhabdoid cell lines the 
transcription of CDKN1A is correlated with the enforced re-expression of SMARCB1 
(Zhang, Davies et al. 2002, Kang, Cui et al. 2004). Interestingly, SMARCB1 re-
expression not only increases the binding to CDKN2A and CDKN1A promoters, but also 
evicts the polycomb complex silencing proteins such as BMI-1, followed by H3K4 
methylation and H3k27 demethylation (Kia, Gorski et al. 2008, Kuwahara, Charboneau 
et al. 2010, Knutson, Warholic et al. 2013). Recently, chip analysis revealed that in 
Rhabdoid cells both in vitro and in vivo, the loss of SMARCB1 causes an aberrant 
activity of Aurora A: the re-expression of SMARCB1 in Rhabdoid tumour cells causes 
SMARCB1 to bind to the Aurora A promoter sequence, resulting in a down-regulation of 
Aurora A and subsequent changes in cell cycle arrest (Lee, Cimica et al. 2011). 
Despite a number of studies re-expressing SMARCB1 in Rhabdoid cells, the 
mechanisms of tumourigenesis are still poorly understood and results suggest that the 
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role played by this gene is highly complex. In fact, re-expression of SMARCB1 does not 
lead to the same effects on CDKN2A, CDKN2A and Cyclin D1 in all Malignant 
Rhabdoid tumours cell lines (Versteege, Medjkane et al. 2002, Kuwahara, Charboneau 
et al. 2010, Kuwahara, Wei et al. 2013). Moreover, the lack of SMARCB1 subunits in 
SWI/SNF doesn’t compromise the chromatin remodelling activity (Phelan, Sif et al. 
1999), indicating that its abnormal action in Malignant Rhabdoid tumours could be 
caused by an aberrant action of SMARCA4. It was also demonstrated that the 
simultaneous deletion of SMARCA4 and SMARCB1 in mice prevents the development 
of tumour (Wang, Sansam et al. 2009), instead in Malignant Rhabdoid Tumour cells 
knocking out SMARCA4 causes a dramatic growth arrest (Betz, Strobeck et al. 2002, 
Versteege, Medjkane et al. 2002, Zhang, Davies et al. 2002, Doan, Veal et al. 2004).  
 
1.3.2.4 SMARCA4 subunit in SMARCB1 deficient cells: loss of a delicate balance 
This evidence suggests that in Malignant Rhabdoid tumours tumourigenesis may be 
caused not simply by the loss of SMARCB1 gene, but also by an aberrant activity of the 
ATPase subunits of the SWI/SNF complex as result of the SMARCB1 deletion. In fact 
the loss of SMARCB1 may lead to unregulated activity of the SWI/SNF complex that 
may modify the expression of gene normally involved in the senescence and in the 
control of the cell cycle.  
Even without SMARCB1 subunits the SWI/SNF complexes are still capable of 
remodelling chromatin. This is due to the fact that the SWI/SNF complex does not 
require an intact structure: even in the absence of additional subunits SMARCA4, 
BRM, BAF155 and BAF170 are characterised by an activity comparable with that of 
the whole SWI/SNF complex (Phelan et al, 2009). 
Deficiency of SMARCB1 leads to a mis-regulation of the SWI/SNF complex, even if the 
genome-wide consequence of this is still largely unknown. It has been demonstrated 
that the SMARCB1 loss causes a deregulation of the epigenetic transcriptional 
regulatory activities of the SWI/SNF complex and contributes to cancer Initiation. In 
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Malignant Rhabdoid cells tumour development may be caused by an aberrant activity of 
ATPase of the SWI/SNF complex, due to an incorrect expression of the SWI/SNF-
dependent genes (Hasselblatt, Gesk et al. 2011). Moreover, new studies in SMARCB1-
deficient Rhabdoid cell lines have indicated that knock-down of SMARCA4 causes cell 
cycle arrest at G0-G1, ultimately resulting in cell death (Wang, Sansam et al. 2009). 
Similar results have been detected upon the reintroduction of SMARCB1 into Malignant 
Rhabdoid Tumour cells (Betz, Strobeck et al. 2002, Versteege, Medjkane et al. 2002, 
Zhang, Davies et al. 2002). Interestingly, in vivo a suppression of SMARCA4 in 
SMARCB1 deficient mice causes a decrease of tumour development underlining the 
participation of this subunit in carcinogenesis (Wang, Sansam et al. 2009). This suggests 
that in SMARCB1-deficient cell lines an inhibition of the ATPase subunit 
SMARCA4 may be sufficient to inhibit tumour progression. 
 
 Next generation sequencing and array-based analysis 1.4
techniques: new techniques in tumour characterisation 
 
 Next generation sequencing  1.4.1
The introduction of the Maxam-Gilbert method in the 1970s opened the field of 
genomic analysis by DNA sequencing. In 1977 Frederick Sanger developed a more 
accurate method based on the selective incorporation of chain-terminating di-
deoxynucleotides by DNA polymerase during in vitro DNA replication (Sanger, Nicklen 
et al. 1977). The Sanger sequencing method is still used in most medical and research 
laboratories. In 1990 the Human Genome Project (HGP) was launched with the purpose 
of sequencing the entire length of the human genome and identifying and mapping all of 
the genes within it. The study was released in 2003, resulting in high-throughput 
sequencing of 99% of the human euchromatic portion (Schmutz, Wheeler et al. 2004).  
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HGP developed the first generation sequencing method, based on Sanger method. 
Although at the time Sanger sequencing was considered gold standard for nucleotide 
sequencing, this approach showed limitations in accuracy, speed and cost. Over the past 
10 years DNA sequencing methods have improved, resulting in a much cheaper and 
higher throughput alternative to the traditional Sanger sequencing.  
The fast development and wide applications of next-generation sequencing (NGS) 
technologies provide more complete and accurate genomic information. Thus improving 
not just knowledge in translation genomics, but also a better understanding of cancer 
and other complex diseases, leading to improvement of diagnostics, prognostics, and 
therapies (Grada and Weinbrecht 2013). In fact one of the most promising potential 
applications of genome-wide studies is identification of gene signatures that can 
improve not just the clinical parameters but also the understanding of pathways 
involved. In fact NGS have high sensitivity and also give much longer sequences reads 
than other methods.  
 Transcriptome profiling: RNA sequencing 1.4.2
Development of NGS allows more comprehensive studies of all components of the 
genome, including transcriptome, as a complete set of transcripts in a cell. The 
transcriptome is the result of genome expression and consists of all the RNA molecules 
(including mRNAs, non-coding RNAs and small RNAs) produced in a cell or collection 
of cells. Study of the transcriptome is essential to understand the contribution of 
alteration expression of genetic in development and diseases such as cancer (Brown 
2002). In the past few years application of NGS methods, such as RNA-sequencing 
(RNA-seq) in transcriptome analysis has allowed detection of differentially expressed 
genes in disease and even detection of splicing variants gene polymorphism (de 
Magalhaes, Finch et al. 2010, Zhao, Fung-Leung et al. 2014).  
RNA-seq technology has considerable advantages when performing transcriptome 
profiling, detecting novel transcripts, and allele-specific expression and splice junctions. 
In contrast, to older techniques RNA sequencing is a sequence-based and tag-based 
approach to determine directly the cDNA sequence, improving sensitivity to low 
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abundance transcripts (Brown 2002). In particular, species- or transcript-specific probes 
are not used in RNA-Seq providing far more precise gene expression levels. Moreover, 
this approach allows detection of novel transcripts and other changes, such as single 
nucleotide variants, insertions and deletions, gene fusions and novel transcripts (Grada 
and Weinbrecht 2013). 
The most widely used NGS platforms for RNA-seq are SOLiD, Ion Torrent (Life 
Technologies) and HiSeq (Illumina). The platforms differ in their library preparation 
while sample input requirements and the number of cDNA fragments sequenced per run 
are similar. Hiseq and Ion torrent sequence using a “sequencing by synthesis” (SBS) 
approach, which allows base-by-base sequencing; instead SOLiD adopt a “sequencing 
by ligation”, using a DNA ligase (Liu, Li et al. 2012). NGS platforms share a similar 
workflow that involves template preparation, library preparation and amplification 
sequencing and data analysis (Figure 1.23) (Wang, Gerstein et al. 2009). 
High-throughput sequencing of RNA opens the possibility of analysing millions of RNA 
transcripts and isoforms within a single assay. For this reason RNA-seq is becoming 
more appealing to clinical application as diagnostic and prognosis tests (Meldrum, 
Doyle et al. 2011, Van Keuren-Jensen, Keats et al. 2014). At present RNA-seq is 
extensively used in research, especially in understanding the association between 
variations in the transcriptome and tumourigenesis. In-depth quantitative studies in a 
variety of cancers identify novel mutations, disclosing the benefit of this technique in 
disease classification by exome sequencing. Massive parallel sequencing provides in-
depth analysis of the genome, allowing also characterisation of promoter usage, rare 
splicing events, epitranscriptome modifications, allele-specific expression or nonsense-
mediated decay (Wang, Gerstein et al. 2009, Meldrum, Doyle et al. 2011).  
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Figure 1.23 RNA workflow. The samples are prepared by direct 
fragmentation of cDNA or RNA in order to obtain small fragments (200-
500bp). Each cDNA fragments are amplified by PCR and adapters (blue) are 
added to create the RNA-seq library for directional sequencing. Short 
sequence reads are aligned with a genome of reference or a de novo 
assembled transcript; the reads can generally be mapped to four categories: 
exonic, partially overlaps exon, intronic or between genes.  
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 DNA-protein interaction: ChIP sequencing 1.4.3
For years understanding of transcriptional regulation has been based on 
characterisations of genetic modulation of specific genes or gene families. However, the 
observation of changes in gene expression without alteration in DNA sequence has 
revealed the importance of epigenetic mechanisms in gene regulation (Baylin and Jones 
2011). In particular it has become clearer that analysis of the chromatin state and the 
DNA-protein interaction is essential to fully understand transcriptional modulation 
(Park 2009). 
Chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) 
nowadays is the standard technique to investigate and study transcription factor binding, 
histone modifications (Northrup and Zhao 2011). ChIP-Seq is a modification of ChIP-
Chip (hybridization microarray based technique), consisting of a combination of 
chromatin immunoprecipitation and next-generation sequencing of extracted DNA 
fragments (Johnson, Mortazavi et al. 2007, Robertson, Hirst et al. 2007). ChIP-seq 
allows us to assay in vivo protein-DNA binding on a genome scale. In fact, the direct 
sequencing of the DNA fragment results in a higher resolution, the possibility to better 
filter out artefacts and higher coverage than the earlier array methods (Figure 1.24) 
(Johnson, Mortazavi et al. 2007, Park 2009, Ashoor, Hérault et al. 2013).  
ChIP-seq is becoming popular technique, especially after ENCODE project has been 
launched in 2003. This project aims to characterise not only specific DNA-protein and 
RNA interaction sequences, but also those regulatory elements on the DNA responsible 
for gene expression modulation. Moreover, the rapid development of the next 
generation sequencing platform has contributed to make ChIP-seq a more robust 
technique, increasing precision and replicability (Park 2009). 
Recently studies show ChIP-seq approaches provide additional information, 
complementary to those collected by mRNA-level measurements. Combination of data 
between NGS techniques allows a better understanding of mechanisms involved in gene 
expression regulation (Gilchrist, Fargo et al. 2009, Gupta, Wikramasinghe et al. 2010, 
Tummala, Mali et al. 2010, Mokry, Hatzis et al. 2012). In the past few years ChIP-seq 
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has been used widely to characterise genome-wide transcription factor-binding site in a 
variety of tumours. For instance, this technique was applied to breast pathology tissue 
allowing a better definition of the role of epigenetic alterations in breast cancer and 
characterisation of useful biomarkers (Fanelli, Amatori et al. 2010, Ross-Innes, Stark et 
al. 2012). 
 
 
Figure 1.24 ChIP-seq work flow. Proteins are cross-linked to their bound 
DNA by formaldehyde treatment and chromatin is sheared and 
immunoprecipitated with antibody-bound magnetic beads. The 
immunoprecipitated DNA is used to create a next-generation sequencing 
library. Specifically a library is created by addition of single adenosine 
residues, adaptor ligation and PCR with primers compatible with the 
sequencing platform. Following cluster generation, sequencing is performed 
on next-generation sequencing platforms (Kidder, Hu et al. 2011). 
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 Array-based analysis techniques: Methylation array 1.4.4
In the past decade studies on DNA methylation and its implication in human diseases 
have grown dramatically. Alteration of the epigenetic machinery in humans is often 
associated with aberrant methylation, especially resulting in the development and 
progression of cancer. The implication of DNA methylation in regulating gene 
expression has led to a progressive development of commercial epigenetic profiling 
platforms.  
Currently whole genome arrays are available, providing genome-wide epigenetic 
profiling analysis. The most widely used arrays rely on bisulfite conversion to measure 
methylation of CpG dinucleotides. Other options for measuring methylation include, 
whole-genome bisulfite sequencing, restriction enzyme-enriched sequencing, affinity -
enrichment-based sequencing, and locus-specific methylation analysis i.e. through 
bisulfite Sanger sequencing. All of these approaches are based on sodium bisulfite 
conversion, enzyme restriction digestion or affinity enrichment.  
CpG-specific arrays constitute the most widely used technique. In particular, the new 
generation array Infinium Human Methylation 450K BeadChip (Figure 1.25) allows 
coverage of 99% of all NCBI Reference Sequence (RefSeq) and assesses the 
methylation status of more than 480,000 CpG overall. Comparison with previous 
technologies shows that 450K methylation array has higher accuracy and 
reproducibility (Bibikova, Barnes et al. 2011, Sandoval, Heyn et al. 2011). This array is 
currently used in epigenome-wide association studies (EWAS) and in the International 
Cancer Genome Consortium (ICGC) project. 
Currently most of the oncology clinical tests are based on cytogenetic analysis to detect 
genetic aberrations (Cottrell, Al-Kateb et al. 2014). The limited information provided by 
these diagnostic tests has opened a discussion to introduce methylation array-based 
analysis in clinics. In fact, methylation status analysis can disclose candidate biomarkers 
(Lange, Campan et al. 2012, Naumov, Generozov et al. 2013, de Araujo, Marchi et al. 
2014, Karlsson, Jonsson et al. 2014, Klajic, Busato et al. 2014, Li, Li et al. 2014, Yu, 
McIntosh et al. 2014, Zhang, Xing et al. 2014) which can improve the understanding of 
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cancer heterogeneity and mechanisms of drug resistance. Moreover, the development of 
new software for analysis of Infinium Human Methylation 450 BeadChip has improved 
its use, especially for large-scale clinical studies (Wu, Gu et al. 2013).  
 
 
Figure 1.25 Overview of the Infinium Human Methylation 450 BeadChip 
method. DNA is extracted from the sample and bisulfite converted: 
bisulphite converts cytosine residues to uracil, but not 5-methylcytosine 
residues. Bisulfite converted DNA is hybridised onto a Chip and analysed 
using BeadXpress read. The data are analysed using bioinformatics tools. 
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 Summary and Aims 1.5
Atypical Teratoid Rhabdoid Tumours (ATRTs) and Extra Cranial Rhabdoid Tumours 
(ECRT) are rare and aggressive malignancies of the central nervous system (CNS). 
These tumours are most commonly found in infants and toddlers, after the age of 5 
years ATRT and ECRT are a rarity. Cytogenetic analysis has revealed deletions or 
alterations at chromosome locus 22q11, which cause inactivation of SMARCB1. These 
mutation often are acquired de novo, however a subset of patients have been show a 
germ line mosaicism.  
Due to the young age of the patients and the rarity of these malignancies there is no 
defined standard of care, and treatment options have to be tailored to a child's age and 
metastatic status. Generally treatment involves a combination of therapies including 
surgery, radiation and high dose chemotherapy. Outcome varies on the basis of age of 
patient, mutation type and tumour staging. In particular, patients with germ line 
mutation, younger than 1 year or with metastatic disease have very poor prognosis. 
SMARCB1 has been indicated as a tumour suppressor gene and its role in 
tumourigenesis has been explored by studies performed in Rhabdoid cell lines. 
SMARCB1 suppression is directly linked to disruption of cell cycle by deregulation of 
the CDKN2A/ CDK4/Cyclin D1/Rb/E2F pathway. Furthermore, the re-introduction of 
SMARCB1 in Rhabdoid cells is sufficient to induce cell cycle arrest in G0-G1 phase. In 
vivo heterozygous SMARCB1 knock-out and conditional mice show predisposition to 
cancer, developing frequent malignancy in the head, neck, the spine and occasionally 
kidney. Interestingly SMARCB1+/_ are more prone to develop highly aggressive and 
frequently metastatic tumours than the control mice. The remarkable genomic stability 
i.e. no other recurrent mutations are found Malignant Rhaboid Tumours and Atypical 
Teratoid Rhabdoid Tumours suggests that SMARCB1 deletion is the primary gene for 
Rhabdoid tumour development. However the discovery of SMARCA4 mutation in a 
number of Rhabdoid patients and SMARCB1 mutation in other CNS tumours indicates a 
more complex scenario.  
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SMARCB1 encodes for SMARCB1 protein which is part of the SWI/SNF chromatin 
remodelling complexes. SWI/SNF complexes play an important role in epigenetic 
mechanism, regulating gene expression without alteration in DNA sequence. In fact 
SWI/SNF complexes directly remodel chromatin structure and recruit a variety of 
transcription factors, co-activators and co-repressors, modulating gene expression and 
driving DNA repair. SWI/SNF complexes are important in the differentiation of 
mammalian tissues (for example neuronal tissue), cell differentiation and in 
tumourigenesis. The discovery of mutation of a variety of subunits has disclosed the 
involvement of the SWI/SNF complexes in tumour development. In fact, not only 
SMARCB1 mutation but also SMARCA4, ARID1A and ARID1B have been found 
mutated in a variety of very aggressive malignancies.  
Despite the relative simple biology (Jackson, Sievert et al. 2009, Lee, Stewart et al. 
2012), there is not an effective cure for Malignant Rhabdoid tumours and Atypical 
Teratoid Rhabdoid Tumours, mainly because their rarity. Since the discovery of multiple 
mutations of the SWI/SNF complexes in a variety of tumours, the interest in these 
malignancies has been raised. Recently Genome-wide approaches (such as SNP-array) 
have been used to profile Malignant Rhabdoid tumours and Atypical Teratoid Rhabdoid 
Tumour patients, although lack of patient material and the cost of these techniques have 
limited their application. Recently microarray profiling of MRT and ATRT patients 
shows a common gene signature regardless the location when compared with other 
paediatric tumours (Birks, Donson et al. 2013). Cross-referencing of genome-wide 
profiling between patients and Rhabdoid cell line identifies up regulation of multiple 
genes such as GLI1 (responsible for activation of the Hedgehog-GLI pathway) end 
EZH2 (associated with tumour progression and poor prognosis) and down regulation of 
IFN-responsive genes and Aurora A (both regulate mitotic spindle checkpoint) (Jagani, 
Mora-Blanco et al. 2010). However Malignant Rhabdoid Tumours and Atypical 
Teratoid Rhabdoid Tumours display different gene signatures, implying that SMARCB1 
modulates different factor in base of the tissue. 
More recently, high-throughput sequencing of RNA and methylation profiling has been 
extensively used to identify the epigenetic association with gene expression in 
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tumourigenesis. This has allowed cancer researchers to characterise tumourigenic events 
and finally to identify specific genes and pathways involved in tumour development. At 
this time there are no published data available for RNA-seq or methylation profiling of 
Malignant Rhabdoid tumours / Atypical Teratoid Rhabdoid Tumours patient or cell 
lines. Application of NGS and DNA methylation microarrays in studying Rhabdoid 
tumourigenesis would improve the knowledge of the disease, permitting a better 
stratification of patients and better therapies.  
This project aims to discover the precise mechanism of action of SWI/SNF complexes 
in Rhabdoid Tumours and the effect of SMARCB1 loss on function, with the following 
specific aims. 
1. To understand how loss of SMARCB1 affects epigenetic mechanisms and 
ultimately gene expression, using novel DNA-methylome profiling and Next 
Generation Sequencing. Characterisation of the downstream effects of 
SMARCB1 loss will aid understanding of the biology of Rhabdoid Tumours as 
wells as the process of chromatin remodelling as a whole. 
2. To achieve a comprehensive genome-wide analysis of Rhabdoid malignancies; 
to investigate differential patterns of DNA methylation and gene expression in 
primary material that may provide a better diagnosis and stratification of 
patients. 
3.  To cross-reference next generation transcriptome and methylome data of 
primary Malignant Rhabdoid tumours and in functional model primary data to 
create a genome-wide catalogue of SMARCB1 –dependent tumourigenic 
changes.  
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Sample ID Centre Location Age 
Year.Month 
Sex 
NMB776 Bristol Brain 1.5 M 
NMB777 London/GOSH Brain 1.5 F 
NMB778 London/GOSH Right frontal 
tumour 
6.1 F 
NMB834 London/GOSH Frontal tumour 6.6 F 
NMB836 Southampton Posterior fossa 0.6 M 
NMB842 Birmingham Left fronto-
parietal 
1.5 F 
NMB843 Southampton Intramedullary 
region 
1.2 F 
NMB846 Bristol Frontal recurrence 1.8 M 
NMB853 London/GOSH Brain 1.4 M 
NMB854 London/GOSH Posterior fossa 2.1 M 
NMB856 Newcastle Posterior fossa 4.8 M 
NMB876 Bristol Brain 1.5 M 
NMB878 London/GOSH Brain 1.5 F 
NMB885 London/GOSH Right frontal 
tumour 
6.1 F 
NMB888 London/GOSH Frontal tumour 6.6 F 
 Primary tumour cohorts 2.1
A representative cohort of 39 primary Malignant Rhabdoid Tumours was used for 
investigations reported in Chapter 4, 6 and 7. The cohort comprised 15 Atypical 
Rhabdoid Tumours (Table 2.1) and 24 Extra Cranial Rhabdoid Tumours (Table 2.2) 
were collected from multiple centres throughout the UK in collaboration with the 
CCLG bio bank (ww.cclg.org.uk/tissue-bank). All samples were evaluated at the 
referring centre and subsequently centrally review by the CCLG bio bank. 
 
 
Table 2.1 Primary ATRT cohort clinical data. Patient ID, centres where
samples were collected age in years at diagnosis, location and sex are
shown.  
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Sample ID Centre  Location  Age 
Year.Month 
Sex 
NMB835 Bristol Abdomen 1.4 M 
NMB838 London/GOSH Abdomen 0.4 F 
NMB839 London/GOSH Abdomen 0.1 M 
NMB840 London/GOSH Thoracic cavity 0.4 M 
NMB841 Newcastle Kidney 1.4 F 
NMB844 London/GOSH Kidney 0.3 M 
NMB845 London/GOSH Kidney 1.2 M 
NMB847 Sheffield Kidney 0.6 F 
NMB848 Sheffield Kidney 6.2 M 
NMB849 Sheffield Paraspinal 0.3 F 
NMB850 Sheffield Cervival spine 2.4 M 
NMB852 Glasgow Kidney 0.3 M 
NMB860 Manchester Kidney 0.5 F 
NMB861 Manchester Bladder 7.7 M 
NMB862 Manchester Liver 1.12 M 
NMB863 Manchester Extra-renal 0.7 F 
NMB864 Manchester Buttock 4.7 F 
NMB865 Manchester Kidney 3.7 M 
NMB877 London/GOSH Left Kidney 3.7 M 
NMB879 Leeds Recurrent Kidney 1.1 M 
NMB880 Leeds Liver 1.3 M 
NMB881 Manchester Kidney 2.4 M 
NMB886 Southampton Kidney 0.7 F 
NMB896 Glasgow Abdomen 8.6 M 
  
 
 
  
Table 2.2 Primary ECRT cohort clinical data. Patient ID, centres where
samples were collected age in years at diagnosis, location and sex are
shown.  
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 Cell lines 2.2
 
 Cell line cultures 2.2.1
The role of SMARCB1 in tumourigenesis was investigated in four different human cell 
lines; three were Extra Cranial ECRT (G401, A204, and STA-WT1) and one Atypical 
Teratoid Rhabdoid Tumours (CHLA-266), all with SMARCB1 deficiency. The 293T cell 
line was used as host cells for the lentiviral packaging system. The different culture 
media used are listed in Table 2.3. 
Cells were seeded at an appropriate density in T175cm2 flasks and incubated at 37°C in 
the presence of 5% carbon dioxide. Cells were passaged upon growth to 80-90% 
confluence. Cells were treated with trypsin, and then centrifuged to generate a cell 
pellet. Pellets were re-suspended in an appropriate volume of media before being 
counted either manually through the use of a haemocytometer or electronically via the 
TC-10 automatic cell counter (BIO-RAD). The viability was measured by staIning an 
aliquot of the cells with Trypan blue (BIO-RAD). 
 Cells were stocked by transferring into cryovials in freezing media (10% DMSO, 50% 
Foetal Calf Serum, and 40% cell media). Initially the vials were placed in a freezing 
container (Thermo Scientific) at -80°C for 24 hours and subsequently transferred to 
liquid nitrogen. 
 
 Proliferation assay 2.2.2
To assess the proliferative capability of stably transfected cells a colorimetric method 
CellTiter 96® AQueous (Promega) was used. The reagent provided contains MTS 
tetrazolium compound (3- (4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2 
- (4-sulfophenyl) -2H-tetrazolium) which is bio-reduced by cells into a coloured 
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Media Cell line Composition  
 
RPMI 10% 
 
G401, A204 
 
1% L-glutamine  
1% penicillin/streptomycin  
10% foetal bovine  
RPMI 1640 (Sigma-Aldrich) 
 
RMPI 20% STA-WT1 1% L-glutamine  
1% penicillin/streptomycin  
20% foetal bovine  
1% sodium pyruvate 
RPMI 1640 (Sigma-Aldrich) 
 
IMDM 20% CHLA-266 1% L-glutamine  
1% penicillin/streptomycin  
20% foetal bovine  
IMDM (Sigma-Aldrich) 
0.1% insulin –transferrin –selenium  
(Invitrogen) 
 
DMEM 10% 293T 1% L-glutamine  
1% penicillin/streptomycin  
10% foetal bovine  
DMEM (Sigma-Aldrich) 
Table 2.3 Media used for culturing cell lines. 
Formazan product. The conversion is due to the production of NADPH or NADH by 
dehydrogenase enzymes in metabolically active cells.  
Briefly every 12 or 24 hours 10µl of MTS solution was added directly to the media. The 
absorbance of Formazan product (directly proportional to the number living cells) was 
measured at 490 nm using a FLUOstar Omega (BMG Labtech) plate reader. All 
measurements were taken in triplicate. 
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  Treatment of Malignant Rhabdoid tumours cell lines with 5-aza-2’-2.2.3
deoxycytidine 
The 5-azaCdR treatment was conducted over a period of 5 days. Briefly 5-azaCdR 
(Sigma-Aldrich) was added at a concentration of 0.1mg/mL. On days 3 and 4, the media 
in each flask was replaced with fresh media and supplemented with 5-azaCdR where 
necessary. On day 5, cells were harvested by trypsinisation. Cell pellets were stored at -
80 oC. 
 
 SDS-PAGE and Western Blot 2.3
 
 Protein extraction and quantification 2.3.1
Protein was extracted from 1x106 cells. 50 μl ice cold urea buffer (90% 8.8 M urea, 2% 
5 M NaH2PO4 and 8% 1 M Tris pH 8.0) was added to 1x106 cells and vortexed for 15 
seconds. Samples were incubated for 30 minutes on ice and then centrifuged at 15,000 
rpm for 30 minutes at 4°C. The supernatant was collected and stored at -80°C. Proteins 
extracted were quantified using the BCATM Protein Assay Kit (Pierce) according to the 
manufacturer’s instructions. Briefly in a 96 well plate 200μl of Working Reagent was 
added to 5μl of each protein sample. A series of standard protein concentrations 
containing bovine serum albumin (from 2mg to 0 mg) were prepared using the standard 
provided in the BCA. The samples were incubated at 37°C for 30 minutes, the 
absorbance of the protein solutions were measured at 562 nm using a FLUOstar Omega 
(BMG Labtech) plate reader. 
 Protein electrophoresis and blotting 2.3.2
Loading buffer (see Appendix) was added to 50 μg of protein and the sample denatured 
at 99°C for 5 min, spun briefly and kept on ice. The samples and a molecular weight 
marker (Movex Sharp Protein Standard, Invitrogen) were loaded in a 4-20% 
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Buffer  Composition 
 
Running Buffer 
 
 
0.3% w/v Tris (Sigma Aldrich) 
1.44% w/v Glycine (Sigma Aldrich) 
0.1% w/v SDS (Sigma Aldrich) 
dd H2O 
 
2X Loading Buffer 
 
2% w/v Bromophenol Blue (Biorad) 
5% v/v 1 M Tris, pH 7 (Sigma Aldrich) 
25% v/v mL 20% SDS (Sigma Aldrich) 
2% v/v β-Mercaptoethanol (Sigma Aldrich) 
ddH2O 
 
Transfer Buffer 
 
 
0.3 % w/v Tris (Sigma Aldrich) 
1.44 % w/v Glycine (Sigma Aldrich) 
0.1 % w/v SDS (Sigma Aldrich) 
20 % v/v Absolute Ethanol (Sigma Aldrich) 
dH20 
 
Blocking solution 
 
5% w/v Non-Fat Dry Milk (Sigma Aldrich) 
1X TBS 
1% v/v Tween-20 (Sigma Aldrich) 
dH20 
 
TBS pH 7.6 
 
0.24% w/v Tris (Sigma Aldrich) 
0.84% w/v NaCl (Sigma Aldrich) 
 
T-TBS 
 
1X TBS (Sigma Aldrich) 
 1% v/v Tween-20 (Sigma Aldrich) 
 
polyacrylamide Amersham ECL Gel (GE Healthcare, UK). The run was performed at a 
constant 160 mV in Tris – Glycine Running Buffer. The electrophoresed proteins were 
transferred to a nitrocellulose membrane (Pierce) in a Tris-Glycine-Ethanol Transfer 
Buffer, by application of an electrical field of 100 mV for 45 min. They were then 
incubated in blocking solution. All solutions are listed in Table 2.1 
 
Table 2.4 Buffers used for Western Blot  
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Antibody Vendors 
Brg-1 H-88 (sc-10760) Santa Cruz Biotechnology 
Anti-BAF47 (612110) BD Biosciences 
Anti-Beta Actin (ab49900) Abcam 
HRP Goat Anti-Mouse IgG (554002) BD Biosciences 
HRP Rabbit Anti-Mouse IgG (ab6728) Abcam 
 
 
 The membrane was incubated in a solution composed of primary antibodies (in 
blocking buffer (1:1000) (Brg-1 H-88, Santa Cruz Biotechnology; antibody BAF47, BD 
Biosciences) for 1 hour at room temperature. It was washed three times in a solution of 
T-TBS (Table 2.4 ) then incubated in a diluted specific secondary antibody (1:5000) for 
1 hour at room temperature and washed in T-TBS as before. The blot was developed 
using SuperSignal West Pico Chemiluminescent Substrate (Pierce) and imaged using 
GBox Chemi XL1.4 (Syngene). All antibodies are indicated in Table 2.5. 
 
 
 Expression quantitation by real time PCR 2.1
 
 DNA/RNA extraction, purification  2.1.1
DNA was extracted from pellets of 1x106 cells using the DNeasy Blood and Tissue Kit 
(Qiagen) according to the manufacturer’s instructions. RNA was extracted from pellets 
of 1x106 cells using the Total RNA Purification Kit (Norgen Biotek). Briefly the cells 
were re-suspended in the kit Lysis buffer and DNA or RNA bounded to a membrane. 
The membrane was washed twice with a kit washing buffer. DNA and RNA were eluted 
Table 2.5 Antibodies used for Western Blot 
 60 
 
in an appropriate volume of TE buffer and ddH20 (Invitrogen) respectively. DNA 
samples were stored at -20 oC, and RNA samples at -80 oC. 
 
2.1.1.1 Phenol/chloroform extraction of DNA 
An equal volume of Phenol/Chloroform/Isoamyl alcohol (25:24:1, Sigma Aldrich) was 
added to the DNA sample. The sample was then centrifuged at 14000 x g for 5 minutes 
at 4°C. The aqueous phase was transferred into a new tube and an equal volume of 
Chloroform (Sigma Aldrich) was added. The upper aqueous phase was removed to a 
new tube after the centrifugation at 14000 x g for 5 minutes at 4°C. 1µl Glycogen 
(Fermentas) (20mg/ml) and 10% 3M Sodium Acetate (Sigma Aldrich), pH 5.5 was 
added prior to the addition of two volumes of Absolute Ethanol (Sigma Aldrich). After 
incubation at -80˚C for 30 minutes, the sample was centrifuged at 14000 x g for 10 
minutes at 4°C. The supernatant was discarded and the pellet was washed with 1mL 
70% ethanol. The pellet was left to air dry then dissolved in an appropriate volume of 
ddH20 or TE. 
 
 
 DNA/RNA quantification and quality assessment. 2.1.2
Quantification of DNA and RNA was conducted using the NanoDrop 1000 (Thermo 
Scientific). DNA/RNA purification was performed on samples and DNA and RNA 
quality has been assessed by Bioanalyser (Agilent Technologies), using Agilent DNA 
1000 Kit and Agilent RNA 6000 Nano Kit respectively, following the manufactures 
procedure. Briefly, the chips were filled with a gel matrix and DNA or RNA ladder was 
added to each well; in the provided well DNA or RNA sizing ladder has been added. 
The chip was then vortexed and run on Agilent 2100 Bioanalyser. 
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Oligonucleotide 
 Name 
Length 
(bp) 
Tm 
(oC) 
GC% Sequence, 5’-3’ 
GAPDH Fwd 20 58.4 50 CGACCACTTTGTCAAGCTCA 
GAPDH Rev 20 62.5 60.0 GACTGAGTGTGGCAGGGACT 
INI1 Fwd 20 59.5  50.0 CAGCCTGGGAGAAAGAGAAA 
INI1 Rev 18 61.4 61.1 GCCCCGATGAATGGAGAC 
p16 Fwd 20 60.1 55.0 ACCAGAGGCAGTAACCATGC 
p16 Rev 20 59.6 60.0 CCTGTAGGACCTTCGGTGAC 
p21 Fwd 20 60.7 55.0 CCGAAGTCAGTTCCTTGTGG 
p21 Rev 20 61.4 55.0 CATGGGTTCTGACGGACATC 
CD44 Ex4 Fwd 19 64.4 57.8 GTCACAGACCTGCCCAATG 
CD44 Ex5 Rev 20 64.0 55.0 CCTGAAGTGCTGCTCCTTTC 
GLI2 Ex2 Fwd 20 63.2 45.0 AAGCAAGAAGCCAAAAGTGG 
GLI2 Ex3 Rev 20 63.9 55.0 TGGTACCTTCCTTCCTGGTG 
GLI3 Ex2 Fwd 20 64.2 50.0 CGAACAGATGTGAGCGAGAA 
JARID2 Ex7 Fwd 20 64.0 50.0 GTCACGCAGATTCAGCACAT 
JARID2 Ex8 Rev 20 64.0 45.0 TAATCAGCCGGAAAAAGCAG 
NTN4 Ex8 Fwd 21 63.3 38.0 AAGGCATTCTGTGGAATGAAA 
NTN4 Ex9 Rev 20 63.9 50.0 GGATTGGACAAGTGCATCCT 
Table 2.6 q-PCR oligonucleotides used to evaluate differential expression. 
 Oligonucleotides 2.1.3
All oligonucleotides were synthesised by Sigma Aldrich and re-suspended in nuclease 
free H2O (Invitrogen) to a concentration of 100µmol/µl. Primers for q-PCR were 
designed (Table 2.6) using Primer3Plus software (version 4.0.0 and previously; 
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). The transcript 
sequences of genes were taken from Ensembl (http://www.ensembl.org/index.html). The 
primers were checked for non-specific binding using UCSC In-Silico PCR software 
(https://genome.ucsc.edu/).  
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 Quantitative polymerase chain reaction 2.1.4
A total of 1000ng of RNA was converted into cDNA using the iScriptTM cDNA 
Synthesis Kit (BIO-RAD) in accordance with the manufacturer’s instructions.  
The cDNA was amplified using the Platinum SYBR Green qPCR Supermix – UDG 
with ROX kit (Invitrogen, USA) using a ViiA7 machine (Applied Biosystems, UK). The 
master mix provided is composed of AmpliTaq® DNA Polymerase and SYBR® Green 
cyanine dye, which as a result of binding to DNA absorbs blue light (λmax = 497 nm) 
and emits green light (λmax = 520 nm). General reaction conditions are indicated in 
Table 2.7. 
 
 
 
 
 
 
2.1.4.1 Relative quantification of gene expression data using the ΔΔCT method 
The relative quantification measures the relative change in mRNA expression levels of a 
gene by comparing to the levels of another RNA. This method does not require a 
calibration curve and the gene expression is compared against a reference gene. In this 
study we chose GAPDH as a reference gene; a constantly expressed endogenous gene.  
Gene expression was calculated using the ΔΔCT method which assumes that each PCR 
cycle will double the amount of amplicons in the reaction (amplification efficiency = 
100%) or at least that the amplification efficiency is roughly equal between the 
reference and gene of interest (Livak and Schmittgen, 2001). 
Polymerase Reagent Final Vol. Cycling 
AmpliTaq® 
DNA 
Polymerase 
( SYBR® Select 
Master Mix) 
SYBR® Select Master Mix  5.1µl 50oC, 2’ 
95 oC, 10’ 
40cycles: 95oC, 15’’ 
  60oC, 35’’ 
95°C, 15’’ 
60°C, 1’ 
Forward Primer (10mM) 0.2μl 
Reverse Primer (10mM) 0.2ul 
DNA Template (1ng/µl) 4ul 
dH2O  0.5µl 
Table 2.7 General PCR reaction and conditions 
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The fold change expression values have been calculated using this formula:  
Fold change expression =2-ΔΔCt 
Where: ∆∆Ct = [∆Ct sample1 – ∆Ct sample2] 
And ∆Ct = [Ct sample – Ct endogenous control] 
 
 Lentiviral Production and Infection  2.2
For Lentiviral particle production, 3.5x106 HEK293T cells were co-transfected with 7.5 
µg of expression vector and the packaging vectors 6 µg of psPAx2 and 1.8 µg pVSVg 
using Calcium Phosphate Transfection (CalPhos Transfection Kits, Clontech). Between 
twelve hours and fifteen hours after transfection, fresh media was added. Forty-eight 
hours after transfection, supernatant was collected and concentrated by ultrafiltration in 
Centricon Plus 100 (Millipore). Particles were aliquoted and stored at -80°C.  
 
 Determining viral titre 2.2.1
Particle titre was determined by infection of 5x104 HEK293T cells in serial dilutions, 
from 10-3 to 10-7. Twenty-four hours after infected cells was selected by addition of 
Puromycin (Invitrogen) to the media to the final concentration of 1μg/mL. Seven days 
after infection the cells were fixed with 70% Ethanol (Sigma Aldrich) and stained with 
Hexadimethrine bromide (Sigma Aldrich). The blue-stained colonies were counted 
using a microscope at a magnification of 40X. The lentiviral titre was calculated by 
multiplying the number of colonies per well by the dilution factor. 
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 Multiply of infection  2.2.2
Multiplicity of infection (MOI) refers to the number of virions added per cell during 
infection. MOI was determined by infection of 5x104 cells of each Rhabdoid cell line in 
serial dilutions (from MOI of 1 to 100). Twenty-four hours later infected cells was 
selected by addition of Puromycin (Invitrogen) to the media to the final concentration of 
1μg/mL. Seven days after infection the cells were harvested, counted and the viability 
was measured by staining an aliquot of the cells with Trypan Blue (BIORAD). RNA 
was extracted and converted in cDNA to evaluate the relative quantification of gene 
expression of CDKN2A, CDKN1A and CD44 (oligopeptides in Table 2.6). The ideal 
MOI was that condition presenting the greatest number of infected cells and an 
overexpression of CDKN2A, CDKN1A and CD44.  
 
 Stable lentiviral infection of Rhabdoid cells 2.2.3
Lentiviral infection of Rhabdoid cells was carried out aiming to transduce about 60%-
80% of the total amount of cells in each experiment. Briefly, 15 minutes before the 
infection Polybrene (Invitrogen) was added into Rhabdoid cells culture media at a final 
concentration of 8 µg/ml. Viral particles (MOI of 100) were directly added to the media 
and the cells were incubated for 24 hours at 37°C and 5% CO2. To select for infected 
cells, Puromycin (Invitrogen) was added to the media to a final concentration of 
1μg/mL. The selection was prolonged up to 36 hours (SMARCA4 D/N, SMARCA4 w/t 
and C2979T SMARCA4 stable infection) or 7 days (SMARCB1 stable infection) post-
infection, when cells were harvested. 
 
 Bacterial strains 2.3
Bacterial strains used in this study were all genetically modified Escherichia coli 
organisms High Efficiency 5-alpha Competent E. coli (NEB). 
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  Plasmids 2.3.1
2.3.1.1 PCDH-CMV-MCS-EF1-Puro 
The self-inactivating, CMV-derived, lentiviral vector pCDH-CMV-MCS-EF1-Puro was 
purchased from Systems BioScience. pCDH-CMV-MCS-EF1-Puro contains Ampicillin 
resistant genes for selection of the plasmid in E.coli and a Puromycin-resistant marker 
for selection of the transfected/transduced cells.  
 
2.3.1.2 SMARCB1 wild type 
The pCDH-EF1-PURO-SMARCB1 plasmid was produced by PCR amplifying the 
whole SMARCB1 coding sequence from pCDNA 3.1-SMARCB1 (a gift from Frederique 
Quignon, Institute Curie). Restriction sites for XbaI and BamH1 were added to the 
Forward and Reverse primers respectively. The PCR product was digested and 
directionally ligated into the multiple cloning site of pCDH-EF1-Puro (Systems 
Biosciences). 
 
2.3.1.3 pBABE SMARCA4 wild type and dominant negative 
 pBABE SMARCA4 and pBABE SMARCA4 (K->R) were purchased from Addgene 
(plasmid 1959 and plasmid 1960). Propagation of all the vectors (excluding pSIN-
SIEW) was conducted in the E. coli strain DH5α. 
In order to transfect the human cell lines using lentiviral technology, both SMARCA4 
sequences were cloned into the more suitable pCDH-CMV-MCS-EF1-Puro expression 
vector. 
Also the pBABE SMARCA4 wild type was modified in order to create the C2979T 
mutated SMARCA4 clone. 
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2.3.1.4 Packaging plasmids 
Two components are required to generate second generation Lentivirus: Packaging 
Plasmid for producing viral particle and envelope plasmid along with the expression 
vector. The plasmids used are psPAX2 and pMD2G (kindly donated by Dr Paul 
Sinclair). The former contains a robust CAG promoter for efficient expression of 
packaging proteins; the latter plasmid contains the VSV-G coding sequence, required for 
the pseudotyping of the viral envelope. 
 
 Bacterial culture 2.3.2
Bacterial strains were grown in Luria-Bertani (LB) (Table 2.8) medium with antibiotic 
selection from a single colony. Stocks of bacteria were stored at -70° C in a minimum  
of 25% glycerol (v/v). Microbiological LB agar plates or broth media, 10 ml, were 
inoculated using a metal loop into LB Plate (Table 2.8) cultures were stored at 4°C 
wrapped in Parafilm.  
 
 
 
 
 
 
 
 
Buffer Composition  
Luria-Bertani (LB) medium 
 
 
1% w/v Tryptone (Sigma Aldrich), 
0.5% w/v Yeast extract (Sigma 
Aldrich), 1% NaCl (Sigma Aldrich), 
pH 7.5, ddH2O. 
Luria-Bertani (LB) agar 1% w/v Tryptone (Sigma Aldrich), 
0.5% w/v Yeast extract (Sigma 
Aldrich), 1% NaCl (Sigma Aldrich), 
1.5% agar (Sigma Aldrich), pH 7.5, 
ddH2O 
Table 2.8 Buffer used for bacterial culture and composition 
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 Harvesting of bacteria from broth cultures and extraction of nucleic acids 2.3.3
Bacterial cultures bigger than 1.5 mL were harvested by centrifugation at 4600 rpm for 
15 minutes; cultures smaller than 1.5ml were harvested at 13,000 rpm for 3 min. 
Plasmids were isolated from cultures using a plasmid purification kit (Qiagen or 
Invitrogen), according to manufacturer’s instructions. Briefly the bacterial pellets were 
re-suspended in a provided Lysis buffer with RNAse and the DNA bound to a 
membrane. After elution, the DNA was re-suspended first in isopropanol and then in 
70% ethanol. The DNA pellets were re-suspended in an appropriate volume of TE 
buffer.  
 
  Quantification of nucleic acids by spectroscopy 2.3.4
DNA extracted from the plasmid was quantified using the ND-1000 (NanoDrop 
Technologies). Nucleic acids absorb between 260nm and 280 nm. A ratio of ~1.8 
between these wavelengths was taken to indicate good sample purity. 
 
 DNA manipulation techniques 2.3.5
2.3.5.1 DNA restriction 
New England Biolabs and Promega restriction endonucleases have been used (Table 
2.9). Appropriate restriction endonucleases were selected in silico using 
(http://tools.neb.com/NEBcutter2). Restriction enzyme digests were performed 
according to the manufacturer’s instructions. Briefly, 10 units of enzyme were used in a 
reaction mixture containing appropriate buffer, 1µg of DNA and incubated at 37°C for 
1-2 hours in thermo-cycler. The enzymes ware inactivated by heat for 20 minutes. 
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2.3.5.2 Agarose electrophoresis 
Restriction enzyme digests required for further applications were separated by agarose 
gel electrophoresis. Agarose (Bioline) concentration varied from 0.8% to 1% (w/v) 
depending on the predicted size of DNA fragments. Agarose was suspended in TBE, 
boiled and supplemented with Redgel (Biotium) in a concentration of 0.01% (v/v). 
DNA samples were mixed with DNA loading buffer (Promega). Sizes of DNA sample 
were evaluated using a DNA marker (Promega) chosen depending on the estimated size 
of the products (Table 2). A constant voltage was applied across the gel and the DNA 
size was visualised using Syngene G-box 
 
2.3.5.3 Purification of digested DNA  
The digested plasmid DNA required for further applications were purified using a Gel 
Extraction kit (GeneJET™ Gel Extraction Kit) according to the manufacturer’s 
protocol. The gel was dissolved with a provided buffer and the DNA bound to a 
membrane; after cleaning the column with a wash buffer, the DNA was eluted in TE 
buffer. 
 
 
 
Restriction endonuclease Manufacture  
EcoR1, EcoRV, Not1, Sal1 and Xba1 
 
Promega 
BsrG1, BstB1, Sap1, Swa1 and Xba1 New England Biolabs 
Table 2.9 Restriction endonuclease used for DNA manipulation 
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Oligonucleotide 
 Name 
Length 
(bp) 
Tm 
(oC) 
GC% Sequence, 5’-3’ 
C2729T Fwd 16 60.7 69.0 GCCGCCTGCTGCTGAT 
C3565T Rev 16 62.5 69.0 CGATGCGGTGGGCTCA 
BRG1 Fwd 20 63.7 50.0 AACGCACAGACCTTCAACCT 
BRG1 Rev 20 63.8 50.0 CAGCATCTTGTAGGCCATGA 
BRG1 SHORT Rev 20 67.9 55.0 CGGATCCGGGACCTGAAATA 
pBABE 5’ 17 55.4 52.9 CTTTATCCAGCCCTCAC 
pBABE 3’ 21 60.4 47.6 GGAATGTGTGTCAGTTAGGGT 
pBABE 5’ Xba1 25 55.4 52.0 GCTCTAGACTTTATCCAGCCCTCAC 
pBABE 3’ BstB1 30 60.4 50.0 ACCCTAACTGACACACATTCCTTGCAAGCC 
C2729T Fwd Sap1 33 58.0 51.5 AAGCTCTTCTATGGGCACACCGCTGCAGAACAA 
C2729T Rev Sap1 33 64.0 63.6 AAGCTCTTCTCATCAGCAGCAGGCGGCGGGGTG 
BRG1 Fwd BsrG1 20 64.0 50.0 CAGTCAGCGCTTATGGTCAA 
LNCX 25 67.4 48.0 AGCTCGTTTAGTGAACCGTCA GATC 
SP6 18 42.6 33.3 ATTTAGGTGACACTATAG 
T7 20 50.9 40.0 TAATACGACTCACTATAGGG 
Table 2.10 Oligonucleotides used for screening of bacterial colonies and 
DNA manipulation. 
2.3.5.4 Oligonucleotides 
All oligonucleotides were synthesised and designed as previously described (see section 
2.33). The primers used to re-create a mutated SMARCA4 are in Table 2.10. Primers 
were designed using the transcript sequence from Ensembl (ENST00000344626) and 
sequence of pBABE-puro (Plasmid 1764, Addgene). Existing primers sequences (SP6, 
T7 and LNCX) were taken from the corresponding plasmid supplier’s website 
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2.3.5.5 Polymerase chain reaction (PCR) 
PCR was used to amplify specific regions of DNA. Template DNA for colony screening 
or molecular cloning was amplified by PCR, using Gene Amp PCR System 9700 
thermocycler. For routine colony screening High fidelity PCR PFU polymerase 
(Agilent), TaqMan® Fast Master (Applied Biosystem) and Phusion® High-Fidelity 
DNA Polymerase (NEB) were used according to manufacturer’s instructions. For 
negative controls the same reactions were run without the addition of a DNA template. 
General reaction conditions are indicated in Table 2.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymerase Reagent Final Conc. Cycling 
Fast PCR mix 
(Applied 
Biosciences) 
GeneAmp® Fast PCR Master Mix 
(2x) 
1x 94oC, 5/10’ 
35 cycles:  
94oC, 1’ 
XXoC, 1’ 
72oC, 25’’/kb 
72oC, 7’ 
4°C ∞ 
Forward Primer (10mM) 1μM 
Reverse Primer (10mM) 1μM 
DNA Template XX 
dH2O up to 20μl XX 
 
Cloned Pfu 
(Agilent) 
Pfu Buffer (10x) 1x 98oC, 45” 
35 cycles:  
98oC, 45” 
XXoC, 45” 
72oC,60’’/kb 
72oC, 10’ 
4°C ∞ 
 
dNTPs (25mM) 250μM 
Forward Primer (10mM) 0.5μM 
Reverse Primer (10mM) 0.5μM 
Pfu DNA polymerase 
 (2.5 u/μl) 
1.25ul 
DMSO (100%) 3% 
DNA Template XX 
dH2O up to 25μl XX 
 
Phusion 
High-Fidelity 
DNA Polymerase 
(NEB) 
HF Buffer (5x) 1x 98oC, 30” 
35 cycles:  
 98oC, 10” 
XXoC, 30” 
72oC, 20’’/kb 
72oC, 7’ 
4°C ∞ 
 
dNTPs (25mM) 200µM 
Forward Primer (10mM) 0.5μM 
Reverse Primer (10mM) 0.5μM 
DMSO (100%) 3% 
Phusion Polymerase (2u/μl) 0.5ul 
DNA Template XX 
dH2O up to 25μl XX 
XX= Varying amount e.g. annealing temperature, DNA template and dH2O 
Table 2.11 General PCR reaction conditions for each polymerase. 
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 Cloning 2.3.6
 
2.3.6.1 Cloning PCR amplicons 
High fidelity PCR PFU polymerase (Agilent) was used to create the specific sequence 
of DNA. Cloned Pfu DNA Polymerase was used according to the manufacturer’s 
protocol: 1μl cloned Pfu DNA polymerase buffer (10×), 1μl dNTP mix (25mM), 0.5μg 
DNA, 1μl cloned Pfu DNA polymerase (2.5u/μl) and up to 10μl dH2O. Reaction 
incubated at 72oC for 30 minutes, reaction terminated by gel extraction. 
 
2.3.6.2 Transformation  
Plasmids were transformed into High Efficiency 5-alpha Competent E. coli (NEB), 
according to the manufacturer’s protocol. 1µl pUC19 (provided) and 5µl of ddH2O 
were used as positive control and negative control respectively. Transformants were 
selected in LB plates containing 100 μg/ml ampicillin. 
 
2.3.6.3 Blunt and cohesive ended ligation  
T4 DNA Ligase (Invitrogen) was used according to Table 2.12. The reaction was 
incubated at 16oC, overnight with no dilution after deactivation, product was stored at -
20 oC (5μl was used for transformed).  
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2.3.6.4 TA Cloning 
SMARCA4 blunt ended PCR fragments products have been incorporate the pGEM T-
Easy Vector (Promega). The pGEM T-Easy is a commercial vector with a thymine 
group added to the break in the plasmid. The Lac-Z operon present in the vector allows 
a preliminary screening on IPTG/X-gal plates.  
Before blunt ended ligation 3’ adenosine were added to allow for TA cloning. AmpliTaq 
Gold® DNA Polymerase (Applied Biosystems) was used according to manufacturer’s 
specification: 2μl PCR Buffer I (10×), 0.4μl dATP (10mM), 1.0μg DNA, 0.5μl 
AmpliTaq Gold® DNA Polymerase (5.0 u/μl) and up to 20μl dH2O. Reaction incubated 
at 72oC for 20mins, reaction terminated by gel extraction.  
Ligation was carried out according to the manufacturer’s protocol with a molar ratio of 
vector: insert of 1:3. Reaction conditions were: 5μl Rapid Ligation Buffer (2×), 1.0μl 
pGEM®-T Easy Vector (50ng/μl), DNA (2μl control insert DNA for positive control, 
dH2O for the background control), 1μl T4 DNA ligase (3 u/μl) and up to 10μl dH2O. If 
needed reaction was scaled to allow for larger quantities of insert DNA. The reaction 
was incubated overnight at 4oC and 2μl transformed as above.  
 Cohesive End Blunt End 
T4 DNA Ligase (U)  0.1 1.0 
Amount of DNA  
Vector (fmol)  3-30 15-60 
Insert (fmol)  9-90 45-180 
Vector: Insert ratio 3:1 3:1 
Temperature (°C) 23-26 14 
Time (h) ≥1 24 
Reaction volume (μl) 20 20 
Reaction stopped with 1µl 0.5M EDTA, then diluted with 80µl dH2O and stored at 4oC. 
Table 2.12 Conditions used for blunt and cohesive end ligations. 
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2.3.6.5 Site-directed mutagenesis: C2979T SMARCA4 
To create the C2979 mutation in the SMARCA4 gene the PCR mutagenesis protocols by 
Ko and Ma (2005) were followed. Short and long mutant fragments were generated by 
PCR (Phusion, NEB; 98oC, 30”; 35 cycles: 98oC, 10”; 55oC, 30”; 72oC 30/60”; 72oC, 
7’), then products were purified by phenol/chloroform extraction and digested by Sap1 
at 37oC for 2 hours (NEB). The digested fragments were purified by standard 
phenol/chloroform extraction and ligated with 400U of T4 DNA ligase (NEB) at 160C 
overnight to generate a ~3000bp fragment. The ligated fragment was purified from 
0.7% agarose gel by Gel Extraction Kit (Fermentas). 1μl was diluted 1:100 (dH2O) as a 
template for a PCR using Phusion® High-Fidelity DNA Polymerase (NEB) with 
BsrG1_FOR primer and 3’pBABE untagged primer (product ~3000bp); the insert was 
ligated into pGEM T-Easy (Promega). Sequence validation used sequencing primer sets 
8-14 with the C2729T mutation set (Table 2.13) 
2.3.6.6 Sequencing  
To confirm that the correct SMARCA4 and SMARCB1 sequences ware cloned in the 
various expression vectors and intermediate plasmids, sequencing was performed using 
the primers listed in Table 2.13. Sequencing was performed by DBS Genomics 
(Durham) and resultant traces were analysed using ABI Sequence Scanner software 
(Applied Biosystem). 
 
 
 
 
 
 
 74 
 
Oligopeptide 
 Name 
Length 
(bp) 
Tm 
(oC) 
GC% Sequence, 5’-3’ 
BRG1 SEQ1 Fwd 18 63.84 66.67 TCCTTCTCTAGGCGCCGG 
BRG1 SEQ1 Rev 20 60.11 50.00 TGCATGTTGTCCTGAGGGTA 
BRG1 SEQ2 Fwd 18 60.58 66.67 CCACTGTCTGCAGCTCCC 
BRG1 SEQ2 Rev 20 58.89 60.00 GGCTGGAACTGGACTAGAGG 
BRG1 SEQ3 Fwd 18 62.73 66.67 CCCAAGGTTACCCCTCGC 
BRG1 SEQ3 Rev 20 60.21 50.00 GAGGCCTGCTGTAATTTGGA 
BRG1 SEQ4 Fwd 18 63.57 61.11 CGGGATGCAGCAGCAGAT 
BRG1 SEQ4 Rev 19 61.20 57.89 TCTGCTTCTGGTGCAGTGG 
BRG1 SEQ5 Fwd 20 60.60 55.00 ACCCCTCAGAAGCTGATTCC 
BRG1 SEQ5 Rev 20 59.85 55.00 CTCCTGCTCGATCTTCTGCT 
BRG1 SEQ6 Fwd 20 60.36 55.00 GGAGACAGCCCTCAATGCTA 
BRG1 SEQ6 Rev 20 60.41 50.00 GCGTCTGTCCTTCTGCATTT 
BRG1 SEQ7 Fwd 20 60.91 55.00 GCTCATGGCTGAAGATGAGG 
BRG1 SEQ7 Rev 20 59.95 45.00 CATCTTGCTTGGCATTCTCA 
BRG1 SEQ8 Fwd 20 60.02 55.00 AGCGATGACGTCTCTGAGGT 
BRG1 SEQ8 Rev 20 60.06 55.00 TCGTACGTCGTCAGCAAGAC 
BRG1 SEQ9 Fwd 20 60.15 55.00 CTCCGTGGTGAAGGTGTCTT 
BRG1 SEQ9 Rev 20 59.87 50.00 GCAGACATGTCGCACTTGAT 
BRG1 SEQ10 Fwd 20 59.98 55.00 CCGACGACTCAAGAAGGAAG 
BRG1 SEQ10 Rev 20 59.27 50.00 TGCTGAGCAGGAAGATGAAG 
BRG1 SEQ11 Fwd 20 60.66 55.00 CTCAGGCTTGATGGAACCAC 
BRG1 SEQ11 Rev 20 60.23 40.00 ATGCGCATGAACAGATCAAA 
BRG1 SEQ12 Fwd 20 60.12 55.00 GACGAGACCGTCAACCAGAT 
BRG1 SEQ12 Rev 20 60.05 55.00 CCACTGCTGCTGTCCTTGTA 
BRG1 C2979T Fwd 20 60.07 50.00 GCCAAGATCCGTTGGAAGTA 
BRG1 C2979T Rev 19 59.87 52.63 AGGTGCTGCAGCTCTTGAA 
PCDH SEQ Rev 18 60.80 67.00 GGACTGTGGGCGATGTGC 
INI1 SEQ Fwd 20 56.40 45.00 TGACGCCTGAGATGTTTTCA 
INI1 SEQ Rev 20 58.40 50.00 CCACATGGATGTTCAGCTTG 
Table 2.13 Oligonucleotides used for sequencing recombinant plasmid. 
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 Chromatin Immunoprecipitation 2.4
Chromatin immunoprecipitation was performed in the A204 and G401 Rhabdoid cell 
line, using the MAGnify ChIP Kit (Invitrogen). Briefly at 7-days post infection with 
SMARCB1 lentivirus particles, the cells were detached by trypsin treatment. Up to 107 
cells were re-suspended in 500 µl pf PBS and formaldehyde was added for a final 
concentration of 1% and incubated for 8 min. Room-temperature 1.25 M glycine was 
added to stop the reaction and incubated for 5 minutes at room temperature. The cells 
were washed twice with cold PBS and 1x106 cells were re-suspended in 50 µl of 
provided lysis buffer and incubated on ice for 10 min. 
Cell lysate was sheared into ~100–300 bp fragments using Biorupt Standard (High 
Power, 30 cycles of 30 seconds ON, 30 seconds OFF). The sonicated mixture was spun 
at 14,000 rpm 15 minutes at 4°C and diluted following the manufacture’s direction. 700 
µl RIPA Buffer were added to the supernatant. Aliquots were stored at –80°C in low 
binding tubes. The size of the chromatin was checked by agarose gel electrophoresis of 
purified and de-cross-linked samples using a 2% agarose gel. 
The antibodies (Table 2.14) were coupled to Dynabeads® (Invitrogen), incubated for 1 
hour at 4°C. Chromatin was bound to the beads by 2-hours incubation at 4°C. The 
coupled beads were washed according to manufacturer’s instructions using the provided 
washing buffer.  
Reverse formaldehyde crosslinking of the chromatin was performed as described in the 
manual, adding to the beads the de-crosslinking buffer and the Proteinase K (provide in 
the kit). DNA purification magnetic beads were used to isolate and purify the chromatin.  
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Antibody Vendors 
Brg-1 H-88 (sc-10760) Santa Cruz Biotechnology 
INI1 C-20 (sc-16189) Santa Cruz Biotechnology 
IgG Mouse  Invitrogen (MAGnify kit) 
IgG Rabbit  Invitrogen (MAGnify kit) 
IgG Goat (ab37373) Abcam 
H3k27me (c15410069) Diagenode 
H3k4me (c15410030) Diagenode 
Table 2.14 Antibodies used for Chromatin Immunoprecipitation  
 
 Chromatin enrichment determination 2.4.1
Real-time PCR was used to quantify enrichment levels using the purified DNA obtained 
by ChIP. All qPCR experiments in this study were carried out as described in section 
2.3.4. Oligonucleotides used were previously used in ChIP experiments in Rhabdoid 
cell lines (Kuwahara, Charboneau et al. 2010, Kuwahara, Wei et al. 2013). 
2.4.1.1  Data analysis and normalisation of ChIP-qPCR data: Percent input method 
This method represents the ChIP-qPCR results of the IPs as a percentage of the total 
amount of chromatin that was present before the immunoprecipitation step. 
First, triplicates were averaged. Second, the input Ct value was corrected since the input 
sample extracted was one hundredth of the total chromatin in the IP samples before 
immunoselection. A 10-fold increase in product is represented as -3.32.  
Ct Corrected input = (Ct input – 3.32) 
Then the ∆Ct between the IP samples and the input sample was calculated for each of 
the 3 replicates. 
∆Ct= (Ct sample - Ct Corrected input) 
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Oligonucleotide 
 Name 
Length 
(bp) 
Tm 
(oC) 
GC% Sequence, 5’-3’ 
DAZL Fwd 24 62.4 41.7 TGAAACTTATATGCAGCCCACAAC 
DAZL Rev 24 61.8 45.8 AATAAGCCGGAGGTACAACATAGC 
RASSF1A Fwd 21 63.3 57.1 CCTCTGTGGCGACTTCATCTG 
RASSF1A Rev 21 61.8 47.6 TAGTGGCAGGTGAACTTGCAA 
HTATIP2 Fwd 21 67.4 57.1 CAGCATGGCCGAAACAGAAGC 
HTATIP2 Rev 24 67.4 50.0 ACCCAGGCAACAGAATCCAACATC 
GAPDH Fwd 23 61.7 43.5 CAAGGTCATCCATGACAACTTTG 
GAPDH Rev 22 64.1 59.1 GTCCACCACCCTGTTGCTGTAG 
Table 2.15 Oligonucleotide used for sequencing bisulfite-converted DNA. 
The %input value was calculated as: 
%input =2-(∆Ct) 
The data was then corrected for any background signals indicated in the IgG control: 
%input corrected= %input Ab – %input IgG 
 
 
 Assessment of gene methylation status 2.5
  
 Assessment of 5-aza-2’deoxycytidine-induced demethylation  2.5.1
RNA from 5-azaCdR-treated cell lines was first extracted and then converted into cDNA 
(see section 2.2.1 and 2.2.4). The induced de-methylation by the 5-aza treatments was 
tested by PCR using the primers outlined in Table 2.15.  
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PCR was performed using AmpliTaq Gold DNA Polymerase (Life Technologies) or 
Phusion High-Fidelity DNA Polymerase (NEB) according to the reaction conditions 
depicted in Table 2.16. PCR products were separated by gel electrophoresis in a 1% 
agarose, before being imaged using the SynGene imaging system.  
 
 
 
 
 
 
 
 
 
 
 
 
 Bisulphite conversion and sequencing 2.5.2
Bisulfite conversion is used to deaminate unmethylated cytosine to produce uracil in 
DNA, while methylated cytosines results in protection from the conversion to uracil. 
DNA bisulfite treatment allows the assessment of DNA methylation status by direct 
Polymerase Reagent Final Conc./Vol. Cycling 
Fast PCR mix 
(Applied 
Biosciences) 
10x Buffer II 2µl 94oC, 5’ 
40 cycles: 
94oC, 30’’ 
XXoC, 30’’ 
72oC, 30’ 
4°C ∞ 
MgCl2 1.2μl 
dNTPs (5 mM) 200µM 
Forward primer (10 μM) 0.5μM 
Reverse primer (10 μM) 0.5μM 
 Phusion Polymerase (2u/μl) 0.5ul 
 DNA Template XX 
 dH2O up to 25μl XX 
    
Phusion 
High-Fidelity 
DNA Polymerase 
(NEB) 
HF Buffer (5x) 1x 98oC, 30” 
35 cycles: 
98oC, 10” 
XXoC, 30” 
72oC, 20’’ 
72oC, 7’ 
4°C ∞ 
 
 
dNTPs (25mM) 200µM 
Forward Primer (10mM) 0.5μM 
Reverse Primer (10mM) 0.5μM 
DMSO (100%) 3% 
Phusion Polymerase (2u/μl) 0.5ul 
DNA Template XX 
dH2O up to 25μl XX 
Table 2.16 General PCR reaction conditions for each polymerase used to 
amplify DNA intended to sequencing. 
 79 
 
sequencing. DNA from 5-azaCdR treated cells was bisulfite converted using the EpiTect 
Bisulfite Kit (Qiagen) in accordance with the manufacturer’s instructions.  
The human genomic sequences of the candidate genes were extrapolated from the 
UCSC Genome Browser (http://genome.ucsc.edu/). The human genomic sequences of 
the candidate genes were extrapolated from the UCSC Genome Browser 
(http://genome.ucsc.edu/). Primers specific to the bisulfite-converted sequences of 
candidate genes were designed using MethPrimer software 
(http://www.urogene.org/methprimer/) and are listed in Table 2.17 and Table 2.18. 
PCR was performed using AmpliTaq Gold DNA Polymerase with buffer II and MgCl2 
(Life Technologies) or with Phusion High-Fidelity DNA polymerase (NEB). PCR 
products were purified using the PureLink PCR Purification Kit (Life Technologies) and 
sequencing was performed by DBS Genomics (Durham) or Eurofins Genomics 
(Ebersberg, Germany). The resultant traces were analysed using ABI Sequence Scanner 
software v2 (Applied BioSystems). The general PCR reaction conditions are delineated 
in Table 2.18. 
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Oligonucleotide 
 Name 
Length 
(bp) 
Tm (oC) GC
% 
Sequence, 5’-3’ 
GOLPH1 BDNA RS 
Rev 
26 59.20 42.31 TCCTCCAACAATAAACAAA
CATTAAT 
KRT80 Bis Fwd 25 62.90 40.0 TTATTTAAGGGGGTAGGAG
AGAAGA 
KRT80 Bis Rev 25 62.90 28.00 CCAAAAAAACTCTTTAACA
ACCAAA 
KRT80 BDNA FS 
Fwd 
25 59.89 56.00 TTATTTAAGGGGGTAGGAG
AGAAGA 
KRT80 BDNA FR 
Rev 
25 57.01 60.00 TACCCAAAATAACTACCCTA
CACTC 
PSORS1C1 Bis Fwd 30 56.60 6.60 ATGGATTTTATTATATATTTT
ATTTTTTTT 
PSORS1C1 Bis Rev 27 62.50 37.00 CACCTTCTAAATACCATCCT
CTCTAAA 
PSORS1C1 BDNA FS 
Fwd 
29 53.82 55.17 TGGATTTTATTATATATTTTA
TTTTTTTT 
PSORS1C1 BDNA FS 
Rev 
27 59.94 51.85 TCACCTTCTAAATACCATCC
TCTCTAA 
PSORS1C1 BDNA RS 
Fwd 
30 52.78 46.67 ATTATTAGTATTTTTTATTTT
TTAGATGTT 
PSORS1C1 BDNA RS 
Rev 
24 55.36 50.00 TTCTCTCTCTTCTCCAATAA
AAAC 
S100A10 Bis Fwd 25 58.50 28.00 TTTTGAGTTATTATTTGAAG
GAGAG 
S100A10 Bis Rev 25 60.40 28.00 CCAAAAAATCAAACCTACA
ATAAAC 
S100A10 BDNA FS 
Fwd 
23 52.52 52.17 TTGAGTTATTATTTGAAGGA
GAG 
S100A10 BDNA FS 
Rev 
22 52.13 68.18 AAAATCAAACCTACAATAA
ACC 
ST5 Bis Fwd 26 62.90 34.60 AAGGAGTTTTTAGATAGTT
GTTGGGA 
ST5 BDNA FS Rev 25 53.62 56.00 ACTTCTAAACTTAAAACCA
AAATCT 
ABR Bis Fwd 24 62.70 33.30 GGTTGGTGTTTGGATTTTTA
GATT 
ABR Bis Rev 25 62.00 36.00 CAAACCCCTAACTTTCTACC
AAATA 
Table 2.17 Oligonucleotides used for sequencing bisulfite-converted 
DNA. 
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Oligonucleotides 
 Name 
Length 
(bp) 
Tm (oC) GC
% 
Sequence, 5’-3’ 
BHLHE40 Bis Fwd 25 61.50 36.00 TAGTTGAGTTAGTTGGTGAT
TTGGT 
BHLHE40 Bis Rev 25 62.80 32.00 CACAAAAAACTAATATTCC
CCTCAA 
BMF Bis Fwd 30 58.40 20.00 GGTAGTAAAAATTTGATTTT
ATTTAGTGTA 
BMF Bis Rev 30 56.70 6.60 ATTCTTTATTTTTATTTTATTT
TCAAATAT 
BMF BDNA FS Fwd 26 50.68 34.62 AAATTTGATTTTATTTAGTG
TAAATA 
BMF BDNA FS Rev 30 51.95 26.67 CAAAACATAATATATATTCTT
TATTTTTAT 
BMF BDNA RS Fwd 30 58.01 50.00 CAACAAAAATCTAATTTCAT
CCAATAC 
BMF BDNA RS Rev 27 58.50 40.74 TTAGAAAAATGTATTTGTAG
TTGAGGG 
CCR7 Bis Fwd 27 61.30 29.60 TTAGAAAAATGTATTTGTAG
TTGAGGG 
CCR7 Bis Rev 26 57.20 23.00 ATAACCAAAAAACAATACC
AATATAC 
CCR7 BDNA FS Fwd 27 58.35 44.44 TTAGAAAAATGTATTTGTAG
TTGAGGG 
CCR7 BDNA FS Rev 25 53.82 68.00 TAACCAAAAAACAATACCA
ATATAC 
CCR7 BDNA RS Fwd 22 55.33 68.18 GTTAGGGGGTAATGTTAGT
GTG 
CCR7 BDNA RS Rev 30 55.00 56.67 TAACCTAACTACCTTTTACA
TAACTACTCT 
GALNT1 Bis Fwd 25 62.40 32.00 TATTTGGGTTTTTGTTAGGT
TGAGT 
GANLT1 Bis Rev 25 62.50 40.00 ATAACCCTCCTACCTACATT
CCATT 
GOLPH1 Bis Fwd 24 60.60 20.80 ATTTGTTTGTTTTTTTGTTTT
GTG 
GOLPH1 Bis Rev 25 58.00 24.0 CAAAAAACTACTTAAAAAA
TTCCAC 
GOLPH1 BDNA RS 
Fwd 
25 58.43 64.0 TTAGGGATAGTGGTTATGGG
TAGTT 
ST5 Bis Rev 29 55.7 17.20 AAAAATAAATCTACTTCTAA
ACTTAAAAC 
ST5 BDNA FS Fwd 30 55.81 46.67 GTAAAGAGTTTAAGGAGTT
TTTAGATAGTT 
Table 2.18 Oligonucleotides used for sequencing bisulfite-converted DNA. 
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 Introduction 3.1
Next generation sequencing has become an important part of molecular biological and 
patient profiling. In particular, techniques such as RNA-seq, ChIP-seq and methylation 
arrays are used to give a more systematic analysis of the whole genome, allowing better 
understanding of epigenetic and regulatory morphology, gene expression regulation and 
DNA-protein binding. 
This project was focused on changes in gene expression and methylation and how the 
DNA binding of SWI/SNF complex changes after SMARCB1 re-expression. The 
strategy aims to select a set of candidate genes/pathways with interesting features as 
potential Malignant Rhabdoid Tumours drug targets. Furthermore, the experiments 
carried out in the Rhabdoid cell lines have been cross-referenced to a set of primary 
data, to characterise the key biological features of these tumours. 
 
 RNA sequencing pipeline 3.2
The next generation sequencing technologies present more advantages than previous 
technologies such as microarrays. For instance, RNA-seq does not require a fully 
annotated transcriptome and has better resolution and sensitivity (Martin and Wang 
2011). RNA-seq is more widely used next generation sequencing technique, providing 
access to high-level transcriptomic information, such as novel promoters and isoforms, 
fusion genes, aberrations, alternative splicing and novel transcript (Oshlack, Robinson 
et al. 2010). Many approaches have recently been developed to extract such information 
from RNA-seq data, however creating a solid analysis pipeline remains an ongoing 
challenge. Additionally, RNA-sequencing generates millions of raw sequence reads 
which are processed by multiple computational processing steps. In this study pipeline 
analysis was tailored to characterise changes in gene expression following SMARCB1 
re-expression in Malignant Rhabdoid Tumour cells and expression patterns in patient 
material. 
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 Samples preparation  3.2.1
Samples were prepared as indicated in section 1.1.1. After quantification with picogreen 
and quality evaluation by Agilent Bioanalyser (section 2.1.1), RNA samples were 
shipped to Aros, Denmark on dry ice for library preparation. 
 
 Library preparation  3.2.2
RNA (0.5 – 10 ng) was amplified using the Ovation RNA-Seq system (NuGEN). 
Briefly cDNA/mRNA hybrid molecules were produced and fragmented to synthesise 
double-stranded cDNA. cDNA was subject to SPIA (Single Primer Isothermal 
Amplification) amplification and ends were repair using T4 DNA polymerase and 
Klenow polymerase. Single A bases ware incorporated to the nucleotide using Klenow 
3’ and 5’ exopolymerase, followed by ligation with a mix of adaptor oligonucleotides 
using T4 DNA ligase. The adaptor ligated nucleotide of approximately 200 bp was 
isolated on a 2% agarose gel. The ligated oligonucleotides were amplified for cluster 
generation by 10 to 15 cycles of ligation mediated PCR (LM-PCR). Subsequently the 
samples were purified and quantitated using the Agilent Bioanalyser. 2 – 4 pM of the 
resulting cDNA libraries were used for sequencing.  
 
 Solexa sequencing (Illumina Hi-seq 2000) 3.2.3
The Illumina sequencing technology is based on “sequencing-by-synthesis” (SBS) 
method, which implies the use of DNA polymerase to extend many DNA strands in 
parallel (Liu, Li et al. 2012). This strategy is characterised by a real-time sequencing 
without template amplification, using indicators of nucleotide incorporation. An 
overview of the workflow of Illumina sequencing is given in Figure 3.1. 
The flow cell surface is coated with single stranded oligonucleotides that correspond to 
the sequences of the adapters ligated during the sample preparation stage. The single 
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stranded oligonucleotides (corresponding to the library adapter ligated sequences) were 
bound to the surface of flow cells, and exposed to reagents for polymerase-based 
extension. The insertion of unlabelled nucleotide and bst polymerase at the free/distal 
end of a ligated fragment "bridges" to a complementary oligonucleotide on the surface. 
Repeated cycles of denaturation and extension result in an amplified cluster of single 
molecules in unique locations on the flow cell surface (cluster station). To identify the 
physical location of a cluster a high resolution image of the flow cell was taken after the 
first incorporation of fluorescent nucleotide. Each fluorescent nucleotide has reversible 
terminator chemistry such that one nucleotide may be added followed by flow cell 
scanning then the terminator chemistry reversed to allow the next fluorescent nucleotide 
to be added. This process is repeated for every nucleotide sequenced. Every single 
image of the flow cell taken in each cycle represents an individual base extension at a 
specific cluster. We aimed to obtain ~90 million reads of ~100 bases, taken from both 
ends of each cDNA fragment (paired-end reads). 
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Figure 3.1 Overview of DNA sequencing using the Illumina platform. RNA is 
first converted in cDNA and fragmented into smaller fragments, using 
nebulization. After end repair, specific adapters are ligated to the ends of 
the fragments, allowing hybridization to a flow cell. Bridge amplification 
creates clusters of fragments with the very same sequence. One strand of 
DNA is detached and the clusters are incubated with fluorescently labelled 
nucleotides. A single base is incorporated at every cycle by a modified DNA 
polymerase. Sequentially images of the flow cell are recorded and a 
computer processes which nucleotide was incorporated at each cluster’s co-
ordinates. Subsequently, images are converted into sequence files by image 
analysis, base calling, and sequence filtering (Churko, Mantalas et al. 
2013). 
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 Primary data processing 3.2.4
The Illumina Genome Analyser (GA), using Sequencing Control Software (SCS) v2.9, 
produced images files as primary output from a sequencing run. Specifically, the initial 
image analysis was performed by Genome Analyser Control Software (GCS), followed 
Real Time Analysis (RTA) for base calling and quality testing. This process (Figure 3.2) 
includes: 
1. Image analysis, which provides the cluster location, cluster intensity and noise 
estimation. 
2.  Base calling, which provides the sequencing of bases for each cluster, a 
confidence level for each base and read filtering, using Bustard RTA software; 
the results are stored in *.bcl binary file containing base call and quality for 
single base in each cycle. 
3. FASTQ generation; to continue the analysis *.bcl fine are converted in *.fastq.gz 
files (compressed FASTQ files) by CASAVA software, creating a text file 
containing nucleotide sequence and its corresponding quality scores. 
 
3.2.4.1 Raw data quality control  
The raw data were subject to a quality control using FastQC program 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). The program produces a 
complete report detailing the composition and the quality of sequence, focusing on 
insert size distribution, true peak calling, detection of sequence duplications and kmer 
content. The Fast QC analysis scrutinises each read, scoring according to the Qphred 
score (Mbandi, Hesse et al. 2014). The Qphred score corresponds to the probability of 
incorrect base call (Table 3.1). Usually a Qphred 20-30 is set as a threshold to 
distinguish useful sequence data. In this study the Qphred value threshold was > 30 the 
quality of sequenced nucleotides generally decreasing slightly from 5’ to 3’ end. 
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QPhred quality score Probability of an  
incorrect base call 
Base call accuracy 
 
10 
 
1 in 10 
 
90% 
20 1 in 100 99% 
30 1 in 1000 99.9% 
40 1 in 10000 99.99% 
Table 3.1. Qphred quality score values and accuracy 
 
Figure 3.2 Overview of the primary data analysis. The high quality images 
of the flow cell are processed to extract cluster location, cluster intensity, 
and noise estimates. In Real Time Analysis (RTA) the processed trace is 
translated into a sequence of bases, creating a *.bcl text file.*.bcl files are 
converted on FASTQ file using CASAVA software; in this step de-
multiplexing is performed.  
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Sequence Alignment (Star Aligner) RNA-STAR: ultrafast universal RNA-seq aligner 
Reads were aligned to the HG19 (UCSC) Homo Sapiens genome using Splice 
Transcripts Alignment and Reconstruction tool (STAR) (Dobin, Davis et al. 2013). This 
software permits a novel alignment strategy for de novo detection of the splice junctions 
(exons), not requiring any previous a priori annotation. The algorithm is strategically 
designed to identify maximum mappable length of a read, multiple loci to which a read 
can be aligned, to estimate the relative probabilities of these alignments. STAR stores 
alignment of nucleotide sequences in *.Aligned.out.sam files which are subsequently 
converted in *.BAM files to be used in other programs. 
 
3.2.4.2 Alignment Quality Control (SeqQC) 
The quality of the alignment was assessed using SeQC V2.1 a program designed to 
check a wide range of metrics showing the overall quality of alignment i.e. number of 
reads aligned (http://genotypic.co.in/SeqQC.html). The program gives an automated 
overview of sequence files with graphical summary reports including number of 
sequences, length distribution, low complexity regions, GC content and user specified 
sequence searches. This is a quality check of raw sequence data, important prior to in-
depth analysis HTSeq: high-throughput sequencing analysis. 
The HTseq-count python script was used to quantify the number of reads mapping to 
exons for each gene (Anders, Pyl et al. 2014). HTseq analyses how many reads overlap 
to a given list of genomic features, in this case exon structure of the genes. Additionally 
to investigate alternative splicing, each exon has been considered as a single feature. In 
addition HTseq allows analysing reads that overlap more than one genomic feature. The 
script permits analysis in three different modes, with respect to overlap resolution: 
union, intersection-strict, and intersection-nonempty (Figure 3.3). In this study the 
union mode was chosen and the reads counted according to the GENCODEv17 
transcriptome library. Using HTseq it is possible to obtain a table with counts 
overlapped with annotated features and discarding multi-alignment reads. 
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Figure 3.3 Illustration of the three overlaps resolution modes, used in the 
high-throughput sequencing analysis (http://sfg.stanford.edu/). 
 
 Differential Expression (DEseq) 3.2.5
DESeq is a commonly used R package to test for differential expression analysis of 
RNA-seq data (Anders and Huber 2010). DEseq is based on the hypothesis of non-
linear relationship between the variance and mean expression levels. DESeq performs 
statistical testing on raw data set obtained from the alignment resulting in differential 
gene expression analysis, throughout the dynamic range of the data. Dispersions are 
estimated using expected mean values from the maximum likelihood estimate of log2 
fold changes, and optimising the Cox-Reid adjusted likelihood. A generalised linear 
model is then fitted and tested for significance. The steps are 1) estimation of size 
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factors 2) estimation of dispersion, 3) negative binomial GLM fitting and Wald 
statistics. In this study DESeq has been applied to RNAseq count data to search for 
differential abundance (or differential expression DE) of a particular gene between 
different conditions (with or without SMARCB1 re-expression) or different tumour types 
(Medulloblastoma vs Malignant Rhabdoid Tumours; Atypical Teratoid Rhabdoid 
Tumours vs Extra Cranial Rhabdoid Tumours). The detection of DE genes is based 
upon a negative binomial parametric model to test a generalised linear model as a means 
of hypothesis testing.  
Initially the raw data is processed to estimate the effective library size (to calculate the 
relative size of each library from the count data) and the counts normalised to the 
effective library size e.g. a library of 120 million reads would have its gene counts 
reduced by a factor of two when compared to a library of size 60 million. Secondly, 
DEseq extrapolates the dispersion (a measure of biological and technical variance) 
directly from the mean. This data may additionally be subjected to a variance stabilising 
transformation (VST) converting the data into an approximately homoscedastic measure 
of expression (variance becomes independent of the mean) applicable as an input for a 
variety of follow up statistical analysis (e.g. Limma, NMF, etc.).  
Statistical tests have been used to determine if the estimated changes in expression 
between the two conditions chosen were significant. DESeq calculates differential 
expression attributes such as False Discovery Rate (FDR), fold change values and p-
values from count data. A variation of Fisher’s exact test was used to calculating exact 
p-values computed from the derived probabilities. To control the false discovery rate, a 
multiple testing correcting Benjamini-Hochberg procedure was applied to the data (p 
value adjusted).  
 
 Differential Exon Usage (DEX-seq) 3.2.6
DEXseq is a similar tool to DESeq, but it identifies differential splicing or differential 
exon usage between two sets of conditions (Anders, Reyes et al. 2012). DEXSeq works 
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by dividing the reads mapped to the same gene into counting bins depending on the 
exons they overlap. Counting bins do not completely correspond to exons since 
different transcripts may have different exon sizes in the same genomic location. In that 
way, a transcript that has varying lengths for the same exon gets assigned to two 
counting bins, one for the shortest exon, and one for the additional bases of the longer 
one, plus more counting bins for the remaining exons. Each unit of non-overlapping 
exon is referred to as an exonic part. DEXSeq also uses a generalised linear model 
(GLM) to model the read counts in exactly the same way as the DESeq (see above) 
however dispersion estimations are performed exon by exon instead of gene by gene 
prior to statistical testing exons are also normalised to the overall number of counts for 
the whole gene so as to provide a measure of exon usage relative to the expression of 
the gene. 
The analysis of the reads with DEXseq gives values such as conditional-maximum-
likelihood estimate for the dispersion, dispersion value used in the test, the p value from 
the test for differential exon usage, the Benjamini-Hochberg-adjusted p value, and log2 
fold change between treatment controls. Furthermore, DEXSeq creates a HTML page 
for each gene that contains the test results for an interactive browsing of the results. 
 
 Transcriptome assembly: differential CDS, promoter usage, TSS usage and 3.2.7
novel isoforms  
Transcriptome assembly is a qualitative analysis of the genome focused on alternative 
splicing, antisense expression, extragenic expression, alternative 5’ and 3’ usage and 
detection of fusion transcripts. Short reads can be aligned not only to a reference 
genome but to an independent genome (de novo approach). De novo assembly aims to 
merge all possible overlapping sequences to form contigs (Garber, Grabherr et al. 2011). 
In RNAseq contigs (or transfrags) represent larger fragments of combined and 
assembled reads, each correspond to transcripts derived from protein-coding genes 
(Figure 3.4).  
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Figure 3.4 Example of a contig assembled by the joining of many short 
reads (http://sfg.stanford.edu/). 
 
In De novo assembly analysis lengths and numbers of contigs are usually shorter and 
more numerous in comparison to the predicted number of transcripts of the reference 
genome. This is caused by the impossibility of joining all contigs unless there is enough 
coverage and overlap between reads. 
The transcript assembly was performed using Cufflinks, a program which maps the 
transcript fragments to a list of input data. Cufflinks analyses *.SAM alignment files 
and can give an indicative value of the relative abundances of transcripts. Cufflinks 
calculates the indicative value of the relative abundances based on the number reads of 
each transcript type. Moreover, it provides coordinates of transcripts and the position of 
exons in relation to their position on the reference genome. Cufflinks analysis finally 
provides FPKM values (Fragments Per Kilo-base of exon per Million fragments 
mapped), which are used to normalise gene expression levels. It also filters out certain 
artefacts and background using rigorous statistical calculation. The analysis resulted in 
three different output data set in *.GTF file format: 
1. Gene expression file which contains estimated values of gene-level expression.  
2. Transcript expression file which contains estimated values of isoform-level 
expression. 
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3. Assembled transcript data set which contains the location of each individually 
assembled transcript, their FPKM and the exon position.  
After having individually assembled each alignment, assemblies from each sample were 
merged together, using the meta-assembler tool Cuffmerge. (Roberts, Pimentel et al. 
2011). This strategy has been chosen to avoid assembling the transcript incorrectly; in 
fact pooling samples in a set can lead to a complex mixture of splice isoforms, 
increasing the possibility of an incorrect transcript assembly. Cuffmerge was used to 
merge de novo assemblies with the GENCODE v17 transcriptome library and thus 
identifies where a transfrag is already known (i.e. completely encapsulated within an 
existing GENCODE v17 gene, a novel isoform (i.e. partially overlaps with an existing 
GENCODE v17 gene) or a completely novel transcript (i.e. no overlap with an existing 
GENCODE v17 gene). Once a merged transcript assembly has been produced this may 
be used as an analysis template for Cuffdiff, which uses statistical methods to calculate 
differential expression between samples. Cuffdiff is a program developed to reduce 
biological variability; learning to count the reads for each gene across the replicates 
Cuffdiff is able to estimate variance between replicates and therefore calculate the 
significance of the expression changing. Moreover, Cuffdiff can identify other features 
beyond change in gene expression, such as the presence of differentially spliced genes 
or genes regulated by promoter switching. Notably, Cuffdiff can identify multiple splice 
variants of the same gene and evaluate relative abundances of isoforms, using Jensen-
Shannon divergence. Gene and transcript expression level changes are listed as simple 
tabular output, containing fold change, p-values, adjusted p-values, gene and transcript 
names and location in the genome. The tool also groups isoforms by TSS 
(Transcriptional Start Site), searching for changes in relative abundance between 
conditions. Similarly coding sequences (CDS) are investigated to distinguish gene 
isoforms with differential expressed protein-coding sequences. Finally, the analyses are 
visualised using CummRbund, (R package) which helps to manage and visualise the 
data. 
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 Transcript fusion detection  3.2.8
RNA-Seq has been also used as an approach to gene fusion discovery (Maher, Kumar-
Sinha et al. 2009, Edgren, Murumagi et al. 2011) and specifically identifies which 
fusion events are responsible for aberrant transcript (Jia, Qiu et al. 2013).  
I use SOAPfuse (Jia, Qiu et al. 2013) in order to detect novel transcript fusions. Initially 
the paired end reads are aligned to the human genome reference and filtered. The 
algorithm searches for paired end reads that map in a discordant manner to the genome 
(span reads) and possible junction reads (junc reads) that can confirm possible fusions 
(Figure 3.5). SOAPfuse also applies filter and quality controls to characterise and 
discard artefacts. The filters reject pseudo-genes and genes with extreme homogeneity 
which are prone to misaligning from further analysis. 
 
 
Figure 3.5 Example of fusion events between gene A and gene B. The fusion 
event is suggested by discordant alignments to the genome (span reads) and 
junctions reads (junc reads) (Jia, Qiu et al. 2013). 
 
After having retrieved pair ends that support possible fusion genes, SOAPfuse is able to 
determinate the upstream and the downstream gene of the fusion. In particular the 
determination is made base on the direction of alignment of the span reads against the 
genome reference (Figure 3.6).  
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With SOAPfuse it is possible to identify: 
1. Intercrhomosomal and intrachromosomal fusion  
2. Gene order inversion  
Additionally the algorithm is able to identify the upstream and downstream gene in the 
fusion events (Figure 3.6). This is possible since the RNAseq data are composed by 
paired end reads (one starts from the 3’, the other from the 5’ ends).  
 
 
Figure 3.6. Patterns observed for paired-end fusion analysis. a) perfectly 
matched to the reference genome; b) gene deletion; c) tandem duplication; 
d) inversion; e) transposon insertion; f) reciprocal translocation. Paired-
end read aligned to the reference genome, variation of the distance and 
orientation of the reads indicate a rearrangement has occurred. Reads that 
map to the plus strand are indicated as right-facing arrows, those that map 
to the negative strand as left-facing arrows (Quinlan and Hall 2012).  
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 Identification of viral integration on human genome  3.2.9
Data nonaligned in the previous alignment step have been analysed for possible virus 
integration site. In particular, the data have been aligned to a virus database. VirusFinder 
2 software have been used to characterise possible viral integration site or fusion (Wang, 
Jia et al. 2013). Specifically, the tool can detect virus infection, co-infection with 
multiple viruses, virus integration sites in host genomes. VirusFinder 2 operates in a 
similar manner of SOAPfuse, mapping contings to UCSC hg19 human reference and 
any then aligning any remaining unmapped reads to a viral genome database.  
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 450K Chip Analysis Methylation Pipeline 3.3
Recent advances in genomics and biochemistry have partially explained the functions 
and mechanism behind DNA modifications. DNA methylation was first observed in 
bacteria and associated with a series of restriction-modification processes (Bestor 1990). 
In the last decade the study of methylation events has highlighted the association of 
DNA methylation with cancer development (Esteller 2008). Different approaches were 
developed, based upon techniques such as bisulfite conversion (Xi and Li 2009), 
digestion with methylation-sensitive restriction enzymes (Hashimoto, Kokubun et al. 
2007), and affinity purification of methylated DNA (Robinson, Stirzaker et al. 2010). 
These techniques require an extensive data processing and analysis to extrapolate the 
information about the methylation status. In this study we genotyped sodium bisulfite 
treated DNA using the Illumina 450K Human Methylation BeadChip assay to evaluate 
the genome-wide level of methylation in patients and changes in methylation pattern 
following SMARCB1 re-expression in Malignant Rhabdoid Tumour cells. 
 
 HumanMethylation450 BeadChip assays 3.3.1
HumanMethylation450 BeadChip (450K) assays are based upon genotyping bisulfite-
converted genomic DNA (gDNA). 450K-array platforms determine a quantitative 
measure of methylation at CpG by hybridisation of amplified bisulfite-converted 
genomic DNA to microarrays using methylation-specific oligonucleotides. The 450K 
DNA Methylation microarray contains 485,512 probes, exploring 19,755 unique CpG 
islands, as well as 3091 probes at non-CpG sites coverage. This allows coverage to 
some extent of a total of 21,231 (99%) UCSC RefGenes (Morris and Beck). An 
overview workflow of the 450K methylation array is given in Figure 3.7. 
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Figure 3.7 Infinium Human Methylation 450K BeadChip workflow. 
Unmethylated cytosines converted to uracil by bisulfite treatment, while 5-
methylcytosines are resistant to conversion. The bisulfite converted DNA is 
subjected to whole genome amplification by PCR with random primers; 
subsequently the DNA is enzymatically fragmented and hybridized to a chip. 
The DNA is bound to two different types of beads, one selective for 
methylated locus (M) and one for the unmethylated (U). CpG targets 
hybridised with beads are incubated with specific probes which enable 
single-base extension and detection. On the left an unmethylated locus has 
been bound with methylated and unmethylated beads. In this case there is a 
single-base mismatch to the M probe which inhibits extension. If the CpG 
locus of interest is methylated, the reverse occurs. 
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Briefly bisulfite treatment results in conversion of non-methylated Cytosines (C) to 
Uracils (U) while methylated Cytosine residues are retained as Cytosine. PCR 
amplification with primers specific for bisulfite modified DNA leads to amplicons 
where Thymines (T) replace Uracils (U) while the non-modified Cytosines do not 
change. The amplified and converted oligonucleotides are hybridised to locus-specific 
oligomer probes bound to individual beads on a BeadChip.  
The 450K BeadChip consists of two types of beads. Infinium assay I uses two different 
site-specific probes, one specific for the methylated locus (M bead type) and the second 
for the unmethylated locus (U bead type). Subsequently, fluorescent-labelled single base 
extension provides the array signals. Methylation status is acquired from the 
fluorescence intensity ratios between unmethylated and methylated bead type 
(Illumina). Infinium II probes instead are attached to unique beads and use different dye 
colours (green and red) to differentiate between Methylated and Unmethylated signals, 
respectively. Dual channel single-nucleotide primer extension is performed, adding 
single base extension with dideoxynucleotides labels. In this case the methylation state 
is determined at the single base extension step. 
 
 Primary data processing 3.3.2
Raw data representing the fluorescence are Initially processed using Beadstudio v3.2 
(Illumina). Specifically, the program converts *.TIFF files produced by BeadScan 
software (Illumina) into idat files containing information of paired probes-colour 
channels. Idat files are processed using the Bioconductor package Minfi (Aryee, Jaffe et 
al. 2014). It also assess quality of the array and calculates background levels computed 
from a set of negative controls (Wu, Irizarry et al. 2004). Minfi calculates ratios 
between methylated (M) and unmethylated fluorescent signals (Beta value) which 
indicates the quantitative measurement of DNA methylation status. Beta-value is 
calculated according to the following formula (Martin-Subero, Ammerpohl et al. 2009): 
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	β ൌ Max	ሺM	intensity, 0ሻMax	ሺU	intensity, 0ሻ 	൅ 	Max	ሺM	intensity, 0ሻ 	൅ 	100 
Max (M, 0) and Max (U, 0) indicate the maximum intensity value between M and 0, U 
and 0, respectively. The number 100 is a constant to standardize beta values. Beta values 
are quantitative measurement of DNA methylation status of specific CpGs: the values 
range from 0 to 1; completely unmethylated and completely methylated respectively. 
 
3.3.2.1 Methylation Microarray Quality Control 
Beadstudio also produces quality control (QC) files as *.txt files which are processed 
with the R package Beadarray (Dunning, Smith et al. 2007) for the identification of 
spatial artefacts. Firstly the data have been analysed using BASH (BeadArray 
Subversion of Harshlight) tool which systematically masks beads with anomalous 
intensity (Cairns, Dunning et al. 2008). This tool is an adaptation of the Harshlight tool 
to the Illumina data to identify three major defects of arrays: localised blemishes 
disrupting a few probes, diffuse defects disrupting larger areas, and extended defects 
which invalidate the entire chip. Subsequently after evaluating the spatial artefacts, β 
values have been re-calculated as previously described.  
In addition to the Beadstudio QC control, Bioconductor “Minfi” package was used as an 
additional QC metric (Du, Kibbe et al. 2008). Minfi analyses raw data from Beadstudio 
to evaluate background normalised the data and calculated M values. Beta values are 
heteroscedastic for highly methylated or low methylated CpG sites (Du, Zhang et al. 
2010). The M-value is a Log2 ratio of the intensities of methylated probe versus 
unmethylated probe according to the following formula: 
 
M ൌ Log2ቆMax	ሺM	intensity, 0ሻ ൅ αMax	ሺU	intensity, 0ሻ ൅ αቇ 
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Max (M, 0) and Max (U, 0) indicate the maximum intensity value between M and 0, U 
and 0, respectively. Α is a constant to regularise M value in order to avoid extreme 
changes in values that can derivate from very small intensity values (between 0 and 1). 
Generally M values have a value between -0.5 and +0.5, which correspond to 
unmethylated and methylated CpG respectively. M values are widely used as metrics in 
downstream applications of methylation pipeline. 
 
3.3.2.2  Subset-quantile Within Array Normalisation (SWAN) to correct InfI/InfII shift 
450K methylation array uses two different types of chemical assay on the same array, 
which results in different dynamic behaviour, requiring data pre-processing to make 
them comparable (Dedeurwaerder, Defrance et al. 2011). The normalisation method 
used in this study assumes a similarity of overall intensity of probes with the same 
number of CpGs (Figure 3.8). However distribution analysis of beta-value from 
different probe types often results in aberrant overall beta-value distributions. To 
improve the overall β-value distribution, raw data produced from InfI and InfII beads 
were normalised using SWAN (Figure 3.9). SWAN normalisation consists of a first 
average quantile distribution of a subset of probes with a similar number of CpGs in the 
probe body; the remaining probes are normalised separately by linear interpolation 
between the subset probes (Maksimovic, Gordon et al. 2012). Subset-quantile 
normalisation results not only in an improvement of the beta value distributions, but 
also in reduction of technical variability and better detection of differential methylation. 
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Figure 3.8 Example of similarity of intensity distributions between Infinium 
I and II probes with the same number of underlying CpGs. (a) One CpG in 
the probe body. (b) Two CpGs in the probe body. (c) Three CpGs in the 
probe body(Maksimovic, Gordon et al. 2012). 
 
Figure 3.9 Overall beta value distribution produced by InfI and InfII results 
in an aberrant distribution. SWAN normalisation of the beta value 
distribution improves the overall distribution and reproducibility between 
replicates (Maksimovic, Gordon et al. 2012). 
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 Differential methylation pattern  3.3.3
The analysis of differential methylation patterns was performed using the 
R/Bioconductor package Limma, using moderated t-statistics (Smyth and Altman 2013). 
Statistical analysis on M values derived from Lumi package was performed to identify 
differentially genetically variant. Limma uses an empirical Bayes method to perform 
hypothesis tests and adjusts the p-values for multiple testing returning calculated fold 
changes, standard errors, t-statistics and p-values. 
 
 Detection of Copy-Number Aberrations (CNAs)  3.3.4
Copy number aberrations were detected from 450K raw data as previously written 
(Sturm, Witt et al. 2012). Highly variant probes were excluded from the analysis; 
specifically probes not included between the 0.05 and 0.85 quantile of median summed 
values or over the 0.8 quantile of the median absolute deviation were discarded. Log-
ratios and background for each sample were derived by considering the median; 
respectively the median value of the control and median absolute deviation of adjacent 
probes. 
 Subsequently, adjacent probes were combined to create genomic windows bigger than 
100kb and smaller than 5Mb. The median probe value was calculated from raw data of 
each probe forming single windows. Median value were used to classify Copy-Number 
events for each window; values less than -0.96 indicated homozygosis, between -0.96 
and -0.24 indicate homozygous deletion, between -0.24 and 0.12 a neutral event, greater 
than 0.72 a gain or high-level amplification. 
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 Unsupervised cluster analysis 3.4
Cluster analysis is a statistical data analysis technique that explores a set of subjects 
aiming to create homogenous groups (cluster) such that subjects in the cluster have high 
similarity but differ from subjects in another cluster. The evaluation of clustering is an 
integral part of this study in order to organise the observed genomic data into 
meaningful structures. 
 
 Hierarchical clustering 3.4.1
Hierarchical clustering analysis permits a grouping of similar objects into clusters, 
producing a tree (called dendogram) that indicated the hierarchy of the clusters. This 
approach allows a visualisation of microarray and/or NGS data grouped together on the 
basis of similarity of their underlying features.  
Hierarchical clustering is the result of a multistep process; Initially all objects are 
merged in a single cluster and gradually divided into smaller homogenous groups 
(divisive clustering). Cluster analysis can be also conducted in an agglomerative manner 
(Figure 3.10). In both cases each object when allocated to a cluster cannot be allocated 
to another. 
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Figure 3.10 Example of hierarchical clustering. Hierarchical Clustering can 
be computed using agglomerative methods, in which clusters are merged 
together to form unique single cluster, or divisive methods, which separate 
objects successively into finer groupings.  
 
In this study agglomerative analysis has been used to explore biological differences. 
Distance between clusters can be calculated with four different procedures (Figure 
3.11), defined by the way clusters are linked to a certain object: 
1. Single linkage; the distance corresponds to the shortest distance between any 
two objects in the two clusters. 
2. Complete linkage; this approach considers the longest distance between any two 
members in the two clusters. 
3. Average linkage; the distance is calculated as the average distance between all 
paired object of the two clusters. 
4. Centroid linkage; the distance equals the distance between the two geometric 
centres (centroids). 
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Figure 3.11 Type of distance between clusters calculation methods. A) 
Single linkage; B) Complete linkage; C) Average linkage; D) Centroid 
linkage. 
 
In hierarchical analysis it is also important to establish dissimilarity or affinity between 
pairs of objects. In particular, there are two different methods: linear measurement 
(Euclidean) and alternative distance measurement (Manhattan). The Euclidian approach 
consists of a straight-linear distance; instead Manhattan is defined as sum of the 
absolute difference between their positions (Figure 3.12).  
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Figure 3.12 Difference of methods to assess dissimilarity or affinity between 
pairs of objects. Euclidean function defines the distance between objects as 
root-sum-of-squares difference; instead the Manhattan method determines 
the distance as the sum of the absolute difference between their positions. 
 
 Partitioning methods: k-means 3.4.2
Another clustering method consists of a partitioning model, which is based on the k-
means algorithm. This procedure differs from the discussed method before, since it 
forms homogenous clusters on the base of within-cluster variation. This vector 
quantisation method groups n observations from a data set in k clusters; each 
observation is assigned to clusters with the nearest mean. 
The algorithm first randomly assigns objects to a pre-defined number of k classes and 
characterises the geometric centre of each cluster. After this step for each single subject 
Euclidean distance to the cluster centre is evaluated and each member is assigned to the 
nearest centroid. These steps are alternated until predetermined number of iterations is 
met, in this case when there is no further change in the assignment of the data points. 
 
 Principal component analysis 3.4.3
Principle component analysis (PCA) is a statistical technique able to identify a limited 
number of key variables (principal component) of a set of variables in order to simplify 
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gene expression analysis. This method allows reduced dimensionality of complex data 
sets and reduces computational costs and error of parameter estimation. PCA is an 
orthogonal transformation method aimed at maximising the component vector variance 
of the data set. The analysis determines the direction that corresponds to maximal 
variance between the data points and projects the obtained data on the hyper plane 
orthogonal of that direction (Figure 3.13). Through this mathematical projection it is 
possible to obtain a simpler data set, in which the dimensions are reduced. 
 
 
Figure 3.13 Example of PCA orthogonal transformation. A) Objects from a 
Data set are described by a complex set of variables; B) New coordinates 
orthogonal to each order are set, pointing to the direction of largest 
variances; C) The new coordinates are used to describe the object of data 
set in a simpler way. 
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 Non-negative matrix factorisation 3.4.4
Non negative matrix factorization (NMF) is a statistical analysis based on an algorithm 
that reduces the dimension of NGS or microarray data (Brunet, Tamayo et al. 2004, 
Devarajan 2008). In particular, it permits the characterisation of aggregate patterns of 
gene expression (metagene) from thousands of genes. In contrast to other clustering 
methods NMF clusters genes and samples by factorisation into matrices with non-
negative entries; this results in an analysis with higher biological significance than PCA 
or HC. 
NMF is more complex algorithmically, however it permits decomposition of data and 
also cross-referencing of different data set (Figure 3.14). Data sets are composed of 
expression levels of N genes in M samples. The data are compressed into an expression 
matrix V composed by values N × value M; rows represent expression levels of the N 
genes in the M samples.  
Metagenes (positive linear combination of the N genes) are obtaining by factorisation of 
the matrix A into two matrices characterised by positive entries. Specifically, the two 
matrix derived are W (composed by N genes x k metagene) and H (composed by k 
metagene x M samples), which are approximately equivalent to the matrix A. Each k 
column of the first matrix defines a metagene, while each M column of H matrix 
corresponds to metagene expression pattern of the corresponding sample. 
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Figure 3.14 Example of NMF analysis of expression data sets composed by 
N genes, M samples and imposed k=2. Matrix V is a mock microarray 
expression data: low expressed genes are coloured in green, with the high 
expressed in red. Matrix W is composed of k metagenes and the number of 
gene and each column corresponds to the expression level of each sample 
for a given metagene. Matrix H = N sample with k metagenes; in this case 
each column represents a metagene profile for each sample. Heat colour 
maps are used to indicated metagene expression levels (dark blue= 
minimum ; dark red= maximum). 
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 Consensus-based unsupervised clustering approach 3.4.5
Unsupervised cluster analysis was undertaken in order to investigate the difference 
between Malignant Rhabdoid Tumours (MRT) and Medulloblastomas as well as 
whether there were any subgroups within the MRT cohort, defined by differences in 
their methylation and expression patterns. In this analysis a consensus-clustering based 
approach was applied Initially on RNA-seq and 450K-methylation data sets in order to 
determine the most robust clustering. Better definition was achieved using filtered data. 
The selection of optimal numbers of clusters was performed using NMF (see section 
3.3.4). Each combination of 2:6 (x) metagenes and 2:6 (y) clusters were tested repeating 
the following steps 50 times. The most stable cluster was selected based on the average 
modal cluster score across all samples. The determination of the optimal number of 
metagenes and clusters was necessary for the consensus clustering approach. 
 
 Gene pathway analysis 3.5
High-throughput sequencing techniques have greatly increased the amount of biological 
data, enabling comprehensive biological investigations. However, the large amount of 
data has to be effectively interpreted in order to accurately understand the underlying 
biology of the condition being studied. Modern approaches are available to simplify 
data sets into a smaller set, identify significant genes or proteins. In particular, in this 
study data sets have been interrogated to identify groups of SMARCB1 dependent genes 
actively involved in the same pathway. 
 
 Gene Set Enrichment Analysis (GSEA) 3.5.1
Gene Set Enrichment Analysis (GSEA) is considered a rigorous and complete statistical 
method to classify correlation between genes and group them into uniform classes 
(Subramanian, Tamayo et al. 2005). In this study GSEA analysis has been used to 
explore differentially expressed genes, allowing me to identify SMARCB1 dependent 
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differentially regulated pathways both in primary tumours and in cell lines. GSEA 
analysis requires a data set pre-processing step, which ranks genes according to a 
phenotype or profile determining the distribution of the set of genes across a priori 
predefined gene-sets. The ranked data sets are further statistically processed and for 
each gene set an enrichment score (ES) is given; ES corresponds to the degree of 
correlation between the ranked gene list and a priori predefined gene-sets. Next an 
empirical phenotype-based permutation test is used to calculate significance levels of 
the observed ES, estimating p-values relative to ES null distribution. Finally, ES are 
normalised to the size of the original set, yielding normalised enrichment scores (NES) 
and false discovery rate (FDR) is computed for each NES. FDR corresponds to the 
estimated probability that genes identified as differentially expressed are false positive. 
GSEA also provides *.txt files and visual data report, which allow a simple 
understanding of the enrichment of the data set of interest when compared to a priori 
predefined gene-sets.  
 
 Ingenuity pathway analysis (IPA®) 3.5.2
Ingenuity pathway analysis (IPA®, Ingenuity® Systems, www.ingenuity.com) is a web-
based program which interrogates experimental data to extrapolate biological pathway 
information. IPA is based on the Ingenuity Knowledge Base, curated collection of 
biological and chemical interactions and functional annotations mainly derived from 
over 200,000 peer-reviewed biomedical publications or integrated from third-party 
databases. The database is periodically reviewed and curated by content and modelling 
experts. Moreover all this information has been used to generate a molecular network 
(interactome), a projection of physical, transcriptional and enzymatic interactions 
between molecules. The interactome is used to calculate networks which may simplify 
the understanding of the biological processes in a data set of interest, in the context of 
existing knowledge of interactions. 
 In this study RNA-seq data sets from both cells and primary tumours have been 
analysed using IPA in order to facilitate the molecular analysis and explore how loss of 
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SMARCB1 affects pathways, focusing on those implicated in tumourigenesis. Files 
containing the results from the RNA-seq experiment were uploaded into the Ingenuity 
Pathways Knowledge Base. After having applied a cut-off of 2-fold, the molecules 
retrieved were compared to the IPA global molecular network based on their 
connectivity, using Fischer Exact tests and a p value of <0.05. IPA analysis produced a 
score for each interaction network produced, based on the number of eligible molecules 
present in the network, the total number of eligible molecules investigated and the total 
number of molecules present in the Ingenuity Knowledge Base. Finally, the networks 
recovered by the analysis have been ranked based on the IPA score and further analysed. 
  
 Discovery Database for Annotation, Visualisation and Integrated (DAVID)  3.5.3
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) is a web 
base tool which strategically extracts biological meanings from a gene data set (Dennis, 
Sherman et al. 2003). DAVID is based on DAVID knowledgebase comprehensive of 40 
heterogeneous gene annotation resources (NCBI and UniProt annotation).  
A selected list of genes based upon RNA-seq data from primary material or cell lines 
are submitted to the online DAVID tool. These are first scored based upon gene-gene 
similarity with the a priori assumption that genes are functionally related. Next the data 
sets are functionally grouped into biological modules, corresponding to biological 
processes. In biological systems genes can be active in more than one processes, 
therefore DAVID’s agglomerate algorithm allows the allocation of a gene to more than 
one functional group. Statistically significant results are determined by applying 
Fisher’s exact test (P ≤0.05) which is adjusted for multiple testing. 
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 Establishing the Role of SMARCB1 Chapter 4
Loss in Malignant Rhabdoid 
Tumour Cells 
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 Introduction  4.1
Rhabdoid Tumours are characterised by loss of SMARCB1 gene, they do not 
demonstrate any other consistent mutation or chromosomal aberrations (Hasselblatt, 
Isken et al. 2013). The discovery of SMARCB1 as the single cause of tumourigenesis in 
Rhabdoid Tumours has highlighted this gene as a potent tumour suppressor. Research 
into the effects of re-expression of SMARCB1 in a Rhabdoid cell line has been 
previously attempted; yet little is known about its consequence on the whole genome. 
Previous work has demonstrated that SMARCB1 re-expression causes cell cycle arrest in 
G1, following upregulation of genes such as CDKN2A and CDKN1A and recruitment of 
Rb (Oruetxebarria, VenturSMARCB1 et al. 2004,Chai, Charboneau et al. 2005, 
Kuwahara, Charboneau et al. 2010). It has also been demonstrated that SMARCB1 
plays an important role in chromatin remodelling and its re-expression increases the 
binding to CDKN2A and CDKN1A promoters by changing the methylation status of 
histone marks H3k4 and H3k27. 
It has been speculated that SMARCB1 loss not only affects gene expression but also 
methylation. In fact, SMARCB1 is part of the SWI/SNF complex and several 
SWI/SNF-related factors have been associated with transcriptional silencing through 
DNA methylation (Dennis, Fan et al. 2001). Specifically it has been hypothesised that a 
selective interaction of these complexes with MeCP2 might change the chromatin 
structure to a repressive state (Chandler, Guschin et al. 1999). Moreover, in SMARCA4 
and BRM deficient carcinoma cells CD44 and E-cadherin are hyper-methylated and 
induction of the two ATPse domains, as well as 5-aza-2-deoxycytidine treatment, re-
establishes the methylation and expression level (Banine, Bartlett et al. 2005). In 
Rhabdoid cells, the implication of SMARCB1 in the methylation machinery has been 
studied in only a few cell lines, in which re-expression of SMARCB1 has been combined 
with the 5-aza-2'-deoxycytidine demethylating agent (Muhlisch, Schwering et al. 2005, 
Kia, Gorski et al. 2008). These two isolated experiments showed how re-establishment 
of SMARCB1 function affected the methylation status and expression of CDKN2B and 
CDKN2A in MON cells and RASSF1A in G401 and BT-16 cells. Notably, SMARCB1 
re-expression directly evicts the prebound PRC1 and PRC2 component of the PcG 
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complex and subsequently causes loss of methylation of H3k27 at the CDKN2A 
promoter locus (Kia, Gorski et al. 2008). 5-aza-2-deoxycytidine treatment in the renal 
Rhabdoid G401 cell line results in hypomethylation and re-expression of RASSF1A 
(Muhlisch, Schwering et al. 2005), a gene found often to be hypomethylated in a variety 
of cancer (Dammann, Schagdarsurengin et al. 2003). In contrast, RASSF1A expression 
in the Atypical Teratoid Rhabdoid Tumours derived BT16 cell line does not alter upon 
5-aza-2-deoxycytidine treatment, suggesting a different methylation status dependent on 
the location. 
Other subunits of the SWI/SNF complex have been found mutated in a variety of 
cancer. However, the most frequently mutated subunit is not SMARCB1 but the ATPse 
subunit SMARCA4, suggesting its role as potent tumour suppressor. In SMARCA4 
deficient tumour cells re-expression of wild-type SMARCA4-SMARCA4 causes 
induction of CD44 and of CDKN2A and cell cycle arrest by RB recruitment (Strobeck, 
Knudsen et al. 2000, Strobeck, DeCristofaro et al. 2001). Moreover heterozygous 
inactivation of SMARCA4-SMARCA4 in mice predisposes to epencephalic and apocrine 
tumours development (Bultman, Gebuhr et al. 2000). All these effects have been also 
observed when SMARCB1 is restored in Rhabdoid cell lines, suggesting SMARCB1 and 
SMARCA4 subunits might act together in maintenance of cell homeostasis. Recently, a 
germline nonsense mutation and somatic inactivation of SMARCA4/SMARCA4 in 
SMARCB1 positive Rhabdoid patients has been also observed, supporting the 
hypothesis of a Rhabdoid Tumour Predisposition Syndrome (Hasselblatt, Gesk et al. 
2011). The presence of this mutually exclusive mutation suggests that in Rhabdoid cells 
tumourigenesis might be the result of disruption of remodelling activities of these two 
SWI/SNF subunits.  
This part of the study was focused upon building Rhabdoid cell models in which 
SMARCB1 was stably expressed. Moreover, aberrant DNA methylation has been also 
explored, by treatment of cell lines with 5-aza-2'-deoxycytidine specific inhibitors of 
DNA methylation. The role of SMARCA4 in Rhabdoid development has also been 
investigated, blocking SMARCA4 activity by insertion of a dominant negative 
SMARCA4. In order to have a wider and exhaustive catalogue of malignant Rhabdoid 
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events, four cell lines were subjected to experiments: G401, STA-WT1 A204, and 
CHLA-266 derived respectively from primary Rhabdoid tumour of the kidney, liver and 
the brain. These four cell lines represent the most common location of tumours, giving 
the possibility to study the role of SMARCB1 at different location in tumour 
development. Furthermore G401, A204 and STA-WT1 cell lines have previously been 
established as a model to study SMARCB1 re-expression; however this approach has 
never been attempted in cells derived from Atypical Teratoid Rhabdoid primary tumour.  
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 Aims 4.2
The study reported in this chapter aimed to: 
 Assess the effect of SMARCB1 re-expression in gene expression, cell 
morphology, and cell growth and at the chromatin level in Rhabdoid cells 
derived from different location.  
 Investigate the methylation status in Rhabdoid cells and how it changes 
following treatment with 5-aza-2'-deoxycytidine. 
 Understanding the role of SMARCA4 in Rhabdoid Tumours.  
 Develop and validate functional genomic Rhabdoid cell line models.  
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 Re-expression of SMARCB1 in established Malignant Rhabdoid 4.3
cells lines                
 SMARCB1 causes growth arrest and senescence cell formation in Rhabdoid 4.3.1
cell lines 
In order to investigate the tumourigenic mechanism involved in Rhabdoid tumour, we 
first established a stable SMARCB1 expression system in Rhabdoid cells via a lentiviral 
approach. Previous work reported early effects (usually 72h) of SMARCB1 re-
expression, however late ones have not yet characterised. In this study, we performed a 
preliminary time-course induction of SMARCB1 in the G401 cell line followed by 
microarray analysis, in order to describe the late responses and the non-transient change 
in cells. We observed that SMARCB1 re-expression caused a general disruption of 
expression up until the 7th day post infection, with particular emphasis on expression 
patterns involving cell cycle control and differentiation (Figure 4.1). In fact, microarray 
analysis of the RNAs isolated at various times showed that hundreds of genes where 
both up and down regulated, but generally that expression was stable after the 7th day 
following SMARCB1 re-expression. Given this result RNA from all four Rhabdoid cell 
lines was collected at the 7th day post infection. 
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Figure 4.1 SMARCB1 induction affects gene expression in the G401 cell line 
(time course). Microarray analysis evidenced hundreds of differentially 
expressed genes, here shows as a log2 ratio of expression compared to the 
empty vector. A total of 1256 genes were down-regulated (A) and 374 were 
up regulated (B) following SMARCB1rexpression. 
 
Following infection, the shape of SMARCB1 induced cells appeared different from 
vector control infectants by visual inspection. Specifically, the cells acquired flat and 
large morphology, with an increased adhesion to the extracellular matrix. This cellular 
re-arrangement in Rhabdoid cells has been often associated with cellular senescence 
(Versteege, Medjkane et al. 2002, Reincke, Rosson et al. 2003, Oruetxebarria, Venturini 
et al. 2004). SMARCB1 re-expression not only resulted in flattened appearance and 
senescence-associated large shape (Figure 4.2) but also in the dramatic decrease of cell 
proliferation, this effect was observed from the 3rd day post infection onwards (Figure 
4.3).  
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Figure 4.2 Change in cell morphology after SMARCB1 induction in 
Rhabdoid cell line (7 days). After re-expression of SMARCB1 the cell 
morphology has visibly changed: the cells are bigger, flat with evident 
changes in shape. Western blot from cell lysates obtained from uninfected 
cell (Un), from cell infected with pcdh-mcs1-ef1-puro (PCDH) and 
SMARCB1-pcdh-mcs1-ef1-puro (hSNF5). Proteins were extracted at 7 days 
post infection. Protein from the 293t cell line has been used as positive 
control. STA-WT1 cell line is characterized by SMARCB1 point mutation 
and retains SMARCB1 protein.  
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Figure 4.3 Effect of SMARCB1 re-expression on survival (growth) in G401 
and A204 Rhabdoid cells. SMARCB1 re-expression causes significant 
growth arrest within 96 hours post infection, compared to the control-vector 
infectants. The Rhabdoid cells were infected with pcdh-mcs1-ef1-puro 
(PCDH) and SMARCB1-pcdh-mcs1-ef1-puro (SMARCB1) and measurements 
taken between 72h-144 hours post-infection. The graphs show results of 
three individual experiments. 
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Figure 4.4 Effect of SMARCB1 re-expression on survival (growth) in STA-
WT1 and CHLA-266 Rhabdoid cells. SMARCB1 re-expression causes 
significant growth arrest within 96 hours post infection, compared to the 
control-vector infectants. The Rhabdoid cells were infected with pcdh-mcs1-
ef1-puro (PCDH) and SMARCB1-pcdh-mcs1-ef1-puro (SMARCB1) and 
measurements were taken post infection (72h-144 hours).In the graphs are 
indicated results of three individual experiments. 
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 SMARCB1 induces CDKN2A, CDKN1A and CD44 over-expression in 4.3.2
Malignant Rhabdoid Tumour cell lines  
SMARCB1 re-expression in Malignant Rhabdoid Tumours deregulates expression of 
genes that control cell cycle regulation such as CDKN2A, CDKN1A and CD44 
(Kuwahara et al, 2010; Kuwahara et al, 2013; unpublished data). The RNA levels of 
these gene were analysed 7 days post infection and were measured by quantitative RT-
PCR. The cell lines G401 and A204 cell line show an increase of CDKN2A (5.4 fold and 
7.3 fold respectively), CDKN1A (33 fold and 23.4 fold respectively) and CD44 (11.1 
fold and 1x106 fold respectively) compared to the vector control infectants and 
untreated cells (Figure 4.5). The expression values obtained are similar to those 
previously observed in our time course (data not indicated) and those in the literature 
(Kuwahara, Charboneau et al. 2010). STA-WT-1 showed a significant increase of 
CDKN1A (27 fold) and CD44 expression (45.1 fold) similar to G401 and A204 but no 
substantial increase in CDKN2A expression (2.2 fold). CHLA 266 showed increases in 
expression of CDKN1A expression similar to the other cell lines (19.5 fold), but no 
increase in CDKN1A and expression of CD44 was undetectable in both untreated cells 
and the empty vector control (Figure 4.6).  
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Figure 4.5 SMARCB1 re-expression induces changes in gene expression in 
G401 and A204. RNA was extracted at 7 days post infection with pcdh-
mcs1-ef1-puro (vector control) and SMARCB1-pcdh-mcs1-ef1-puro. The 
mRNA levels were measured by real-time qRT-PCR and normalised to beta-
2-microglobulin. Values are the mean of 3 independent measurements. 
Untreated cells (Un) were used as a control. 
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Figure 4.6 SMARCB1 re-expression induces changes in gene expression in 
G401 and A204. RNA was extracted at 7 days post infection with pcdh-
mcs1-ef1-puro (vector control) and SMARCB1-pcdh-mcs1-ef1-puro. The 
mRNA levels were measured by real-time qPCR and normalised for beta-2-
microglobulin. Values are the mean of 3 independent measurements. 
Untreated cells (Un) have been used as control. 
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Changes in the recruitment of the SWI/SNF complex caused by SMARCB1 re-
expression in Malignant Rhabdoid Tumours were also investigated at the CDKN2A and 
CDKN1A locus. Chromatin immunoprecipitation was performed on immunoprecipitated 
DNA using antibodies for SMARCB1, SMARCA4, H3k4me and H3k27me and 
appropriate control IgGs at 7 days post infection in the A204 and G401 cell line. Re-
expression of SMARCB1 alters binding at a locus within 1 kb of CDKN2A and CDKN1A 
of the TSS (Transcriptional Start Site) with maximal enrichment at the TSS in both 
A204 and G401 cell lines (Figure 4.7). Similar results were obtained using a 
SMARCB1 antibody, in contrast with results previously described by Kuwahara 
(Kuwahara, Mora-Blanco et al. 2013), who reported a general increase throughout the 
whole region (Figure 4.8). In our experiment SMARCB1 re-expression increases the 
levels at the CDKN2A and CDKN1A TSS of H3K4me3 (Figure 4.10), a chromatin mark 
associated with gene activation, whilst inhibiting the repressive H3K27me3 marks. 
These results indicate that SMARCB1 actively binds to the TSS in combination with the 
SMARCA4 ATPse subunit, promoting methylation of the H3K4 in a stable manner 
(Figure 4.9). 
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Figure 4.7 SMARCB1-dependent recruitment of SMARCA4 at the CDKN2A 
(p16) and CDKN1A (p21) locus after SMARCB1 re-expression in G401 and 
A204 cells. At 7 days after SMARCB1 re-expression. Chromatin was 
extracted for Chip assay, performed using antibody against SMARCA4 and 
precipitated DNA was measured by Q-PCR at various locations spanning the 
CDKN1A and CDKN2A locus; Values are the mean of triplicates. Empty 
vector infected cells (pCDH) were used as a control. 
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Figure 4.8 Recruitment of SMARCB1 at the CDKN2A (p16) and CDKN2A 
(p21) locus after SMARCB1 re-expression in G401 cells. At 7 days following 
SMARCB1 re-expression. Chromatin was extracted for Chip assay, 
performed using antibody against SMARCB1 and precipitated DNA was 
measured by Q-PCR at various locations spanning the CDKN1A and 
CDKN2A locus; Values are the mean of triplicates. Empty vector infected 
cells (pCDH) were used as a control. 
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Figure 4.9 Recruitment of H3k4me3 histone modification at the CDKN2A 
(p16) and CDKN2A locus after SMARCB1 re-expression in G401 and A204 
cells. At 7 days following SMARCB1re-expression. Chromatin was extracted 
for Chip assay, performed using antibody against H3k4me3 and precipitated 
DNA was measured by Q-PCR at various locations spanning the CDKN1A 
and CDKN2A locus; Values are the mean of triplicates. Empty vector 
infected cells (pCDH) were used as a control. 
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Figure 4.10 Recruitment of H3k27me3 histone modification at the CDKN2A 
(p21) and CDKN2A locus following SMARCB1 re-expression in G401 and 
A204 cells. At 7 days following SMARCB1 re-expression Chromatin was 
extracted for Chip assay, performed using antibody against H3k27me and 
precipitated DNA was measured by Q-PCR at various locations spanning the 
CDKN1A and CDKN2A locus; Values are the mean of triplicates. Empty 
vector infected cells (pCDH) were used as a control. 
 
 
 
 
 133 
 
 Effects of 5-aza-2-deoxycytidine treatment on methylation 4.4
status of Malignant Rhabdoid cells 
In this part of the study all four Malignant Rhabdoid Tumour (MRT) cell lines (G401, 
A204, CHLA266, STA-WT1) have been treated with the DNA demethylating agent 5’-
aza-2’deoxycytidine (5-azaCdR), in order to analyse to what extent the gene expression 
profile of MRT is controlled by methylation status and to investigate if changes in gene 
expression upon SMARCB1 re-expression are the result of methylation status 
modification. 5-azaCdR is a demethylating agent that irreversibly binds DNA 
methyltransferase enzymes (DNMTs), resulting in a block of their methyltransferase 
function. As a result, 5-azaCdR induces significant demethylation in human cell lines 
(Jones 2012). 
We investigated the effect in methylation in three genes: RASSF1A, DAZL and HTATIP2 
were examined; the first gene has been found up-regulated in G401 cell line in response 
of 5-azaCdR (Muhlisch, Schwering et al. 2005). The latter in Medulloblastoma cell 
lines (Anderton, Lindsey et al. 2008). Up-regulation of DAZL and HTATIP2 was 
observed in all cell lines upon treatment with 5-azaCdR. RASSF1A was modestly 
upregulated in A204, STA-WT1 and CHLA-266 but not in G401 (Figure 4.11).  
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Figure 4.11 RT-PCR for DAZL (A), RASSF1A (B), HTATIP2(C) and GAPDH 
(D) in Malignant Rhabdoid Tumour cells treated with 5-azaCdR. D283cell 
(Medulloblastoma) line was used as control, as well as a no template. 5-
azaCdR treatment causes upregulation of these three genes through a 
methylation dependent process.  
 
We also analysed the effect of 5-azaCdR treatment on the expression of SMARCB1 
dependent genes CDKN2A, CDKN1A and CD44 in order to understand the role of 
methylation in SMARCB1 dependent regulation (Figure 4.12 and Figure 4.13). 
Interestingly, comparative analysis of the mRNA level between SMARCB1 re-
expressing infected Malignant Rhabdoid Tumour cells and 5-azaCdR treated cells 
revealed equivalent changes in expression, suggesting SMARCB1 expression may 
induce demethylation and therefore changes in expression 
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Figure 4.12 5-azaCdR induces changes in CDKN2A and CDKN1A expression 
in Rhabdoid cells in a similar manner to that observed following SMARCB1 
re-expression. RNA was extracted at 5 day after treatment. The mRNA levels 
were measured by real-time qPCR and normalised to beta-2-microglobulin. 
Values are the mean of 3 independent measurements. Untreated cells (Un) 
and empty vector infected cell (PCDH) have been used as controls 
expression is quoted relative to the untreated control. 
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Figure 4.13 5-azaCdR induces change in CD44 expression gene expression 
in Rhabdoid cells in a similar manner to that observed in SMARCB1 re-
expression. RNA was extracted at 5 day after treatment. The mRNA levels 
were measured by real-time qPCR and normalised to beta-2-microglobulin. 
Values are the mean of 3 independent measurements. Untreated cells (Un) 
and empty vector infected cell (PCDH) have been used as controls 
expression is quoted relative to the untreated control. 
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 SMARCA4 ATPse subunits acts as proto-oncogene in 4.5
Malignant Rhabdoid Tumour 
The role of the SMARCA4 subunit in Rhabdoid Tumours development has been also 
investigated. A dominant negative SMARCA4 (K785R) was re-expressed in G401 and 
A204 cell lines using lentiviral infection. We observed after 36 hours post infection a 
change in the cellular shape of the SMARCA4 DN infectants: the cells appeared smaller 
with a dense cytoplasm while the organelles evolved into a tight and packed 
conformation (Figure 4.14). These features are more related with apoptosis than 
senescence (Elmore 2007). Also we observed a drastic decrease of cell growth 
following SMARCA4 inactivation (Figure 4.15). 
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Figure 4.14 Change in cell morphology after SMARCA4 induction in 
Rhabdoid cell line (48 hours post infection). The cell morphology has 
visibly changed: the cells are visibly smaller in size and the cytoplasm is 
dense in comparison to the SMARCA4 W/T and the empty vector control 
infectants. SMARCA4 D/N protein validation by western blot was possible 
just in G401, due to the poor quality of the protein extracted. Protein from 
293t cell line has been used as positive control. Untreated cells (Un) and 
empty vector infected cell (PCDH) have been used as negative control. 
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Figure 4.15 Effect of SMARCA4 ATPse activity inhibition on survival 
(growth) in G401 and A204 Rhabdoid cells. SMARCA4 D/N causes drastic 
growth arrest within 36 hours post infection, compared to the SMARCA4 WT 
and control-vector infectants. Growth was measured using MTT assay 
absorbance measurements were taken between (76h-168hours) post 
infection. Results of three individual experiments are indicated. Untreated 
cells (Un) and empty vector infected cell (PCDH) have been used as 
negative controls. 
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In order, to understand the mechanism of cell growth arrest caused by SMARCA4 
inhibition, an apoptotic assay against caspases III and VII was performed. Caspases III 
and VII are cleaved directly by caspase VIII or by the intrinsic BID (a BH3 domain-
containing proapoptotic Bcl2 family member,) pathway (McIlwain, Berger et al. 2013). 
In accordance with the change in cell morphology, at 36 hour post infection in both 
G401 and A204 cell lines we detected an increase in apoptotic response; however this 
response decreases after 48 hours after SMARCA4 D/N induction, in agreement with the 
rapid loss of cell viability (Figure 4.16 and Figure 4.17) In particular caspase cleavage 
is triggered by both SMARCA4 WT and DN forms although cleavage is twice as great in 
the DN form. This returns to levels similar to untreated by 96 hours for the WT form but 
not for SMARCA4 DN. 
 
Figure 4.16 Effect of SMARCA4 expression on apoptosis in the G401 cell 
line. Expression of SMARCA4 D/N induces strong early apoptosis which 
compromises cell viability. Caspase cleavage was measured by luminescent 
measurements were taken (24h-96hours) post infection. Graphs show results 
of three individual experiments. Untreated cells and empty vector infected 
cell (PCDH) were used as negative controls. 
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Figure 4.17 Effect of SMARCA4 inhibition on apoptosis in the A204 cell 
line. Expression of SMARCA4 D/N induces strong early apoptosis which 
compromises cell viability. Expression of SMARCA4 D/N induces strong 
early apoptosis which compromises cell viability. Caspase cleavage was 
measured luminescent measurements were taken (24h-96hours) post 
infection. Graphs show results of three individual experiments. Untreated 
cells and empty vector infected cell (PCDH) were used as negative controls. 
 
After SMARCA4 D/N induction cells appeared visibly deteriorated after 36 hours post 
infection: DNA and RNA extraction was successful at only this time point. Nevertheless 
mRNA levels of CDKN2A, CDKN1A and CD44 in A204 and G401 cell lines were 
measured by Q-PCR and reveal that inhibition of SMARCA4 ATPse activity results in 
an up-regulation only of CDKN1A, reflecting previous reports (Kang, Cui et al. 2004). 
However, SMARCA4 D/N expression does not affect the expression of CDKN2A and 
CD44, suggesting that SMARCA4 regulates transcription in a different a manner to 
SMARCB1 (Figure 4.18). Interesting also the WT form induces increase of CDKN2A 
and CDKN1A; this could be due to early detection of the mRNA level, while the cells 
were still under the effect of the Puromycin selective agent. 
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Figure 4.18 Expression of SMARCA4 induces change in expression of 
CDKN1A, but not CDKN2A and CD44 in G401 and A204 cells. RNA was 
extracted 36 hours day post infection. The mRNA levels were measured by 
real-time qPCR and normalised to GAPDH. Relative expression values are 
the mean of 3 independent measurements normalised to empty vector 
infected cell (PCDH) which was used as a control.  
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 Discussion 4.6
 
 Characterisation of the effects of SMARCB1 loss in Malignant Rhabdoid 4.6.1
cells  
Earlier studies showed that re-expression of SMARCB1 in Rhabdoid cell lines causes 
arrest of cell growth by SWI/SNF recruitment and activation of CDKN2A and CDKN1A 
in early stage. For the first time characterisation of the late effects of SMARCB1 re-
expression has been attempted in four cell lines, derived from different location of the 
body.  
A preliminary microarray time course study was performed on a G401 cell line in which 
SMARCB1 has been re-expressed. Hundreds of genes were deregulated in response to 
SMARCB1 induction; in particular SMARCB1’s effect on gene expression gradually 
increased until the 7th day post infection, when a stable steady-state was reached. Based 
on these findings the 7th day post infection was set as a time point for our experiment, 
aiming to investigate the late effect of SMARCB1 re-expression.  
In this study SMARCB1 induction was strategically performed in four different cell 
lines. Cell lines (G401, A204, STA-WT1 and CHLA-266) derived from different 
locations of the body, reflecting the complexity of the Rhabdoid Tumours. SMARCB1 
re-expression in Rhabdoid cells causes a reversion of the cells tumourigenic status into 
one of permanent senescence: cells showed characteristic changes in morphology such 
as enlarged and flattened cytoplasmic shape and increased granularity. This is 
concomitant, in part, to a persistent up-regulation CDKN2A, CDKN1A and CD44 and 
therefore to an arrest of cell growth. These effects were detectable in all four Rhabdoid 
cell lines (with the exception that CD44 is not expressed by CHLA-266), regardless of 
the original tumour site of origin.  
SMARCB1 encodes the SMARCB1 subunit of a chromatin remodelling complex 
(SWI/SNF). Here we demonstrated SMARCB1 function plays an essential role in 
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recruitment of the SWI/SNF complex at chromatin level. In particular formaldehyde 
cross-linking and chromatin immunoprecipitation (ChIP) ware used to investigate 
occupancy of the CDKN2A and CDKN1A promoters in living Rhabdoid tumour cells. 
SMARCB1 re-expression persistently triggers activation of CDKN2A and CDKN1A 
promoters concomitant SMARCA4 recruitment to their respective promoters, 
accompanied by increase of H3K4me (gene activation marker) and decrease of 
H3K27me (repressive marker). 
In conclusion, this study demonstrated that SMARCB1 re-expression alone induced 
senescence in Rhabdoid cell lines, by a lasting up-regulation of CDKN2A and CDKN1A 
and CD44 through direct recruitment of SMARCA4 and H4k4me3 at the TSS of these 
genes. 
 
 Effects of SMARCB1 loss on methylation in Malignant Rhabdoid cells 4.6.2
Demethylating agent 5-azaCdR has been extendedly used to elucidate the implication of 
methylation in gene expression and tumourigenesis. Recently, a study in glioblastoma 
patients suggests a correlation between SMARCB1 loss and change in methylation status 
(Zunarelli, Bigiani et al. 2011) moreover, ChIP analyses show a direct effect of 
SMARCB1 in methylation modifications at the histone level and in recruiting SWI/SNF 
complexes at the promoter region of CDKN2A and CDKN1A. 
In this study Rhabdoid cell lines were treated with 5-azaCdR to investigate SMARCB1 
involvements in the DNA methylation process. Transcriptional activation of DAZL 
(embryonic germ cell marker), RASSF1A (Ras associate oncogene) and HTATIP2 
(metastasis suppressor gene) was observed followed 5-azaCdR treatment in a variety of 
paediatric cancer cell lines, including Medulloblastoma (Harada, Toyooka et al. 2002). 
These findings suggest that aberrant methylation at the promoter of DAZL, RASSF1A 
and HTATIP2 promotes tumourigenesis in Rhabdoid Tumours  
 145 
 
DNA methylation and histone lysine methylation are one of a number of processes 
contributing to transcriptional regulation. Methylation of H3k4 appears to inhibit 
methylation at CpG Islands (Weber, Hellmann et al. 2007), as confirmed by the 
methylation at histone H3k4 in primary human leukaemia cells, following 5-azaCdR 
treatment (Zou, Ma et al. 2012). In Rhabdoid cell lines 5-azaCdR treatment induced up-
regulation of CDKN2A, CDKN1A and CD44, in a similarly manner but with a lesser 
magnitude to that observed following SMARCB1 re-expression. These observations 
validate the hypothesis that hSNF5 and SWI/SNF complexes regulate gene expression 
by direct modulation of DNA- methylation.  
 
 Tumourigenesis induced by SMARCB1 loss is affected by aberrant activity 4.6.3
of SMARCA4 ATPse subunit 
The SMARCA4 ATPse subunit has been found mutated or silenced in a variety of 
tumours and mutations of the SMARCA4 gene are more common than SMARCB1 (Shain 
and Pollack 2013). The presence of germline nonsense mutations and/or somatic 
inactivation of SMARCA4 in Rhabdoid patients have also provided evidence of 
SMARCA4 involvement in Rhabdoid tumourigenesis (Schneppenheim, Fruhwald et al. 
2010, Hasselblatt, Gesk et al. 2011). SMARCA4’s role in Rhabdoid Tumours has 
previously been partially demonstrated in G401, A204 and SMARCB1-conditional mice, 
in which siRNA knock down of SMARCA4 induced growth arrest in G401 cell and 
blocked tumour formation in mice (Wang, Sansam et al. 2009).  
A dominant/negative and a wild type SMARCA4 were stably induced in G401 and 
A204 Rhabdoid cells. Disruption of SMARCA4 activity causes a drastic arrest of cell 
growth, inducing apoptosis. In response to cleavage of caspase III and VII the cells 
undergo apoptosis just 48 hours post infection, showing cell shrinkage, nuclear 
fragmentation and chromatin condensation. SMARCA4 D/N expression in Rhabdoid 
cells also leads to an up-regulation of CDKN2A, while CDKN1A and CD44 remain 
unchanged.  
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In conclusion, stable inactivation of SMARCA4 ATPse activity causes cell growth 
arrest in part by induction of apoptosis. These findings validate the hypothesis of an 
aberrant activity of SMARCA4, following SMARCB1 deletion. However, this study also 
demonstrates that these two SWI/SNF complexes, even though they are part of the same 
protein complex and the same tumourigenic process acts upon different genes and 
therefore different pathways.   
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 Genomic and Methylation Analysis Chapter 5
of Malignant Rhabdoid Tumours  
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 Introduction  5.1
In the last decade DNA and RNA microarrays have provided invaluable information on 
biological mechanisms, resulting in understanding of pathogenesis, in characterisation 
of biomarkers for diagnosis and in the prediction of therapeutic responses. However, 
these technologies present various limitations, overcome by the development of next-
generation sequencing (NGS) technologies and more sophisticated and precise array 
methods. NGS provides an unprecedented resolution and throughput which allows the 
exploitation of entire genome and transcriptome sequences. Whole-genome sequencing 
has been extensively carried out to identify genomic alterations, gene fusions, somatic 
mutations and alternatively spliced forms in colon, lung, breast, prostate and pancreatic 
cancers, Ovarian Clear Cell Carcinoma, Hepatocellular Carcinoma, Leukemia and 
Melanoma (Ku, Cooper et al. 2013). Aberrant DNA methylation is a well recognised 
hallmark of most cancers. New generations of methylation arrays have been used to 
interrogate methylation sites across the genome at single-nucleotide resolution. A 
comprehensive view of the methylation landscape has been evaluated in Choroid Plexus 
Tumours, Lymphoblastic Leukaemia, Medulloblastoma, Paediatric Glioblastoma, 
characterising distinct methylomic events for each cancer group (Castelo-Branco, 
Choufani et al. 2013).  
Although previous studies have comprehensively evaluated molecular profiling of 
primary cancer such as Medulloblastoma, few studies were performed in Malignant 
Rhabdoid Tumours (Ma, Kao et al. 2010, Sullivan, Yankovich et al. 2012, Takita, Chen 
et al. 2014). Moreover, RNA expression profiling of these malignancies were performed 
just by Affymetrix arrays, while methylation profiling has never been published. In the 
past few years just two studies have attempted to investigate the overall differential 
gene expression of Rhabdoid Tumours: these studies characterised a limited number of 
significantly deregulated genes in Rhabdoid Tumours when compared with other 
paediatric malignancy and identified gene signatures (down-regulation of genes 
associated with PRC occupancy and genes associated with chromatin 
processing/remodeling) that might distinguish Extra Cranial Rhabdoid (ECRT) from 
Atypical Teratoid Rhabdoid Tumours (ATRT) (Birks, Donson et al. 2013). However 
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these analysis are limited by the number of primary samples and the technique used: 
samples were were processed by different laboratories and analysed using different 
platforms. 
In this study, for the first time we collected 39 primary Rhabdoid samples (13 Extra 
Cranial Rhabdoid Tumours and 26 Atypical Teratoid Rhabdoid Tumours) and analysed 
them using Genome-wide approaches. In particular, this is the first study to characterise 
global transcriptional and methylomic changes in paediatric cancer using high-
throughput techniques. This approach gives a unique opportunity to identify the 
complex mechanism of tumourigenesis in Rhabdoid Tumours and to provide a 
catalogue of tumourigenic events that can be further investigated. 
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 Aims 5.2
The genome-wide relationship between gene methylation and expression in Malignant 
Rhabdoid Tumours has not previously been investigated. Using global DNA 
methylation and whole transcriptome studies on primary Rhabdoid Tumours , this study 
aims: 
 To characterise differential patterns of DNA methylation and gene expression, 
and their roles in development of Malignant Rhabdoid Tumours  
 To investigate possible methylation-dependent gene expression alterations 
dependent on SMARCB1 
 To identify possible subgroups with specific methylation or gene expression 
events correlating with clinico-pathological features of primary tumours. 
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 RNAseq analysis identifies Malignant Rhabdoid Tumours as a 5.3
single biological entity containing subgroups 
In this section a genomic analysis was designed to test the hypothesis that patterns of 
gene expression were shared within the Rhabdoid Tumours , regardless of the location 
of the malignancies. In this analysis 23 Rhabdoid primary tumours (11 Atypical Teratoid 
Rhabdoid Tumours and 12 Extra Cranial Rhabdoid Tumours) were compared with 251 
Medulloblastoma samples to characterise transcriptomic and methylation diversity 
within the two paediatric malignancies. Medulloblastoma was chosen as an outgroup 
control primarily because a large volume of comparable RNA-seq data was available 
and because it is another paediatric embryonal tumour.  
 
 Primary samples preparation  5.3.1
23 SMARCB1 negative Malignant Rhabdoid Tumour (MRT) primary samples were 
collected from multiple centres throughout the UK in collaboration with the CCLG bio 
bank (ww.cclg.org.uk/tissue-bank). All samples were evaluated at the referring centre 
and subsequently centrally review by the CCLG bio bank. RNA was extracted from 
frozen sample following the previously described procedure (section1.1.1).  
RNA integrity number (RIN score) was evaluated for each sample, using a Bioanalyzer. 
All RNA samples were scored with a RIN greater than 7. Figure 5.1 shows an example 
of the Bioanalyzer trace (sample nmb 845)  
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Figure 5.1 Electropherogram of sample nmb845 with 8.3 RIN score  
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 RNA-seq QC analysis 5.3.2
All samples submitted for sequencing were considered to have passed quality control 
checks as measured by FASTQC. For instance, 100% of samples presented a Phred 
score across all bases higher than 30 (Figure 5.2). 
 
 
Figure 5.2 Per base sequence quality derived from sample nmb 845 from a 
FASTQC html report. The red line represents the median value, while the 
blue line the quality. The plot presents 3 different background shading: 
green indicates good quality score. 
 
3 of the 10 examined quality modules in the FASTQC analysis presented warnings: Per 
base sequence content, Per base GC content and Sequence Duplication levels however 
this is typical of the platform and library preparation used every sample analysed 
regardless of type shows these issues and should not be considered problematic. In Per 
base sequence content the proportion of the four DNA bases for each base position in a 
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sequence is calculated. For per base GC the proportion is considered only for the G and 
C content (Figure 5.4 and Figure 5.4 ). This ratio is expected to be almost zero between 
the different bases of a sequence run, however in a practical sense high variability in the 
first 10 bases is often observed as result of non-random priming (Hansen, Brenner et al. 
2010) but does not in itself imply false sequence.  
 
 
Figure 5.3 Per base sequence content analysis of sample nmb843 from 
FASTQC html report. High variability of the first 10 bases was observed in 
all samples of our data set; this phenomenon is more plausibly constitutive 
biases rather than batch effect. 
 
The sequence duplication levels module evaluates the first 50 cycles to estimate the 
degree of duplication for every sequence in the data set. In our cases approximately 
25% of the analysed sequences presented a degree of duplication higher than 10, 
consistent with the hypothesis of biases due to random priming (Figure 5.5).  
 155 
 
 
Figure 5.4 Per base GC content of sample mnb 843 from FASTQC html 
report. High variability of the first 10 bases was observed in all samples of 
our data set; this phenomenon is more plausible to be constitutive biases 
rather than batch effect.  
 
Figure 5.5 Sequence duplication levels plot of sample mnb483 from FASTQC 
html report. The 10th column includes all duplication levels greater or 
equal 10. 
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 QC analysis  5.3.3
 
5.3.3.1 Unsupervised analysis  
*.Bam files were converted to read counts using the python script HTseq-count (as 
detailed in section 4.2.2.2) to facilitate accurate comparisons between samples. 
Normalisation consists of dividing the gene counts by the total number of reads in each 
library. The resulting data was then subject to a log2 variance stabilising transform (vst) 
using the DE-seq package (R/Bioconductor) and then subjected to unsupervised 
clustering approachs (PCA, HC, and NMF), attempting to detect true biological 
differences between Rhabdoid and Medulloblastoma primary tumours. The analysis was 
conducted considering all the Medulloblastoma samples for the NMF, GSEA and 
DAVID, however for clarity of visualisation PCA analysis and heatmap were computed 
on a smaller subset of 92 primary tumours.  
Principal component analysis (PCA) was carried out with a subset of 5377 gene 
transcripts these were filtered as those genes showing high variance and expression; i.e 
with all samples showing a vst score greater than 5, an interquartile range greater than 4 
and/or an overall range greater than 6 (prop = 0.2, A=5, Gap = 6, interquartile range 
IQR = 4). The PCA plot shows the tendency of sample data to form two different groups 
tending to cluster the Rhabdoid group separate from Medulloblastoma (Figure 5.6). 
NMF/consensus clustering was used to identify the optimal number of metagenes and 
clusters (see section 3.34). The stability of the clustering was evaluated by considering 
cophenetic correlation coefficient and dispersion coefficient. Cophenetic correlation is 
defined as the Pearson correlation between the distances of sample induced by the 
consensus matrix and their cophenetic distances from a hierarchical clustering based on 
these distances (Brunet, Tamayo et al. 2004); dispersion coefficient defines the general 
quality of the clustering consistency (Kim and Park 2007). Metagenes were computed 
using the above filtered genes and showed a cophenetic correlation coefficient value 
equal to 1 with a 4 and a 5 metagene solution, while dispersion coefficient indicated an 
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increase directly proportional to the number of the metagenes ( Figure 5.7). Two 
robust consensus clusters were identified for k=4. 
 
 
Figure 5.6 Unsupervised Principal Component Analysis of DEseq data set 
distinguishes two different biological groups. In red are represent 
Medulloblastoma primary sample while in blue the Rhabdoid. The x-axis is 
the first component; the y-axis is the second principal component.  
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Figure 5.7 Visualisation of cophenetic correlation and dispersion measures 
to assess the stability of clustering associated with each rank k for the 
Rhabdoid and Medulloblastoma derived DEseq data. Dotted line indicates 
randomised data and non-dotted actual data. 
 
We performed the unsupervised NMF analysis (k=4) in the gene subset for all samples 
to determine if there was evident structure in the expression information that reflected 
the tumour phenotype. Analysis of the data revealed clear patterns of gene expression 
that separated the Rhabdoid and Medulloblastoma Tumours (subdived into 3 metagenes: 
corrrsponding to WNT, SHH and a third subgroup). The HC algorithm also confirmed 
the clustered subgroups of samples. To evaluate the reproducibility of this analysis, the 
data were randomly re-clustered 100 times (McShane, Radmacher et al. 2002). The 
consensus analysis reconfirmed the 5 subgroups (Figure 5.9).  
The heatmap and box plot indicated in Figure 5.9 contains the top 20 differentially 
expressed genes (defined by p-value) and illustrates the consistency of the separation 
between Medulloblastoma and Rhabdoid Tumours. 
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Figure 5.8 Unsupervised NMF and hierarchical cluster analysis (K=4) on 
DEseq data set characterises four different metagene classes. Rhabdoid and 
Medulloblastoma are two different groups, the genetic complexity of 
Medulloblastoma (characterized by 4 different subgroups: WNT, SHH, and 
Group 3 and Group 4 clustered togheter) are retained in this analysis. The 
matrices were coloured 0 (deep blue, indicating samples never in the same 
cluster) to 1 (dark red, indicating samples always in the same cluster). 
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Figure 5.9 Heatmap of gene expression showing the 20 most significantly 
differentially regulated genes between Medulloblastoma and Rhabdoid 
Tumours as caluclated by adjusted p-value from DESeq2. Each row 
represents a gene and each column a sample. Overexpressed (pale red to 
dark red) and underexpressed transcripts (pale blue to dark blue). 
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5.3.3.2 Supervised analysis 
Raw count values were analysed in a pair wise fashion using DESeq2 in R. DESeq2 
identifies differentially expressed genes using a statistical method based on the negative 
binomial distribution (Anders & Huber 2010). It computes False Discovery Rate (FDR), 
folds change and adjusted p-values which are then subjected to the Benjamini-Hochberg 
correction for multiple testing. The data set was first tested for variance dispersion, p-
value distribution and FDR. Estimation of the data variance is one of the most important 
steps in the differential expression analysis. In particular, this test allows to distinguish 
noise due to technical error and evaluate if variation observed are real biological effects 
and not a result of experimental conditions. Figure 5.1 represents the estimate of 
dispersion in our data set, where the black dots represent the empirical dispersion values 
and the red line the fitted values. The means across the genes were equally distributed, 
as indicated by the dispersion trend. DESeq computes also a preliminary differential 
gene expression significance test, calculating the significance of change in expression of 
gene between two conditions (in this case Rhabdoid and Medulloblastoma primary 
tumours). This test returns adjusted p-values, mean count values and log2 fold change. 
The analysis is visualised using an MA plot where log2 fold values for each gene are 
plot against the means and the significant differential expression genes at 10% FDR are 
coloured in red (Figure 5.10, Figure 5.11). 
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Figure 5.10 Gene expression dispersion estimation and model fitting of 
Rhabdoid and Medulloblastoma derived DEseq data. Each dot represents a 
per gene dispersion estimation and the red line the fitted mean dispersion 
function. 
 
Figure 5.11 Per gene dispersion estimates from Rhabdoid and 
Medulloblastoma derived DEseq data. Differentially expressed genes 
Log2fold versus mean expression over all samples. Red dots represent genes 
marked as differentially expressed at 10% FDR, when Benjamini and 
Hochberg method is applied. The lines on the top and on the bottom of the 
plot represent genes with a very low or very high log fold change (i.e. the 
value off scale). 
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Next a supervised cluster analysis was performed. Supervised clustering classifies the 
objects in order to capture between-class variations with prior knowledge on data 
clusters previously obtain (Dettling and Buhlmann 2002). First the DEseq data were 
filtered in order to obtain a data set composed of 157 significant genes (adjusted p-value 
< 0.001; moderated log fold change ≤ -3 and ≥ +3). PCA analysis was performed 
confirming the ability of these 157 genes to distinguish between between Rhabdoid and 
Medulloblastoma primary tumours (Figure 5.12). Filtered data were used to generate a 
supervised heatmap which visualises distinct gene expression of Rhabdoid and 
Medulloblastoma primary groups (Figure 5.13).  
 
Figure 5.12 Supervised principal component analysis of 157 genes selected 
as significantly differentially expressed between Rhabdoid Tumours and 
Medulloblastoma distinguishes two different biological groups. In red are 
represented Medulloblastoma primary sample while in blue the Rhabdoid. 
The x-axis is the first component; the y-axis is the second principal 
component. 
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Figure 5.13 Supervised heatmap of gene expression in Medulloblastoma and 
Rhabdoid Tumours. Overrepresented (pale red to dark red) and 
underrepresented transcripts (pale blue to dark blue). Each row represents a 
gene while each column represents a sample. Overexpressed (pale red to 
dark red) and underexpressed transcripts (pale blue to dark blue).  
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The DEseq results were filtered for values with an adjusted p-value greater than 0.0001 
and a moderated log2 fold change less than -4 or greater than 4. In Table 5.1 are 
indicated the 20 most differentially expressed genes as a result of filtering, relative 
difference in expression of these genes is indicated in Figure 5.14 and Figure 5.15. 
Twelve were associated with tumour progression (*), two involved in cell proliferation 
(+), one directly involved in tumour invasion and angiogenesis (-), one indicated as 
potent tumour suppressor genes (~) and one acting in neurodevelopment proliferation of 
neural progenitor cells (#) (www.genecards.org). Complete list in Appendix I. 
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Gene Symbol Adjusted p-value Moderate log2fold 
KRT8* 1.31E-51 2.691206 
AMER2* 7.10E-37 2.446738 
HMGA2* 4.96E-26 2.001177 
TNNT1 + 1.48E-23 1.617837 
POSTN * 6.01E-34 1.59003 
INSM1 * 2.14E-33 1.582486 
S100A4 -  9.74E-48 -1.700879104 
KIF21B 1.50E-37 -1.728031529 
ST18 ~ 2.52E-29 -1.744469767 
SRRM4 1.06E-34 -1.756456049 
COL5A2*  4.18E-39 -1.78873522 
NEUROD1 * 1.18E-82 -1.813588525 
IGF2BP2 + 3.20E-25 -1.819608749 
S100A11 * # 7.95E-35 -1.944165165 
IMPG2 1.79E-53 -1.945484655 
S100A10*# 1.19E-40 -1.951875084 
EPHA8 1.38E-60 -1.958972254 
UNCX# 9.58E-71 -2.012249694 
NEUROG1* 1.26E-75 -2.024899986 
BARHL1 * 7.88E-94 -2.048115239 
 Table 5.1 Differentially expressed genes in Rhabdoid vs Medulloblastoma
primary tumours. Functional annotation of genes relevant to cancer is
shown in the table with * for genes associated with tumor progression 
(*),+ for genes involved in cell proliferation,- for genes directly 
correlated with tumour invasion and angiogenesis, ~ for genes indicated 
as potent tumour suppressor genes # for genes acting in neurodevelopment 
proliferation of neural progenitor cells (#). 
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Figure 5.14 Relative difference in expression of 1-12 of most deregulated 
genes between Rhabdoid Tumours (RT) and Medulloblastomas (MB). Box-
plots show Variant stabilised transformed across the samples. Within 
Boxplots median score (thick black line) and inter-quartile ranges (extent of 
box) and range (whiskers) are indicated. 
 
 168 
 
 
Figure 5.15 Relative difference in expression of 13-20 most deregulated 
genes between Rhabdoid Tumours (RT) and Medulloblastomas (MB). Box-
plots show Variant stabilised transformed across the samples. Within 
Boxplots median score (thick black line) and inter-quartile ranges (extent of 
box) and range (whiskers) are indicated. 
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In particular, AMER2 (upregulated in Rhabdoid Tumours) has been characterised as a 
negative regulator of Wnt signalling (Pfister, Tanneberger et al. 2012), while HMGA2 
causes tumourigenesis by enhancing E2F1, by binding to DNA and introducing 
structural alterations in chromatin. (Fedele, Visone et al. 2006). ST18 is also indicated as 
a tumour suppressor gene in breast cancer (Jandrig, Seitz et al. 2004). NEUROG1 has 
been found methylated in uveal melanoma together with RASSF1A (Merhavi, Cohen et 
al. 2007).  
 
 Cluster analysis identifies two major subgroup in the Rhabdoid cohort 5.3.4
mainly related to location of the malignacies 
In this section we investigated further our Rhabdoid cohort to understand what if any 
was the significant effect of tumour site on biology. The analysis was first performed 
unsupervised, as described in the previous section (3.35). 
 
5.3.4.1 Unsupervised analysis  
Principal component analysis (PCA) was carried out with a subset of 1243 genes 
transcripts (prop = 0.1, A=2, Gap = 3, IQR = 2) from HTseq-count normalised counts 
transformed into vst data. The PCA plot shows the tendency of sample data to cluster 
into two separate groups, mainly correlated with the location of the malignancies: Extra 
Cranial tumours and brain tumours although two Atypical Teratoid Rhabdoid Tumours 
appear to group with extracranial rhaboid tumours(Figure 5.16). 
NMF/consensus clustering approach was used to identify the optimal number of 
metagenes and clusters (see section 3.34). Metagenes were produced for ranks k=2 to 
k=5 evaluation of cophenetic and dispersion coefficients indicated that the most robust 
consensus clustering was k= 2 and 3 (Figure 5.17). 
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Figure 5.16 Unsupervised principal component analysis on DEseq data set 
identifies two major subgroups within the Rhabdoid cohort. In red are 
represented Atypical Teratoid Rhabdoid Tumours (ATRT) primary sample 
while in blue the Extra Cranial Rhabdoid Tumours (ECRT). The x-axis is the 
first component; the y-axis is the second principal component. 
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Figure 5.17 Visualisation of cophenetic correlation and dispersion measures 
to assess the stability of clustering associated with each rank k for the 
Rhabdoid derived DEseq data. The dotted line indicates randomised data 
and non-dotted actual data. 
 
Consensus NMF unsupervised analysis (k=2) in the 1243 gene subset reveals two 
separated patterns of gene expression associated with primary tumour location; in 
particular one biological group is composed of Extra Cranial Rhabdoid Tumours and the 
second by Atypical Teratoid Rhabdoid Tumours (Figure 5.18).  
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Figure 5.18 Unsupervised NMF and hierarchical cluster analysis (K=2) on 
RNAseq data sets characterises two metagene classes mainly correlated 
with the location of the primary Rhabdoid Tumours. Extra Cranial Rhabdoid 
(ECRT) and Atypical Teratoid Rhabdoid Tumours (ATRT) are separated into 
two different groups. The matrixes are coloured 0 (deep blue, indicating 
samples never in the same cluster) to 1 (dark red, indicating samples always 
in the same cluster). 
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The heatmap in Figure 5.19 illustrates the gene pattern between different Extra Cranial 
Rhabdoid Tumours and Atypical Teratoid Rhabdoid Tumours. 
 
Figure 5.19 Heatmap of gene expression showing the 20 most highly 
expressed and differentially regulated genes between Extra Cranial 
Rhabdoid (ECRT) and Atypical Teratoid Rhabdoid Tumours (ATRT) of the 
brain. Each row represents a gene and each column a sample. 
Overexpressed (pale red to dark red) and under-expressed transcripts (pale 
blue to dark blue).  
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Supervised analysis 
DEseq results were filtered down to 243 significantly differentially expressed genes 
(adjust p-value < 0.01; moderated log fold change ≤ -2 and ≥ +2). PCA analysis 
confirmed the presence of two subgroups within the rhaboid tumours (Figure 5.20). 
 
Figure 5.20 Supervised principal component analysis on DEseq data set 
identifies two major subgroups in Rhabdoid cohort. In red are represented 
Atypical Teratoid Rhabdoid Tumours (ATRT) primary sample, while in blue 
the Extra Cranial Rhabdoid Tumours (ECRT). The x-axis is the first 
component; the y-axis is the second principal component. 
 
 
 
 175 
 
Filtered data were used to generate a supervised heatmap (Figure 5.21). Supervised 
analysis demonstrated that Extra Cranial Rhabdoid and Atypical Teratoid Rhabdoid 
Tumours have different gene patterns and the presence in the cohort of few Atypical 
Teratoid Rhabdoid Tumours with mix expression features.  
 
Figure 5.21 Heatmap of gene expression showing the highly expressed and 
differentially regulated genes between Extra Cranial Rhabdoid (ECRT) and 
Atypical Teratoid Rhabdoid Tumours (ATRT) of the brain. Each row 
represents a gene and each column a sample. Overexpressed (pale red to 
dark red) and underexpressed transcripts (pale blue to dark blue). 
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DEseq results were filtered for values with an adjusted p-value greater than 0.0001 and 
moderated log fold change less than -4 or greater than 4. In Table 5.2 are indicated the 
20 most differentially expressed genes after filtering and ranked by relative diffrence in 
expression. These genes are indicated in Figure 5.22 and in Figure 5.23. Eleven were 
associated with tumour progression (*), two involved in cell proliferation (+), three 
directly involved in tumour invasion and angiogenesis (-), one indicated as tumour 
suppressor genes (±), one gene indicated as oncogene and four acting in 
neurodevelopment proliferation of neural progenitor cells (#). Complete list in 
Appendix I. 
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Gene Symbol Adjusted p value Moderated log2fold 
TMPRSS15* 3.81E-11 6.104431 
GJB2*-  2.41E-07 4.489234 
RERG*  1.83E-06 4.172613 
COL6A3 *+  3.94E-08 4.139891 
FIBIN *- 1.29E-05 4.103162 
EMILIN1 1.19E-07 3.865497 
ABCA8 2.68E-05 3.558311 
C7 6.48E-05 3.42491 
MGP 0.000452 3.374596 
SEMA3A* - 0.000713 3.173271 
RFX4 *- 2.45E-16 -7.12075 
NCAN 3.87E-18 -7.19482 
PMP2* 5.43E-16 -7.29577 
C1orf61~+ 1.85E-17 -7.32828 
MT3*- 4.60E-17 -7.338 
SALL3# 3.71E-15 -7.36159 
PTPRZ1 1.09E-20 -7.62713 
GFAP*#  6.94E-25 -8.42908 
FABP7*#  2.76E-22 -8.64199 
SOX1 ± # 6.23E-32 -9.83142 
  
 Table 5.2 Differentially expressed gene in Extra-cranial Rhabdoid 
(ECRT) vs Atypical Teratoid Rhabdoid Tumours (ATRT). Moderated 
log2fold change is given as a ratio between ECRT and ATRT.
Functional annotation of genes relevant to cancer are shown in the
table with * for genes associated to tumor progression ,+ involved in 
cell proliferation,- directly correlated with tumour invasion and
angiogenesis, ~ oncogene, # for genes acting in neurodevelopment 
proliferation of neural progenitor cells, ± tumor suppressor genes.  
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Figure 5.22 Relative differences in expression of 1-12 most deregulated 
genes between Extra Cranial Rhabdoid Tumours (ECRT) and Atypical 
Teratoid Rhabdoid Tumours (ATRT). Boxplots show Variant stabilised 
transformed expression across the samples. Boxplots show median score 
(thick black line), range (whiskers) and inter-quartile ranges (extent of 
box). 
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Figure 5.23 Relative diffrence in expression of 13-20 most deregulated 
genes between Extra Cranial Rhabdoid Tumours (ECRT) and Atypical 
Teratoid Rhabdoid Tumours (ATRT). Boxplots show Variant stabilised 
transformed expression across the samples. Boxplots show median score 
(thick black line), range (whiskers) and inter-quartile ranges (extent of 
box). 
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Interestingly Atypical Teratoid Rhabdoid Tumours showed up-regulation of those genes 
related with neurodevelopment, proliferation of neural progenitor cells, and neuro-
oncogenesis. For instance, GFAP is expressed in Glioblastoma and Chordomas 
(Theurillat, Hainfellner et al. 1999, Santos, Carvalho et al. 2009), moreover its up 
regulation is correlated with increased expression of the B-FABP family in Glioma 
(Godbout, Bisgrove et al. 1998). SOX family proteins have a key role in embryonic and 
postnatal development and lead tumourigenesis in a wide number of cancers; in 
hepatocellular carcinoma hypermethylation of SOX1 causes abnormal activation of 
Wnt/β-catenin signalling pathway and is a marker for cortical neural progenitor cells 
(Elkouris, Balaskas et al. 2011, Tsao, Yan et al. 2012). 
 
RNA-seq metagene projection onto existing primary Malignant Rhabdoid Tumours 
microarray data sets 
The metagene difference between Extra Cranial Rhabdoid Tumours and Atypical 
Teratoid Rhabdoid Tumours was further studied by interactive exploration of gene 
expression measurements obtained by RNA-seq in combination with pre-existing gene 
expression analysis. In particular, the metagene patterns were projected onto three data 
set (Birks, Kleinschmidt-DeMasters et al. 2010, Gadd, Sredni et al. 2010, Williamson 
unpublished data), using a data-driven learning process. 
The three data sets came from different laboratories and were acquired on different 
microarray technologies, Affymetrix HGU133plus2 for Birks and Williamson’s data set 
and Affymetrix HGU133 for the Gadd’s cohort. Metagene projection methodology was 
applied as previously described by Tamayo et al. (Tamayo, Scanfeld et al. 2007). For the 
analysis a rank of k = 2 as metagene factors was used, in accordance with my previous 
analysis of cophenetic correlation and dispersion measurement in my RNA-seq data set. 
Fig. 2 shows the resulting heat maps for the test sets and projected model. This analysis 
showed clearly the two metagene associate with the Extra Cranial and the brain 
biological phenotypes across technology platform although not exclusively. In particular 
Extra Cranial Rhabdoid Tumours constitute mainly a unique and clear subgroup, 
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although some Extra Cranial Rhabdoid and Atypical Teratoid Rhabdoid Tumours 
samples present features of both metagenes. This confirms the difference in gene 
signature we observed in our cohort.  
 
 
 
Figure 5.24 Heatmaps of metagene projection of Malignant Rhabdoid 
Tumour primary samples. These heatmaps show the metagene expression 
levels for each sample. Extra Cranial Rhabdoids (ECRT) are indicated in 
pink while the Atypical Teratoid Rhabdoid Tumours (ATRT) are indicated in 
purple. Heat maps of the RNA-seq projected model (top) and of the Gadd’s 
Cohort after metagene projection (bottom) are indicated. The test data was 
acquired using HGU133a microarray platforms on a total of 10 ECRT. 
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Figure 5.25 Heatmap of metagene projection of Malignant Rhabdoid Tumour 
primary samples. These heat maps show the metagene expression levels for 
each sample. Extra Cranial Rhabdoids (ECRT) are indicated in pink while 
the Atypical Teratoid Rhabdoid Tumours (ATRT) are indicated in Purple. 
Heat maps of Birks’ and Williamson’s data set after metagene projection is 
indicated. Both data tests were acquired using HGU133plus2 microarray 
platforms. In blue is indicated Birks’s cohort, constituting a total of 18 
ECRT. Williamson data set is indicated in dark pink and it is composed of 
23 Extra Cranial primary tumours and 7 Atypical Teratoid Rhabdoid 
Tumours.  
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 DEXSeq analysis: differential exon usage  5.3.5
DEXSeq divides reads mapped to the same gene into contigs depending on the exons 
overlapped. Each count does not coincide with exons but with exonic parts since 
transcripts often present exons with different sizes in the same genomic location. 
Therefore two transcripts characterised by different lengths for the same exon are 
assigned two counts (one for the shortest exon, and one for the longer one), plus the 
counts for the remaIning exons.  
DEXseq, as well as DEseq, computes False Discovery Rate (FDR), fold change and 
adjusted p-values which are subjected to the Benjamini-Hochberg correction for 
multiple testing. The data set was firstly tested for variance dispersion, p-value 
distribution and FDR, as previously described (section 5.3.3). Figure 5.26 represents the 
estimate of dispersion in our data set, where the black dots represent the empirical 
dispersion values and the red line the fitted values. The means across the genes were 
equally distributed, as indicated by the dispersion trend. A differential exon usage 
significance test between two conditions (Rhabdoid vs Medulloblastoma primary 
tumours and Extra Cranial Rhabdoid Tumours vs Atypical Teratoid Rhabdoid Tumours) 
was calculated (Figure 5.26, Figure 5.27, Figure 5.28, Figure 5.29). 
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Figure 5.26 Differential exon usage dispersion estimation and model fitting 
of Rhabdoid and Medulloblastoma derived DEXseq data. Each dot 
represents exonic part dispersion estimation and the red line the fitted mean 
dispersion function. 
 
Figure 5.27 Per exonic part dispersion estimates of Rhabdoid and 
Medulloblastoma derived DEXseq data. Differentially used exons Log2fold 
change versus mean expression over all samples. Red dots represent exonic 
parts significantly differentially used in 10% FDR in Rhabdoid primary 
tumours, when the Benjamini and Hochberg method is applied. The lines on 
the top and on the bottom of the plot represent exon usage with a very low 
or very high log fold change (the value off scale). 
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Figure 5.28 Differential exon usage dispersion estimation and model fitting 
of Rhabdoid Tumour DEXseq data. Each dot represents exonic part 
dispersion estimation and the red line the fitted mean dispersion function. 
 
Figure 5.29 Differentially used exons Log2fold change versus mean 
expression over all samples. Red dots represent exonic parts differentially 
used at 10% FDR, when Benjamini and Hochberg method is applied. The 
lines on the top and on the bottom of the plot represent genes with a very 
low or very high log fold change (the value off scale).  
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5.3.5.1  Detection of differentially used exons between Malignant Rhabdoid Tumours 
and Medulloblastoma primary tumours 
The DEXseq analysis provides a list of genes and their respective exonic parts, 
described by adjusted p-value (calculated using Benjamini and Hochberg method) and 
log2 fold change (calculated by dividing the mean of Rhabdoid primary samples by the 
mean of Medulloblastoma primary samples.)  
The DEXseq results were filtered for values with an adjusted p-value greater than 
0.0001 and log2 fold change less than -2 or greater than 2, moreover only protein 
coding genes were analysed, resulting in 2002 significant genes with differential exon 
usage. In Table 5.3 are indicated the 30 most differentially used exons as a result of 
filtering (Full results can be found in Appendix 2). From the 30 genes in the table, four 
were associated with tumour progression, two with cell cycle, one indicated as potent 
tumour suppressor genes and one involved in autophagy in breast cancer and generally 
high expressed in brain tissue (http://www.genecards.org/). Complete list in Appendix I. 
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Gene Symbol Exon Adjusted  
p value 
log2fold 
 OSTM1 E020 7.42E-05 2.691206 
GNE + E023 7.22E-07 2.446738 
ARGLU1 * E010 1.86E-07 2.001177 
BAHD1 E001 1.00E-16 1.617837 
STK32C E016 6.43E-09 1.59003 
ACTR3B E009 8.79E-14 1.582486 
TUBA1C * E002 1.35E-06 -1.700879104 
SPRYD3 E013 1.02E-08 -1.728031529 
FARSB E017 7.45E-15 -1.744469767 
MGST2 E016 1.22E-09 -1.756456049 
HES6 ~ E024 2.86E-06 -1.78873522 
DERL1 E014 5.91E-07 -1.813588525 
C6orf89 + E006 9.62E-07 -1.819608749 
SYPL1 E009 1.36E-83 -1.944165165 
OCIAD2 * E001 1.88E-06 -1.945484655 
LYRM2 E007 7.74E-06 -1.951875084 
RPS27L # E001 1.61E-12 -1.958972254 
GOLIM4 E012 3.79E-07 -2.012249694 
DNAJC1 E006 2.27E-05 -2.024899986 
JOSD1 E023 1.31E-06 -2.048115239 
SLC29A4 E001 5.01E-05 -2.059570348 
MAP1LC3A * E002 7.07E-05 -2.13733565 
PPIA E022 1.68E-08 -2.261613246 
DHRS7B E001 1.71E-11 -2.265327266 
PPIA E021 3.83E-06 -2.312175449 
NCS1 E002 3.18E-05 -2.318299372 
LDLRAD3 E010 2.97E-05 -2.583835253 
MRPL32 E010 1.72E-08 -2.963216251 
SLC48A1 E004 1.69E-06 -9.939249198 
  
 
 
 
 
Table 5.3 Genes with differentially used exons in Rhabdoid vs
Medulloblastoma primary tumours. Functional annotation of genes
relevant to cancer is shown in the table with + for genes associated with
cell cycle such as apoptosis, * for genes associated with tumor
progression, and # indicates genes related to autophagy in cancer and ~
tumour suppressor genes.  
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HES6 is an interesting candidate for further analysis since it has been associated with 
both genesis and progression of prostate cancer. In particular, it promotes growth and 
migration advantages to prostate cells by interaction with Notch signalling. Figure 5.30 
shows the differential expression at the exon level of HES6 obtained with DEXSeq. 
HES6 in Rhabdoid primary samples shows in particular different usage at exon 1 
(contigs 25-24 and 22-16) resulting in the usage of alternative transcripts start sites. 
 
 
Figure 5.30 HES6 shows differential exon usage in Rhabdoid Tumours 
compared with Medulloblastoma sample (exonic parts 16-22 and 24-25). 
The red and blue lines do not correspond directly to exons, but to exonic 
parts, Exon usage (read counts normalised to the overall expression of the 
gene) is indicated in red for Medulloblastoma patients and in blue for 
Rhabdoid primary tumours. At the bottom is included an annotated 
transcript model.  
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The TUBA1C gene was found to be highly expressed (Caracciolo, D'Agostino et al. 
2010) and hypermethylated in Medulloblastoma cell lines (Dolores Hamilton, data 
unpublished). In Figure 5.31 Medulloblastoma primary sample show an increase usage 
especially of the Exonic Parts 5-12, this effect results in aberrant expression, while in 
the Rhabdoid samples exon usage is significantly elevated in exonic parts 16-19 and 21.  
 
 
Figure 5.31 TUBA1C shows differential exon usage in Medulloblastoma 
tumours compared with Rhabdoid sample (exonic parts 5-12). The red and 
blue lines do not correspond directly to exons, but to exonic parts, Exon 
usage (read counts normalised to the overall expression of the gene) is 
showed in red for Medulloblastoma patients and in blue for Rhabdoid 
primary tumours. At the bottom is included an annotated transcript model 
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The RPS27L gene is a nuclear protein which is found up-regulated in a variety of 
cancers, including breast, colon and liver cancer (Ganger, Hamilton et al. 1997, Ganger, 
Hamilton et al. 2001, Atsuta, Aoki et al. 2002). However RPS27L also has a tumour 
suppressor activity, since it regulates p53 activity by abrogating Mdm2-induced p53 
degradation (He and Sun 2006). Figure 5.32 shows the differential exon usage of 
RPS27L gene in Rhabdoid Tumours (Exonic parts 1,5,6,10,11,15); noticeably the first 
transcript contains an open reading frame.  
 
 
Figure 5.32 Differential exon usage of RPS27L in Rhabdoid sample tumours 
(Exonic parts 1,5, 6, 10, and 11). The red and blue lines do not correspond 
directly to exons, but to exonic parts, Exon usage (read counts normalised 
to the overall expression of the gene) is indicated in red for 
Medulloblastoma patients and in blue for Rhabdoid primary tumours. At the 
bottom is included an annotated transcript model. 
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5.3.5.2  Detection of differentially used exons between Extra Cranial Rhabdoids 
tumours and Atypical Teratoid Rhabdoid Tumours.  
The DEXseq data set was filtered for values with an adjusted p-value greater than 0.01 
and log2 fold change less than -2 or greater than 2, moreover only protein coding gene 
were analysed. This filtering characterises 561 genes with significant differential exon 
usage. In Table 5.4 are indicated the 30 most differentially used exons as result of 
filtering. From the 30 genes in the table, five were associated with tumour progression , 
two gene involved in Wnt pathway , one associated with regulation of pluripotency and 
angiogenetic factors and one directly regulated by MicroRNA. 
DCLK1 and RNF220 are two interesting candidates: both are involved in Notch and 
Wnt pathway regulation (Chandrakesan, Weygant et al. 2014, Ma, Yang et al. 2014, Qu, 
May et al. 2014). Interestingly, the relationship between these two genes has not been 
studied, however  this analysis shows in Extra Cranial Rhabdoid Tumours an increase 
usage in exonic part 2 affecting exon number 2 (Figure 5.33), while RNF220 usage is 
decreased from exonic part 1 to 17 affecting exons number 1, 4 , 5 and 9 (Figure 5.34) . 
This indicated a possible effect on the Wnt pathway and /or Notch signalling regulation 
via differential exon usage. Complete list in Appendix I. 
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Gene Symbol Exon Adjusted  
p value 
log2fold 
MATR3# E015 0.000620502 9.541355489 
FRMD4B E038 0.003767638 2.686008583 
LIMCH1+ E015 0.003066572 2.46342767 
ABR E099 0.000639142 2.214450991 
DCLK1~ E002 1.44E-05 2.173069156 
MBP* E043 0.000620502 2.015855785 
AC024560.3 E001 0.019082575 -5.796040636 
CCT7 E001 8.84E-05 -5.80737613 
CCT7 E002 4.06E-05 -5.944955916 
RFTN1 E032 0.002379 -6.528080996 
SPAG16 E038 1.04E-05 -6.991812374 
SPAG16 E039 1.41E-06 -7.08877491 
SUMF1 E010 9.93E-05 -7.471278383 
PRCP E017 9.55E-06 -7.521447266 
SUMF1 E012 3.10E-05 -7.579783724 
RCN1* E008 6.34E-07 -7.77565421 
RNF220 + E003 1.79E-05 -10.43948157 
KAT7 E019 2.44E-05 -10.49322879 
UBA6-AS1 E028 6.91E-07 -10.50189736 
SEMA4A * E001 3.41E-05 -15.91598894 
MLLT4* E017 0.000153 -17.31556728 
HOPX* E025 7.07E-05 -6.99181 
 
 
 
 
 
 
Table 5.4 Genes with differentially used exon in Rhabdoid primary tumours
Functional annotation of genes relevant to cancer are shown in the table
with + for genes involved in Wnt pathway, * for genes associated with tumor
progression, and # indicates genes regulated by MicroRNA and ~gene
regulating pluripotency and angiogenetic factors genes.  
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Figure 5.33 Differential exon usage of DCLK1 in Rhabdoid sample tumours 
(Exonic part 2). The red and blue lines do not correspond directly to exons, 
but to exonic parts, Exon usage (read counts normalised to the overall 
expression of the gene) is indicated in red for Atypical Teratoid Rhabdoid 
Tumours (ATRT) and in blue for the Extra Cranial Rhabdoid Tumours 
(ECRT). At the bottom is included an annotated transcript model. 
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Figure 5.34 Differential exon usage of RNF220 in Rhabdoid sample tumours 
(exonic parts 1- 17). The red and blue lines do not correspond directly to 
exons, but to exonic parts, Exon usage (read counts normalised to the 
overall expression of the gene) is indicated in red for Atypical Teratoid 
Rhabdoid Tumours (ATRT) and in blue for the Extra Cranial Rhabdoid 
Tumours (ECRT). At the bottom is included an annotated transcript model. 
 195 
 
HOPX has been indicated as tumour suppressor gene in a variety of cancer, such as 
pancreatic, colorectal and lung cancer (Waraya, Yamashita et al. 2012, Cheung, Zhao et 
al. 2013, Yamashita, Katoh et al. 2013) and found methylated in poor differentiated 
colorectal, oesophageal and gastric cancer (Yamashita, Kim et al. 2008, Ooki, 
Yamashita et al. 2010, Katoh, Yamashita et al. 2012). HOPX is a critical nodes of Wnt 
pathway in lung tumours (Pacheco-Pinedo, Durham et al. 2011). Figure 5.35 shows the 
differential expression at the exon level of HOPX obtained from DEXSeq analysis. 
HOPX in in Extra Cranial Rhabdoid Tumours samples shows in particular significant 
differential exon usage at Exonic parts 18-19 and 25-26, to determine differential 
recruitment of an alternative splicing. 
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Figure 5.35 Differential exon usage of HOPX in Rhabdoid Tumours (Exonic 
parts 11- 17; 25 and 26). The red and blue lines do not correspond directly 
to exons, but to exonic parts, Exon usage (read counts normalised to the 
overall expression of the gene) is indicated in red for Atypical Teratoid 
Rhabdoid Tumours (ATRT) and in blue for the Extra Cranial Rhabdoid 
Tumours (ECRT). At the bottom is included an annotated transcript model. 
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 450K methylation array confirm different biological group in 5.4
CNS tumours  
This section aimed to test the hypothesis that differential patterns of methylation exist 
within Rhabdoid Tumours. Characterisation of methylation pattern can improve the 
understanding of the epigenetic mechanism involved in SMARCB1 loss. A total of 39 
arrays were analysed on 450K methylation microarray (25 Atypical Teratoid Rhabdoid 
Tumours, 14 in Extra Cranial Rhabdoid Tumours). 
 
 Primary samples preparation and sequencing 5.4.1
43 Rhabdoid primary samples were collected from multiple centres throughout the UK 
in collaboration with the CCLG bio bank (ww.cclg.org.uk/tissue-bank). All samples 
were evaluated at the referring centre and subsequently centrally review by CCLG bio 
bank. DNA was extracted as per described methods (1.1.1). 
 
 QC analysis  5.4.2
The quality of the data was analysed using the Minfi package, at a pre-processing stage. 
First, bisulfite conversion was evaluated: incomplete or failure of the bisulfite 
conversion might results in biases to the analysis. This process consists of evaluation of 
the red and green control channel raw data, converting them into methylated and 
unmethylated signal. Quality analysis is computed separately for the InfI (Infinium I) 
and InfII (Infinium II) control probes (Error! Reference source not found. ).  
β values were derived using the BASH algorithm (section 4.2.2.3): Beta values can be 
fully unmethylated (0), fully methylated (1). In order to filter anomalous methylation 
intensities, the distribution of beta values were further analysed to determine the quality 
of the data. Overall, the majority of samples from our cohort proved to be of good 
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quality with less than one percent of CpG sites with detection p-values (indicating good 
signal from an individual priobe) equal or greater than 0.001 (Figure 5.37)  
  
Figure 5.36 Control strip plot of 450K methylation data. Quality evaluation 
for InfI (left) and InfII (right) is indicated. Distribution of signal intensity 
for each of the quality control probes in both is plotted. Control probes in 
successfully converted samples present similar distribution in both 
channels. 
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 Probes 
classification 
% 
All probes  Methylated 7029 (11.6%) 
Hemimethylated  12599 (57%) 
Unmethylated 5762 (31.5%) 
CpG Island  Methylated 1659 (6.3%) 
 Hemimethylated  2561 (9.7%) 
 Unmethylated 1091 (4.15%) 
Non CpG Island Methylated 5370 (20.4%) 
 Hemimethylated  10038 (38.0%) 
 Unmethylated 4671 (17.7%) 
  
Figure 5.37 Overall density distributions of beta values and the density 
distributions in primary Rhabdoid cohort. Kernel density plot illustrates the 
bimodal distribution of β-values for primary tumours analysed. 
 Global patterns of DNA methylation in Rhabdoid Tumours  5.4.3
The cohort set, 26290/40000 probes (p< 0.01) showed evidence of methylation (β 
score > 0.333) in one or more samples with a mean beta value of 0.59. The distribution 
of average methylation status within test cohorts is summarised in Table 5.5. In 
particular, there was a very marked difference in the methylation status of probes 
located within and outside of CpG islands: only 5311/40000 probes were located within 
CpG islands, in contrast the majority of the probes were located outside the CpG Island. 
 
 
 
 
Table 5.5 Global methylation distribution among Malignant Rhabdoid
primary tumours and Medulloblastomas test cohorts (26290 probes).
Average methylation scores were calculated for all probes across the
training and test cohort. For three probe categories (all probes, probes
located within CpG islands and probes located outside of CpG islands), the
number of unmethylated (average β < 0.333), methylated (average β >
0.667) and hemi-methylated probes (0.333 < average β ≤ 0.666) are shown
for the total cohort.  
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 Cluster analysis identifies 5 distinct DNA methylation subgroups 5.4.4
 
5.4.4.1 Unsupervised analysis  
In order to explore differences in methylation status between Rhabdoid and 
Medulloblastoma primary tumours an unsupervised clustering approach (PCA, HC, and 
NMF) was used. The rationale behind choosing Medulloblastoma as a comparator group 
was the same as for the expression studies, namely it was a related embryonal tumour 
type. Principal component analysis (PCA) was performed on a subset of probes selected 
as the most variable CpG probes within the data set. The PCA plot shows the tendency 
of that data to cluster into two biological groups: a group formed by Rhabdoid samples 
and one mainly constituted by Medulloblastoma (Figure 5.38). 
 
Figure 5.38 Unsupervised principal component analysis of 450K 
methylation profiles of primary Medulloblastoma and Rhabdoid Tumours 
distinguishes two biological groups. Points in red represent 
Medulloblastoma primary samples while Rhabdoid Tumours are indicated in 
blue. The x-axis is the first component; the y-axis is the second principal 
component.  
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A consensus clustering approach (repetitions =100) was Initially applied to the data set 
to identify the optimal number of metagenes and clusters. The stability of the cluster 
was determined by evaluating cophenetic correlation and dispersion coefficient, as 
previously described. Metagenes were computed between ranks (number of metagenes) 
2 to 6 on the most variable CpG probes. The most robust consensus clustering was 
chosen as k=4 (Figure 5.39). 
 
 
Figure 5.39 Cophenetic correlation and dispersion measures to assess the 
stability of clustering associated with each rank k for the methylation data 
set. Dotted line shows randomised while data undotted shows actual data. 
 
Consensus NMF and unsupervised hierarchical clustering confirmed the pattern 
observed in the expression data: that Rhabdoid Tumours mainly (41/43) form a unique 
group regardless of the location of the malignancy, with the exception of two samples 
(Figure 5.40). These two sample are unde review to asses if they are missdiagnosed 
Atypical Teratoid Rhabdoid Tumours or they present low expression of SMARCB1. 
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Figure 5.40 Unsupervised NMF and hierarchical cluster analysis (K=4) on 
Rhabdoid and Medulloblastoma derived 450K methylation data set. 
Rhabdoid and Medulloblastoma are clustered in different groups, the 
genetic complexity of Medulloblastoma (characterized by 4 different 
subgroups: WNT, SHH, Group 3 and Group 4) are retained in this analysis. 
The matrices were coloured 0 (deep blue, indicating samples never in the 
same cluster) to 1 (dark red, indicating samples always in the same cluster). 
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The heatmap indicated in Figure 5.41 contains the top 100 differentially methylated 
probes (as defined by delta value) and illustrates the difference in methylation between 
Medulloblastoma and Rhabdoid primary tumours. 
 
Figure 5.41 Heatmap of methylation showing the 100 most differentially 
methylated probes between Medulloblastoma and Rhabdoid Tumours. Each 
row represents a CpG probe and each column a sample. Hypermethylated 
(pale red to dark red) and Hypomethylated CpGs (pale blue to dark blue). 
Medulloblastoma primary samples are represented by side bars in Red while 
Rhabdoid patients are indicated in blue. 
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5.4.4.2 Supervised analysis  
To further investigate the difference between Medulloblastoma and Rhabdoid Tumours 
methylation data were filtered in order to obtain a subset composed only of those CpGs 
which were most significantly differentially methylated. PCA analysis was computed 
using a subset of 3267 probes. These confirmed the magnitude of the difference in 
methylation between Rhabdoid and Medulloblastoma primary tumours (Figure 5.42) 
and also the two Medulloblastoma samples under investigation remained outliers from 
the group.  
 
 
Figure 5.42 Supervised principal component analysis of 450K methylation 
profiles of primary Medulloblastoma and Rhabdoid Tumours distinguishes 
two biological groups. Points in red represent Medulloblastoma primary 
samples while Rhabdoid Tumours are indicated in blue. The x-axis is the 
first component; the y-axis is the second principal component.  
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In order to highlight the most Rhabdoid specific methylation events. The results were 
filtered for CpG probes with an adjusted p-value greater than 0.0001 and a mean delta 
(mean difference) beta value less than -0.6 or greater than 0.6. In Table 5.6 are indicated 
the 20 most differentially methylated probes as result of filtering and their associated 
genes, relative diffrence in methylation staus are indicated in Figure 5.43 and Figure 
5.44 (complete list at appedix 2). Five were associated with tumour progression (*), 
three with cell cycle (+), one indicated as candidate tumour suppressor genes (~) and 
two involved in neuro-development (#) (http://www.genecards.org/). Complete list in 
Appendix I. 
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Probes Gene 
Symbol 
Average Delta 
values 
LogFold 
change 
Adjusted 
p value 
cg02899346 RTN2 0.744696 7.413367 9.38E-39 
cg19378416 OGFOD3 0.72519 6.34529 8.72E-43 
cg25820257 RTN2 0.717721 6.302051 1.74E-43 
cg00092518 PHF11~ 0.711333 6.985098 1.43E-33 
cg01063813 STAT6* 0.7081 6.464976 8.35E-41 
cg01005968 RTN2 0.628437 4.981123 6.86E-36 
cg10253465 RTN2 0.626719 5.184367 2.67E-38 
cg05367028 PRKAG2* -0.60039 -4.589 2.79E-41 
cg14792075 KIF26B* -0.60148 -4.53975 1.22E-31 
cg13036593 TNXB*  -0.60257 -4.99831 7.79E-32 
cg26758486 SDK2 -0.75876 -8.27617 6.78E-33 
cg20181739 SH3RF3 -0.7637 -7.03077 2.94E-47 
cg04389398 ORC5 -0.76494 -7.23292 3.08E-42 
cg14992000 COL20A1 + -0.76503 -7.22481 1.67E-51 
cg15084433 SND1+  -0.76827 -7.49857 3.37E-47 
cg13524328 FBXW8*+ # -0.78451 -6.90548 2.09E-52 
cg01807313 FBXW8 -0.79331 -7.49232 3.64E-49 
cg16111737 FBXW8 -0.79347 -7.24504 1.71E-51 
cg27396830 DRAXIN# -0.79429 -7.70371 1.67E-51 
cg25620901 HEATR2 -0.81378 -8.26217 4.13E-48 
 
 
 
Table 5.6 Selected significantly differentially methylated probes in Rhabdoid
vs Medulloblastoma primary tumours (adjust pvalue <0.01; Mean Delta
values ≥+0.6 ≤-0.6). Functional annotation of genes relevant to cancer is
shown in the table with + for genes associated with cell cycle such as
apoptosis, * for genes associated with tumour progression, and # indicates
genes related to autophagy in cancer and ~ tumour suppressor genes.  
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Figure 5.43 Relative difference in methylation status of 12 of 20 most 
deregulated genes between Rhabdoid Tumours (RT) and Medulloblatomas 
(MB). Box plots show β-values across the samples; median score (thick 
black line) and inter-quartile ranges (extent of box).  
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Figure 5.44 Relative difference in methylation status of 8 of 20 most 
deregulated genes between Rhabdoid Tumours (RT) and Medulloblastomas 
(MB). Boxplots show β-values across the samples; median score (thick black 
line) and inter-quartile ranges (extent of box). 
 
Many of the most significant alterations in methylation status occur in known 
oncogenes. The PHF11 gene is associated with Ewing sarcoma and hypermethylation of 
this gene together with NPTX2 is related with poor prognosis; also 36-50% of 
osteosarcomas showed methylation of PHF11 gene (Alholle, Brini et al. 2013). In 
Neurofibromatosis type 1 down-regulation of TNXB affects cell–extracellular matrix 
interactions, eventually causing tumourigenesis (Levy, Ripoche et al. 2007); Variants of 
TNXB linked with NOTCH4 variant gene were related with Age-related macular 
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degeneration. FBXW8 controls cell cycle regulation promoting proteolysis of Cyclin 
D1; moreover in vivo studies showed its significant role in growth control: most 
Fbxw8−/− embryos die in utero, however a third showed abnormal development of the 
placenta (Okabe, Lee et al. 2006). Finally DRAXIN is involved in development of pre-
cerebellar neurons, particularly it plays a repulsive role in axon outgrowth and nuclei 
migration (Riyadh, Shinmyo et al. 2014). 
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 Rhabdoid Tumours present different DNA methylation subgroups mainly 5.4.5
related to location of malignancy  
 
5.4.5.1 Unsupervised analysis  
Differences in methylation status between Extra Cranial Rhabdoid and Atypical 
Teratoid Rhabdoid Tumours were analysed using an unsupervised clustering approach 
(PCA, HC, and NMF). Principal component analysis (PCA) was performed using a 
subset of 936 probes (p<0.01) chosen as the CpGs which showed the greatest amount of 
variability across samples (Delta value <0.5 and >0.5). The PCA plot shows the 
tendency of that data to cluster into two biological groups, mainly although not 
exclusively related to the location of the tumours at the diagnosis (Figure 5.45).  
 
Figure 5.45 Unsupervised principal component analysis on 450K 
methylation data set characterises two subgroups within Rhabdoid Tumours. 
Points in red represent Atypical Teratoid Rhabdoid Tumours (ATRT) whilst 
Extra Cranial Rhabdoid Tumours (ECRT) are indicated in blue. The x-axis 
is the first component; the y-axis is the second principal component.  
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A consensus cluster (repetitions =100) analysis was Initially carried out to identify the 
optimal number of metagenes and clusters. The stability of the cluster was determined 
by evaluating the cophenetic correlation and dispersion coefficient, as previously 
described. Metagenes were calculated for ranks k= 2 to k=6, k= 2 was chosen as the 
most consistent subgrouping according to cophenetic correlation and dispersion 
coefficient (Figure 5.46). Consensus NMF and unsupervised hierarchical clustering 
identifies two subgroups mainly related to the location of the malignancies (Figure 5.47) 
with some exceptions for instance 2 Atypical Teratoid Rhabdoid Tumours grouped with 
the majority in Extra Cranial group and 4 in Extra Cranial Rhabdoid Tumours with the 
majority od the malignacies located in the brain . 
 
 
Figure 5.46 Cophenetic correlation and dispersion measures to assess the 
stability of clustering associated with each rank k for the methylation data 
set.  
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Figure 5.47 Consensus unsupervised NMF and hierarchical cluster analysis 
k=2) on Rhabdoid Tumour derived 450K methylation data set. Primary 
Rhabdoid Tumours are clustered into two different classes, mainly related to 
tumour locations. The matrixes were coloured 0 (deep blue, indicating 
samples never in the same cluster) to 1 (dark red, indicating samples always 
in the same cluster). 
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The heatmap Figure 5.48 in contains the top 100 most significantly differentially 
methylated probes (defined by p-value <0.01; delta value <0.5 and >0.5) and 
demonstrates the difference in methylation between Extra Cranial Rhabdoid and 
Atypical Teratoid Rhabdoid Tumours as well as those ATRT or ECRT which do not fall 
into their appropriate groups. 
 
Figure 5.48 Heatmap of gene expression showing the 100 most differentially 
methylated probes between Atypical Teratoid Rhabdoid Tumours (ATRT) and 
Extra Cranial Rhabdoid Tumours (ECRT). Each row represents a CpG probe 
whilst each column a sample. Hypermethylated (pale red to dark red) and 
Hypomethylated transcripts (pale blue to dark blue). In red are represent 
ATRT while ECRT are indicated in blue. 
 214 
 
5.4.5.2 Supervised analsyis  
In order to judge the effect of selecting only those CpG probes which were significantly 
differentially methylated the 450K methylation data were filtered in a supervised 
fashion to create a subset composed only of CpGs which were significant differentially 
expressed. Specifically a PCA analysis (Figure 5.49) was performed using a subset of 
316 probes (β value <-0.35 and >0.35; p<0.01) and confirmed the tendency of that data 
to cluster in two biologically groups, mainly related to the location of the tumours at the 
diagnosis (Figure 5.42) but with two obvious exceptions where Atypical Teratoid 
Rhabdoid Tumours samples have grouped with in Extra Cranial Rhabdoid Tumours. 
 
 
Figure 5.49 Supervised principal component analysis on Malignant 
Rhabdoid Tumour 450K methylation data set distinguishes two biological 
groups, related to the tumour location. Points in red represent Atypical 
Teratoid Rhabdoid Tumours (ATRT) and Extra Cranial Rhabdoid Tumours 
(ECRT) are indicated in blue. The x-axis is the first component; the y-axis is 
the second principal component.  
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The heatmap in Figure 5.50 contains the top 100 differentially methylated probes 
between the two different methylomic sub-groups found with the Rhabdoid Cohort and 
shows clear differences in methylation status between the two groups as well as the 
more obvious discrepancies between tumour location and methylation group. 
  
Figure 5.50 Heatmap of gene expression showing the most differentially 
methylated probes in Rhabdoid Tumours in supervised fashion. Each row 
represents a CpG probe whilst each column a sample. Hypermethylated 
(pale red to dark red) and hypomethylated transcripts (pale blue to dark 
blue). In red are represented Atypical Teratoid Rhabdoid Tumours (ATRT) 
and Extra Cranial Rhabdoid Tumours (ECRT) are indicated in blue. 
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The methylation data set was subsequently filtered (adjusted p-value greater than 0.0001 
and delta beta-value less than -0.7 or greater than 0.7) in order to identify significant 
methylated probes that define the two methylomic subgroups. Table 5.7, Figure 5.51 
and Figure 5.52 show the 20 most differentially methylated probes resulting from this 
filtering (full results in Appendix 2). Four CpG probes are related to genes known to be 
associated with tumour progression (*), two with cell cycle (+), one indicated as a 
potent tumour suppressor genes (~), one described as an oncogene (-) and one as a 
diagnostic marker and potential therapeutic target for lung cancer 
(http://www.genecards.org/). Complete list in Appendix I. 
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Probes Gene 
Symbol 
Average Delta 
values 
LogFold 
change 
Adjusted 
p value 
cg16865446 PAX6* ~ 0.50883 4.20386 0.000105 
cg02380334 CCDC177 0.490687 4.366351 0.000105 
cg05124021 PTPRN2 0.480161 3.979788 0.000164 
cg02226645 MIR124-2 0.478548 3.9015 0.000206 
cg05226008 DLC1~ 0.461443 3.837403 0.000452 
cg07139509 CCDC177 0.452786 3.804627 0.000616 
cg08641706 LINC01102 0.448127 4.256806 0.00011 
cg13480937 ASTN1 0.445405 3.401604 0.001051 
cg27260617 AGTR1* 0.437639 3.192388 0.001466 
cg01587682 PAX6 0.43528 3.482271 0.001271 
cg12634591 HOXD3* -0.40403 -3.40501 0.000818 
cg25094569 WT1*- -0.41285 -3.57374 0.000574 
cg13638420 WT1 -0.41796 -3.13113 0.00204 
cg22968401 PIPOX -0.42332 -3.13263 0.001507 
cg00016913 PIPOX -0.42385 -3.5515 0.000452 
cg09047573 NME5* -0.42387 -3.74244 0.000619 
cg09387749 HOXD3 -0.42725 -3.69163 0.000987 
cg19344626 NWD1 -0.43282 -3.34403 0.001337 
cg13321745 MSI1# -0.43886 -3.56569 0.000574 
cg19113668 ST5* -0.44959 -3.88558 0.000248 
 
 
 
 
 
Table 5.7 Differentially methylated probes in Extra-cranial vs Atypical
Teratoid Rhabdoid Tumours (adjust pvalue <0.01; Average delta values
≥+0.4 ≤-0.4). Functional annotation of genes relevant to cancer is shown in
the table with * for gene associated with tumour progression, + with cell
cycle, ~ for tumour suppressor genes, - for oncogene and # for gene
described as diagnostic marker and potential therapeutic target.  
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Figure 5.51 Relative difference in methylation status of 12 of the most 
deregulated genes between Atypical Teratoid Rhabdoid Tumours (ATRT) and 
Extra Cranial Rhabdoid Tumours (ECRT). Boxplots show β-values across 
the samples; median score (thick black line) and inter-quartile ranges 
(extent of box). 
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Figure 5.52 Relative difference in methylation status 8 of 20 most 
deregulated genes between Atypical Teratoid Rhabdoid Tumours (ATRT) and 
Extra Cranial Rhabdoid Tumours (ECRT). Boxplots show β values across 
the samples; median score (thick black line) and inter-quartile ranges 
(extent of box). 
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 Many of the CpGs highlighted are associated with genes with a relevant role in 
tumourigenesis or development. For instance, PAX6 is essential in the maintenance of 
neural stem and progenitor cells and plays oncosuppressive role in Oligodendroglioma 
(Appolloni, Calzolari et al. 2012). DLC1 is a tumour suppressor gene with implication 
in a broad range of human cancer; it encodes for RhoGAP and therefore regulates 
kinases such as Akt, PKC and PKD (Ko, Chan et al. 2013). HOXD3 is part of the 
homeobox genes, which play a key role in regulation of cardio-vasculature development 
and are expressed in normal placental development and essential in human foetal 
growth (Murthi 2014). WT1 have been found fused with EWS in Desmoplastic small 
round-cell tumours; this fusion creates a tumourigenic chimeric protein which promotes 
aberrant neuronal differentiation (Kang, Park et al. 2014). Msi1 is overexpressed in 
Lung cancer and suggested as a diagnostic marker (Wang, Yu et al. 2013); interestingly 
this gene directly regulates Wnt and Notch signalling pathways and is involved in 
neuronal development in vivo (Wang, Yin et al. 2008, Lan, Yu et al. 2010, Rezza, Skah 
et al. 2010). 
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 Discussion 5.5
This chapter employed novel and extensive profiling technology for the characterisation 
of Rhabdoid Tumours. Rhabdoid Tumours were compared with paediatric 
Medulloblastoma malignancies to identify gene signatures that might explain 
pathogenesis. Because of the similar location of the mass at diagnosis Rhabdoid 
Tumours of the brain (ATRT) it is noteworthy that they are still misdiagnosed as 
Medulloblastoma tumours. In addition, analysis was carried out on the Rhabdoid 
Tumour Cohort alone to ask whether the biology driving Rhabdoid tumourigenesis 
differs according to different location in the body. 
 
 Malignant Rhabdoid Tumours are a unique biological group, with distinct 5.5.1
methylation and expression pattern 
Unsupervised gene expression analysis using RNA-seq of a Rhabdoid and 
Medulloblastoma cohort identified separate disease groups, underlining the clear 
difference in term of their molecular biology between these two tumours and that 
Rhabdoid Tumours as a whole form a single biological entity. Interestingly, consensus 
NMF analysis identifies a distinct gene pattern for Rhabdoid malignancies separate 
from all four Medulloblastoma subgroups (SHH, WNT and a heterogeneous group). 
Comparative analysis distinguished significant upregulation of AMER2, HMGA2 genes 
and down-regulation of ST18 and NEUROG1 genes in Rhabdoid Tumours. AMER2 is 
involved in Wnt signalling, a pathway which directs a wide range of developmental 
processes. HMGA2 actively enhances E2F, which is transcriptionally activated by 
SMARCA4. ST18 is a known tumour suppressor gene in Breast cancer and it has been 
suggested to be involved in Leukemogenesis, however the mechanism is still unknown. 
Methylation of NEUROG1 causes tumourigenesis in uveal melanoma, concurrently 
with hypermethylation of RASSF1A.  
Study of alternative usage of exons was performed to investigate the complexity of 
transcriptional processing in Rhabdoid Tumours. The comparative analysis against 
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Medulloblastoma identified 2002 genes with significantly differentially used exons, 
including HES6, TUBA1C and RPS27L. HES6 is involved in Notch pathway, 
mechanism found deregulated in the paediatric soft tissue sarcomas; TUBA1C is 
generally overexpressed in Medulloblastoma cell line while RPS27L is involved in P53 
pathways. 
Investigation of methylation status was carried out in Rhabdoid Malignancies using 
450K methylation array. The analysis was performed by comparing Rhabdoid primary 
tumours with Medulloblastoma primary samples. Unsupervised analysis revealed two 
unique groups, one corresponding to Medulloblastomas and another to Rhabdoid 
Tumours, further confirming that Rhabdoid Tumours form a unique biological entity. 
Consensus NMF identified the same groups previously described in the RNAseq 
analysis. The investigation of specific methylomic patterns revealed amongst others 
hypermethylation of PHF11, TNXB and hypomethylation of FBXW8 DRAXIN genes in 
Rhabdoid Tumours. TNXB is down-regulated in Neurofibromatosis and also liked to 
NOTCH pathway, however the tumourigenic mechanism is still unknown. FBXW8 and 
DRAXIN play significant roles in cell growth, in embryonal and neuronal development 
respectively. 
These findings are partially discordant with previously classification of Rhabdoid 
Tumours. The WHO organisation catalogues these malignancies as two different entities 
both characterised by SMARCB1 deletion; this classification is still followed in clinics 
where Atypical Teratoid Rhabdoid Tumours and Extra Cranial tumours are treated with 
different regimen. Moreover, Birks et al. showed that Extra Cranial Rhabdoid and 
Atypical Teratoid Rhabdoid Tumours when compared with other CNS tumours shared a 
restrict number of deregulated genes. On the contrary we show that Rhabdoid Malignant 
Tumours are a unique and characteristic entity sharing many commonly expressed genes 
and methylated CpGs, with a very different biology from other CNS paediatric tumours. 
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 Gene expression and methylation status reveals subgroups in Rhabdoid 5.5.2
Malignant Tumours, mainly related to tumour location  
Further investigation of the Rhabdoid primary cohort were undertaken to identify 
biological subgroups. Unsupervised analysis of the RNA-seq gene expression data 
distinguished two separate subgroups, one mainly but not exclusively consisting of in 
Extra Cranial Rhabdoid Tumours and one mainly consisting of Atypical Teratoid 
Rhabdoid Tumours. Consensus NMF analysis confirmed two distinct gene patterns, 
separating the cohort into two metagenes related to the location of the primary tumours 
at diagnosis. Metagene projection of the results from our cohort onto three different data 
set acquired using Affymetrix array confirmed and validated the difference between 
Extra Cranial and Atypical Teratoid Rhabdoid Tumours as described by our cohort.  
Gene expression analysis identified a significant subgroup of differentially expressed 
genes related to tumour progression, invasion and angiogenesis. Expression of genes 
involved in neurodevelopmental proliferation, such as GFAP, B-FABP and SOX1, were 
up-regulated in Atypical Teratoid Rhabdoid Tumours. Upregulation of GFAB is often 
detected in Glioblastoma and Chordomas as well as in Glioma (Theurillat, Hainfellner 
et al. 1999, Santos, Carvalho et al. 2009), where B-FABP family is also deregulated 
(Godbout, Bisgrove et al. 1998). SOX family proteins have a key role in embryonic and 
postnatal development and lead tumourigenesis in a wide number of cancers; in 
Hepatocellular Carcinoma hypermethylation of SOX1 causes abnormal activation of 
Wnt/β-catenin signalling pathway and is a marker for cortical neural progenitor cells 
(Elkouris, Balaskas et al. 2011, Tsao, Yan et al. 2012). 
Differential exon usage also indicates differences between the in Extra Cranial 
Rhabdoid Tumours and the Atypical Teratoid Rhabdoid Tumours. The analysis 
characterises 561 genes with significant differential exon usage in genes involved in 
Wnt signalling. DCLK1 and RNF220 genes are linked with regulation of the Notch and 
Wnt pathways; the relationship between these two genes is unknown. Wnt pathway is 
also deregulated by HOPX in lung tumour by and increased expression of Mycn 
(Pacheco-Pinedo, Durham et al. 2011).  
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Analysis of the methylation status of the Rhabdoid cohort confirms the presence of two 
methylomic defined subgroups mainly related to tumour location. Relative hyper-
methylation in Extra Cranial Teratoid Tumours was detected in CpGs associated with 
PAX6 and DLC1 (Appolloni, Calzolari et al. 2012); these genes play an oncosuppressive 
role in Oligodendroglioma. In Atypical Teratoid Rhabdoid Tumours HOXD3 and Msi1 
are relatively hypermethylated: HOXD3 is essentially expressed in normal placental 
development while Msi1 directly regulates the Wnt and Notch signalling pathways 
(Murthi 2014). 
Taken as a whole these analyses of Rhabdoid primary tumour expression and 
methylation profiles demonstrate the fact that even though these malignancies share a 
common biology when compared with other paediatric tumours, they differ significantly 
in their gene expression and methylation status. In particular, Atypical Teratoid 
Rhabdoid Tumours show a deregulation of a variety of genes involved in neurogenesis 
and neural-differentiation, whilst genes that define in Extra Cranial Rhabdoid Tumours 
have been differentially expressed in a variety of tumours without a clear link to a 
specific tissue. Interestingly, in Atypical Teratoid Rhabdoid Tumours a deregulation and 
change in methylation of genes regulating Wnt and Notch signalling was observed, 
indicating that this pathway might play an important role on the tumourigenesis of these 
malignancies 
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 Establishing the Role of SMARCB1 Chapter 6
loss in Malignant Rhabdoid 
Tumours  
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 Introduction 6.1
Malignant Rhabdoid Tumours present a very simple biology, since the only consistent 
mutation detected is loss of the SMARCB1 gene and its respective encoded protein. 
Previous work, has demonstrated that SMARCB1 re-expression induces a reversion of 
the tumourigenic phenotype of the cells, causing cell senescence by blocking cell cycle 
in G1. The effect of SMARCB1 on gene expression has been previously studied by a 
number of people (Medjkane, Novikov et al. 2004, Gadd, Sredni et al. 2010); however 
the understanding of this mechanism was limited by the number of the cell lines and by 
the techniques used. In these studies microarray experiments were carried out in MON, 
STA-WT1, G401 cell lines upon SMARCB1 re-expression and in a SMARCB1 murine 
cancer model cells (Guidi, Sands et al. 2001, Medjkane, Novikov et al. 2004, Morozov, 
Lee et al. 2007, Gadd, Sredni et al. 2010). Just one study was focused on exploring the 
downstream effect of SMARCB1 re-expression, while other studies were more focused 
on a better understanding of previously described pathways. In particular, microarray 
analysis highlights the effect of SMARCB1 re-expression on gene expression and in 
particular how it causes up-regulation of several cell cycle control genes such as 
CDK1A and CDK2A, involvement of cell growth and actin cytoskeleton organisation 
genes such as E2F and Rho-GAP4 (Medjkane, Novikov et al. 2004), re-expression of 
senescence genes such as SERPINE2 (Gadd, Sredni et al. 2010) and down-regulates 
mitotic genes such as TOP2A, and Aurora A (Morozov, Lee et al. 2007). However, these 
investigations did not attempt to address the genome-wide effects of SMARCB1 loss in 
order to understand downstream effects as well as to identify therapeutically targetable 
genes. 
This part of the study was focused on studying the genomic effect of SMARCB1 re-
expression in Rhabdoid cell models. Gene expression analysis using RNA-seq together 
with DNA methylation analysis by 450K methylation array was performed for the first 
time in four SMARCB1 stable infected Rhabdoid cell lines. Moreover, to understand 
SMARCB1 function in methylation, cell lines treated with the demethylating agent 5-
aza-2’-deoxycytidine were also subjected to sequencing by RNA-seq. The 
bioinformatics analysis and data integration pursued in this study allowed me to 
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uncover the general scale and nature of genomic and epigenetic aberrations caused by 
SMARCB1 loss in Rhabdoid Tumours. 
 
 Aims 6.2
The study reported in this chapter aimed to: 
 Assess the effect of SMARCB1 re-expression on gene expression and 
methylation status in Rhabdoid cells derived from different location.  
 Explore gene expression changes in Rhabdoid cells following treatment with 5-
aza-2'-deoxycytidine. 
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 Integrated genomic and epigenetic analysis identifies 6.3
downstream target genes dependent on SMARCB1  
For the first time a genome-wide analysis combining expression analysis with 
methylation profiling was carried out in Rhabdoid cell lines to collect an extensive 
catalogue of late effects of SMARCB1 re-expression on gene regulation and methylation 
status. In this analysis the previously generated (see Chapter 4) SMARCB1 positive cell 
lines were analysed using an RNA-seq and 450K methylation approach. 
 
 RNA-seq analysis  6.3.1
6.3.1.1 Primary samples preparation  
RNA from the cell was extracted as indicated in section 1.1.1 RNA integrity number 
(RIN score) was evaluated for each sample, using a Bioanalyzer. All the RNA samples 
were scored with a RIN greater than 9.  
 
6.3.1.2 RNA-seq QC analysis 
All samples sequenced successfully passed the RNA quality control checks, in 
particular in every sample the average Phred score across all bases was greater than 30 
(Figure 5.2). As was the case in the sequenced primary sample, FASTQC analysis 
presented warnings for the per base sequence content, per base GC content (Figure 6.2 
and Figure 5.4) and sequence duplication levels (Figure 6.4). This confirmed the high 
variability on the first bases as result of random priming. 
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Figure 6.1 Per base sequence quality derived from sample G401 
SMARCB1+ from FASTQC html report. The red line represents the median 
value, while the blue line the quality. The plot presents 3 different 
background shading: green indicates a good quality score. 
 
Figure 6.2 Per base GC content (B) of sample G401 SMARCB1+ from 
FASTQC html report. High variability of the first 10 bases was observed in 
all samples of our data set. 
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Figure 6.3 Per base sequence content analysis (A) and Per base GC content 
(B) of sample G401 SMARCB1+ from FASTQC html report. High variability 
of the first 10 bases was observed in all samples of our data set; this 
phenomenon is more plausibly constitutive biases rather than batch effects.  
 
Figure 6.4 Sequence duplication levels plot of sample G401 SMARCB1+ 
from FASTQC html report. The 10th column includes all duplication levels 
greater than or equal to 10. 
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6.3.1.3 DESeq analysis  
Raw count values were analysed in a pair wise fashion using DESeq2 in R. The 
negative binomial method was used to identify differentially expressed genes, as 
described in section 3.16. Estimates of dispersion in the data set are indicated in Figure 
5.10, where the black dots represent the empirical dispersion values and the red line the 
fitted values. Figure 5.11 represents the differential expression estimation between 
SMARCB1 re-expressing cell lines and the control infectants, where the red dots 
represents genes marked as differentially expressed at 10% FDR.  
 
 
Figure 6.5 Gene expression dispersion estimation and model fitting of 
SMARCB1 re-expressing cells (SMARCB1) and control infectants (PCDH). 
Each dot represents per gene dispersion estimation and the red line the 
fitted mean dispersion function. 
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Figure 6.6 Testing for differential expression between SMARCB1 re-
expressing cells and control infectants. Log2fold versus mean expression 
over all samples. Red dots represent genes marked as differentially 
expressed at 10% FDR, when Benjamini and Hochberg correction is 
applied. The lines on the top and on the bottom of the plot represent genes 
with a very low or very high log fold change (value off scale). 
 
Clustering analysis 
DEseq results were filtered to subset only significant genes (adjusted p-value < 0.01; 
moderated log fold change ≤ -2 and ≥ +2). PCA analysis was performed on this subset 
of 493 genes; the analysis identified two separate subgroups, one constituted by control 
infectants and the other cell lines re-expressing SMARCB1 (Figure 6.7). Thus 
confirming the changing expression pattern and reflecting the change in phenotype of 
Rhabdoid cells following SMARCB1 re-expression. 
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Figure 6.7 Supervised principal component analysis on Rhabdoid cell lines 
expression distinguishes two different biological groups. Red points 
represent SMARCB1 re-expressing Rhabdoid cells (SMARCB1) and blue 
points vector control infected Rhabdoid cells (PCDH). The x-axis is the first 
component; the y-axis is the second principal component. 
 
Consensus NMF supervised analysis (k=2) was carried out on the selected genes 
identifying two different metagenes; one for the SMARCB1 positive cells and one for 
the control cells (Figure 6.8).  
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Figure 6.8 Supervised NMF and hierarchical cluster analysis (K=2) on 
expression data from SMARCB1 re-expressing cells (SMARCB1) and control 
infectants (PCDH). The matrices were coloured 0 (deep blue, indicating 
samples never in the same cluster) to 1 (dark red, indicating samples always 
in the same cluster). 
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Filtered data were used to generate a heatmap with the top 100 deregulated genes 
(Figure 6.9) revealing that SMARCB1 re-expression mainly causes significant up 
regulation of the majority of the genes analysed.  
 
 
Figure 6.9 Heatmap of significantly differentially expressed genes in 
SMARCB1 re-expressing Rhabdoid cells (SMARCB1) and in vector control 
infected Rhabdoid cells (PCDH). Each row represents a probes and each 
column a sample. Overexpressed (pale red to dark red) and under-expressed 
transcripts (pale blue to dark blue). 
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Gene Symbol Adjusted p-value Moderated log2fold 
DNA2 *  1.21E-19 7.552249108 
RBM20 2.54E-49 6.976379538 
PLS1*  2.62E-13 6.69712796 
DBP 4.33E-18 6.333667579 
MSX2*- 4.13E-18 6.302317536 
MMRN1 3.90E-34 6.249127503 
LBX1-+ 5.21E-38 5.883944727 
ABHD2 1.16E-29 5.725973275 
EMP2 *- 3.30E-37 5.426349508 
CDC25C* 1.91E-07 5.187714389 
GNG4 3.67E-22 5.184757846 
SERPINF1 # 1.90E-21 5.161774575 
CDC42BPG* 0.000397 -1.602650115 
ENTPD7 6.01E-08 -1.848080725 
SLC16A9* + 2.44E-06 -2.071080896 
  
In Table 6.1 are indicated the 15 most differentially expressed genes as a result of 
filtering, the relative difference in expression of these genes are indicated in Figure 6.10 
and Figure 6.11. Seven genes are associated with tumourigenesis (*), one instead is 
indicated as an antiangiogenic factor (#) two involved in cell proliferation (+), two 
directly involved in tumour invasion (-) (http:.///www.genecrads.org). Complete list in 
Appendix I. 
 Table 6.1 Selected differentially expressed genes in SMARCB1 re-
expressing Rhabdoid cells vs vector control infected Rhabdoid cells. 
Functional annotation of genes relevant to cancer is shown in the table
with * for genes associated with tumourigenesis,+ for genes involved in
cell proliferation,- for genes directly correlated with tumour invasion,#
for genes indicated as inhibitors of tumourigenesis and tumour invasion. 
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Figure 6.10 Relative difference in expression of 9 of 15 most deregulated 
genes between SMARCB1 re-expressing Rhabdoid cells (SMARCB1) and 
vector control infected Rhabdoid cells (PCDH). Boxplots show variant 
stabilised transformed expression across the samples. Boxplots show median 
score (thick black line) and inter-quartile ranges (extent of box). 
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Figure 6.11 Relative difference in expression of 6 of 15 most deregulated 
genes between SMARCB1 re-expressing Rhabdoid cells (SMARCB1) and 
vector control infected Rhabdoid cells (PCDH). Boxplots show variant 
stabilised transformed expression across the samples. Boxplots show median 
score (thick black line) and inter-quartile ranges (extent of box). 
 
DNA2 encodes for the human nuclease/helicase DNA2 protein, involved in repair 
replication-associated DNA double-strand breaks (DSBs). Depletion of the DNA2 
causes chromosomal aberrations and inter-nuclear chromatin bridges, affecting nuclear 
DNA stability (Duxin, Dao et al. 2009). SERPINF1 is involved in a variety of biological 
process, including neuronal development (Tombran-Tink, Chader et al. 1991); 
deregulation of SERPINF1 following SMARCB1 re-expression has also been previously 
described (Gadd, Sredni et al. 2010). LBX1 is a developmentally regulated homeobox 
gene involved in neurogenesis; interestingly although LBX1 is physiologically 
expressed during neuronal differentiation, a high expression level is associated with 
higher tumour grades in breast cancer (Yu, Smolen et al. 2009).  
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6.3.1.4 DEXSeq analysis: differential exon usage  
Raw count values were analysed to study alternative splicing and other forms of 
alternative isoform expression, using a negative binomial method i.e. DEXSeq (see 
method Chapter 3). In Figure 6.12 estimates of dispersion in the data are indicated, 
whereby the black dots represent the empirical dispersion values and the red line the 
fitted values; the MA plot shows the distribution of exon usage for each gene, 
comparing vector control cells and SMARCB1 re-expressing Rhabdoid cells.  
 
A B  
Figure 6.12 Per exon usage dispersion estimation and model fitting (A) and 
testing for differential exon usage of genes (B) comparing SMARCB1 re-
expressing cells and control infectants. A) Each dot represents per exon 
dispersion estimation and the red line the fitted mean dispersion function. 
B) Log2fold change versus mean expression over all samples. A red dot 
represents exons marked as differentially used at 10% FDR, when Benjamini 
and Hochberg method is applied. The lines on the top and on the bottom of 
the plot represent exons with a very low or very high log fold change (value 
off scale). 
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Gene Symbol Exon Adjusted  
p value  
log2fold 
EMC10 E009 1.23E-07 1.619989 
FAM60A* E015 1.25E-07 1.56494 
LAMB1 E012 5.29E-08 1.53708 
ALG13#  E036 2.37E-07 1.487411 
ERC2* E002 4.12E-09 1.331395 
SYNPO E012 5.90E-07 1.321838 
AP2S1 E002 1.68E-11 1.28767 
NUMA1*  E035 4.50E-08 -6.27551 
RUSC1 E025 5.61E-07 -6.57386 
SCOC  E024 2.95E-08 -6.71161 
DLD E027 8.48E-11 -7.01253 
MAPKAP1 E013 3.11E-07 -7.58521 
PRKD2 * E009 5.48E-10 -10.8838 
BTG4 ~ E020 3.26E-08 -11.2854 
PGAM1* E016 2.86E-12 -11.7591 
6.3.1.5 Detection of differentially used exon in gene SMARCB1 dependent 
The DEXseq results were filtered for values with an adjusted p-value less than 0.05 and 
log2 fold change less than -1 or greater than 1. Moreover, only protein coding genes 
were analysed; 59 genes with significantly differential exon usage were identified. Table 
6.2 shows 15 genes with the most significantly differentially used exons following 
filtering. Of the 15 genes in the table three were associated with tumour progression (*), 
one involved in autophagy (+) one described as tumour suppressor genes (~) and as a 
biomarker of poor outcome in Neuroblastomas (#) (http:.///www.genecrads.org). 
Complete list in Appendix I. 
  
 
 
Table 6.2 Genes with differentially used exons in SMARCB1 re-expressing 
Rhabdoid cells vs control infected cells. Functional annotation of genes
relevant to cancer is shown in the table with * for genes associated with
tumour progression, + indicates genes related to autophagy, ~ tumour 
suppressor genes (~) and as biomarker of worst outcome (#).  
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BTG4 is part of the anti-proliferative BTG family; down-regulation and 
hypermethylation of BTG4 was observed in gastric cancer and its re-expression in cell 
lines causes tumour growth inhibition (Dong, Tu et al. 2009), however it is highly 
expressed in preimplantation embryos (Buanne, Corrente et al. 2000). Figure 6.13 
shows the differential exon usage of BTG4 obtained from DEXSeq analysis. Exonic 
parts 1 is affected by SMARCB1 re-expression in Rhabdoid cells indicating a probable 
alternative transcriptional start site.  
 
 
Figure 6.13 BTG4 shows differential exon usage in response to SMARCB1 
re-expression (contigs 1). Exon usage for SMARCB1 re-expressing Rhabdoid 
cell lines are indicated in red (SMARCB1) and blue for control infectants 
(PCDH). An annotated transcript model is included at the bottom. 
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The protein encoded by PGAM1 plays an important role in cell proliferation; 
interestingly it has been reported to be up-regulated in many cancers and it also 
associated with activation of tumour suppressor protein Nm23-H1 (Engel, Seifert et al. 
1998). Figure 6.14 shows the differential splicing at an exon level of BTG4 obtained 
from DEXSeq analysis. SMARCB1 re-expression in Rhabdoid cells directly deregulates 
usage of Exonic parts 4 (exon number 3), activating an alternative splicing of 160 amino 
acids. 
 
 
Figure 6.14 PGAM1 shows differential exon usage in response to SMARCB1 
re-expression (Exonic parts 4). Exon usage for SMARCB1 re-expressing 
Rhabdoid cell line is showed in red (SMARCB1) and blue for control 
infectants (PCDH). An annotated transcript model is included at the bottom. 
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6.3.1.6 Validation of the DEXseq analysis  
My SMARCB1tial investigation used results retrieved from DEXseq package without 
any additional filtering, and gave different results from the analysis presented in this 
chapter. However, this approach lead to false positive results that were either 
unconvincing when examined by eye or difficult to further validate by RT-PCR i.e. a 
higher proportion of false positives: exonic parts with low raw counts emerged as 
significant, mainly because of the absence of raw counts in other exons in the same 
gene. In the analysis presented here only genes with a high number of normalised reads 
(>100) in a high number of samples (>75%) were used and this has helped to 
characterise exons that are truly significant differentially used.  
However from the 100 top genes with differentially exon usage obtained using the 
preliminary analysis, two genes MYLK and IL17RE were identified as of interest. MYLK 
was regulated by MTA2 in gastric cancer cells modulates the cytoskeleton and 
participates in cell invasion (Zhou, Ji et al. 2013). Figure 6.15 shows the differential 
exon usage of MYLK obtained with DEXSeq and in particular the different usage at 
exon 4 (exonic parts 10 and 16). qPCR was performed in all four cell lines after 
SMARCB1 re-expression and in the vector control infectants to validate the 
differentially used exons identified (Figure 6.16), in particular primers were designed 
to span the differentially used exons identified in the analysis ; SMARCB1 re-expressing 
G401 and A204 showed the most significant changes in usage of exon 4 with an 
increase of usage of 2.7 and 4.8 fold change respectively; STA-WT1 showed a less 
significant change in usage of exon 4 upon SMARCB1 re-expression while CHLA-266 
did not show change in exon usage of this gene. 
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Figure 6.15 MYLK shows differential exon usage in response to SMARCB1 
re-expression (Exonic parts 11 and 16). Exon usage for SMARCB1 re-
expressing Rhabdoid cell lines are indicated in red (SMARCB1) and control 
infectants (PCDH) in blue. An annotated transcript model is included at the 
bottom. 
 245 
 
 
Figure 6.16 SMARCB1 re-expression induces differential usage of MYLK 
exon 4 in Malignant Rhabdoid cell lines. RNA was extracted at 7 days post 
infection with pcdh-mcs1-ef1-puro (PCDH) and SMARCB1-pcdh-mcs1-ef1-
puro (SMARCB1). The mRNA levels were measured by real-time qPCR and 
normalised for GAPDH. Values are fold change relative to control infectants 
and are the mean of 3 independent measurements. 
 
IL17RE belong to the cytokines IL-17 and encodes for the IL17RE protein which forms 
heterodimers with IL17RA; the complex L-17RA-IL-17RE mediates activation of IL-17 
signalling in inflammation and participates in tumourigenesis (Al-Samadi, Kouri et al. 
2014). Figure 6.17 shows alternative splicing at the exon level for IL17RE; in particular 
exonic part 33 was significantly differentially used in response to SMARCB1 re-
expression. qPCR was performed in all four cell lines following SMARCB1 re-
expression and in the vector control infectants to validate differentially used exons 
identified by DEXseq (Figure 6.18); RT-PCRs corresponding to exonic part 23 and 28 
were also analysed for experimental comparison as control. Interestingly, STA-WT1 
showed a significant decrease of exon usage at exonic part 33 (corresponding to exon 
16) with a change in exon usage of -4 fold change when compared with exonic part 23 
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(exon 10). Decrease of expression was also detected in G401; however CHLA-266 and 
A204 cell lines did not show a significant change in exon usage of this gene. 
 
Figure 6.17 IL17RE differential exon usage in response to SMARCB1 re-
expression (contigs 5-12). Splicing for SMARCB1 re-expressing Rhabdoid 
cell line are indicated in red (SMARCB1) and blue for control 
infectants(PCDH). An annotated transcript model is included at the bottom. 
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Figure 6.18 SMARCB1 re-expression induces differential exon usage of 
IL17RE exonic part 23, 28 and 33 in Malignant Rhabdoid cell lines. RNA 
was extracted at 7 days post infection with pcdh-mcs1-ef1-puro (PCDH) and 
SMARCB1-pcdh-mcs1-ef1-puro (SMARCB1). The mRNA levels were 
measured by real-time qPCR and normalised for GAPDH. Values are the 
mean of 3 independent measurements. Exonic parts 23 and 28 were also 
analysed for experimental comparison. 
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Gene ID Position Log2fold pvalue 
XLOC_008212 chr10:123237667-123491375 -1.04304 0.0013 
XLOC_006183 chr10:29656052-29660582 -2.60765 5.00E-05 
XLOC_027266 chr18:22096547-22242163 -1.6866 0.001 
XLOC_027881 chr18:22242527-22251803 -1.79878 0.0021 
XLOC_032441 chr2:150959288-150975090 -1.91077 5.00E-05 
XLOC_034832 chr2:189896598-190305848 2.71254 5.00E-05 
XLOC_035957 chr20:3019951-3053163 -1.16294 5.00E-05 
XLOC_038910 chr22:49599095-49778198 -1.16185 0.0003 
XLOC_050753 chr6:122017749-122409661 -1.58329 5.00E-05 
XLOC_053533 chr7:40165570-41173105 3.01944 5.00E-05 
XLOC_057406 chr8:129733656-129931429 -1.38871 5.00E-05 
6.3.1.7 Novel transcript discovery 
Following the alignment of the reads to the Human Genome hg19, De novo transcript 
assembly was performed separately on each primary Rhabdoid Tumour sample and each 
Rhabdoid cell line using Cuffllinks, as described in section 3.1.8. The individual de 
novo transcriptomes were merged with one another and with the GENCODEv17 
transcriptome library into a single transcriptome using Cuffmerge. Cuffdiff was used to 
identify significantly differentially expressed genes and splicing isoforms between 
SMARCB1 re-expressing Rhabdoid cell lines and control transfected cell lines to 
generate adjusted p-values, mean FPKM (Fragments Per Kilobases per Millon Reads) 
values and fold change for each gene or isoform.  
I focused on characterising genes that do not overlap with the GENCODE 17 transcript 
library and isolated those unknown genes whose expression was significantly altered by 
SMARCB1 expression; data were further filtered to characterise significant gene 
(minimum  FPKM (Fragments per Kilobases per million) in at least one condition > 5). 
Table 6.3 shows the 12 novel transcripts as result of this filtering.  
Table 6.3 List of significant possible novel transcript individualised in de
novo transcriptome analysis. hg19 position in the genome is included.  
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Gene ID GenScan 
prediction 
High 
conservation 
DNA 
Hyper- 
sensitivity 
H3K27Ac  
marks 
XLOC_008212 Yes Yes Yes Yes 
XLOC_006183 Yes Yes No No 
XLOC_027266 Yes Yes Yes Yes 
XLOC_027881 Yes Yes No No 
XLOC_032441 Yes Yes Yes Yes 
XLOC_034832 Yes Yes No Yes 
XLOC_035957 Yes Yes No No 
XLOC_038910 Yes Yes Yes No 
XLOC_050753 Yes Yes Yes No 
XLOC_053533 Yes Yes Yes Yes 
XLOC_057406 Yes Yes Yes No 
 
These novel transcripts were visualised using a custom track in UCSC Genome 
Browser. In particular, the track corresponding to the prediction program GenScan 
(http://genes.mit.edu/GENSCAN.html) was used to find any potential predicted genes 
within the putative de novo transcriptome sequences, and finally the tracks were 
evaluated against other UCSC annotations. For instance, information such as absence of 
long non-coding RNA (lincRNA), H3K27Ac marks close to active regulatory elements, 
DNase hypersensitivity and conservation amongst species (Table 6.4) were considered. 
Read alignments retrieved from SMARCB1 re-expressing cells and control infectants for 
those transcripts identified as potential novel transcript were compared using Integrative  
Genomics Viewer (IGV).  
 
 
 
 
Table 6.4 Analysis of significant transcript characterised by de novo
transcriptome analysis. For each transcript functional annotations are
indicated.  
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From 12 potentially novel transcripts 2 new potentially transcriptional fragments 
(XLOC_008212, XLOC_053533) and a new potential gene (XLOC_032441) were 
identified. In this study XLOC_053533 and XLOC_032441 were further analysed to 
validate the presence of novel transcripts. 
 
Transcript validation  
The read alignment for these two novel transcripts was verified using Integrative 
Genomics Viewer (Broad Institute). Alignment of reads was essential to identify exon 
boundaries, For instance, 5 exons were found for XLOC_053533 (Figure 6.20), while 6 
exons were determined for XLOC_032441 (Figure 6.20). 
 
 
Figure 6.19 IGV representation of raw read counts that correspond to 
XLOC_053533 and the difference between SMARCB1 re-expressing cells and 
the control infectants.  
 251 
 
 
Figure 6.20 IGV representation of raw read counts that correspond to and 
XLOC_032441 and the difference between SMARCB1 re-expressing cells and 
the control infectants. XLOC_032441 presents reads in both conditions; 
however the read count number in SMARCB1 re-expressing cells were 
significantly higher. 
 
The exon boundaries identified for XLOC_053533 were Initially validated by RT-PCR 
in all four Rhabdoid cell lines, using as a control D283, D425 and DAOY 
Medulloblastoma cell lines. (Figure 6.21 and Figure 6.22). However, SMARCB1 
dependency appeared most evident for exon boundary 3-4 and 4-5 and especially in the 
cell line A204. 
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Figure 6.21 RT-PCR for XLOC_053533 exon boundary 1- 2(A) and exon 
boundary 3-4(B). RT-PCR was performed for each Rhabdoid cell line in 
three different condition: untreated cells (Un), vector control infectants 
(PCDH) and SMARCB1 re-expressing cells (SMARCB1; also a pool of 
SMARCB1 re-expressing cells was used. As a control three Medulloblastoma 
cell lines (MB) were used.  
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Figure 6.22 RT-PCR for XLOC_053533 exon boundary 4-5. RT-PCR was 
performed for each Rhabdoid cell line in three different conditions: 
untreated cells (Un), vector control infectants (PCDH) and SMARCB1 re-
expressing cells (SMARCB1); also a pool of SMARCB1 re-expressing cells 
was used. As a control three Medulloblastoma cell lines were used.  
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RT-PCR products obtained from SMARCB1 re-expressing pool cells were sequenced to 
verify respectively PCR products spanning exons 1 and 2, spanning exon 3 and 4, 
spanning exons 4 and 5. Sanger sequencing confirmed the presence of the exons 
boundaries (Figure 6.23).  
 
Figure 6.23 Sanger sequencing of XLOC_053533 validated the presence of 
exon boundary 1-2, exon boundary 3-4, and exon boundary 4-5 at the locus 
chr7:40165570-41173105. 
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For the novel transcript XLOC_032441, five of the six exons identified were validated 
by RT-PCR (Figure 6.24), which confirmed the presence of an unknown gene at this 
locus on Chromosome 2. However the dependence of expression on SMARCB1 cannot 
be established using RT-PCR although may be evident by quantitative RT-PCR. 
 
 
Figure 6.24 RT-PCR for XLOC_032441 exon boundary 1-2 (A), exon 
boundary 2-3(B) and exon boundary 4-5 (C). Except for exon boundary 1- 2 
RT-PCR was performed for each Rhabdoid cell line in three different 
conditions: untreated cells (Un), vector control infectants (PCDH) and 
SMARCB1 re-expressing cells (SMARCB1); also a pool of SMARCB1 re-
expressing cells was used. As a control three Medulloblastoma cell lines 
(MB) were used.  
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RT-PCR products obtained from SMARCB1 re-expressing pool cells were sequenced to 
verify respectively spanning exons 2 and 3. Sanger sequencing confirmed the presence 
of this exon boundary only in the forward direction (Figure 6.25). Other boundaries 
could not be validated at this time. 
 
 
Figure 6.25 Sanger sequencing validated the presence of exon boundary 2-3 
in the locus XLOC_032441 chr2:150959288-150975090. 
 
The obtained sequences were further analysed using the homology research tool 
BLAST. Interestingly, XLOC_053533 sequences showed homology with PTRTJ gene 
(Chr11: 48101421-48101441) also the XLOC_032441 sequence showed homology with 
genes IL1RAPL1 (ChrX: 28910337-28915794) and PKHD1 (Chr6: 51803515-51809). 
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 450K methylation analysis  6.3.2
 
6.3.2.1 QC analysis  
Quality of the data was performed using Minfi package, as described in section 3.3.2. 
As a result of the pre-processing step the methylated and unmethylated control probe 
signals were evaluated for both InfI (Infinium I) and InfII (Infinium II) chemistries 
(Figure 6.26).  
 
   
Figure 6.26 Control strip plot of 450K methylation data for Rhabdoid cell 
line models. Quality evaluation for InfI (Infinium I A) and InfII (Infinium II 
B) is indicated. Distribution of signal intensity for each of the quality 
control probes in both is plotted. Control probes were successfully 
converted given that samples present roughly similar distribution in both 
channels. 
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β values were derived using the BASH algorithm (section 3.2.2): and their distribution 
analysed to determine the quality of the data. All of the cell line samples pass the quality 
control checks with less than one percent of CpG sites possessing detection p-values 
equal or greater than 0.001 (Figure 6.27). 
 
 
Figure 6.27 Overall density distributions of beta values in Rhabdoid cell 
line models. Kernel density plot illustrates the bimodal distribution of β-
values for the 43 primary tumours analysed. 
 
6.3.2.2 Global patterns of DNA methylation in Rhabdoid Tumours  
The distribution of average methylation status within test cohorts (9506 probes selected 
as those CpGs were most significantly different when SMARCB1 was re-expressed; p< 
0.05) is summarised in Table 6.5. Interestingly, a very marked difference in the 
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 Probes 
classification 
% 
All probes  Methylated  3803 (40%) 
Hemimethylated  86 (0.9%) 
Unmethylated 5615 (59.1%) 
CpG Island  Methylated 2597 (27.6%) 
 Hemimethylated  1 (0.1%) 
 Unmethylated 1181 (12.4%) 
Non CpG Island Methylated 1208 (12.7%) 
 Hemimethylated  85 (0.9%) 
 Unmethylated 4434 (46.6%) 
  
methylation status of probes located within and outside of CpG islands was detected: 
majority of the probes were located outside the CpG Island and unmethylated. 
 
 
 
 
 
Cluster analysis 
450K methylation data were filtered in a supervised fashion to create a subset composed 
of the most significantly differentially methylated CpGs (assessed from 40000 most 
variable CPG probes subsequently tested by limma to an adjusted pvalue <0.01). PCA 
analysis was performed using a subset of 9506 probes and confirms a genome-wide 
change in methylation status related to SMARCB1 re-expression (Figure 6.28). It is also 
notable that one of the cell lines does not alter CHLA266 does not alter its methylation 
Table 6.5 Global methylation distribution among the cell lines (9506 probes
selected as those most variable probes within the data). Average
methylation scores were calculated for all probes across the datasets. For
three probe categories (all probes, probes located within CpG islands and
probes located outside of CpG islands), the number of unmethylated
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status to the same degree upon SMARCB1 re-expression. Changes in methylation are 
generally smaller in this line and it is uncertain at this point why. 
 
Figure 6.28 Supervised principal component analysis on SMARCB1 re-
expressing cell lines vs control infectants. 450K methylation data 
distinguishes two groups. Red points represent vector control infected cells 
(PCDH) while SMARCB1 re-expressing cells (SMARCB1) are indicated in 
blue. The x-axis is the first component; the y-axis is the second principal 
component. 
 
Consensus NMF supervised analysis (k=2) was carried out on the selected genes 
identifying two different metagenes one for the SMARCB1 positive cells and one for the 
control cells (Figure 6.29). As can be seen, one of the cell lines CHLA266 continues to 
group preferentially with the control lines even when SMARCB1 is re-expressed. An 
examination of the individual metagene scores shows that whilst the shift in the 
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SMARCB1 dependent methylation metagene is equivalent in the CHLA266 line is far 
more methylated at the relevant CpG loci to begin with and therefore the shift in 
methylation provoked by SMARCB1 is insufficient to cause the consensus NMF to 
group this cell line with the other SMARCB1 re-expressing lines. Nevertheless, the same 
CpGs are being altered and in the same direction in the CHLA266 so there is no need to 
remove from the analysis or to alter my results. 
 
  
Figure 6.29 (left) Supervised consensus NMF and hierarchical cluster 
analysis (K=2) performed on methylation data from SMARCB1 re-
expressing cells (SMARCB1) and control infectants (pCDH). The matrices 
were coloured 0 (deep blue, indicating samples never in the same cluster) to 
1 (dark red, indicating samples always in the same cluster). (right) a 
heatmap of the methylation metagenes k= 2 extracted from SMARCB1 re-
expressing cells (SMARCB1) and control infectants (PCDH) methylation 
profiles. Shading shows the shift in metagene expression following 
SMARCB1 expression is equivalent in direction but not of equivalent 
magnitude in the cell line CHLA266 (first two columns) 
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Filtered data were used to generate a heatmap (Figure 6.30) revealing that SMARCB1 
re-expression causes up regulation of the majority of the genes analysed again it can be 
seen that the magnitude of hypo and hypermethylation in CHLA266 following 
SMARCB1 expression (1st column) is not equivalent in magnitude.  
 
Figure 6.30 Supervised heatmap of differentially methylated probes in 
SMARCB1 re-expressing Rhabdoid cells (SMARCB1) and in vector control 
infected Rhabdoid cells (PCDH). Overrepresented (pale red to dark red) and 
underrepresented transcripts (pale blue to dark blue). Each row represents a 
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Probes Gene Symbol Average 
Delta values 
LogFold 
change 
Adjusted 
p value 
cg20377673 MIF* -0.63678 -3.92831 0.021081 
cg02524983 LPP*+ -0.62799 -3.90218 0.00116 
cg18680181 KIAA0391 -0.62626 -3.84263 0.009082 
cg24650915 SIL1* -0.62301 -3.86597 0.019342 
cg21171461 RAPGEF1 -0.62141 -4.01879 0.019342 
cg08726522 ST5~ -0.61973 -4.62047 0.021081 
cg12799029 ABR -0.60408 -3.92576 0.020375 
cg26094842 VTI1A -0.6016 -4.06983 0.015605 
cg04604708 CREB3L2* -0.5998 -3.84498 0.002931 
cg20917077 CPA5 -0.59935 -4.17312 0.019342 
cg15947176 C8orf46* 0.47743 5.201754 0.013222 
cg24577594 GALNT2 0.871935 3.677821 0.021081 
cg07438401 SUCLG2 -0.63678 -3.92831 0.009082 
cg21377354 SUSD2*-+ -0.62799 -3.90218 0.000312 
cg22398710 FBXL5* -0.62626 -3.84263 0.037258 
probes and each column a sample. Overrepresented (pale red to dark red) 
and underrepresented transcripts (pale blue to dark blue). 
Table 6.6 shows the 15 most differentially methylated CpGs as a result of filtering. 
Eight of the gene linked to these CpGs were associated with tumour progression (*), 
two promoting metastasis (+), one indirectly involved in tumour invasion and 
angiogenesis (-), one gene indicated as oncogene (~) (http:.///www.genecrads.org). 
Complete list in Appendix I. 
 
 
 
 
Table 6.6 Selected differentially methylated CpGs in response to
SMARCB1 re-expression. LogFold Change is given as a ratio of M-values
between SMARCB1 re-expressing Rhabdoid cells and vector control
infected Rhabdoid cells. Average delta values are the mean change in beta
value between SMARCB1 re-expressing Rhabdoid cells and vector control
infected Rhabdoid cells Functional annotation of genes relevant to cancer
is shown in the table with * for genes associated with tumor progression,
+ for genes promoting metastasis,- for genes correlated with tumour
invasion and angiogenesis, ~ for genes indicated as oncogenes. 
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Interestingly SMARCB1 re-expression induces hypomethylation of ST5; gene included 
also in the top 20 most differentially methylated genes when Extra Cranial Rhabdoid 
malignancies were compared with Atypical Teratoid Rhabdoid Tumours. ST5 encodes 
for p126 protein which interacts with MAP kinase activation pathways in response to 
EGF (Majidi, Hubbs et al. 1998). A smaller isoform p70 is also encoded which is 
considered a tumour suppressor gene (Majidi, Hubbs et al. 1998), however the 
mechanism is not yet understood. One of the two hypermethylated genes is SUSD2, 
which has been recently linked with breast tumourigenesis; the encoded protein 
interacts with Gal-1 and the interaction promotes tumour immune evasion, 
angiogenesis, and metastasis(Watson, Evans et al. 2013). 
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 RNA-seq analysis identifies gene reactivation induced by 5-aza-6.4
2-deoxycytidine treatment in Malignant Rhabdoid cells  
RNA-seq was carried out in the four Rhabdoid cell lines following treatment with the 
demethylating agent 5-aza-2-deoxycytidine (5-azaCdR) to try to elucidate the genome-
wide effect on the epigenetic mechanisms involved in Rhabdoid tumourigenesis.  
 
 RNA-seq analysis  6.4.1
 
6.4.1.1 Primary samples preparation  
RNA from treated cells was extracted as described previously in section 2.1.1. RNA 
integrity number (RIN score) was evaluated for each sample, using an Agilent 
Bioanalyzer. All the RNA samples were scored with a RIN greater than 9.  
 
6.4.1.2 RNA-seq QC analysis 
Samples sequenced successfully passed the RNA quality control checks: all bases 
analyses showed an average Phred-score higher than 30. High variability on the first 
bases as result of random priming was also found, confirming that this effect was not 
related with sample preparation or perform of sequencing.  
 
6.4.1.3 DEseq analysis 
Raw count values were analysed in a pair-wise fashion using DESeq2 in R. 
Differentially expressed genes between cells treated with 5-azaCdR and untreated cells 
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were determined by the negative binomial method of statistical analysis. Dispersion in 
the data set was estimated (Figure 6.31 and Figure 6.32), as well as differential 
expression estimation between cell lines with or without 5-azaCdR treatment (Figure 
6.33). 
 
 
Figure 6.31 Gene expression dispersion estimation and model fitting of 5-
azaCdR treated cells (AZA). Each dot represents per gene dispersion 
estimation and the red line the fitted mean dispersion function. 
 
.  
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Figure 6.32 Gene expression dispersion estimation and model fitting of 
control untreated cell lines. Each dot represents per gene dispersion 
estimation and the red line the fitted mean dispersion function. 
 
Figure 6.33 Testing for differential expression between of 5-azaCdR treated 
cells vs untreated cells: differentially expressed genes Log2fold versus mean 
expression over all samples. Red dots represent genes marked as 
differentially expressed at 10% FDR, when a Benjamini and Hochberg 
method is applied. The lines on the bottom of the plot represent genes with a 
very low or very high log fold change (value off scale). 
 
Clustering analysis 
A subset of significant differentially expressed gene was extracted from the DEseq 
results to identify genes significantly differentially expressed in response to 5azaCdR 
treatment (adjust p-value < 0.01; moderated log fold change ≤ -2 and ≥ +2). PCA 
analysis was performed on a subset of 132 significant genes, and identifies two separate 
subgroups, one consisting of untreated cells and the second of 5-azaCdR treated cells 
(Figure 6.34). This result demonstrates the concerted effect on gene expression of 
demethylation induced by 5-azaCdR. 
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Figure 6.34 Supervised principal component analysis of gene expression 
profiles from 5-azaCdR treated Rhabdoid cell lines and untreated Rhabdoid 
cell lines distinguishes two different biological groups. Points in red 
represent 5-azaCdR treated cells (AZA) and in blue vector control untreated 
cells (CTL). The x-axis is the first component; the y-axis is the second 
principal component. 
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Consensus NMF supervised analysis (k=2) was carried out on the selected genes 
identifying two different metagenes, and confirming the change in expression caused by 
5-azaCdR (Figure 6.35).  
 
 
Figure 6.35 Supervised NMF and hierarchical cluster analysis (K=2) of 5-
azaCdR treated cells (AZA) and untreated cells (CTL) DEseq data. The 
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matrices are coloured 0 (deep blue, indicating samples never in the same 
cluster) to 1 (dark red, indicating samples always in the same cluster). 
These significant differentially expressed filtered genes were used to generate a 
heatmap revealing that 5-azaCdR treatment causes up regulation of the majority of the 
genes analysed (Figure 6.36).  
 
 
Figure 6.36 Supervised heatmap of selected significantly differentially 
expressed genes in 5-azaCdR treated cells (AZA) and untreated cells (CTL). 
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Gene Symbol Adjusted p-value Moderate log2fold 
GPX1 * 1.45E-06 4.207726 
TKTL1*  2.63E-07 4.114281 
RRAD* 2.93E-09 4.097312 
MAEL 3.25E-15 3.804456 
ACRC 1.97E-10 3.417875 
COL7A1* 7.36E-26 3.402389 
TDRD12 3.64E-08 3.133676 
COL9A3 8.77E-10 3.049116 
ZSCAN4 * 1.61E-05 2.993179 
CLDN6* 0.000668 2.954359 
RFPL4B 8.23E-10 2.942049 
CCNA1*  2.09E-20 2.887184 
COL3A1 2.01E-08 -2.00126 
BCL2 ~ 1.47E-07 -2.00128 
FGFBP3 7.52E-17 -2.31185 
Overexpressed (pale red to dark red) and under-expressed transcripts (pale 
blue to dark blue). Each row represents a gene and each column a sample. 
Table 6.7 shows the 15 most differentially expressed genes ranked by fold change. 
Seven genes are associated with tumour progression (*) and one gene indicated as 
oncogene (~) (http:.///www.genecrads.org). Complete list in Appendix I. 
 
 
 
 
GPX1 encodes for the anonymous antioxidant proteins, which plays an important role in 
inflammatory response; in GPX1 together with GPX2 knockout mice Polycomb (PcG) 
target genes show changed in methylation status especially in embryonic stem cells 
(Hahn, Hahn et al. 2008). ZSCAN4 is newly identified embryonic stem cell marker and 
Table 6.7 Differentially expressed gene SMARCB1 re-expressing Rhabdoid 
cells vs vector control infected Rhabdoid cells. Functional annotation of 
genes relevant to cancer is shown in the table with * for genes associated 
with tumor progression, ~ for genes indicated as oncogenes. 
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recently a direct interaction with Rap1 was described; interestingly Rap1 causes 
senescence, regulating the expression of genes encoding for core histone proteins; 
downregulation of Rap1 increases core histone protein levels causing global changes in 
chromatin stability and therefore in gene expression (Lee and Gollahon 2014). 
 
DEXSeq analysis: differential exon usage  
Alternative splicing and alternative isoform expression were identified from row count 
values using a negative binomial method. Dispersion estimate in the data and 
distribution of exon usage for each gene were also computed comparing untreated cells 
and 5-azaCdR treated cells (Figure 6.37).  
A B  
Figure 6.37 A) Per exon usage dispersion estimation and model fitting (A) 
and testing for differential exon usage of genes (B) comparing untreated 
cells and 5-azaCdR treated cells. A) Each dot represents per exon 
dispersion estimation and the red line the fitted mean dispersion function. 
B) Log2fold versus mean expression over all samples. Red dots represent 
exons marked as differentially expressed at 10% FDR, when Benjamini and 
Hochberg method is applied. The lines on the top and bottom of the plot 
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represent exons with a very low or very high log fold change (value off 
scale). 
6.4.1.4 Detection of differentially used exon following by 5-aza-2-deoxycytidine 
treatment  
The exon level counts were examined by comparing using DEXseq 5-aza-CdR treated 
cells with untreated cells in order to determine a methylation dependent effect upon 
exon usage. The DEXseq results were filtered for values with an adjusted p-value 
greater than 0.05 and log2 fold change less than -1 or greater than 1. Moreover, only 
protein coding genes were analysed; 7196 genes with significant variation in exon usage 
were identified. Table 6.8 shows the 15 most differentially used exons as ranked by log 
fold change. From the 15 genes in the table, five were associated with tumour 
progression (*), one gene is indicated as an oncogene (~) (http:.///www.genecrads.org). 
Complete list in Appendix I. 
PCAM represents an interesting gene, since its role is somewhat ambiguous: a high 
level of expression denotes an aggressive phenotype of oesophageal cancer and it is 
used as biomarker to characterise circulating tumour cells, however absence or low 
expression of EPCAM in circulating tumour cells is also reported (Driemel, Kremling et 
al. 2014). PDE4D encodes a cAMP-specific phosphodiesterases protein and 
interestingly cAMP levels are inversely correlated with tumour progression and grade of 
malignancy in brain (Sengupta, Sun et al. 2011). 
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Gene Symbol Exonic 
part  
Adjust p value log2fold 
BCAR3 ~ E030 6.52E-09 2.951094 
EPCAM* E002 3.28E-08 2.714227 
BBS9 E004 1.43E-10 2.500092 
CPEB4* E012 4.49E-10 2.359447 
RAD51B  E055 0.000303 2.134738 
TENM4 E046 4.66E-05 2.129385 
PDE4D* E037 0.011333 1.96927 
WDR43 E002 0.001071 -0.79376 
RPSAP52 E002 0.008397 -0.80263 
AC003090.1 E007 0.001825 -0.8259 
PSMG3 E007 1.56E-08 -0.83298 
RP11-10A14.4 E004 0.007052 -0.88819 
CHCHD4* E006 1.63E-15 -0.8913 
WRAP53* E005 3.56E-05 -0.91958 
TNIP2 E012 0.00252 -0.98382 
  
 
 
 
 
 
 
 
 
 
 
Table 6.8 Genes with differentially used exons in 5-azaCdR treated 
Rhabdoid cells and untreated cells. Functional annotation of genes
relevant to cancer is shown in the table with * for genes associated with
tumour progression, ~ for oncogenes. 
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 Discussion 6.5
 
 Integrated genomic and epigenetic analysis identifies downstream target 6.5.1
genes dependent by SMARCB1  
Earlier studies have indicated that re-expression of SMARCB1 in Rhabdoid cell lines 
causes broad upregulation of the expression of genes involved in cell cycle, cell growth 
and cytoskeleton organization (Medjkane, Novikov et al. 2004, Morozov, Lee et al. 
2007). Only one study attempted to characterise the downstream effectors of 
SMARCB1, however the analysis was limited to one cell line (Morozov, Lee et al. 
2007). 
RNA-seq was performed in Malignant Rhabdoid Tumour cells upon SMARCB1 re-
expression and accomplished in four cell lines derived from different location of the 
body. Gene expression analysis reveals that SMARCB1 re-expression significantly 
altered 493 genes and 471 were detected to be upregulated. Interestingly, DNA2, 
SERPINF1 and LBX1 were in the top 15 deregulated genes. Deregulation of DNA2 
causes DNA instability as result of chromosomal aberrations and inter-nuclear 
chromatin bridges. In Malignant Rhabdoid Tumours SERPINF1 was already identified 
as a potential therapeutic target (Gadd, Sredni et al. 2010). LBX1 is a gene involved in 
neuro-development and interestingly high expression level is associated with aggressive 
phenotype in breast cancer. Exon usage analysis of Rhabdoid cell lines indicated that re-
expression of SMARCB1 directly affects the exon usage of 493 genes. Many of the top 
100 genes were linked with tumour progression and neurodevelopment; in this list 
FAM60A BTG4, PGAM1, MYLK and IL17RE were identified as potential therapeutic 
targets; FAM60A interacts to chromatin remodel E2F1, which is not usually expressed in 
Malignant Rhabdoid Tumours (Venneti, Le et al. 2011); BTG4 is expressed in embryos 
and down-regulation of this gene promotes tumour cell growth in gastric cancer (Dong, 
Tu et al. 2009); PGAM1 also is involved in cell proliferation and in particular associated 
with activation of tumour suppressor protein Nm23-H1 (Engel, Seifert et al. 1998) 
MYLK modulates the cytoskeleton and participates in cell invasion (Zhou, Ji et al. 
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2013). The protein encoded by IL17RE forms a complex with IL17RA, which mediates 
inflammatory signalling in the brain (Al-Samadi, Kouri et al. 2014). Differential exon 
usage of MYLK and IL17RE was also analysed by qPCR confirming the different 
splicing observed through DEXseq analysis; however only in part as CHLA-266 and 
A204 cell lines did not show a significant change in exon usage of IL17RE gene. 
De novo transcriptome analysis was also performed on RNA-seq raw data to identify 
novel transcripts and new isoforms. Comparison of the de novo transcriptome with 
GENCODE17 transcript library identified 12 possible novel transcripts with expression 
dependent on SMARCB1 re-expression; further analysis identified one possible new 
isoform and a novel gene: XLOC_053533 and XLOC_032441. Exon boundaries and 
relative structures were validated by RT-PCR and Sanger sequencing; BLAST analysis 
of the obtained sequences confirmed the presence of the isoform and the gene; however 
both sequences showed homology for other genes and in particular XLOC_053533 for 
lincRNA. 
Also in all four cell lines after SMARCB1 re-expression, analysis of the methylation 
status was performed; 450K methylation array was carried out in Rhabdoid cell line to 
study the epigenetic effects dependent of SMARCB1 loss. Our analysis indicated that 
SMARCB1 re-expression causes mainly hypomethylation of several genes, in particular 
in this analysis 61 significantly hypomethylated probes and just 2 significantly 
hypermethylated. The top 15 most differentially methylated genes included ST5 
specifically hypomethylation following SMARCB1 re-expression; interestingly this gene 
was also significantly differentially methylated in the comparative analysis between 
Extra Cranial and Atypical Teratoid Rhabdoid Tumours. Instead SUSD2 appeared to be 
hypermethylated following SMARCB1 re-expression; this gene is indirectly linked with 
the activity of Gal-1, promoting angiogenesis, and metastasis (Watson, Evans et al. 
2013). 
The results obtained in this analysis implicate SMARCB1 involvement in the epigenetic 
mechanisms that regulate gene expression. In particular, we here show the direct effect 
of SMARCB1 loss in gene expression and upon methylation. As a result of this 
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investigation we observed that SMARCB1 loss causes deregulation of gene not only 
involved in cell cycle (as previously described), but also those directly involved in 
tumourigenesis, metastasis or others with unknown oncogenic activity. 450K array 
analysis suggests that gene expression in Malignant Rhabdoid Tumours is caused in part 
by aberrant methylation: broad upregulation of genes was observed concomitant with a 
general hypomethylation. Interestingly SMARCB1 re-expression induces mainly 
hypomethylation of non-CpG island-associated promoters and therefore deregulation of 
gene expression; the effect of hypomethylation in non-CpG island genes is not a fully 
understood mechanism.  
SMARCB1 loss not only affects gene expression by changing methylation status, but 
also activates different isoforms: in particular SMARCB1 re-expression induces 
differentially exon usage on 59 genes and therefore expression of different transcript. 
Most of the genes with differentially exon usage upon SMARCB1 re-expression are 
related to tumourigenesis; for example FAM60A which promotes tumourigenesis by 
interaction with chromatin remodelling E2F1 and BTG4 with its downregulation and 
hypermethylation is related to tumour proliferation. 
In conclusion, this integrated analysis characterises the role of SMARCB1 on regulation 
of epigenetic events in Rhabdoid tumourigenesis. In particular, we show that deletion of 
SMARCB1 does not just affect cell cycle controlling genes, but a variety of genes as 
results of a wide epigenetic deregulation, affecting methylation status and alternative 
splicing.  
 
 RNA-seq reveals gene activation in Malignant Rhabdoid cell lines following 6.5.2
5-Aza-Deoxycytidine treatment 
5-azaCdR treatment in Malignant Rhabdoid cell lines causes deregulation of genes 
which are known to be SMARCB1 dependent (see Chapter 4). To obtain a 
comprehensive understanding of gene deregulation in Rhabdoid Tumours and the 
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relationship with methylation status, genome-wide RNA sequencing in four Rhabdoid 
cell lines after 5-azaCdR treatment was performed. 
Study of differential expression identified a total of 132 significant deregulated genes: 
116 were upregulated and 16 downregulated in response to 5-azaCdR treatment. Most 
of the genes were related with tumourigenesis and in particular downregulation of the 
oncogene BCL2 was observed, together with upregulation of GPX1 and ZSCAN4. GPX1 
and ZSCAN4 are both involved in chromatin stability in stem cells, the first modulates 
the methylation of the Polycomb (PcG) target genes while the second regulates together 
with Rap1 core histone protein expression (Lee and Gollahon 2014).  
5-azaCdR treatment in Rhabdoid tumour cells also affects the expression of alternative 
isoforms, In particular, we identified 7196 gene with significant alternative isoform 
regulation in response to 5-aza-CdR treatment. Once again the most significant genes of 
interest present with a tumourigenic potential or function, such as EPCAM and PDE4D. 
High expression of EPCAM is observed in aggressive cancer stem cells, while PDE4D 
is reported liked with tumour progression in brain malignancies (Sengupta, Sun et al. 
2011, Driemel, Kremling et al. 2014).  
This study showed that 5-azaCdR treatment in Rhabdoid tumour cell lines has a broad 
effect on the genome, in a similar manner to that of SMARCB1 re-expression. In 
particular, a general upregulation of gene expression was observed as well as 
deregulation of splicing control. This confirms the direct involvement of SMARCB1 and 
SWI/SNF complexes in genome-wide methylation, resulting in gene expression 
deregulation. Since aberrant DNA methylation drives tumourigenesis in Malignant 
Rhabdoid Tumours, inhibitors of methylation such as 5-azaCdR might conceivably be 
used as a therapy to combat Malignant Rhabdoid Tumours tumourigenesis.  
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 Comparison of Molecular Chapter 7
Signatures from Malignant 
Rhabdoid Tumours and Cell line 
Models Identifies Mechanisms of 
Tumourigenesis 
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 Introduction 7.1
Whole-genome approaches are used to identify the molecular profiles which may be 
used to identify and define diseases. Whole genome profiling is used to profile gene 
expression and to study epigenetic modification, illustrating signatures of gene 
expression and patterns of epigenetic regulation. In Malignant Rhabdoid Tumours 
whole genome profiling identified prognostic genes and gene profiles that might cause 
tumourigenesis (Birks, Donson et al. 2013). However, no study has fully characterised 
epigenetic mechanisms involved in Rhabdoid Tumours. Here integration of data sets 
from multiple whole genome profiling was attempted, to characterise the epigenetic 
modulation of DNA methylation that regulate gene expression. Cross-referencing 
functional models with primary data allows a multi-dimensional characterisation of 
biological systems, improving the understanding of the contribution of genetic and 
epigenetic alterations in tumour progression. 
Whole genome profiling technology provides the opportunity to identify disease-
specific genes and pathways in unprecedented detail. In the past decades studies of 
disease were mainly based on single gene analysis, an approach that may miss 
important effects on pathways; however the introduction of high-throughput 
technologies such as microarray leads to a more comprehensive knowledge of diseases 
by extracting meaning from a much larger number of differentially expressed genes. 
The term pathway refers to collections of genes or proteins that directly or indirectly 
modulate a well-defined biological task. Decades of molecular biology studies have 
defined a wide number of pathways, establishing functional associations between gene 
expression and disease. In particular, following the sequencing of the entire human 
genome accomplished in 2003, pathways analysis has grown exponentially discovering 
a vast number of significant biological signatures, collected in public pathway 
repositories (Ramanan, Shen et al.). Although pathway analysis of expression data is a 
relatively new field, many studies have identified deregulated pathways that reflect 
perturbed genes from expression data, allowing a better understand of biology of 
disease. Pathway analysis in the context of Atypical Teratoid Rhabdoid Tumours was 
previously attempted (Birks, Donson et al. 2011, Knipstein, Birks et al. 2012, Sredni, 
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Huang et al. 2014). Previous studies underlined the presence in Atypical Teratoid 
Rhabdoid Tumours of some deregulated pathways and in particular the BMP pathway 
genes as an indicator of poor prognosis (Birks, Donson et al. 2011). Also the 
involvement of Notch and Wnt signally pathway as well as IFN pathway has been 
observed in Rhabdoid tumour cell lines after SMARCB1 re-expression (Morozov, Lee et 
al. 2007, Gadd, Sredni et al. 2010).  
In this study cross-referencing between RNA-seq and 450K platform was attempted to 
disclose the relationship between methylation and gene expression. Moreover, in order 
to understand the mechanism behind SMARCB1 loss, primary data have been cross-
referenced with model data, in an attempt to find gene signatures of Rhabdoid Tumours 
and gene target that might have a therapeutic relevance. Moreover, a systematic analysis 
comparing changes in gene expression as a result of SMARCB1 re-expression and 
primary tumour profiles was performed to characterise pathways involved in 
tumourigenesis. In particular, an integrated pathway analysis of the gene expression 
signature retrieved from RNA-seq metagene analysis was performed to identify 
downstream SMARCB1 effectors. Cross-referencing between primary and cell line data 
was essential to estimate the significance of genes deregulated after SMARCB1 and the 
relevance of pathways on Rhabdoid Tumour biology. 
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 Aims 7.2
The study reported in this chapter aims to: 
 Identify aberrant epigenetic signature dependent on SMARCB1 loss that cause 
deregulation of gene expression responsible for cancer development in Rhabdoid 
Tumours ; 
 Identify common significant gene expression signatures by comparing gene 
expression from Malignant Rhabdoid primary tumour data with SMARCB1 re-
expressing Rhabdoid cell lines; 
 Identify pathway(s) key to Rhabdoid tumour development which may ultimately 
be targetable therapeutically. 
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 Multiple platform data integration characterises the role of 7.3
SMARCB1 loss in epigenetic deregulation 
 
 Cross-referencing 450K methylation data primary data and model data 7.3.1
To assess the role of SMARCB1 in modulating DNA methylation patterns, methylation 
data from both Rhabdoid primary tumour samples and SMARCB1 re-expressing 
Rhabdoid cell lines were cross-referenced. 450K Rhabdoid primary data sets were 
analysed to identify significant probes from a subset of 418,698 probes (p-value <0.01; 
log Fold Change < -3 and >3). For this study Rhabdoid cell line 450K data sets were re-
analysed calculating Beta-values and mean Delta values in a pairwise fashion (e.g. Beta-
value of G401 SMARCB1 – Beta-value of G401 PCDH); probes with a Delta-value >0.2 
and < -0.2 in ≥3 cell lines were selected. The analysis was focused only on overlapping 
probes with an observed significant change in methylation in response to SMARCB1 re-
expression.  
The significant probes were ranked based upon their Delta-values (the average change 
in Beta-value) obtained from the primary data. The data were further filtered (Delta-
value < -0.2 and log Fold Change <0), to give 63 CpGs consistently hypomethylated in 
response to SMARCB1 re-expression and also significantly hypermethylated in the 
Rhabdoid primary tumour data set as compared to Medulloblastoma. Table 7.1 shows 
the 20 most significant differentially methylated probes, resulting from the analysis. 
Complete list in Appendix I. 
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Probes Gene Symbol Average Delta 
values 
LogFold 
change 
Adjusted 
p value 
cg26284735 BHLHE40 -0.552160333 7.413367 9.38E-39 
cg24577594 GALNT2 -0.509345351 6.34529 8.72E-43 
cg08726522 ST5 -0.503897695 6.302051 1.74E-43 
cg12799029 ABR -0.503414605 6.985098 1.43E-33 
cg02657611 TESK2 -0.474253792 6.464976 8.35E-41 
cg04926380 EXT2 -0.474071043 4.981123 6.86E-36 
cg23264547 EXT2 -0.466024831 5.184367 2.67E-38 
cg24159247 ITPR1 -0.454381015 -4.589 2.79E-41 
cg16530881 CCR7 -0.44269779 -4.53975 1.22E-31 
cg01016122 PSORS1C1 -0.425839909 -4.99831 7.79E-32 
cg05238713 ELP4 -0.425812936 -8.27617 6.78E-33 
cg01290136 SCFD2 -0.422060232 -7.03077 2.94E-47 
cg05033369 FCRLA -0.416578021 -7.23292 3.08E-42 
cg24401262 RP11-439L8.2 -0.401150663 -7.22481 1.67E-51 
cg15918685 GOLPH3 -0.398714181 -7.49857 3.37E-47 
cg27621721 NMNAT1P3 -0.386671934 -6.90548 2.09E-52 
cg00121339 CLEC16A -0.385790623 -7.49232 3.64E-49 
cg03747456 KRT80 -0.383624929 -7.24504 1.71E-51 
cg13780614 GALK2 -0.379932013 -7.70371 1.67E-51 
cg04384810 C14orf159 -0.379845058 -8.26217 4.13E-48 
 
 
 
The top 20 genes were further analysed in order to select those with a function 
pertaining to cancer and also for those associated with known regulation by chromatin 
remodelling factors. This analysis was achieved using the UCSC Genome Browser 
based on Transcription Factor ChIP-Seq data from the Encode project. In particular, the 
analysis identified seven probes corresponding to BHLHE40, GALNT2, ST5, ABR, 
CCR7, PSORS1C1, and KRT80, based on the presence of these features: 
Table 7.1 List of top 20 genes and their associated CpG dinucleotides
resulting in significant hypomethylation following SMARCB1 re-expression 
as a result of cross-filtering of primary and model data.  
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 Evidence according to the ENCODE project of binding sites for SWI/SNF 
subunits such as SMARCB1, SMARCA4 and/or SMARCA2; 
 Relatively high levels of H3K27Ac mark, indicator of active transcriptional 
region and enhancer sequences (Baylin and Jones 2011); 
 Presence of CpG islands located near or at SWI/SNF binding sites; 
 Presence of binding sites for POLR2A (subunit of the RNA polymerase II) and 
CTCF. 
 
7.3.1.1 Validation of selected probes in Rhabdoid cell lines using bisulfite conversion 
The selected differentially methylated CpGs were further investigated. Specifically, 
validation of changes in methylation in these genes was performed by bisulfite PCR in 
SMARCB1 re-expressing Rhabdoid cells, followed by Sanger sequencing. Bisulfite PCR 
to observe the change in methylation status in response to SMARCB1 expression of 
three genes was validated: ABR, BHLHE40 and GALNT2. 
 ABR regulates members of the Rho family of GTP-binding proteins via a GTPase-
activating (GAP) domain and a region with homology to the guanine nucleotide 
dissociation-stimulating domain (Chuang, Xu et al. 1995). BHLHE40 is a transcriptional 
repressor which inhibits proliferation, serum deprivation-induced apoptosis, and 
activation of pro-caspases associated with the mitochondrial pathway of apoptosis 
(Wang, Reiser-Erkan et al. 2010). Glycopeptide-preferring polypeptide N-
acetylgalatosaminyltransferase (GALNT1) initiates O-linked glycosylation of protein by 
catalysing the attachment of the first N-acetylgalatosamine (GalNAc) residue; 
knockdown of GALNT1 reduced proliferation of the bladder cancer cell line and 
abrogates subcutaneous cancer growth in mice (Gaziel-Sovran, Segura et al. 2011). 
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SMARCB1 re-expression induces changes in ABR methylation status  
CpG dinucleotides of interest were first analysed using the UCSC browser (Figure 7.1). 
The location of the CpG dinucleotide on the genome is located within ≈3,000 bp of a 
CpG island and associated with the promoter of an ABR isoform; moreover the 
regulatory region is marked by high levels of H3K27Ac. Also the presence of binding 
sites for SMARCB1, SMARCA4, SMARCC1 and SMARCC2 indicate SWI/SNF 
complex recruitment in this region; POLR2A subunit of RNA polymerase II bind to this 
region and might induce transcription Initiation in conjunction with the remodelling 
activity of the SWI/SNF complex.  
 
 
Figure 7.1 Transcription factor ChIP-Seq data for ABR derived from the 
Encode project. The CpG of interest is indicated by the red arrow. Different 
ABR isoforms and Chip-seq annotation from Encode project are indicated. 
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Sanger sequencing of the bisulfite PCR showed that the CpG dinucleotide at 
Ch17:9841184 is hypomethylated, as a result of SMARCB1 re-expression (Figure 7.2). 
Of the three adjacent CpG dinucleotides identified just one was hypomethylated in all 
cell lines in response to SMARCB1 methylation. 
 
A  
B  
Figure 7.2 Sanger sequencing indicates demethylation of ABR in response to 
SMARCB1 re-expression in G401 cell lines. Forward (A) and reverse 
primers (B) are indicated in green. Blue colour represents matches between 
SMARCB1 and PCDH. Cytosine bases highlighted in red are unmethylated 
and converted into Ts and As in the forward and reverse strand, 
respectively. The trace is given for the CpG of interest (Ch17:9841184). 
Evidence of demethylation is indicated by overlapping traces.  
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SMARCB1 re-expression induces changes in BHLHE4 methylation status  
The CpG dinucleotide of interest (Chr3:5065165) was first analysed using the UCSC 
browser. The CpG dinucleotide of interest is located ~35,000 bp downstream of 
BHLHE40 within a regulatory region characterised by high levels of the H3K27Ac 
mark (Figure 7.3 Transcription factor ChIP-Seq data for BHLHE4 derived from the 
Encode project. The CpG of interest is indicated by the red arrow. Different BHLHE4 
Isoforms and Chip-seq annotation from Encode project are indicated.). Binding sites for 
SMARCB1, SMARCC1, POLR2A and MYC are located in the region proximal to a 
CpG island.  
 
Figure 7.3 Transcription factor ChIP-Seq data for BHLHE4 derived from 
the Encode project. The CpG of interest is indicated by the red arrow. 
Different BHLHE4 Isoforms and Chip-seq annotation from Encode project 
are indicated. 
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Sanger sequencing of the bisulfite PCR showed that CpG dinucleotide Chr3:5065165 is 
partially hypomethylated, as a result of SMARCB1 re-expression (Figure 7.4). 
Moreover, of the five additional CpG dinucleotides identified, three were consistently 
hypomethylated in response to SMARCB1 re-expression. 
 
A  
B  
Figure 7.4 Sanger sequencing indicates demethylation of BHLHE4 in 
response to SMARCB1 re-expression in G401 cell line. Forward (A) and 
reverse primers (B) are indicated in green. Blue colour represents matches 
between SMARCB1 and PCDH. Cytosine bases highlighted in red are 
unmethylated and converted into Ts and As in the forward and reverse 
strand, respectively. The trace is given for the CpG of interest 
(Chr3:5065165). Evidence for demethylation is indicated by overlapping 
traces.  
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SMARCB1 re-expression induces changes in GALNT2 methylation status  
CpG dinucleotide of interest (Chr1:230240631) was analysed using the UCSC browser. 
The CpG of interest was located within the gene body upstream of the promoter (Figure 
7.5). ChIP-Seq data from Encode indicates the binding of the core unit of the SWI/SNF 
complex to the region, as well as POLR2A and MYC. The location is characterised by a 
high levels of H3K27Ac, indicating that the CpG dinucleotide of interest is positioned 
within an active regulatory region.  
 
 
Figure 7.5 Transcription factor ChIP-Seq data for GALNT 2 derived from 
the Encode project. The CpG of interest is indicated by the red arrow. 
Different GALNT2 isoforms and Chip-seq annotation from Encode project 
are indicated. 
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Sanger sequencing of the bisulfite PCR showed that CpG dinucleotide Chr1:230240631 
is hypomethylated, as a result of SMARCB1 re-expression (Figure 7.6). Also three other 
adjacent CpG dinucleotides all showed evidence of hypomethylation in each of the 
Malignant Rhabdoid Tumour cell lines in a SMARCB1 dependent manner. 
 
A B
 
Figure 7.6 Sanger sequencing indicates demethylation of GALNT2 in 
response to SMARCB1 re-expression in G401 cell lines. Forward (A) and 
reverse primers (B) are indicated in green. Blue colour represents matches 
between SMARCB1 and PCDH. Cytosine bases highlighted in red are 
unmethylated and converted into Ts and As in the forward and reverse 
strand, respectively. The trace is given for the CpG of interest 
(Chr3:5065165). Evidence for demethylation is indicated by overlapping 
traces.  
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 Gene expression cross-referencing in model data identifies SMARCB1 role 7.3.2
in epigenetic mechanism  
 
7.3.2.1 Cross-referencing expression data in model data reveals demethylating effects 
of SMARCB1 re-expression  
Cross-referencing methylation array data between primary and model cell lines reveals 
that SMARCB1 promotes demethylation of many CpG islands. In order to understand 
the mechanism of SMARCB1 loss in the methylation-dependent modification of gene 
expression, expression data from SMARCB1 re-expressing cells was compared with the 
expression data set obtained from Rhabdoid cells treated with 5-aza-2-deoxycytidine (5-
azaCdR). In particular, we hypothesised that the re-expression of SMARCB1 could be a 
direct effector of demethylation, in a similar manner to 5-aza-2-deoxycytidine. 
 Significantly differentially expressed genes from DEseq analysis from the two 
conditions were directly compared, revealing 14 genes which were deregulated after 
both SMARCB1 re-expression and 5-azaCdR treatment (Figure 7.7 and Table 7.2). 
 
 
Figure 7.7 Venn diagram of differentially expressed genes as result of 
SMARCB1 re-expression and 5-azaCdR treatment. 
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Gene Symbol Adjusted p-value log2fold change 
(SMARCB1) 
DNA2 1.21E-19 7.552249108 
PODXL 7.46E-43 6.323432896 
SERPINE2 1.85E-18 5.832168685 
PLK2 7.77E-07 4.635228454 
ERC1 4.23E-07 4.323596829 
PDLIM1 2.61E-16 4.288680622 
C3 1.08E-19 4.058441615 
HCLCS1 4.10E-11 3.515754953 
DUSP5 4.22E-07 2.508325668 
UBE4B 0.000227 2.136383472 
ELL2 1.08E-05 2.062217233 
ELF3 3.58E-05 1.957602117 
B4GALNT3 2.20E-05 1.852817531 
PDE4C 9.32E-06 -1.705233083 
  
 
 
 
 
In this list two genes were also previously identified in this study as genes implicated in 
Rhabdoid tumourigenesis. DNA2 was in the top 15 most differentially expressed 
following SMARCB1 re-expression, while PDE4C is part of the family of PDE4 cyclic 
AMP (cAMP)-specific phosphodiesterase together with PDE4D (identified as 
significant deregulated genes in response to 5-azaCdR treatment). Interestingly, both 
PDE4C and PDE4D are two of the few genes showing downregulation following 
SMARCB1 re-expression and 5-azaCdR treatment. Moreover, SERPINE2 was indicated 
to be differentially expressed in primary tumours (Gadd, Sredni et al. 2010) and 
following induction of SMARCB1 in Rhabdoid cell lines (Morozov, Lee et al. 2007). 
Table 7.2 List of the common differentially expressed genes resulting from
SMARCB1 re-expression and 5-azaCdR data cross-referencing. Genes are
ranked based on the moderated log2fold change in SMARCB1 re-
expressing Rhabdoid cells. 
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7.3.2.2 Platform cross-referencing identifies genes directly demethylated by SMARCB1 
We suspected that the small overlapping subsets of genes obtained in the previously 
comparative analysis was a result of the broad and global effect on methylation of 5-
azaCdR treatment but a somewhat more modest effect on expression than SMARCB1 re-
expression. To better understand the correlation between gene expression and changes 
in methylation, cross-referencing analysis between RNA-seq and 450K data in 
Rhabdoid cell re-expressing SMARCB1 was attempted. Significant differentially 
expressed genes (p-value <0.05; moderate log Fold Change <1 and >1; raw count per 
gene with ≥50 counts in at least 3 cell lines) were cross-referenced with significantly 
differentially methylated CpG probes (delta values >0.3 and <-0.3 in at least 3 cell 
lines). 
From the genes which satisfied these criteria four were selected for further 
investigation. GLI2, GLI3, JARID2 and NTN4 genes were selected by a literature search 
for those genes of particular relevance to cancer, and supported by transcription factor 
ChIP-Seq data from Encode, using UCSC Genome Browser. GLI2 regulates the Sonic 
Hedgehog (Shh) signalling pathway and promotes metastasis in prostate and melanoma 
cell lines; moreover GLI1 is reported down-regulated following re-expression of 
SMARCB1 (Thiyagarajan, Bhatia et al. 2007, Alexaki, Javelaud et al. 2010, Jagani, 
Mora-Blanco et al. 2010). Overexpression of GLI3, another member of the Shh 
pathway, is associated with tumourigenesis in colon cancer and with poor survival in 
non-small cell lung cancer patients (Bai, Lin et al. 2013, Iwasaki, Nakano et al. 2013). 
JARID2 is involved in transcriptional repression in leukaemia and promotes 
maintenance of undifferentiated myogenic phenotype in rhabdomyosarcomas (Puda, 
Milosevic et al. 2012, Walters, Villarejo-Balcells et al. 2014). NTN4 is a 
lamSMARCB1n-related molecule which inhibits angiogenesis and tumour cell growth 
in colorectal carcinoma, also NTN4 downregulation is observed in glioblastoma 
promoting cell proliferation (Hu, Ylivinkka et al. 2012, Eveno, Contreres et al. 2013). 
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The mRNA level of these genes was analysed by quantitative RT-PCR following 
SMARCB1 re-expression and compared with mRNA of Rhabdoid cells treated with 5-
azaCdR. We observed a modest increase of GLI2 expression upon SMARCB1 re-
expression (Figure 7.8) in A204 and CHLA-266 (14 and 33-fold, respectively), while a 
more marked upregulation was noticeable in G401 and STA-WT-1 (5545 and 141-fold, 
respectively); similar upregulation was observed after 5-azaCdR treatment in G401, 
A204 and STA-WT-1 (14.8 to 45.8-fold), whereas induction was more modest in CHLA 
(4.2-fold). Expression of GLI3 following SMARCB1 induction (Figure 7.8) was 
substantial in G401 (636.5-fold), whilst more modest increases were observed in other 
cell lines (6.8 to 15.8-fold) Figure 7.9; a small upregulation of GLI3 upregulation was 
observed upon 5-azaCdR treatment (1.2 to 4.4-fold). JARID2 expression (Figure 7.9) 
was modestly increased in A204, STA-WT-1 and CHLA-266 (1.5 to 7.4-fold) in 
comparison to G401 (77.5-fold); a subtle upregulation in all cells were observed in 
response to 5-azaCdR treatment (1.2 to 1.7-fold). In response to SMARCB1 re-
expression NTN4 (Figure 7.9) expression was increased in all cells (2.3 to 17.7-fold) 
with significant over-expression in G401 (1694.9-fold); a very modest upregulation 
upon 5-azaCdR treatment was observed (1.5 to 2.4-fold), except for G401 where 
downregulation was detected (0.8-fold). 
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Figure 7.8 SMARCB1 re-expression induces upregulation of GLI2 and GLI3 
as a result of demethylation and/or SMARCB1 re-expression. The mRNA 
levels were measured by real-time RT-PCR and normalised to beta-2-
microglobulin. Values are given relative to untreated cell lines (Un) or 
empty vector controls (pCDH) as appropriate and were the mean of 3 
independent measurements. Rhabdoid cell re-expressing SMARCB1 are 
indicated with SMARCB1, while cell treated with 5-azaCdR with AZA. 
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Figure 7.9 SMARCB1 re-expression induces upregulation of JARID2 and 
NTN4, as a result of demethylation and/or SMARCB1 re-expression. The 
mRNA levels were measured by real-time RT-PCR and normalised to beta-2-
microglobulin. Values are given relative to untreated cell lines (Un) or 
empty vector controls (pCDH) as appropriate and were the mean of 3 
independent measurements. Rhabdoid cell re-expressing SMARCB1 are 
indicated with SMARCB1, while cell treated with 5-azaCdR with AZA. 
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 Pathway analysis  7.4
 Cross-referencing of multiple gene expression gene sets identifies gene 7.4.1
signatures directly controlled by SMARCB1  
In order to understand in an analytical and systematic manner the gene signature(s) 
involved in Rhabdoid tumourigenesis, we cross-referenced the expression data set 
derived from three analyses (Primary Tumours, Rhabdoid Tumours vs 
Medulloblastoma; Cell line models, SMARCB1 re-expression vs empty vector controls; 
5-aza-CdR treatment, Treated vs untreated) specifically the particular genes which 
constituted and defined the metagenes calculated for each experimental condition. The 
contribution of each gene to a particular defining metagene signature was calculated by 
means of a Pearson correlation coefficient of the expression of each gene with the 
values for each metagene.  
First, the metagene expression signatures discriminating Rhabdoid primary tumour and 
Medulloblastoma were extracted from the expression data and the metagene content 
with respect to individual genes was calculated. This gave a score for each gene of -1 to 
1 where 1 indicates perfect positive correlation of a particular gene with metagene and -
1 perfect anti-correlation. An adjusted p-value was calculated for the correlation of each 
gene with the metagene. The same process was repeated with a metagene signature 
defining the difference between SMARCB1 re-expressing Rhabdoid Tumour cell lines. 
The analysis was focused on finding shared genes between SMARCB1 re-expressing 
cells and Medulloblastoma (which in this analysis corresponds to non Rhabdoid 
phenotype tumours) and vice versa between vector control infectants and Rhabdoid 
primary tumours (which represent the Rhabdoid phenotype) (Figure 7.10). Figure 7.10 
shows in red the genes which form a significant (p <0.01) part of both the primary and 
cell line model. This analysis is far more sensitive than simple cross-referencing of two 
separate DESeq analyses. 
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Figure 7.10 Cross-referencing of two metagene signatures from Malignant 
Rhabdoid Tumours Primary tumours (Rhabdoid) vs Medulloblastomas (Non-
Rhabdoid) and cell model data re-expressing SMARCB1 and control 
infectants reveals common significantly deregulated genes p<0.01 (red). On 
the x-axis are plotted the values for metagene content (correlation of 
individual genes with metagene values) extracted from primary data, while 
the y-axis gives metagene content from the cell line models. 
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Data integration of metagene content identified 187 common genes that defined a 
Rhabdoid/SMARCB1 negative phenotype across the data sets. Table 7.3 lists the top 20 
significant genes as a result of this cross-referencing and ranked by metagene content in 
SMARCB1 re-expressing cells. Complete list in Appendix I.  
Gene Symbol Metagene content 
Medulloblastomas 
Metagene content 
SMARCB1 
re-expressing cells
IDH1 0.218190152 0.985473815 
SUCLG2 0.69429913 0.97669975 
TYSND1 0.249656719 0.97376244 
RARG 0.565913736 0.966783287 
RGS1 0.269581376 0.964187488 
HIC1 0.603438878 0.963633075 
CREG1 0.454614525 0.962206288 
HMHA1 0.276917082 0.959244273 
LHX6 0.257225532 0.954712178 
TGIF2 0.373928224 0.952033316 
TNFAIP8L1 0.555467972 0.947460948 
GNPNAT1 0.575562612 0.945400416 
PIM3 0.251816526 0.940025544 
ELFN1 0.328714614 0.937885973 
ALDH16A1 0.395197109 0.937582613 
GAREML 0.334710923 0.934206727 
LINC00982 0.445616696 0.933444824 
CLN3 0.273734686 0.931034387 
SIX5 0.458252972 0.929795247 
Table 7.3 Top 20 genes that define the Non- Rhabdoid phenotype resulting
from cross-referencing Medulloblastomas metagene content and SMARCB1
re-expressing cell lines metagene content. Each gene constitutes a
significant part of the defining metagene signature of both primary and
functional cell line models.  
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The same analysis was performed by comparing the metagene signature of Rhabdoid 
cells re-expressing SMARCB1 with the metagene content of Rhabdoid cells treated with 
5-azaCdR. The analysis was focused on finding correlations that define a 
SMARCB1/methylation-dependent from both data sets (Figure 7.11). Data integration 
identified 64 common genes strongly correlated with metagenes corresponding to 
SMARCB1 re-expressing cells and 5-azaCdR treated cells. Table 7.3 lists the top 20 
significant genes as a result of this cross-referencing and ranked by metagene content in 
SMARCB1 re-expressing cells. Complete list in Appendix I. 
 
 
Figure 7.11 Cross-referencing of metagene signatures from Rhabdoid cells 
re-expressing SMARCB1 (SMARCB1) and from Rhabdoid cells treated with 
5-azaCdR (AZA) reveals a common gene signature in the data set (in red). 
On the x-axis are plotted the values for metagene content of each gene 
extracted from cells treated with 5-azaCdR, the y-axis shows the metagene 
content values from the SMARCB1 model data set. 
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Gene Symbol Metagene content 
5-azaCdR 
treated cells 
Metagene content 
SMARCB1 
re-expressing cells 
IDH1 0.940223791 0.985473815 
FGFBP3 0.967750489 0.96766879 
FAM19A5 0.900312294 0.958655837 
BMI1 0.922384221 0.958286584 
SPAG6 0.822514539 0.934151603 
ZSCAN10 0.701066641 0.914554305 
H2AFY2 0.82244248 0.911040681 
RAD51B 0.952106848 0.903970282 
IFI35 0.762395879 0.903854604 
DLGAP1-AS3 0.911638216 0.902348866 
DBP 0.867467803 0.900689488 
DNM3OS 0.925276636 0.894459127 
RPRM 0.971562868 0.893505765 
CA11 0.91068111 0.892449763 
CPNE5 0.794414076 0.890840559 
SH2B2 0.867731083 0.886856403 
KLF15 0.959252724 0.884368174 
CCDC74B 0.819681347 0.875987288 
HSF4 0.721212585 0.86557006 
  
 
 
 
 
 
 
Table 7.4 Top 20 genes that defined the Non-Rhabdoid phenotype resulting 
from cross-referencing 5-azaCdR treated cells metagene content and 
SMARCB1 re-expressing cell lines metagene content. Metagene content 
score is indicated.  
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Finally the two gene lists obtained from this analysis was compared again: 13 genes 
common in both lists were identified (Figure 7.12 and Table 7.5).  
 
 
Figure 7.12 Venn diagram of Methylation-dependent Rhabdoid gene 
signatures common between SMARCB1 re-expressing cells and 
Medulloblastomas (SMARCB1-MB) and between SMARCB1 re-expressing 
cells and 5-azaCdR treated cells. 
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Gene Symbol Metagene content 
5-azaCdR 
treated cells 
Metagene content 
SMARCB1 
re-expressing cells 
Metagene content 
Medulloblastomas 
CALY 0.892541 0.776439 0.306465 
CCDC74B 0.819681 0.875987 0.285176 
DNM3OS 0.925277 0.894459 0.628264 
IDH1 0.940224 0.985474 0.21819 
IFI35 0.762396 0.903855 0.537416 
KAZALD1 0.950182 0.827627 0.664685 
KIAA0101 0.747337 0.641398 0.221889 
MACROD1 0.969651 0.787554 0.204009 
NQO2 0.831308 0.757666 0.369473 
PBK 0.909212 0.676959 0.303351 
PHGDH 0.614676 0.848927 0.379996 
PRDM16 0.955471 0.76299 0.429157 
SPC24 0.807937 0.828866 0.35925 
 
 
 
 
CCDC74B alters regulation of mitosis during initiation as well as S-phase and G2-M 
progression (Yao, Bee et al. 2010). Dnm3os is a gene transcribed as a non-coding RNA 
(ncRNA) that contains three micro RNAs (miRNAs), miR-199a, miR-199a, and miR-
214; it is indispensable for normal skeletal development and body growth in mammals 
(Watanabe, Sato et al. 2008). Mutation of IDH1 is frequent in gliomas, although the 
oncogenic mechanism is still not understood (Cohen, Holmen et al. 2013). KAZALD1 is 
highly methylated in sarcomatoid-type peritoneal mesothelioma (Hama, Watanabe et al. 
2012). KIAA0101 protein is overexpressed in breast cancer and modifies directly 
centrosomes (Kais, Barsky et al. 2011). BK/TOPK (PDZ-binding kinase, T-LAK-cell-
originated protein kinase) is a serine-threonine kinase that is overexpressed in a variety 
of tumour cells but whose role in oncogenesis remains unclear (Hu, Gartenhaus et al. 
Table 7.5 Non Rhabdoid gene signatures common between SMARCB1 re-
expressing cells and Medulloblastomas (SMARCB1-MB) and between SMARCB1
re-expressing cell sand 5-azaCdR treated cells. Metagene content score is
indicated.  
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2010). PRDM16 gene is known to be rearranged in Acute Myeloid Leukaemia (AML) 
and Myelodysplasia Syndrome (MDS) (Duhoux, Ameye et al. 2012) 
Ndc80/Hec1assembles as part of a 4-subunit Ndc80 complex that includes Nuf2, Spc24, 
and Spc25. Ndc80/Hec1 is often upregulated in tumours and mice overexpressing 
Ndc80 show increase in cancer formation (Diaz-Rodriguez, Sotillo et al. 2008). 
 
 Gene set enrichment analysis  7.4.2
Gene set enrichment analysis (GSEA) is a computational method that identifies 
statistically significant differences in gene expression between two conditions of an a 
priori defined list of genes (gene set). GSEA requires a ranking of genes defined 
according to two conditions. The GSEA software compares the position of genes in a 
gene set within the predefined gene ranking such that a non-random distribution within 
the ranking would indicate significant enrichment of that gene set. Gene sets are 
typically taken from a molecular signature database i.e. MSigDB based on published 
data or recognised gene ontologies.  
The previous unsupervised RNA-seq metagene analyses were taken as the basis of the 
pre-defined gene ranking. Genes were ranked based on the degree of association 
(Pearson correlation coefficient) to the representative metagene. GSEA was performed 
on these pre-ranked gene lists for all gene expression analysis: primary tumours and 
functional cell models. The parameters were set to identify significantly enriched gene 
sets with a minimum of 15 genes and a maximum of 1000 genes. The GSEA tool 
computed the level of significance (p-value) for each enriched gene set, and a false 
discovery rate (FDR). The enriched gene sets were ranked according to the p-value and 
FDR, and gene sets with a p-value less than 0.05 and an FDR rate less than 0.25 were 
excluded from the results. Using such cut-off values resulted in the selection of only 
those gene sets with highly significant gene enrichment. 
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7.4.2.1 GSEA analysis of differentially regulated signalling pathways in primary 
Rhabdoid Tumours  
GSEA analysis was performed to identify biological processes or cancer signalling 
pathways that are enriched specifically in Rhabdoid Tumours. The analysis was 
performed upon a pre-ranked list of genes ranked according to their correlation with the 
primary Rhabdoid tumour metagene extracted from RNA-seq data. This ranked gene list 
was analysed against the curated gene set database MSigDB C2 (an annotated Gene set 
collected from various sources such as online pathway databases, publications in 
PubMed, and knowledge of domain experts.) and MSigDB C6 (an oncogenic signature 
annotation) (http://www.broadinstitute.org/gsea/index.jsp). 
GSEA analysis against the C2 gene set library reported 1117 out of 3255 gene sets 
presenting an FDR < 25% and p-value <1% and enriched when comparing primary 
Rhabdoid Tumours with Medulloblastoma, Also 26 gene sets were also significantly de-
enriched. Selected upregulated gene sets (positively enriched for Rhabdoid Tumours ) 
are indicated in Table 7.6 and Figure 7.13. These include genes commonly down-
regulated in human alveolar rhabdomyosarcomas, genes co-ordinately up-regulated in 
mouse embryonic stem cells (ESC) and genes involved in p53-Independent G1/S DNA 
damage checkpoint. Selected gene sets significantly de-enriched i.e. were 
downregulated or negatively enriched for Rhabdoid Tumours are indicated in Table 7.6 
and Figure 7.14. These include genes down-regulated and associated with poor survival 
of patients with metastatic Neuroblastoma lacking MYCN amplification; and genes up-
regulated during neuronal differentiation of SH-SY5 neuroblastoma cells in response to 
stimulation by tretinoin. 
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Gene set  ES FDR p-val 
REN_ALVEOLAR_ 
RHABDOMYOSARCOMA_DN 
0.586 0 0 
WONG_EMBRYONIC_ 
STEM_CELL_CORE 
0.563 0 0 
REACTOME_P53_INDEPENDENT_G1_
S_DNA_DAMAGE_CHECKPOINT 
0.772 0 0 
ASGHARZADEH_NEUROBLASTOMA_
POOR_SURVIVAL_DN 
-0.635 6.41E-05 0.001 
LE_NEURONAL_DIFFERENTIATION_
UP 
-0.655 0 0.0019 
KIM_ALL_DISORDERS_OLIGODENDR
OCYTE_NUMBER_CORR_DN 
-0.536 0.0039 0.030 
 Table 7.6 Selected C2 GSEA pathways upregulated and downregulated in
primary Malignant Rhabdoid Tumours. Relative enrichment score (ES), false
discovery rate (FDR) and p-values are also displayed. For details of gene
set contents see MSigDB. 
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Figure 7.13 GSEA enrichment plots of gene sets: Ren alveolar 
rhabdomyosarcomas, Wong embryonic stem cells core and Reactome p53 
independent G1/S DNA damage checkpoint pathways genes in Malignant 
Rhabdoid Tumour (red) vs Medulloblastomas (blue). Genes in all three 
pathways showed significant enrichment in Malignant Rhabdoid Tumours. 
The top portion of the figure plots show the moving enrichment scores (ES) 
adjusted for each gene in the gene set, whereas value of the ranking metric 
for each gene in the gene set is given by a vertical black tick.  
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Figure 7.14 GSEA enrichment plot of Asgharzadeh neuroblastoma poor 
survival, Le neuronal differentiation, Kim all disorders oligodendrocyte 
number corr DN in Malignant Rhabdoid Tumour (red) vs Medulloblastomas 
(blue). Genes in all three pathways showed significant negative enrichment 
in Malignant Rhabdoid Tumours. The top portion of the figure plots show 
the moving enrichment scores (ES) adjusted for each gene in the gene set, 
whereas value of the ranking metric for each gene in the gene set is given by 
a vertical black tick. 
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Gene set  ES FDR p-val 
GLI1_UP.V1_UP 0.412 0.046 0.048 
YAP1_UP 0.403 0.020 0.014 
CAHOY_NEURONAL -0.511 0 0 
 
Analysis against the C6 MSigDB library identified 37 out of 187 genes set significantly 
upregulated and 26 significantly downregulated (FDR < 25% and pvalue <1%) when 
comparing primary Rhabdoid Tumours with Medulloblastoma.  
Selected upregulated gene sets (gene positively enriched for Rhabdoid Tumours) are 
indicated in (Table 7.7 and Figure 7.15): these include genes up-regulated in kidney 
epithelium cells over-expressing GLI1; genes up-regulated in breast cancer cells over-
expressing YAP. Gene sets negatively enriched include genes up-regulated in neurons 
(see Table 7.7 and Figure 7.15);. 
 
 
 
Table 7.7 3 selected C6 GSEA pathways significantly upregulated and
downregulated in Rhabdoid Tumours when compared with
Medulloblastomas. Relative enrichment score (ES), false discovery rate
(FDR) and p-value are also displayed.
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Figure 7.15 GSEA enrichment plot of YAP1, GLI1 upregulated pathways 
genes and CAHOY NEURONAL downregulated pathways in Malignant 
Rhabdoid Tumour (red) vs Medulloblastomas (blue). The top portion of the 
figure plots show the moving enrichment scores (ES) adjusted for each gene 
in the gene set, whereas value of the ranking metric for each gene in the 
gene set is given by a vertical black tick. 
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GSEA identified pathways in accordance with that previously described in the 
comparative analysis and to the literature. Analysis based on the C2 library underlines 
the substantial phenotypic difference between Malignant Rhabdoid and 
Medulloblastoma tumours. Significantly deregulated genes in Rhabdoid Tumours 
present positive enrichment for genes commonly down-regulated in human 
Rhabdomyosarcomas, up-regulated in mouse embryonic stem cells and involved in p53-
Independent G1/S DNA damage checkpoint. This analysis is in accord with previous 
reports that underline the similarity between the Malignant Rhabdoid Tumours and 
Rhabdomyosarcomas (Armeanu-Ebinger, Herrmann et al. 2012). In fact both 
malignancies show distinctive expression of embryonic stem cell markers (Deisch, 
Raisanen et al. 2011) and the upregulation of cell cycle check point genes such as 
NOXA in a p53 independent manner (Kuwahara, Wei et al. 2013). Moreover, previous 
comparative analysis between Medulloblastomas and Rhabdoid Tumours showed a 
substantive difference in neuronal differentiation phenotype (Higashino, Narita et al. 
2003). 
Interesting both GLI1 and YAP1 gene sets are observed to be significantly enriched in 
the c6 library. This again reflects previous observation in Rhabdoid cell lines and in 
Atypical Teratoid Rhabdoid primary Tumours, where GLI1 and YAP1 are upregulated 
respectively (Jagani, Mora-Blanco et al. 2010, Jeibmann, Eikmeier et al. 2014).  
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Gene set  ES FDR p-val 
WONG_EMBRYONIC_STEM_ 
CELL_CORE 
0.5830646 0 0 
LEE_TARGETS_OF_PTCH1_ 
AND_SUFU_DN 
-
0.5977889 
0 0 
7.4.2.2 GSEA analysis distinguishes differentially regulated signalling pathways in 
Extra Cranial Rhabdoid Tumours and Atypical Teratoid Rhabdoid Tumours  
A GSEA analysis was performed by analysing a list of genes ranked according to their 
correlation with a metagene which defined the Extra Cranial Rhabdoid Tumour (ECRT) 
as compared to the Atypical Teratoid Rhabdoid Tumours (ATRT). This pre-ranked list of 
genes was analysed against the C2 and C6 MSigDB gene set libraries. 
Analysis against the C2 library identified 596 significantly enriched genesets (FDR < 
25% and pvalue <1%) out of 3201 and 257 significantly negatively enriched when 
comparing Atypical Teratoid Rhabdoid Tumours to in Extra Cranial Rhabdoid Tumours. 
 
 
 
 
 
Interestingly, the Embryonic stem cell core pathway previously indicated to be 
significantly enriched in the GSEA analysis of primary Rhabdoid Tumours against 
Medulloblastoma was more positively enriched for Atypical Teratoid Rhabdoid 
Tumours and therefore more negatively for Extra Cranial Rhabdoid Tumours. 
Moreover, Extra Cranial Rhabdoid Tumours showed enrichment of a gene set 
describing downregulation of targets of PATCH1 and SUFU (Table 7.8 and Figure 7.16). 
Table 7.8 Two C2 library GSEA pathways upregulated and downregulated in
Atypical Teratoid Rhabdoid Tumours when compared with Extra-cranial
Rhabdoid Tumour. Relative enrichment score (ES), false discovery rate
(FDR) and p-value are also displayed. 
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These results confirm previous observations: Extra Cranial Rhabdoid Tumours. and 
Atypical Teratoid Rhabdoid Tumours express many common stem cell-associated 
transcription factors, however the expression in Atypical Teratoid Rhabdoid Tumours  is 
higher than the Extra Cranial malignancies (Deisch, Raisanen et al. 2011, Venneti, Le et 
al. 2011); PTCH1 collaborates with GLI1 in modulation of the SHH pathway and is 
downregulated in A204 and G401 Rhabdoid cell lines by inhibition of EZH2 (Knutson, 
Warholic et al. 2013).  
 
 
Figure 7.16 GSEA enrichment plot of two genes sets Wong Embryonic stem 
cell core gene (significantly enriched) and the Lee PTCH1 and SUFU 
(significantly negatively enriched) in Atypical Teratoid Rhabdoid Tumours 
(red) vs Extra Cranial Rhabdoid Tumour (blue). The top portion of the 
figure plots show the moving enrichment scores (ES) adjusted for each gene 
in the gene set, whereas value of the ranking metric for each gene in the 
gene set is given by a vertical black tick. 
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Gene set  ES FDR p-val 
KRAS.KIDNEY_UP.V1_UP -0.680105 0 0 
CAHOY_NEURONAL -0.560470 0 0 
 
Analysis of the Atypical Teratoid Rhabdoid Tumours vs Extra Cranial Rhabdoid 
Tumours metagene against the C6 MSigDb library identified 20 significantly enriched 
gene sets (FDR < 25% and pvalue <1%) out of 186 gene sets and 35 significantly 
negatively enriched. These included significant negative enrichment of a set of genes 
associated with the upregulation of KRAS in kidney i.e. positively enriched for Extra 
Cranial Rhabdoid Tumours. The Cahoy neuronal gene set was significantly negatively 
enriched in Extra Cranial Rhabdoid Tumours (Table 7.9 and Figure 7.17).  
 
 
 
Table 7.9 C6 GSEA pathways upregulated and downregulated in Atypical
Teratoid Rhabdoid Tumours when compared with Extra-cranial Rhabdoid
Tumour. Relative enrichment score (ES), false discovery rate (FDR) and p-
value are also displayed. 
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Figure 7.17 GSEA enrichment plot of KRAS pathways and Cahoy neuronal 
pathway in Atypical Teratoid Rhabdoid Tumours (red) vs Extra Cranial 
Rhabdoid Tumour (blue). The top portion of the figure plots show the 
moving enrichment scores (ES) adjusted for each gene in the gene set, 
whereas value of the ranking metric for each gene in the gene set is given by 
a vertical black tick. 
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Gene set  ES FDR p-val 
MARSON_BOUND_BY_E2F4_ 
UNSTIMULATED 
0.6865080 0 0 
GOBERT_OLIGODENDROCYTE_ 
DIFFERENTIATION_UP 
0.5937639 0 0 
REACTOME_CELL_CYCLE 0.6538154 0 0 
REN_ALVEOLAR_ 
RHABDOMYOSARCOMA_DN 
-0.4799 0 0 
MCBRYAN_PUBERTAL_TGFB1_TARG
ETS_UP -0.50800 0 0 
GU_PDEF_TARGETS_UP -0.53733 2.51E-4 0 
 
7.4.2.3  GSEA analysis of differentially regulated signalling pathways in Rhabdoid cell 
lines following SMARCB1 re-expression  
GSEA analysis was performed by analysing a pre-ranked list of genes correlated with a 
metagene that defines the difference between empty vector controls and SMARCB1 re-
expressing Rhabdoid cell lines. This pre-ranked list was analysed by GSEA against 
MSigDB libraries C2 and C6. 
Analysis against the C2 library identified 221 significantly enriched gene sets FDR < 
25% and p-value <1% out of 596 and 323 significantly negatively enriched following 
SMARCB1 re-expression. The analysis indicated a wide number of up-regulated 
pathways involved in cell cycle and differentiation and also a significant enrichment of 
genes with promoters bound by E2F4 (Figure 7.18 and Table 7.10). Significant negative 
enrichment was observed for the alveolar Rhabdomyosarcoma gene set pathway, 
TGFB1 target pathway and the PDEF target genesets after knockdown of PDEF (Table 
7.10 and Figure 7.19 ).  
 
 
Table 7.10 Selected C2 GSEA pathways significantly enriched and negatively
enriched in empty vector controls compared to SMARCB1 re-expressing cell
lines. Relative enrichment score (ES), false discovery rate (FDR) and p-
value are also displayed. 
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Figure 7.18 GSEA enrichment plots of significantly enriched gene sets 
including genes with promoters bound by E2F4, Oligodendrocyte 
differentiation pathway, and Reactome cell cycle annotation. These gene 
sets are positively enriched in empty vector controls (red) vs SMARCB1 re-
expressing cells (blue). The top portion of the figure plots show the moving 
enrichment scores (ES) adjusted for each gene in the gene set, whereas the 
value of the ranking metric for each gene in the gene set is given by a 
vertical black tick. 
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Figure 7.19 GSEA enrichment plot of significantly negatively enriched gene 
sets upregulated including Alveolar Rhabdomyosarcomas down-regulated 
genes, TBFB1 target pathways and PDEF target gene sets. These gene sets 
are negatively enriched after SMARCB1 re-expression (blue) vs the control 
infectants (red). The top portion of the figure plots show the moving 
enrichment scores (ES) adjusted for each gene in the gene set, whereas the 
value of the ranking metric for each gene in the gene set is given by a 
vertical black tick. 
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Gene set  ES FGR p-val 
E2F3_UP.V1_UP 0.5296237 0 0 
RB_DN.V1_UP 0.4704922 0.012 0.001 
E2F1_UP.V1_UP 0.4188982 0 0 
HOXA9_DN.V1_UP -0.50132 0.001 3.30E-4 
TGFB_UP.V1_UP -0.427668 0.007 0.001 
This is in accordance with previous findings; re-expression of SMARCB1 in Rhabdoid 
cell lines causes deregulation of genes involved in the cell cycle, promoting cell 
differentiation, and down-regulating E2F target genes.  
Analysis against the MSigDB C6 library identified 14 significantly enriched (FDR < 
25% and pvalue <1%) gene sets out of 149 and 22 significantly negatively enriched 
after SMARCB1 re-expression. The analysis indicates a significant enrichment of gene 
sets for genes up-regulated in mice over-expressing E2F1 with promoters bound by 
E2F4 and the RB pathway (Table 7.11 and Figure 7.20). Negative enrichment was 
observed for genes upregulated in response to HOXA9 knock-down and for genes up-
regulated by TGFB1 (Table 7.11 and Figure 7.21). 
 
 
 
 
 
 
 
 
Table 7.11 Selected MSigDB C6 GSEA pathways significantly enriched or
negatively enriched in empty vector controls vs SMARCB1 re-expressing cell
lines compared to. Relative enrichment score (ES), false discovery rate
(FDR) and p-value are also displayed. 
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Figure 7.20 GSEA enrichment plot of genesets upregulated in response to 
RB and RBL1, and genesets upregulated in response to E2F3 and E2F1. 
These gene sets are significantly enriched in control infectants (red) vs cells 
re-expressing SMARCB1 (blue). The top portion of the figure plots show the 
moving enrichment scores (ES) adjusted for each gene in the gene set, 
whereas value of the ranking metric for each gene in the gene set is given by 
a vertical black tick. 
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Figure 7.21 GSEA enrichment plot of gene sets related to HOXA9, TGFB1 
pathways. These gene sets are significantly negatively enriched after 
SMARCB1 re-expression (blue) vs the control infectants (red). The top 
portion of the figure plots show the moving enrichment scores (ES) adjusted 
for each gene in the gene set, whereas value of the ranking metric for each 
gene in the gene set is given by a vertical black tick. 
 
Analysis against MSigDb library C2 was again in accordance with previous 
investigations: RB not only is required in Rhabdoid cells to recruit CDK2A, moreover 
E2F1 is downstream of RB and re-expression of SMARCB1 is well known to repress 
E2F1 target genes (Medjkane, Novikov et al. 2004). Also Rhabdoid Tumours show a 
low level of HOXA9 and in our bioinformatics analysis the homologous protein 
HOXD3 was differentially methylated. The results indicate that the TGFbeta pathway is 
also suppressed in Rhabdoid Tumours in a SMARCB1 dependent manner. 
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Gene set  ES FDR p-val 
SENESE_HDAC1_AND_HDAC2_TARGE
TS_DN 0.5937639 0.001 0 
PLASARI_TGFB1_TARGETS_10HR_DN 0.4454557 0.014 0 
NUYTTEN_EZH2_TARGETS_DN 0.3709596 0.014 0 
 
7.4.2.4 GSEA analysis of differentially regulated signalling pathways in Rhabdoid cell 
lines treated with 5-aza-2-deoxycytidine  
GSEA analysis was performed by analysing a pre-ranked list of genes correlated with a 
metagene that defined the difference between untreated controls and 5-aza-CdR treated 
Rhabdoid cell lines. This pre-ranked list was analysed by GSEA against MSigDB 
libraries C2 and C6. 
Analysis against the MSigDB C2 gene set library identified 36 significantly enriched 
genesets (FDR < 25% and pvalue <1%) out of 782 and 47 significantly negatively-
enriched following 5-azaCdR treatment. The significantly enriched gene sets include 
those corresponding to genes down-regulated in osteosarcoma upon knockdown of both 
HDAC1 and HDAC2 and genes down-regulated by TGFB1 stimulation in embryonic 
fibroblast and genes down-regulated in prostate cancer after knockdown of EZH2 (Table 
7.12 and Figure 7.22 ). 
 
 
 
 
 
 
Table 7.12 Selected C2 GSEA gene sets significantly enriched after 5-
azaCdR treatment in Rhabdoid cell lines. Relative enrichment score (ES),
false discovery rate (FDR) and p-value are also displayed. 
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Figure 7.22 GSEA enrichment plots of selected significantly enriched 
genesets describing targets of HDAC1 and HDAC2, down regulated in 
response to TGFbeta activation and EZH2 targets. These genesets are 
positively enriched in Rhabdoid cell lines in the untreated cells (red) 
compared to cell treated with 5-azaCdR (blue). The top portion of the figure 
plots show the moving enrichment scores (ES) adjusted for each gene in the 
gene set, whereas value of the ranking metric for each gene in the gene set 
is given by a vertical black tick. 
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Gene set  ES FGR p-val 
HOXA9_DN.V1_UP 0.3709591 0.09 0 
NOTCH_DN.V1_DN -0.407226 0.22 0.016 
SNF5_DN.V1_UP -0.400573 0.39 0.05 
 
Analysis against the MSigDb C6 library identified 3 significantly enriched (FDR < 25% 
and pvalue <1%) genesets of 115 genes set and 5 significantly negatively enriched 
following 5-azaCdR treatment. The analysis indicates a significant enrichment of gene 
sets for genes down-regulated following knockdown of HOXA9 and a significant 
negative enrichment with genesets consisting of genes downregulated by use of a Notch 
inhibitor and with genesets corresponding to genes upregulated in response to 
SMARCB1 knockout (Table 7.12 and Figure 7.23). 
 
 
GSEA analysis indicates that 5-azaCdR treatment in Rhabdoid Tumours causes a similar 
effect of re-expression of SMARCB1 and further suggests its overlapping function with 
modulation of methylation. HDAC1 is found to be overexpressed in Atypical Teratoid 
Rhabdoid Tumours and the downregulation of this gene is suggested as therapeutically 
relevant (Sredni, Halpern et al. 2013). In addition, inhibition of EZH2 has been 
indicated to cause a tumour regression in Rhabdoid malignancies (Knutson, Warholic et 
al. 2013) and deregulation of the Notch pathway and gene targets of HOX9 and 
TGFbeta pathway highlight some of the common consequence of methylation 
regulation between 5-azaCdR treatment and SMARCB1re-expression. 
 
 
Table 7.13 Selected MSigDB c6 significantly enriched and negatively
enriched gene sets following 5-azaCdR treatment in Rhabdoid cell line.
Relative enrichment score (ES), false discovery rate (FDR) and p-value are
also displayed. 
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Figure 7.23 GSEA enrichment plot of selected significantly enriched 
genesets including targets of HOXA9, NOTCH and SMARCB1 Knockout. 
These genesets are significantly enriched in untreated cells (red) vs 
Rhabdoid cell lines after 5-azaCdR treatment (blue). The top portion of the 
figure plots show the moving enrichment scores (ES) adjusted for each gene 
in the gene set, whereas the value of the ranking metric for each gene in the 
gene set is given by a vertical black tick. 
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 Ingenuity Pathway Analysis 7.4.3
In order, to identify gene expression networks which were enriched for genes 
highlighted in this study, Ingenuity Pathway Analysis V9 (Ingenuity®Systems, 
www.ingenuity.com) was used. Genes were ranked according to their correlation with 
metagenes and an adjusted p-value calculated to define when a gene was a significant 
part of a metagene this was defined for each metagene as previously described in 
section 7.4.1. Gene identifiers were mapped to corresponding genes in the Ingenuity 
Pathways Knowledge Base and the significance of the association between significant 
gene lists and each pathway was computed using a hypergeometric statistical test, 
calculating a p-value to identify association between gene lists and canonical pathways.  
 
7.4.3.1 Analysis of pathway deregulation in SMARCB1 re-expressing Rhabdoid 
Tumour cells 
Analysis of the genes which form a significant part of a metagene defining the 
expression difference between Rhabdoid cells re-expressing SMARCB1 and empty 
vector controls provided the confirmation that SMARCB1 modulates a wide range of 
biological functions. The genes where ranked by the extent of metagene correlation, 
Determining the enrichment of gene sets for each biological function. The statistical 
analysis determined the p-value for each functional category, identifying categories such 
as Cancer, Cell Death, Inflammatory Disease, Cell Death, Cellular Growth and 
Proliferation, Cell-Cell-Signalling, Cell Cycle and Embryonic Development (Figure 
7.24).  
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Figure 7.24 Important biological functions associated with genes that 
defined SMARCB1 re-expressing cell lines. Biological functions associated 
with genes enriched in a metagene defining empty vector controls vs 
SMARCB1 expressing Rhabdoid cells are indicated on the y-axis. Each bar 
corresponds to –log (p-value) for the enrichment of genes in the selected 
pathway. The orange vertical line represents the threshold for significance. 
 
IPA analysis of the data set also identified several important canonical pathways that are 
deregulated as a result of SMARCB1 re-expression. These include, integrin signalling, 
IL-B signalling and signalling of Rho family GTPases. Interestingly, some of the 
functional categories highlighted were also identified in the GSEA analysis (Figure 
7.25). 
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Figure 7.25 Selected canonical pathways associated with genes that defined 
SMARCB1 re-expressing cell lines. Biological functions associated with 
genes enriched in a metagene defining empty vector controls vs SMARCB1 
expressing Rhabdoid cells are indicated on the y-axis. Each bar corresponds 
to –log (p-value) for the enrichment of genes in the selected pathway. The 
orange vertical line represents the threshold for significance. 
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7.4.3.2 Analysis of pathway deregulation in Rhabdoid Tumours  
Analysis of the genes which form a significant part of a metagene defining the 
expression difference between primary Rhabdoid Tumours and Medulloblastoma 
indicate deregulation of a large number of biological functions. The genes where ranked 
by the extent of metagene correlation, Determining the enrichment statistic for each 
biological function. The analysis highlights the modulation of pathway involved in 
neuron system development, organ and cell morphology and cell development (Figure 
7.26).  
 
Figure 7.26 Important biological functions associated with genes whose 
expression defines primary Rhabdoid Tumours. Biological functions 
associated with genes enriched in a metagene defining the difference in 
expression between primary Rhabdoid Tumours and Medulloblastoma are 
indicated on the y-axis. Each bar corresponds to –log (p-value) for the 
enrichment of genes in the selected pathway. The orange vertical line 
represents the threshold for significance. 
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Analysis of the enrichment of canonical pathways identifies deregulation of several 
pathways including Rho signalling, integrin signalling and P13K/AKT signalling 
(Figure 7.27). 
 
 
Figure 7.27 Selected canonical pathways associated with genes whose 
expression defines Rhabdoid Primary tumours. Biological functions 
associated with genes enriched in a metagene defining the difference in 
expression between primary Rhabdoid Tumours and Medulloblastoma are 
indicated on the y-axis. Each bar corresponds to –log (p-value) for the 
enrichment of genes in the selected pathway. The orange vertical line 
represents the threshold for significance. 
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7.4.3.3 Analysis of pathway deregulation in 5-aza-CdR treated Rhabdoid Tumour cells 
Analysis of the genes which form a significant part of a metagene defining the 
expression difference between untreated cells and Rhabdoid cells treated with 5-aza-2-
deoxycytidine indicate significant deregulation of a number of biological functions 
involved in cancer cellular movement and development, cell death and morphology. The 
genes where ranked by the extent of metagene correlation, Determining the enrichment 
statistic for each biological function (Figure 7.28). 
 
 
Figure 7.28 Selected significant biological functions associated with 5-
azaCdR treatment in Rhabdoid Tumours. Biological functions associated 
with genes enriched in a metagene defining the difference in expression 
between untreated cells and 5-aza-CdR treated Rhabdoid Tumour cells are 
indicated on the y-axis. Each bar corresponds to –log (p-value) for the 
enrichment of genes in the selected pathway. The orange vertical line 
represents the threshold for significance. 
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Analysis of the enrichment of canonical pathways highlights pathways involved in 
apoptosis, IL1 signalling, death receptor and PPAR signalling (Figure 7.29). 
 
 
Figure 7.29 Selected canonical pathways associated with 5-azaCdR 
treatment in Rhabdoid Tumours. Biological functions associated with genes 
enriched in a metagene defining the difference in expression between 
untreated cells and 5-aza-CdR treated Rhabdoid Tumour cells are indicated 
on the y-axis. Each bar corresponds to –log (p-value) for the enrichment of 
genes in the selected pathway. The orange vertical line represents the 
threshold for significance 
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7.4.3.4 Custom pathway analysis 
SMARCB1 re-expression and 5-aza-2-deoxycytidine treatment in Rhabdoid cell line 
results in constitutive activation of transcription factors associated with cell death 
signalling, differentiation signalling and with control of cell cycle progression. To 
investigate the outcome of these modulations, the metagene content derived from the 
model experiment and the primary analysis were further investigated by direct 
comparison. The comparison was performed based on the gene ranking of each data set 
assigned by IPA ingenuity.  
Comparative analysis of the pathways involved identified a set of canonical pathway 
that were significantly down–regulated or upregulated in both SMARCB1 re-expressing 
and 5-azaCdR treated Rhabdoid cells with a corresponding significant effect in 
Rhabdoid primary malignancies. In particular, the analysis predicted a significant 
inactivation of integrin signalling and downregulation of actin-based motility of Rho 
signalling by Rho family GTPases pathways in response to SMARCB1 re-expression 
and 5-azaCdR treatment, and predicted relative activation in the primary malignancies 
(Figure 7.30). 
A similar strategy was also used to identify significant upstream regulatory effectors 
that are common to all data sets. Upstream regulatory effectors are identified by IPA 
based upon a statistic describing the ability of an individual regulator to produce the 
expression pattern observed. The more of the deregulated expression that can be 
potentially explained by an upstream effector the greater the p-value. This 
computational analysis was performed to indicate which biological processes are 
affected by SMARCB1 re-expression. The investigation identified a variety of effectors, 
which were predicted to be activated in response to SMARCB1 re-expression and 5-
azaCdR treatment and oppositely downregulated in Rhabdoid primary tumours. 
Interestingly, one of the most significant effectors was TGFB1, a pathway whose 
involvement was also determined by GSEA analysis (Figure 7.31).  
Molecular activity prediction analysis was used to predict and hypothesise a plausible 
pathway, based upon IPA’s custom pathways feature and evidence of significant 
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enrichment of genes within the data sets. Specifically, the TGF-beta pathway was 
further investigated. As indicated in Figure 7.32, Figure 7.33 and Figure 7.34 a 
significant enrichment of targets regulated by TGFbeta receptor were identified across 
the data set: in particular SMARCB1 and 5-azaCdR treatment positively regulated the 
pathway in a similar manner, while in Rhabdoid primary data the same pathway was 
deregulated in an opposite manner. 
 
Figure 7.30 Heatmap of the top 20 common canonical pathways identified 
by comparative analysis. Intensity represents standard deviations from the 
mean (Z-score). Inactivation (pale blue to dark blue) and activation of 
pathway (pale read to dark read) is represented by the appropriate colour. 
Each row represents a canonical pathway and each column a data set. 
SMARCB1 and AZA refer to Rhabdoid cells expressing SMARCB1 or treated 
with 5-AZA-CdR. Primary refers to primary Rhabdoid Tumours. 
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Figure 7.31 Heatmap of the top 20 upstream effectors identified by 
comparative analysis. Intensity represents standard deviations from the 
mean (Z-score). Activation (pale blue to dark blue) and inactivation of 
pathway (pale read to dark read) is represented by the appropriate colour. 
Each row represents a canonical pathway and each column a data set. 
SMARCB1 and AZA refer to Rhabdoid cells expressing SMARCB1 or treated 
with 5-AZA-CdR. Primary refers to primary Rhabdoid Tumours  
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Figure 7.32 Modulation of the TGF-beta pathway is associated with 
Rhabdoid Tumourigenesis. Expression data from SMARCB1 re-expressing 
cells was overlaid onto the canonical pathway using IPA. The genes which 
are coloured in bold red and green are genes deregulated in Rhabdoid 
primary tumours (red =up, green = down). Green and red arrows indicate a 
predicted down and up-regulating interaction respectively.  
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Figure 7.33 Modulation of the TGF-beta pathway is associated with 
Rhabdoid Tumourigenesis. Expression data from 5-azaCdR treated cells was 
overlaid onto the canonical pathway using IPA. The genes which are 
coloured in bold red and green are genes deregulated in Rhabdoid primary 
tumours (red =up, green = down).Green and red arrows indicate a predicted 
down and up-regulating interaction respectively.  
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Figure 7.34 Modulation of the TGF-beta pathway is associated with 
Rhabdoid Tumourigenesis. Expression data from Rhabdoid primary samples 
was overlaid onto the canonical pathway using IPA. The genes which are 
coloured in bold red and green are genes deregulated in Rhabdoid primary 
tumours (red =up, green = down). Green and red arrows indicate a 
predicted down and up-regulating interaction respectively. 
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 Conclusion  7.5
 
 Role of SMARCB1 in methylation modulation  7.5.1
An investigation of the role of SMARCB1 in epigenetic modulation was performed 
through a systematic analysis of the data across different platform and experimental 
conditions. Firstly changes in methylation status following SMARCB1 re-expression 
was compared with 450K methylation array data from primary tumours. The analysis 
identified 63 CpGs that were significantly demethylated in response to SMARCB1 and 
normally methylated in Rhabdoid primary tumours. Bisulfite Sequencing of ABR 
(regulator of the Rho family), BHLHE40 (transcription repressor that induces apoptosis) 
and GALNT2 (promoter of tumour invasion) confirmed the hypomethylating effect of 
SMARCB1 re-expression in Rhabdoid cell lines.  
To better understand the mechanism by which SMARCB1 induces hypomethylation in 
Rhabdoid cell lines, significant expression data from cell lines re-expressing SMARCB1 
and treated with the demethylating agent 5-azaCdR were cross-referenced. The analysis 
identified 14 genes deregulated in both conditions. The list contains three genes that 
were also found differentially expressed following SMARCB1 re-expression (DNA2), in 
response to 5-azaCdR treatment (PDE4C- PDE4D) and in primary tumours 
(SERPINE2). Also to understand the effect of hypomethylation on gene expression 
caused by SMARCB1, cross-referencing of RNAseq and 450K platforms in SMARCB1 
re-expressing data was performed. A selection of genes GLI2 and GLI3 (Shh pathway 
regulator), JARID2 (promoter of undifferentiated Rhabdomyosarcomas) and NTN4 
(inhibitor of angiogenesis) were further analysed. In particular qPCR of RNA from 
SMARCB1 re-expressing Rhabdoid cells and 5-azaCdR treated Rhabdoid cells revealed 
an overexpression of these genes to some extent in almost all genes in both conditions 
but most notably in GLI2. This validated the hypothesis that SMARCB1 modulates gene 
expression in part by provoking a methylation modification in Rhabdoid Tumours.  
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 Pathway analysis  7.5.2
Analysis of the pathways involved in Rhabdoid tumourigenesis was performed using a 
different method. Overall cross-referencing across expression data sets was performed 
in order to disclose gene signature and pathways involved in Rhabdoid tumourigenesis. 
7.5.2.1 Gene expression cross-referencing identifies signature of Rhabdoid phenotype 
First, gene expression data set cross-referencing was applied across the experimental 
conditions and primary tumours aimed at exploring gene signatures across data sets that 
could defined a Rhabdoid phenotype and characterise direct targets of SMARCB1 loss. 
In particular, the gene content of appropriate metagenes was overlapped, to identify 13 
genes SMARCB1/methylation dependent genes correlated with a Rhabdoid phenotype. 
Interestingly, all 13 genes are involved in tumourigenesis in a variety of cancer though 
for most the mechanisms and exact function is not fully understood e.g. CCDC74B 
(implicated in mitosis regulation and cell cycle regulation), Dnm3os ( gene transcribed 
into a non-coding RNA indispensable for body growth in mammals), IDH1 (mutation of 
this gene has an oncogenic function in Gliomas), KAZALD1 (highly methylated in 
Sarcomatoid-type peritoneal mesothelioma) and KIAA0101 (overexpressed in breast 
cancer and modifies directly centrosomes). 
 
7.5.2.2 GSEA analysis identifies deregulated pathways responsible for tumourigenesis 
in Rhabdoid Tumours  
Metagene contents were analysed using GSEA to classify gene sets that share common 
biological (C2: cured annotations) and tumourigenic functions (C6: oncogenic 
signature).  
GSEA analysis of primary Rhabdoid Tumour metagene content indicated a variety of 
pathways deregulated. In particular, significant enrichments in Rhabdoid patients were 
observed for genes commonly down-regulated in human alveolar rhabdomyosarcomas 
when compared with Medulloblastomas; genes up-regulated in embryonic stem cells 
and genes involved in G1/S DNA damage checkpoint in a p53 independent manner. 
 342 
 
Significant negative enrichment instead was detected for gene sets that resemble the 
Medulloblastomas phenotype. This was in accordance with what was previously 
reported in the literature and in this study.  
Study of the metagene that defined Extra Cranial Rhabdoid Tumours (ECRT) gave, not 
surprisingly, fewer significantly enriched gene sets correspond to deregulated pathways. 
A significant enrichment of gene sets describing downregulation of targets of PATCH1 
and SUFU was found; and a significant negative enrichment of a gene set corresponding 
to genes up-regulated in kidney epithelium cells over-expressing KRAS and to genes up-
regulated in breast cancer cells over-expressing YAP.  
Re-expression of SMARCB1 in Rhabdoid Tumours significantly deregulates a wide 
number of pathways. Most significantly enriched genesets reflect in part the changes in 
phenotype that occurs in Rhabdoid cell upon SMARCB1 re-expression i.e. cell cycle 
progression and recruitment of SWI/SNF complexes. Significant enrichment was 
detected for gene sets involved in cell cycle and differentiation, and corresponding to 
genes with promoters bound by E2F4. Significant negative enrichment was found for 
alveolar Rhabdomyosarcomas gene set pathway, the TGF-Beta target pathway and 
downregulation in response to HOXA9 knockdown and PDEF target.  
GSEA analysis was also performed on metagenes that defined Rhabdoid cells treated 
with 5-azaCdR: significant enrichment of gene sets describing genes down-regulated 
following knockdown of HOXA9 and a significant negative enrichment of a gene set 
composed of genes downregulated when using a Notch inhibitor and a gene set 
corresponding to genes upregulated in response of SMARCB1 knockout. 
In conclusion, the GSEA analysis underlines the differences between the data set 
previously described in this study. Also it reconfirmed the subtle differences between 
Atypical Teratoid Rhabdoid Tumours and in Extra Cranial Rhabdoid Tumours and the 
similar effect on gene expression caused by SMARCB1 re-expression and 5-azaCdR 
treatment in Rhabdoid cells. 
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7.5.2.3  Ingenuity Pathway analysis  
IPA pathway analysis was performed in order to characterise a common pathway 
deregulated across functional models and primary data.  
Expression data were analysed separately, confirming what was observed by GSEA 
analysis. Specifically, a general deregulation of cell cycle gene control, cell morphology 
and cell developmental pathways were observed across all the data sets, as expected. 
Interestingly, canonical pathway analysis reveals deregulation of integrin pathway and 
Rho–related pathway across both functional models and primary data. Comparative 
analysis of the data sets in IPA identified 21 canonical pathways that were upregulated 
in response to SMARCB1 re-expression and 5-azaCdR and downregulated in the 
Primary tumours. Most of these pathways were also observed in GSEA, such as 
Signalling of Rho family GTPse, Glioblastoma pathways, etc. Moreover, comparative 
analysis identifies 13 significant upstream regulators, included TGFB1, TNF, TP53 and 
IFNG. The TGFbeta pathway was further analysed and molecular activity prediction 
was computated for this pathway.  
The cross-referencing data analysis indicated that TGFbeta was deregulated negatively 
in primary Rhabdoid Tumours , while in SMARCB1 re-expressing cells and 5-azaCdR 
treated cells an opposite effect was observed. TGFbeta is a potent growth inhibitor and 
perturbation of the signalling pathway promotes cancer cell growth and finally 
metastasis (Akhurst and Derynck 2001). Importantly TGFbeta is linked with other 
effectors deregulated in our study, such as the Rho family (ABR), and GLI2 (early gene 
target of the TGF-β/SMAD pathway) (Dennler, Andre et al. 2007).  
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 Conclusion  Chapter 8
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 Introduction 8.1
Malignant Rhabdoid Tumours are an aggressive malignancy that occurs in infants and 
young children. They can occur in soft tissue (Extra Cranial Rhabdoid Tumours ), in the 
brain and in the spinal cord (Atypical Teratoid Rhabdoid Tumours ). This malignancy 
presents a biallelic inactivation at chromosome 22 of SMARCB1, this deletion 
characterises these tumours (Jackson, Sievert et al. 2009). However, malignancies 
located in the brain can be misdiagnosed as Medulloblastoma or PNET, since they share 
locations and histological features. Moreover, these malignancies are treated with 
combination of therapies including surgery, radiation and high dose chemotherapy, often 
producing severe side effects (EURHAB).  
SMARCB1’s role in tumourigenesis has been previously investigated in vivo and in vitro. 
SMARCB1 +/- and conditional SMARCB1 knock-out mice develop malignancies and 
undifferentiated sarcomas, indicating the oncogenic effect of SMARCB1 loss (Bultman, 
Gebuhr et al. 2000, Roberts, Leroux et al. 2002). In Rhabdoid cell lines re-expression of 
SMARCB1 induces arrest of the cell cycle in G1 and changes in cell morphology 
associated with senescence, down-regulation of E2F targets, activation of Rb and up-
regulation of CDKN2A and CDKN1A (Versteege, Medjkane et al. 2002, Chai, 
Charboneau et al. 2005). Moreover ChIP experiments demonstrate that SMARCB1 re-
expression directly recruits SWI/SNF complexes at promoter region of CDKN2A and 
CDKN1A and evicts the polycomb complex silencing proteins followed by H3K4 
methylation and H3k27 demethylation (Kusafuka, Miao et al. 2004, Kuwahara, 
Charboneau et al. 2010, Kuwahara, Mora-Blanco et al. 2013). Microarray analysis in 
Rhabdoid cell lines identifies up-regulation of genes controlling cell cycle, senescence 
markers and repression of mitotic genes following SMARCB1 re-expression (Birks, 
Donson et al. 2013).  
SMARCB1’s role in tumourigenesis has been also investigated in primary Rhabdoid 
Tumours by whole genome profiling and Single Nucleotide Polymorphism Profiling 
(SNP) assays (Jackson, Sievert et al. 2009). In particular, comparison between Atypical 
Teratoid Rhabdoid Tumours and other CNS paediatric tumour (such as 
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Medulloblastoma and Glioblastoma) identified downregulation of neuronal 
development and differentiation genes, up-regulation of histone deacetylase inhibitors 
genes (HDACi) and up-regulation of BMP pathway genes(Ma, Yang et al. 2014). Just 
one study attempted to analyse the difference in expression between Atypical Teratoid 
Rhabdoid Tumours and in Extra Cranial Rhabdoid Tumours. Specifically, this 
investigation showed that in Extra Cranial Rhabdoid and Atypical Teratoid Rhabdoid 
Tumours share a common dysregulation of cell cycle and epigenetic genes, suggesting 
the possibility of a therapy effective in both malignancies (Birks, Donson et al. 2013). 
While gene expression profiling in Rhabdoid cell lines and Primary malignancies was 
performed, an analytical and comprehensive analysis of the epigenetic effects of 
SMARCB1 loss has yet to be attempted. Investigating the implication of SMARCB1 in 
the epigenetic machinery may open the way not only to a complete understanding of the 
SMARCB1 mechanism of tumourigenesis, but also to characterising potential 
therapeutic targets.  
The current study was conceived to provide new understanding of the tumourigenic 
mechanism of Rhabdoid Tumours. Though comprehensive gene expression and 
methylation profiling of Rhabdoid primary malignancies and of SMARCB1 re-
expressing cell lines, this research aimed to catalogue events dependent on SMARCB1. 
The data collected were finally analysed in such a way as to characterise pathways and 
genes associated with tumourigenesis and potentially therapeutic targets. 
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 DNA methylation and gene expression profiling of Rhabdoid 8.2
Tumours characterise a unique a coherent tumour type when 
compared with other embryonal and neuronal malignancies 
A better understanding of the molecular mechanisms driving tumourigenesis in 
Rhabdoid malignancies is necessary to characterise deregulated genes and possible 
therapeutic targets. Few studies have tried to compare gene expression of Rhabdoid 
primary tumours in order to disclose similarities and differences among Rhabdoid 
malignancies from differently locations. In particular Birks compared microarray gene 
expression profiles of Atypical Teratoid Rhabdoid Tumours tumour samples with 
already published microarray data for Rhabdoid kidney tumours. In this study found 
only a few common gene signatures consistently affected by SMARCB1 expression, 
such as LMO4, SLC2A3 and THBS. However, this research showed several technical 
limitations and in particular the platform used and the different origin of the data.  
In this study for the first time RNAseq and 450K methylation array were performed in a 
total of 39 primary Malignant Rhabdoid Tumours, investigating the epigenetic 
difference between these two malignancies. The current study was conducted to 
investigate gene signatures that drive Rhabdoid Tumours located in different parts of the 
body. The analysis was conducted in parallel with Medulloblastoma samples identified 
as a unique and homogenous group characterised by a common embryonal and neuronal 
gene signature and epigenetic events.  
Our findings indicate that in Extra Cranial Rhabdoid and Atypical Teratoid Rhabdoid 
Tumours have common origins despite the location of the malignancies when compared 
with Medulloblastomas. Gene expression and methylation profiling revels that 
Malignant Rhabdoid Tumours are a unique and coherent group from the other 
Medulloblastoma subgroups. In particular, genes associated with multiple processes 
such as cell proliferation, cell cycle, stem cell regulation and neurodevelopment 
emerged as differentially expressed and methylated compared with Medulloblastomas. 
This suggests that SMARCB1 loss causes common deregulation of downstream 
biological mechanisms regardless of the tumour location. 
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The cohort was further interrogated to understand differences among the Rhabdoid 
Tumours. Gene expression and methylation profiling characterised two significant 
subgroups, in line with the previous findings. In particular, the analysis distinguished 
Extra Cranial Rhabdoid Tumours from Atypical Teratoid Rhabdoid Tumours. Extra 
Cranial Rhabdoid Tumours show significant enrichment and change in methylation 
profiling of genes associated muscle contraction and development, whilst in Atypical 
Teratoid Rhabdoid Tumours mainly genes involved in neurodevelopmental 
proliferation, such as GFAP, B-FABP and SOX1. Atypical Teratoid Rhabdoid Tumours 
also showed differentially expressed genes related to tumour progression, invasion, 
angiogenesis and hypermethylation of genes related to Wnt and Notch signalling 
pathways.  
In conclusion the high-throughput profiling provided by this study showed that 
Rhabdoid Tumours are a unique biological identity compared with other CNS paediatric 
malignancies. Consistent with what has been previously published, the data sets also 
showed differences in gene expression and methylation status among Rhabdoid arising 
in different locations, indicating that the location of the tumours might be related to 
other genetic factors in conjunction with SMARCB1 deletion.  
 
 Patterns of methylation and gene expression may have utility for disease 8.2.1
sub-classification  
In this study we established that Rhabdoid Tumours are characterised by a distinct 
molecular signature, in comparison to other CNS paediatric tumours; nevertheless this 
high-throughput research characterised two different subtypes of malignancies mainly 
correlated with the primary location of the tumours, indicating the involvement of 
different molecular mechanisms. The two observed subgroups were validated in three 
independent trials cohorts, reported in chapter 6.  
Rhabdoid Tumours are malignancies that are difficult to diagnose, since the mass is 
often located in the location typical of more common paediatric tumours. For instance, 
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Neuroblastoma, Nephroblastoma, Congenital Blastic Nephroma and Clear Cell Sarcoma 
of the kidney present foci similar to Extra Cranial Rhabdoid, while Atypical Teratoid 
Rhabdoid Tumours are often misdiagnosed as Medulloblastoma or CNS Primitive 
Neuroectodermal Tumour (PNET). Rhabdoid Tumours are now diagnosed by 
immunohistochemical staining, however absence or decrease of SMARCB1 in 
immunohistochemistry reactivity is also observed in Renal Medullary Carcinoma, 
Epithelioid sarcoma, poorly differentiated Synovial Sarcoma, Ewing sarcoma 
Schwannomatosis (Rousseau, Noguchi et al. 2011), Chordomas (Mobley, McKenney et 
al. 2010) and Choroid Plexus Carcinoma.  
In this study I have indicated the utility of DNA methylation and next generation 
sequencing not just for disease sub-classification, but also for diagnostics. These 
findings provide insights into the molecular pathways involved in Rhabdoid 
tumourigenesis and will contribute to a better understanding, and treatment of these 
malignancies. Also the use of molecular profiling in clinics will improve diagnostic and 
in particular to avoid misinterpreting SMARCB1 immuno-reactivity or tumour location. 
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 Epigenetic effect of SMARCB1 deletion if Rhabdoid Tumours  8.3
Malignant Rhabdoid Tumours are characterised by a biallelic inactivation at 
chromosome 22 of SMARCB1 (Jackson, Sievert et al. 2009). SMARCB1 is indicated as 
potent tumour suppressor and its implication in tumourigenesis has been previously 
demonstrated both in vivo and in vitro. In particular, re-expression of SMARCB1 in 
Rhabdoid cell lines determines deregulation of genes related with cell cycle and cell 
proliferation (Medjkane, Novikov et al. 2004, Morozov, Lee et al. 2007).  
To further investigate the role of SMARCB1 in tumourigenesis, for the first time RNA-
seq and 450K were performed in Rhabdoid cell lines in which SMARCB1 was re-
expressed and also treated with 5-aza-2’-deoxycytidine. The research aimed to 
understand the effect of SMARCB1 loss in the epigenetic mechanism and characterise 
genes and pathway directly dependent on SMARCB1 that could be targeted in Malignant 
Rhabdoid Tumours 
The investigation in SMARCB1 re-expressing cells indicated that SMARCB1 causes 
mainly hypomethylation and upregulation of a wide number of genes involved in 
neurodevelopment and promoting metastasis and angiogenesis. Interestingly, we 
observed that SMARCB1 re-expression causes gene deregulation by provoking 
alternative splicing. RNAseq analysis also indicates that SMARCB1 deregulates a 
significant number of genes and isoforms, whose role needs to be defined.  
Treatment of Rhabdoid cell lines with 5-aza-2’-deoxycytidine showed a general 
upregulation of genes involved in chromatin stability and in modulation of Polycomb 
target genes. Combining data from primary and functional models (SMARCB1 re-
expression/5-aza-CdR treatment) highlighted 13 genes which were appropriately 
deregulated in all conditions, suggesting a SMARCB1 demethylating effect. In fact, 
cross-referencing across platform and data sets from primary samples and SMARCB1 
re-expressing cell lines suggests that SMARCB1 may cause gene deregulation by 
directly modulating methylation modifications. In particular, direct upregulation caused 
by hypomethylation was observed in GLI1, GLI3, JARID2, NTN4, GALNT2, BHLHE4 
and ABR.  
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In conclusion, this study investigated the epigenetic mechanism of SMARCB1 and 
characterised downstream effectors of SMARCB1 that can be targeted for arresting the 
growth of Rhabdoid cells. In particular, we show that SMARCB1 is actively involved in 
the methylation machinery and its deletion causes deregulation of expression of a 
variety of gene and also activates alternative splicing. 
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 Integrative analysis of model and primary data indicate 8.4
activation of a variety of pathways dependent on SMARCB1 
deletion  
Previous profiling of primary Rhabdoid Tumours and SMARCB1 re-expressing 
Rhabdoid cell lines indicated that multiple pathways are deregulated following 
SMARCB1 deletion. However, only a few genes such as Cyclin D1 were suggested as 
possible drug target in Rhabdoid Tumours in children. 
In this study for the first time, cross-referencing between data sets was strategically used 
to characterise SMARCB1-dependent Rhabdoid tumour gene signatures that may be 
used as therapeutic targets. In particular we identified 13 genes which expression was 
re-established after both SMARCB1 re-expression and 5-aza-2’-deoxycytidine treatment 
and correlated with non Rhabdoid Tumours. All 13 genes are cancer-related and for 
most of them the tumourigenic mechanism is still not completely understood. 
Interestingly Dnm3os (gene transcribed into a non-coding RNA that contains three 
micro RNAs (miRNAs), miR-199a, miR-199a, and miR-214) was identified as part of 
this set, suggesting that SMARCB1 might also recruit SWI/SNF complexes at miRNA 
promoters. 
A comparison of gene signatures between functional models and primary samples also 
provided a rational way to analyse pathways involved in Rhabdoid tumourigenesis. The 
investigation identified a variety of canonical pathways and biological functions that 
were deregulated in Rhabdoid primary tumours and re-established following SMARCB1 
induction and 5-aza-2’-deoxycytidine treatment. Specifically the analysis distinguished 
pathways and upstream regulators mainly involved in cell cycle progression, 
recruitment of SWI/SNF complexes, Interferon Gamma, RhoA signalling, TP53 
signalling, etc. Finally, molecular activity prediction analysis based on ingenuity 
annotation identified TGFbeta as a likely significant upstream regulator of the 
tumourigenic pathway in Rhabdoid Tumours.  
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In conclusion, this study has indicated the importance of cross-referencing model data 
and primary profiling to identify genes and pathways that drive tumourigenesis in 
Rhabdoid Tumours. A subset of genes were identified as SMARCB1/methylation 
dependent genes and also correlated with a Rhabdoid phenotype. Moreover pathway 
analysis indicates deregulation of several pathways and upstream regulator involved in 
Rhabdoid tumourigenesis that will be further investigated to understand their potential 
as candidates for developing targeted therapy.  
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 Limitations 8.5
This study investigated the role of SMARCB1 both in cells and primary tumours. In 
particular SMARCB1 was re-expressed in Rhabdoid cell lines using a lentivirus 
approach. Re-expression or overexpression of genes is a technique used extensively in 
genetic studies. However, the mRNA level of the re-expressed genes is often higher than 
the biological samples and level of rexpression inconsistent amongst replicates. 
Additionally, in this study the lentiviral approaches used CMV as constitutive promoter 
that induces continual induction of the genes of interest, contrary from what normally 
happens physiologically. However, the cell line STA-WT1 which maintains SMARCB1 
protein (even if in a lower levels) and the effect on gene expression caused by 5-aza-2’-
deoxycytidine treatment suggested that the effect of SMARCB1 re-expression was not 
simply due to expression at a non-physiological level. Nevertheless, inducible 
promoters would improve the experimental condition, since the intensity of the gene of 
interested could be modulated.  
qPCR and Western Blot analysis show an increase of the SMARCB1 mRNA levels and 
protein levels following transduction, however this study is limited in its ability to 
provide evidence of incorporation of SMARCB1 protein into the SWI/SNF complex. 
Despite ChIP results showing a change in recruitment of SMARCA4 at the gene 
promoter following SMARCB1 rexpression, this does not fully confirm the involvement 
of SMARCB1 in the functional and physiological activity of the SWI/SNF complexes. 
Comparison of SMARCB1, SMARCA4 and other constitutive subunits binding 
measured by ChIP-seq will give a better understanding of the dynamic recruitment of 
the SWI/SNF complex in Malignant Rhabdoid Tumours.  
Introduction of both SMARCA4 D/N and WT in Rhabdoid cell lines causes activation of 
apoptosis and upregulation of CDKN2A and CDKN1A in A204 and G401 cell lines. 
However this effect typically had to be measured at an early time point and so the effect 
could be caused by Puromycin selective treatment. This also is balanced by the fact that 
cells in which SMARCA4 WT was induced did not show changes in morphology nor 
arrest of cell growth in longer-term culture. Unfortunately time did not allow for further 
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analysis or developing an inducible system. The molecular effect of mutant SMARCA4 
in Rhabdoid cell lines should be further investigated.  
The profiling study on primary tumours aimed to understand the mechanism of 
tumourigenesis and characterise the differences between Rhabdoid Tumours based on 
the location of the malignancies. Despite the fact that all Malignant Rhabdoid Tumours 
cluster in a different metagene when compared with Medulloblastoma, the data 
suggested that the cohort is not simply composed of two classes purely divided by 
tumour location. In fact, projection of the metagene that characterised  Extra Cranial 
Rhabdoid tumours and Atypical Teratoid Rhabdoid Tumours onto other platforms 
further supports the non-exclusivity of the two groups i.e. some Atypical Teratoid 
Rhabdoid resemble Extra Cranial Rhabdoid tumours molecularly and vice versa. The 
presence of a further third molecular subgroup should also not be ruled out: some Extra 
Cranial Rhabdoid tumours and Atypical Teratoid Rhabdoid Tumours appear to present 
mixed features showing gene signatures of both the bigger subgroups. In our cohort of 
23 primary samples just 2 presented this phenotype. Studies of a larger cohort may 
provide a more accurate ability to detect this possible third group and finally to 
characterise it.  
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 Future work 8.6
 
 Implication of gene deregulation in Rhabdoid Tumourigenesis 8.6.1
The present study aimed to collect a catalogue of data to inform as to critical genes and 
pathways involved in Rhabdoid tumourigenesis. This work was able to characterise the 
epigenetic modification caused by SMARCB1 loss and extract gene signatures that 
might explain the mechanism behind Rhabdoid malignancies. Despite the validation of 
some of the findings, further investigation will be required to establish the role of the 
deregulated genes extracted from this comparative analysis. High-throughput genetic 
screening perhaps with a CRISPR library may also be useful to identify genes that are 
involved in Rhabdoid tumourigenesis. 
 
 Characterisation of pathways 8.6.2
Comparative analysis between platform and data sets provided a method to identified 
possible pathways involved in cancer development in Rhabdoid Tumours. However 
deregulation of gene expression does not always causes changes at the protein level, and 
it also has been observed that upregulation of mRNA may also cause downregulation of 
the protein effector (Cham, Xu et al. 2003). Further investigation of the changes in 
protein levels as results of SMARCB1 re-expression in Rhabdoid cell lines will be 
performed by proteomic study. In particular, stable isotope labelling proteomics in 
Rhabdoid cell lines re-expressing SMARCB1 will be used to separate, identify and 
analyse those proteins affected by SMARCB1. This approach will give us the possibility 
to compare protein levels and gene expression and finally determine the tumourigenic 
pathways involved in Rhabdoid Tumours. 
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 Characterisation of SMARCA4 D/N effect in gene expression and 8.6.3
methylation status 
A preliminary study of SMARCA4 role was attempted. Here we showed that SMARCA4 
D/N induces apoptosis and a rapid cell death. However some increase in apoptosis was 
also observed when the wild type form was induced. It is still not clear if the effect was 
caused by the early time point of the experiment and no analysis of the molecular 
biology (RNA-seq) has yet been performed. An inducible system will provide a better 
model to study, since no process of selection is required. Moreover, RNA-seq and 450K 
methylation of Rhabdoid cells with induction of SMARCA4 D/N will be performed and 
compared to the experimental data set of this study. 
 
  Single cell sequencing  8.6.4
Malignant Rhabdoid Tumours and in particular Atypical Teratoid Rhabdoid Tumours 
present a neuroepithelial, peripheral epithelial, and mesenchymal element in addition to 
Rhabdoid features. Moreover, in this study it can also be indicated that a small subset of 
primary tumours showed a mixed genotype that may reassemble both the two major 
subgroup we have characterised. Moreover, SMARCB1 is not necessarily completely 
deleted in all Rhabdoid Tumours, and low levels of mutated protein may still be 
detected. Single cell sequencing will provide a better understanding of the many 
biological processes that occur in individual cells and better characterise the Rhabdoid 
Tumours we observe. Moreover, this will provide an analysis of the functions of 
individual cells in the context of its microenvironment, which might explain the 
development of these tumours in such different locations of the body. 
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 Final Conclusion 8.7
This project aimed to characterise the effects of SMARCB1 in Rhabdoid cell lines and 
identified genes that might be therapeutically targeted. High throughput sequencing and 
methylation array were used to outline a better picture of the role of SMARCB1 in gene 
expression modulation. Moreover cross-referencing between platforms and primary and 
experimental data was applied to find gene signatures that resemble a non Rhabdoid 
phenotype and understand the effect on methylation of SMARCB1 re-expression in 
Rhabdoid Tumours. 
This investigation has made a substantial contribution to knowledge in the field by 
defining the gene expression and methylation characteristics of primary Malignant 
Rhabdoid Tumours and defined the extent to which their gene expression and 
methylation profile is dependent upon SMARCB1 loss. In this study I have indicated 
that whilst Malignant Rhabdoid Tumours form a single biological entity they can be 
further sub-grouped into at least two groups. Also here I show the direct effect on 
methylation status caused by SMARCB1 re-expression and the consequential change in 
expression, in a similar manner we observed following 5-aza-2’-deoxycytidine. I have 
catalogued a series of SMARCB1-dependent genes as well as pathways, which may now 
be further explored as potential novel therapeutic targets. 
Furthermore, we have indicated that next generation profiling of primary tumours are 
useful in patient stratification, and in particular in diagnosis of all paediatric tumours 
that present SMARCB1 deletion and are phenotypically similar to Malignant Rhabdoid 
Tumours. 
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450K methylation array  
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 Appendix I\450K\ table.deltavalue.filtered.probes_MB_vs_MRT 
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Systems Biology Approach to Identify Mechanism of Tumourigenesis 
Caused by Loss of SMARCB1 in Malignant Rhabdoid Tumors  
Martina Finetti, Alicia Del Carpio Pons, Benjamin Skalkoyannis, Mathew Selby, 
Amanda Smith, Stephen Crosier, Simon Bailey, Steve Clifford, Daniel Williamson 
Poster presentation 
 
Background 
Malignant Rhabdoid Tumours are caused by a biallelic inactivation of a single gene 
(SMARCB1) which encodes a core subunit of the hSWI/SNF chromatin remodeling 
complex. hSWI/SNF regulates hundreds of downstream genes/pathways. Despite 
knowing that SMARCB1 mutation causes MRT no studies have systematically identified 
specific downstream pathways critical to tumourigenesis. Understanding these 
downstream effects is critical to identifying therapeutic targets that can improve the 
survival of MRT patients. 
Method 
To reveal the global transcriptional changes caused by SMARCB1 deletion, we 
performed RNA-seq and 450k-methylation analyses in MRT human primary 
malignancies (n>30) and in 4 MRT cell lines in which Lentivirus was used to re-express 
SMARCB1 (G401, A204, CHLA-266, STA-WT1). Moreover to understand the 
dynamics of chromatin binding/remodeling following SMARCB1 re-expression we 
performed ChIP-seq in functional models. 
Results 
We show that primary MRTs present a unique expression/methylation profile which 
confirms that MRT broadly constitute a single tumor type, when compared with other 
paediatric tumours. However despite their common cause MRT can be can sub-grouped 
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by location (i.e CNS or kidney). We observe that re-expression of SMARCB1 in MRT 
cell lines determines activation/inactivation of specific downstream pathways (IL-
6/TGFbeta), genome-wide alterations in methylation and consequently gene expression. 
Loss of SMARCB1 also promotes expression of aberrant isoforms and novel transcripts 
and causes genome-wide changes in SWI/SNF binding. 
Conclusion 
Our transcriptome and methylome analysis in primary MRT and in functional models 
allow us to study in unprecedented detail the effect of SMARCB1 loss in MRTs. 
Through integration of our data using systems biology methods we have provided for 
the first time a genome-wide catalogue of SMARCB1 tumourigenic changes in both 
primary and functional models. We have isolated and validated critical genes/pathways 
and biological mechanisms which may ultimately be targetable therapeutically and will 
lead to better treatments for what is currently one of the most lethal paediatric cancers 
known. 
Acknowledgements 
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Characterising critical pathways in ATRT tumourigenesis: a genome-
wide analysis of primary tumours and functional genomic models 
 Martina Finetti, Alicia del Carpio Pons, James Wood, Benjamin Skalkoyannis, 
Matthew Selby, Amanda Smith, Stephen Crosier, Simon Bailey, Steve Clifford, Daniel 
Williamson 
Proferred Paper 
  
Rhabdoid tumours are rare aggressive tumours of early childhood which may occur at 
any location in the body; most frequently in the CNS (ATRT - Atypical Teratoid 
Rhabdoid Tumours) and kidney. >90% of Rhabdoid tumours have biallelic inactivation 
of SMARCB1; a core subunit of the SWI/SNF complex. Inactivation of SMARCB1 
provokes widespread chromatin remodelling and affects the expression of many 
hundreds of downstream genes/pathways. Understanding which of these downstream 
effects is critical to ATRT tumourigenesis will allow us to rationally predict how loss of 
SMARCB1 may be counteracted therapeutically. We performed RNA-seq and 450K-
methylation array on primary rhabdoid tumorus (n>30) and on 4 rhabdoid tumour cell 
lines in which lentivirus was used to re-express SMARCB1. Integrative bioinformatics 
analyses were performed to cross-reference results from our functional models with 
primary ATRT and define key biological effects. We show that whilst Rhabdoid tumours 
have a common and characteristic biology they show distinct sub-grouping of their 
expression and methylation profiles by location; ATRT are distinguishable from Extra 
Cranial Rhabdoid Tumours. We show that loss of SMARCB1 leads not only to 
deregulated expression of hundreds of genes, but also expression of aberrant isoforms, 
switches in promoter usage and expression of novel transcripts. We show that genome-
wide methylation patterns are altered by SMARCB1 loss with consequent changes in 
expression. We have critically analysed the genomic changes downstream of SMARCB1 
loss to isolate pathways which are potentially critical downstream targets in ATRT. 
Using next generation sequencing and chromatin immunoprecipitation we are 
developing a high-resolution picture of the downstream consequences of SMARCB1 
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loss to both the transcriptome and methylome, these results are being cross-referenced 
and verified in primary ATRT. This will provide an excellent resource to isolate, from 
amongst the many hundreds of possible downstream effects, key tumourigenic 
pathways or events which may be ultimately targetable therapeutically. 
 
 
Finetti M. A. , D. C. P. A., Selby M., Smith A.,  Crosier S., Wood J., Skalkoyannis B.,  
Bailey S., Clifford S., Williamson D. (2014). "Characterising critical pathways in ATRT 
tumourigenesis: a genome-wide analysis of primary tumours and functional genomic 
models." NEURO-ONCOLOGY (16th International Symposium on Pediatric Neuro-
Oncology (ISPNO) in conjunction with the 8th St. Jude-VIVA Forum). 
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Mechanism of tumourigenesis caused by loss of SMARCB1 in 
Malignant Rhabdoid Tumors 
M. Finetti, A. Del Carpio Pons, J. Wood, B. Skalkoyannis, M. Selby, A. Smith, S. Crosier, 
S. Bailey, S. Clifford, D. Williamson 
Poster presentation 
 
Introduction: MRT (Malignant Rhabdoid Tumor) are aggressive pediatric tumors [1,2] 
with no currently effective treatment [3]. They may occur at any location in the body, 
although most often in the CNS (known as Atypical Teratoid Rhabdoid Tumor [ATRT]) 
or kidney [2]. Despite this phenotypic heterogeneity they are uniquely homogeneous 
genetically; >90% MRT have biallelic inactivation of SMARCB1 [4−7]. SMARCB1 
encodes a core subunit of the hSWI/SNF complex which effects widespread chromatin 
remodeling and regulates hundreds of downstream genes/pathways formation [8,9]. Re-
expression of SMARCB1 causes growth arrest and differentiation in MRT cells [10−12]. 
However, to date few studies have identified specific critical downstream pathways in 
MRT tumourigenesis. Understanding these downstream effects is critical in identifying 
therapeutic targets that can improve the survival of MRT patients. 
Methods: RNA-seq and 450K-methylation array has been performed on primary MRTs 
(n > 30). To understand SMARCB1’s role in MRT tumorigenesis, we re-expressed 
SMARCB1 using lentivirus in 4 MRT cell lines (G401, A204, CHLA-266, and STA-
WT1). RNA-seq, 450K methylation and ChIP was performed after 7 days. We 
performed an integrative bioinformatics analysis to cross-reference results from our 
functional models with primary MRT. Results: Expression and methylation profiling 
showed that MRTs present a unique and defined expression/methylation profile which 
confirms that MRT broadly constitute a single tumor type regardless of location. 
However, primary MRT and ATRT can be further sub-grouped by tumor location: this 
may suggest that extra- and intra-cranial MRT − despite their common cause − have 
different downstream effects or cells of origin. Re-expression of SMARCB1 in MRT cell 
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lines results in genome-wide alterations in methylation with consequent effects on gene 
expression. Interestingly, we found that SMARCB1 was not only responsible for changes 
in gene expression, but controls promoter usage and expression of novel transcripts. 
Moreover, ChIP results show the effect of SMARCB1 loss on SWI/SNF chromatin 
binding. 
Conclusion: Using next generation sequencing we analyzed the effect of SMARCB1 
loss on the methylome and transcriptome in MRTs. Our ability to integrate the data 
across platforms provides the possibility to research, isolate and demonstrate many 
hundreds of possible downstream effects. This approach aims to characterize and 
understand MRT tumourigenesis and to identify the most critical tumorigenic 
genes/pathways which may ultimately be targeted therapeutically. 
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Next-generation sequencing identifies the mechanism of 
tumourigenesis caused by loss of SMARCB1 in Malignant Rhabdoid 
Tumours 
M.A. Finetti , M. Selby , A. del Carpio Pons , J. Wood , B. Skalkoyannis , A. Smith , S. 
Crosier , S. Bailey , S. Clifford , D. Williamson 
Poster presentation 
 
Introduction: 
 Malignant Rhabdoid Tumours (MRT) are unique malignancies caused by biallelic 
inactivation of a single gene (SMARCB1). SMARCB1 encodes for a protein that is part 
of the SWI/SNF chromatin remodelling complex, responsible for the regulation of 
hundreds of downstream genes/pathways. Despite the simple biology of these tumours, 
no studies have identified the critical pathway involved in tumourigenesis. The 
understanding of downstream effects is essential to identifying therapeutic targets that 
can improve the outcome of MRT patients.  
Methods:  
RNA-seq and 450k-methylation analyses have been performed in MRT human primary 
malignancies (n > 30) and in 4 MRT cell lines in which lentivirus was used to re-express 
SMARCB1 (G401, A204, CHLA- 266, and STA-WT1). The dynamics of chromatin 
binding and remodelling following SMARCB1 re-expression has been analysed by 
ChIP-seq. The MRT cell lines were treated with 5-aza-2’-deoxycytidine followed by 
global gene transcription analysis (RNA-seq and 450k-methylation) to investigate how 
changes in methylation lead to tumourigenesis. 
Results: We show that primary MRTs present a unique and distinct 
expression/methylation profile which confirms that MRT broadly constitute a single and 
different tumour type from other paediatric malignancies. However despite their 
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common cause MRT can be can sub-grouped by location (i.e. CNS or kidney). We 
observe that re-expression of SMARCB1 in MRT cell lines determines 
activation/inactivation of specific downstream pathways such as IL-6/TGFbeta. We also 
observe a direct correlation between alterations in methylation and gene expression in 
CD44, GLI2, GLI3, p16, p21 and JARID after SMARB1 re-expression. Loss of 
SMARCB1 also promotes expression of aberrant isoforms and novel transcripts and 
causes genome-wide changes in SWI/SNF binding. 
Conclusion: The next generation transcriptome and methylome analysis in primary 
MRT and in functional model give us detailed downstream effect of SMARCB1 loss in 
MRTs. The integration of data from both primary and functional models has provided, 
for the first time, a genome-wide catalogue of SMARCB1 tumourigenic changes 
(validated using systems biology). Here we show how a single deletion of SMARCB1 is 
responsible for deregulation of expression, methylation status and binding at the 
promoter regions of potent tumour-suppressor genes. The genes, pathways and 
biological mechanisms indicated as key in tumour development may ultimately be 
targetable therapeutically and will lead to better treatments for what is currently one of 
the most lethal paediatric cancers. 
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